[{"id": "per_0001", "slug": "nazif-alic", "name": {"display": "Nazif Alic", "sort": "Alic, Nazif"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Ageing and Gene Regulation", "organisation": "University College London (Department of Genetics, Evolution & Environment; Institute of Healthy Ageing)", "sources": ["https://profiles.ucl.ac.uk/195-nazif-alic"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "London", "region": "England", "country_code": "GB", "sources": ["https://profiles.ucl.ac.uk/195-nazif-alic"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://profiles.ucl.ac.uk/195-nazif-alic/thumbnail", "page_url": "https://profiles.ucl.ac.uk/195-nazif-alic", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Nazif Alic leads a laboratory at UCL's Institute of Healthy Ageing that uses the fruit fly to study how transcriptional regulation shapes adult physiology, metabolism and lifespan, with a particular interest in gene regulation by all three eukaryotic nuclear RNA polymerases. His group reported in Nature (2017) that RNA polymerase III limits longevity downstream of TORC1, linking a core nutrient-sensing pathway to a specific transcriptional machinery. Later work showed that transient activation of the FOXO transcription factor dFOXO in youth leaves a transcriptional memory, via chromatin remodelling and Xbp1, that reduces later-life mortality (Nature Aging, 2022), and that disrupting tRNA biogenesis or removing the Pol III repressor Maf1 in neurons can improve later-life health and extend lifespan (PLoS Biology, 2025). He trained at the University of New South Wales and came to UCL as an EMBO/Marie Curie fellow with Linda Partridge before starting his own laboratory in 2013; he has been Professor at UCL since October 2023.", "word_count": 157, "sources": ["https://profiles.ucl.ac.uk/195-nazif-alic", "https://www.ucl.ac.uk/life-sciences/alic-lab", "https://www.nature.com/articles/nature25007", "https://www.nature.com/articles/s43587-022-00312-x"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 30, "source_url": "https://scholar.google.com/citations?user=z5fXShsAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All-time h-index; profile 'Professor, University College London', verified ucl.ac.uk email"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=z5fXShsAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": "https://uk.linkedin.com/in/nazif-alic-0094a312b", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0003-0356-6600", "status": "verified"}, "official": [{"label": "UCL profile", "url": "https://profiles.ucl.ac.uk/195-nazif-alic"}, {"label": "Alic Lab", "url": "https://www.ucl.ac.uk/life-sciences/alic-lab"}]}, "sources": [{"url": "https://profiles.ucl.ac.uk/195-nazif-alic", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.ucl.ac.uk/life-sciences/alic-lab", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=z5fXShsAAAAJ&hl=en", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://www.nature.com/articles/nature25007", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://www.nature.com/articles/s43587-022-00312-x", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0002", "slug": "julie-andersen", "name": {"display": "Julie Andersen", "sort": "Andersen, Julie"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor", "organisation": "Buck Institute for Research on Aging", "sources": ["https://www.buckinstitute.org/lab/andersen-lab/", "https://scholar.google.com/citations?user=oPoiPtsAAAAJ&hl=en"], "source_type": "lab_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Novato", "region": "CA", "country_code": "US", "sources": ["https://www.buckinstitute.org/visit-us/", "https://scholar.google.com/citations?user=oPoiPtsAAAAJ&hl=en"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.buckinstitute.org/wp-content/uploads/2018/06/Julie-Andersen-new2.jpg", "page_url": "https://www.buckinstitute.org/lab/andersen-lab/", "source_type": "lab_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Julie Andersen is a professor at the Buck Institute for Research on Aging whose laboratory studies the age-related processes that drive neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Her group's premise is that ageing, the major shared risk factor, offers a common target, and it works to identify therapeutics that slow or prevent these conditions. Current work includes small molecules that enhance autophagy, the cell's clearance of damaged proteins and components, and approaches to remove senescent cells that can damage neighbouring tissue, tested in human induced pluripotent stem cells, C. elegans and mice in collaboration with other Buck laboratories. She trained at UCLA and Massachusetts General Hospital and held a faculty position at the USC School of Gerontology before joining the Buck. According to her Buck biography she has published more than 170 papers, holds three patents, and has received a Parkinson's Pioneer Award from the National Parkinson's Foundation, a Glenn Award for Research in Biological Mechanisms of Aging and an Ellison Medical Foundation senior scholarship. She has also worked with biotech companies and medical foundations, including Roche and the Michael J. Fox Foundation.", "word_count": 185, "sources": ["https://www.buckinstitute.org/lab/andersen-lab/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 71, "source_url": "https://scholar.google.com/citations?user=oPoiPtsAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All-time h-index; profile 'Professor, Buck Institute for Research on Aging', verified buckinstitute.org email"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=oPoiPtsAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/julie-k-andersen-49b88a34", "status": "verified"}, "x": {"url": "https://x.com/JKAndersenBuck", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Andersen Lab, Buck Institute", "url": "https://www.buckinstitute.org/lab/andersen-lab/"}]}, "sources": [{"url": "https://www.buckinstitute.org/lab/andersen-lab/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.buckinstitute.org/visit-us/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=oPoiPtsAAAAJ&hl=en", "type": "scholar_profile", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0003", "slug": "rozalyn-anderson", "name": {"display": "Rozalyn Anderson", "sort": "Anderson, Rozalyn"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Medicine; Director, Metabolism of Aging Program", "organisation": "University of Wisconsin–Madison School of Medicine and Public Health", "sources": ["https://metabolismofaging.wisc.edu/staff/anderson-rozalyn/", "https://www.medicine.wisc.edu/directory/anderson_rozalyn"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Madison", "region": "WI", "country_code": "US", "sources": ["https://metabolismofaging.wisc.edu/staff/anderson-rozalyn/", "https://andersonlab.medicine.wisc.edu/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.medicine.wisc.edu/sites/default/files/styles/large/public/images/905.jpg?itok=0h4OFRWp", "page_url": "https://www.medicine.wisc.edu/directory/anderson_rozalyn", "source_type": "institution_page", "credit": "UW–Madison Department of Medicine", "checked": "2026-09-23"}, "impact": {"text": "Rozalyn Anderson studies how nutrition and metabolism connect to health and longevity, with a focus on the mechanisms behind caloric restriction (CR), reduced calorie intake without malnutrition. Her work in rhesus monkeys at the University of Wisconsin showed that CR improves survival and lowers the incidence of age-related diseases in a primate, extending findings from yeast, worms, flies and mice. Her laboratory, housed in the Geriatrics Research, Education and Clinical Center at the William S. Middleton Memorial VA Hospital, seeks the regulatory pathways recruited by CR to understand why vulnerability to cancer, diabetes, cardiovascular disease and neurodegeneration rises with age. She began studying CR as a postdoctoral fellow with David Sinclair at Harvard Medical School and continued with Richard Weindruch in Madison, joining the UW Department of Medicine faculty in 2010 and becoming full professor in 2021. She directs the Metabolism of Aging program, is Co-Editor in Chief of the Journals of Gerontology: Biological Sciences, and is a Fellow of the American Aging Association and the Gerontological Society of America. Her honours include the AFAR Breakthroughs in Gerontology Award, a Glenn Award and the GSA Nathan Shock New Investigator Award.", "word_count": 190, "sources": ["https://metabolismofaging.wisc.edu/staff/anderson-rozalyn/", "https://www.medicine.wisc.edu/directory/anderson_rozalyn", "https://andersonlab.medicine.wisc.edu/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 45, "source_url": "https://scholar.google.com/citations?user=YgnrzXsAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All-time h-index; profile affiliation 'University of Wisconsin Madison', verified wisc.edu email"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=YgnrzXsAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/rozalyn-anderson-b84504ab/", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Metabolism of Aging Program profile", "url": "https://metabolismofaging.wisc.edu/staff/anderson-rozalyn/"}, {"label": "Department of Medicine directory", "url": "https://www.medicine.wisc.edu/directory/anderson_rozalyn"}, {"label": "Anderson Lab", "url": "https://andersonlab.medicine.wisc.edu/"}]}, "sources": [{"url": "https://metabolismofaging.wisc.edu/staff/anderson-rozalyn/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.medicine.wisc.edu/directory/anderson_rozalyn", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://andersonlab.medicine.wisc.edu/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=YgnrzXsAAAAJ&hl=en", "type": "scholar_profile", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0004", "slug": "adam-antebi", "name": {"display": "Adam Antebi", "sort": "Antebi, Adam"}, "categories": ["scientist", "academic"], "current_title": {"title": "Director, Department of Molecular Genetics of Ageing", "organisation": "Max Planck Institute for Biology of Ageing", "sources": ["https://www.age.mpg.de/antebi/biography", "https://www.age.mpg.de/antebi", "https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/adam-antebi"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Cologne", "region": "North Rhine-Westphalia", "country_code": "DE", "sources": ["https://www.age.mpg.de/antebi/biography"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.cecad.uni-koeln.de/fileadmin/_processed_/7/6/csm_antebi_adam_03504_2_860a65d12a.jpg", "page_url": "https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/adam-antebi", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Adam Antebi has been a director at the Max Planck Institute for Biology of Ageing in Cologne since 2008, where his Department of Molecular Genetics of Ageing studies the regulatory mechanisms behind the decline of organismal homeostasis with age. The lab works mainly in the nematode C. elegans, the short-lived African turquoise killifish and human cells, combining genetics with transcriptomic, proteomic, metabolomic and lipidomic profiling. Its reported findings include that small nucleoli are a cellular hallmark of longevity, that regulation of the one-carbon folate cycle is a shared metabolic signature of longevity, and that reduced spliceosome fidelity can inhibit mTORC1 signalling to promote longevity (Nature Aging, 2022). Recent work addresses fasting and refeeding, including AMPK complex activity (Nature Aging, 2023), and diapause and stem cell resilience in killifish (Nature Aging, 2025). He trained at MIT with Gerald Fink and at Johns Hopkins, led a group at the MPI for Molecular Genetics in Berlin and was on the Baylor College of Medicine faculty before moving to Cologne. He is an honorary professor at the University of Cologne, directs an International Max Planck Research School, was elected to EMBO in 2016 and held an ERC Advanced Grant on nucleolar regulation of longevity.", "word_count": 200, "sources": ["https://www.age.mpg.de/antebi/biography", "https://www.age.mpg.de/antebi", "https://www.age.mpg.de/person/129100", "https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/adam-antebi"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 58, "source_url": "https://scholar.google.com/citations?user=I6c86kQAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All-time h-index; profile affiliation 'Max Planck Institute for Biology of Aging', verified age.mpg.de email"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=I6c86kQAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Department Antebi, MPI for Biology of Ageing", "url": "https://www.age.mpg.de/antebi"}, {"label": "CECAD profile", "url": "https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/adam-antebi"}, {"label": "Antebi Lab on X (lab account, linked from CECAD profile)", "url": "https://twitter.com/AntebiLab"}]}, "sources": [{"url": "https://www.age.mpg.de/antebi/biography", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.age.mpg.de/antebi", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.age.mpg.de/person/129100", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/adam-antebi", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=I6c86kQAAAAJ&hl=en", "type": "scholar_profile", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0005", "slug": "mary-armanios", "name": {"display": "Mary Armanios", "sort": "Armanios, Mary"}, "categories": ["scientist", "academic", "doctor"], "current_title": {"title": "Professor of Oncology; Director, Telomere Center at Johns Hopkins", "organisation": "Johns Hopkins University School of Medicine", "sources": ["https://profiles.hopkinsmedicine.org/provider/mary-armanios/2708607", "https://doi.org/10.1056/evidra2600012"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "June 2026 NEJM Evidence affiliation (Department of Oncology and Telomere Center at Johns Hopkins) confirms current role"}, "other_positions": [], "location": {"city": "Baltimore", "region": "MD", "country_code": "US", "sources": ["https://profiles.hopkinsmedicine.org/provider/mary-armanios/2708607"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://cdn-images.kyruus.com/providermatch/johnshopkins/photos/500/armanios-mary-1588628390.jpg", "page_url": "https://profiles.hopkinsmedicine.org/provider/mary-armanios/2708607", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Mary Armanios is a physician-scientist at Johns Hopkins who studies diseases caused by telomere dysfunction, a mechanistic link between ageing biology and specific human disorders. Telomere-shortening syndromes were first recognised in dyskeratosis congenita, a rare premature-ageing syndrome that predisposes to bone marrow failure and cancer. Her group showed that mutations in essential telomerase components cause familial idiopathic pulmonary fibrosis (New England Journal of Medicine, 2007), and her Hopkins profile states that such mutations are the most common known cause of the disease and its familial forms. Later work identified NAF1 loss-of-function mutations in familial pulmonary fibrosis-emphysema, evaluated the diagnostic use of clinical telomere length measurement, described familial clonal haematopoiesis in a long-telomere syndrome (NEJM, 2023) and linked T cell immune deficiency to squamous cancers in short-telomere syndromes (Cancer Cell, 2023). She directs the Telomere Center at Johns Hopkins, whose multidisciplinary Telomere Clinic at the Sidney Kimmel Comprehensive Cancer Center cares for patients with suspected telomere disorders, and is Associate Director of Cancer Research Career Enhancement at the Kimmel Cancer Center. She is Professor of Oncology, with additional professorships in Genetic Medicine, Molecular Biology and Genetics, and Pathology.", "word_count": 187, "sources": ["https://profiles.hopkinsmedicine.org/provider/mary-armanios/2708607"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 53, "source_url": "https://scholar.google.com/citations?user=f1b4RIQAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All-time h-index; profile name and affiliation 'Johns Hopkins University School of Medicine' match; Scholar shows a verified pitt.edu email"}, {"kind": "h_index", "for_category": "doctor", "platform": "google_scholar", "value": 53, "source_url": "https://scholar.google.com/citations?user=f1b4RIQAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Same Google Scholar profile as academic_scientist entry"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=f1b4RIQAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Johns Hopkins Medicine profile", "url": "https://profiles.hopkinsmedicine.org/provider/mary-armanios/2708607"}, {"label": "Telomere Clinic at Johns Hopkins", "url": "https://www.hopkinsmedicine.org/kimmel-cancer-center/the-telomere-clinic-at-johns-hopkins"}]}, "sources": [{"url": "https://profiles.hopkinsmedicine.org/provider/mary-armanios/2708607", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=f1b4RIQAAAAJ&hl=en", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1056/evidra2600012", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0006", "slug": "peter-attia", "name": {"display": "Peter Attia", "sort": "Attia, Peter"}, "categories": ["communicator", "doctor", "entrepreneur"], "current_title": {"title": "Founder", "organisation": "Early Medical", "sources": ["https://peterattiamd.com/about/", "https://earlymedical.com/"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Austin", "region": "TX", "country_code": "US", "sources": ["https://peterattiamd.com/about/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://earlymedical.com/wp-content/uploads/2023/09/peter-attia-952x1024.jpg", "page_url": "https://earlymedical.com/", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Peter Attia is a physician and public communicator on longevity medicine. He founded Early Medical, a practice that, in its own description, applies what he calls \"Medicine 3.0\" with the aim of lengthening both lifespan and healthspan, and hosts the podcast The Peter Attia Drive, which features long-form interviews with researchers and clinicians on exercise, nutrition, sleep, emotional health and disease prevention. He is the author of Outlive: The Science and Art of Longevity, listed on his site as a #1 New York Times bestseller, and publishes a weekly newsletter and premium research articles. He received his MD from Stanford University School of Medicine, trained for five years in general surgery at the Johns Hopkins Hospital, and spent two years as a surgical oncology fellow at the National Cancer Institute working on immune-based therapies for melanoma. He is based in Austin, Texas.", "word_count": 142, "sources": ["https://peterattiamd.com/about/", "https://earlymedical.com/", "https://www.cbsnews.com/news/peter-attia-steps-down-as-cbs-news-contributor/", "https://www.nbcnews.com/business/media/peter-attia-leaves-cbs-news-contributor-role-fallout-epstein-files-rcna260314"]}, "metrics": [{"kind": "audience", "for_category": "communicator", "platform": "youtube", "value": 1040000, "source_url": "https://www.youtube.com/@peterattiamd", "checked": "2026-09-23", "status": "verified", "note": "subscribers; channel page displays rounded figure '1.04M subscribers'"}, {"kind": "audience", "for_category": "communicator", "platform": "podcast", "value": null, "source_url": "https://peterattiamd.com/category/podcast", "checked": "2026-09-23", "status": "unavailable", "note": "The Peter Attia Drive; no publicly verifiable listener/download count found"}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": "https://x.com/PeterAttiaMD", "checked": "2026-09-23", "status": "unavailable", "note": "follower count requires login"}, {"kind": "audience", "for_category": "communicator", "platform": "newsletter", "value": null, "source_url": "https://peterattiamd.com/newsletter", "checked": "2026-09-23", "status": "unavailable", "note": "weekly newsletter; subscriber count not disclosed"}, {"kind": "audience", "for_category": "communicator", "platform": "book", "value": null, "source_url": "https://peterattiamd.com/about/", "checked": "2026-09-23", "status": "unavailable", "note": "Outlive described on his site as a #1 New York Times bestseller; no verifiable sales figure"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Early Medical", "label": "Early Medical publicly disclosed total funding", "value": null, "currency": "USD", "scope": "total_disclosed", "source_url": "https://earlymedical.com/", "checked": "2026-09-23", "status": "unavailable", "note": "Private medical practice; targeted search (2026-09-23) found no publicly disclosed external funding round or total."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Biograph", "label": "Biograph publicly disclosed total funding", "value": null, "currency": "USD", "scope": "total_disclosed", "source_url": "https://techcrunch.com/2025/02/28/startup-co-founded-by-longevity-guru-peter-attia-emerges-from-stealth/", "checked": "2026-09-23", "status": "unavailable", "note": "Attia co-founded Biograph (with John Hering) per TechCrunch (28 Feb 2025); backers named (Vy Capital, Human Capital, Alpha Wave, WndrCo) but 'Biograph declined to specify how much funding it has raised'. Aggregator totals (e.g. indexed.vc) not used."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": "https://x.com/PeterAttiaMD", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Peter Attia MD website", "url": "https://peterattiamd.com/"}, {"label": "Early Medical", "url": "https://earlymedical.com/"}, {"label": "YouTube channel", "url": "https://www.youtube.com/@peterattiamd"}]}, "sources": [{"url": "https://peterattiamd.com/about/", "type": "personal_site", "accessed": "2026-09-23"}, {"url": "https://earlymedical.com/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.youtube.com/@peterattiamd", "type": "platform_page", "accessed": "2026-09-23"}, {"url": "https://www.cbsnews.com/news/peter-attia-steps-down-as-cbs-news-contributor/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://www.nbcnews.com/business/media/peter-attia-leaves-cbs-news-contributor-role-fallout-epstein-files-rcna260314", "type": "news", "accessed": "2026-09-23"}, {"url": "https://techcrunch.com/2025/02/28/startup-co-founded-by-longevity-guru-peter-attia-emerges-from-stealth/", "type": "news", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-24", "phase": "3"}}, {"id": "per_0007", "slug": "gil-atzmon", "name": {"display": "Gil Atzmon", "sort": "Atzmon, Gil"}, "categories": ["scientist", "academic"], "current_title": {"title": "Full Professor, Department of Human Biology, Faculty of Natural Sciences", "organisation": "University of Haifa", "sources": ["https://cris.haifa.ac.il/en/persons/gil-atzmon/", "https://doi.org/10.1007/s10522-026-10451-y"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Affiliated, Departments of Medicine and Genetics", "organisation": "Albert Einstein College of Medicine", "sources": ["https://doi.org/10.1007/s10522-026-10451-y"]}], "location": {"city": "Haifa", "region": "Haifa District", "country_code": "IL", "sources": ["https://crsa.haifa.ac.il/2023/11/19/professor-gil-atzmon-phd/", "https://doi.org/10.1007/s10522-026-10451-y"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://cris.haifa.ac.il/files-asset/32325952/Gil_Atzmon.jpg?w=160&f=jpg", "page_url": "https://cris.haifa.ac.il/en/persons/gil-atzmon/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Gil Atzmon is a geneticist whose work centres on how the genome and epigenome relate to disease, health and exceptional longevity, with a long-running focus on centenarians and Ashkenazi Jewish cohorts. Trained in population genetics at the Hebrew University, he completed a fellowship in human genetics at Albert Einstein College of Medicine and rose to associate professor there before joining the University of Haifa, where he is a full professor in the Department of Human Biology and works on epigenetics and genomics of ageing. His most-cited ageing papers, as listed on his Google Scholar profile, include reports of a distinctive lipoprotein phenotype and genotype associated with exceptional longevity (JAMA, 2003), functionally significant IGF-1 receptor mutations in centenarians (PNAS, 2008) and common variation in the insulin/IGF-1 signalling pathway associated with human longevity (Aging Cell, 2009). He also contributed to large consortium studies, including the 2014 NEJM report linking age-related clonal haematopoiesis to adverse outcomes and a meta-analysis of genome-wide association studies of longevity (Nature Communications, 2019). His 2026 publications list both the University of Haifa and the Departments of Medicine and Genetics at Albert Einstein College of Medicine.", "word_count": 187, "sources": ["https://cris.haifa.ac.il/en/persons/gil-atzmon/", "https://crsa.haifa.ac.il/2023/11/19/professor-gil-atzmon-phd/", "https://scholar.google.com/citations?user=Wde8tD0AAAAJ&hl=en", "https://doi.org/10.1007/s10522-026-10451-y"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 74, "source_url": "https://scholar.google.com/citations?user=Wde8tD0AAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All-time h-index; profile affiliation 'University of Haifa', verified univ.haifa.ac.il email; profile linked from University of Haifa CRSA page"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=Wde8tD0AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0001-6895-3607", "status": "verified"}, "official": [{"label": "University of Haifa research profile", "url": "https://cris.haifa.ac.il/en/persons/gil-atzmon/"}, {"label": "Center for Research and Study of Aging profile", "url": "https://crsa.haifa.ac.il/2023/11/19/professor-gil-atzmon-phd/"}]}, "sources": [{"url": "https://cris.haifa.ac.il/en/persons/gil-atzmon/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://crsa.haifa.ac.il/2023/11/19/professor-gil-atzmon-phd/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=Wde8tD0AAAAJ&hl=en", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1007/s10522-026-10451-y", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0008", "slug": "steven-austad", "name": {"display": "Steven Austad", "sort": "Austad, Steven"}, "categories": ["scientist", "academic", "communicator"], "current_title": {"title": "Distinguished Professor; Protective Life Endowed Chair in Healthy Aging Research, Department of Biology", "organisation": "University of Alabama at Birmingham", "sources": ["https://www.uab.edu/cas/biology/people/faculty/steven-n-austad", "https://scholars.uab.edu/2487-steven-austad"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "UAB Scholars lists a new 'Professor Distinguished' appointment in Biology from 3 Aug 2026; several secondary/center appointments ended 30 Jun 2026. Endowed chair title taken from the department page."}, "other_positions": [], "location": {"city": "Birmingham", "region": "AL", "country_code": "US", "sources": ["https://scholars.uab.edu/2487-steven-austad"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.uab.edu/cas/biology/images/images/people/faculty/steven-austad-2022.jpg", "page_url": "https://www.uab.edu/cas/biology/people/faculty/steven-n-austad", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Steven Austad is a biogerontologist at the University of Alabama at Birmingham known for comparative and evolutionary studies of ageing and for public communication about the science of longevity. Originally field-based, his research moved to the laboratory and focuses on species that age more slowly than humans, such as clams that live more than 500 years and hydra that show no signs of ageing, to find ways to slow ageing. His lab also develops measures of laboratory-animal health, so that life-extending treatments can be judged on healthspan as well as lifespan, and studies why the sexes often respond differently to such treatments. He directs the UAB Nathan Shock Center of Excellence in the Basic Biology of Aging and serves as Scientific Director of the American Federation for Aging Research. He was elected a Fellow of the AAAS in 2016 and chaired UAB's Department of Biology from 2014 to 2022. A former newspaper reporter and lion trainer with an English literature degree, he writes for general audiences; his books include Methuselah's Zoo: What Nature Can Teach Us About Living Longer, Healthier Lives (MIT Press, 2022). His most-cited Google Scholar entry is titled \"Why do we age?\".", "word_count": 195, "sources": ["https://www.uab.edu/cas/biology/people/faculty/steven-n-austad", "https://scholars.uab.edu/2487-steven-austad", "https://scholar.google.com/citations?user=8HPaM2oAAAAJ&hl=en"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 81, "source_url": "https://scholar.google.com/citations?user=8HPaM2oAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All-time h-index; profile 'S Austad', University of Alabama at Birmingham, verified uab.edu email, top paper 'Why do we age?'"}, {"kind": "audience", "for_category": "communicator", "platform": "bluesky", "value": 433, "source_url": "https://bsky.app/profile/austad.bsky.social", "checked": "2026-09-23", "status": "verified", "note": "followers, read from Bluesky public API (app.bsky.actor.getProfile); profile bio matches (aging biology, criminal justice)"}, {"kind": "audience", "for_category": "communicator", "platform": "book", "value": null, "source_url": "https://www.uab.edu/cas/biology/people/faculty/steven-n-austad", "checked": "2026-09-23", "status": "unavailable", "note": "Author of trade books incl. Methuselah's Zoo (MIT Press, 2022); no verifiable sales figures"}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "Possible account x.com/StevenAustad seen in search results only; not confirmed and count requires login"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=8HPaM2oAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UAB Department of Biology profile", "url": "https://www.uab.edu/cas/biology/people/faculty/steven-n-austad"}, {"label": "UAB Scholars profile", "url": "https://scholars.uab.edu/2487-steven-austad"}, {"label": "UAB Nathan Shock Center", "url": "http://www.uab.edu/shockcenter/"}, {"label": "Bluesky", "url": "https://bsky.app/profile/austad.bsky.social"}]}, "sources": [{"url": "https://www.uab.edu/cas/biology/people/faculty/steven-n-austad", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholars.uab.edu/2487-steven-austad", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=8HPaM2oAAAAJ&hl=en", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://bsky.app/profile/austad.bsky.social", "type": "platform_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0009", "slug": "johan-auwerx", "name": {"display": "Johan Auwerx", "sort": "Auwerx, Johan"}, "categories": ["scientist", "academic", "entrepreneur"], "current_title": {"title": "Full Professor; Nestlé Chair in Energy Metabolism, Laboratory of Integrative Systems Physiology", "organisation": "EPFL (École Polytechnique Fédérale de Lausanne), School of Life Sciences", "sources": ["https://people.epfl.ch/johan.auwerx?lang=en"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Co-founder", "organisation": "Mitobridge (acquired by Astellas, 2017)", "sources": ["https://people.epfl.ch/johan.auwerx?lang=en", "https://newsroom.astellas.com/2017-12-01-Astellas-Acquires-Mitobridge-Under-Existing-Collaboration"]}, {"title": "Co-founder", "organisation": "Carex", "sources": ["https://people.epfl.ch/johan.auwerx?lang=en"]}, {"title": "Co-founder", "organisation": "PhytoDia", "sources": ["https://people.epfl.ch/johan.auwerx?lang=en"]}], "location": {"city": "Lausanne", "region": "Vaud", "country_code": "CH", "sources": ["https://people.epfl.ch/johan.auwerx?lang=en"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://people.epfl.ch/johan.auwerx/photo", "page_url": "https://people.epfl.ch/johan.auwerx?lang=en", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Johan Auwerx is a physician-scientist at EPFL in Lausanne, where he holds the Nestlé Chair in Energy Metabolism and leads the Laboratory of Integrative Systems Physiology. He uses molecular physiology and systems genetics to study metabolism in health, ageing and disease, in particular how diet, exercise and hormones control metabolism by changing the activity of transcription factors and their cofactors. According to his EPFL biography, his work contributed to the development of nuclear-receptor agonists into drugs now used for high blood lipids, fatty liver and type 2 diabetes, and he was among the first to recognise transcriptional cofactors as energy sensors and effectors of metabolic homeostasis; this work validated those cofactors as drug targets and spurred clinical use of natural compounds such as resveratrol to modulate their pathways. He co-founded several biotech companies, including Carex, PhytoDia and Mitobridge, a mitochondrial-therapeutics company acquired by Astellas in 2017. He trained as an MD and PhD in molecular endocrinology at KU Leuven and as a postdoctoral fellow at the University of Washington. He was elected to EMBO in 2003, and his awards include the Prix Marcel Benoist (2016), the EASD Minkowski Prize and the Danone International Prize for Nutrition.", "word_count": 196, "sources": ["https://people.epfl.ch/johan.auwerx?lang=en", "https://newsroom.astellas.com/2017-12-01-Astellas-Acquires-Mitobridge-Under-Existing-Collaboration"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 205, "source_url": "https://scholar.google.com/citations?user=Kf5YXGYAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All-time h-index; profile 'Professor at the EPFL', verified epfl.ch email"}, {"kind": "h_index", "for_category": "doctor", "platform": "google_scholar", "value": 205, "source_url": "https://scholar.google.com/citations?user=Kf5YXGYAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Same Google Scholar profile as academic_scientist entry"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Mitobridge", "label": "Mitobridge publicly reported Series A funding (2013)", "value": 45000000, "currency": "USD", "scope": "single_round", "source_url": "https://www.biocentury.com/article/291394/astellas-acquires-build-to-buy-mitobridge", "checked": "2026-09-23", "status": "verified", "note": "BioCentury (Astellas acquisition article, Dec 2017): 'Astellas, MPM and Longwood Founders Fund participated in Mitobridge's $45 million series A round in 2013' (text read via a library proxy mirror of the same BioCentury article). Astellas' own release confirms the Oct 2013 Series A (MPM, Longwood, Astellas) and 2011 MPM seed but gives no amounts; seed amount undisclosed. Acquisition terms ($225M upfront + up to $225M) are not funding raised."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Carex", "label": "Carex publicly disclosed total funding", "value": null, "currency": "", "scope": "total_disclosed", "source_url": "https://people.epfl.ch/johan.auwerx?lang=en", "checked": "2026-09-23", "status": "unavailable", "note": "Co-founding listed on EPFL bio; no funding disclosure found"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "PhytoDia", "label": "PhytoDia publicly disclosed total funding", "value": null, "currency": "", "scope": "total_disclosed", "source_url": "https://people.epfl.ch/johan.auwerx?lang=en", "checked": "2026-09-23", "status": "unavailable", "note": "Co-founding listed on EPFL bio; no funding disclosure found"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=Kf5YXGYAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "EPFL people page", "url": "https://people.epfl.ch/johan.auwerx?lang=en"}]}, "sources": [{"url": "https://people.epfl.ch/johan.auwerx?lang=en", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=Kf5YXGYAAAAJ&hl=en", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://newsroom.astellas.com/2017-12-01-Astellas-Acquires-Mitobridge-Under-Existing-Collaboration", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.biocentury.com/article/291394/astellas-acquires-build-to-buy-mitobridge", "type": "news", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0010", "slug": "darren-baker", "name": {"display": "Darren Baker", "sort": "Baker, Darren"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Biochemistry and Molecular Biology; Professor of Pediatrics", "organisation": "Mayo Clinic", "sources": ["https://www.mayo.edu/research/faculty/baker-darren-j-ph-d-m-s/bio-00027985"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Rochester", "region": "MN", "country_code": "US", "sources": ["https://doi.org/10.1038/s43587-026-01148-5", "https://doi.org/10.1016/j.neuron.2026.06.020"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://scholar.googleusercontent.com/citations?view_op=medium_photo&user=IY6dtJwAAAAJ", "page_url": "https://scholar.google.com/citations?user=IY6dtJwAAAAJ&hl=en", "source_type": "scholarly_profile", "credit": "Google Scholar", "checked": "2026-09-29"}, "impact": {"text": "Darren Baker studies how senescent cells, which stop dividing but secrete factors that affect surrounding tissue, contribute to ageing, cancer and neurodegeneration. His team developed the INK-ATTAC transgenic mouse, in which p16-expressing senescent cells can be selectively and inducibly eliminated. Using this model in a progeroid mouse, he and colleagues reported in Nature (2011) that clearing p16Ink4a-positive senescent cells delays ageing-associated disorders such as cataract formation, providing direct genetic evidence that senescent cells drive age-related pathology. His group then extended the work to naturally aged mice, showing that accumulation of these cells drives pathology in many organs and shortens healthy life while leaving the tumour-suppressive senescence programme intact. This line of research underpins the rationale for senolytics, drugs that remove senescent cells without genetic engineering and are now in early-stage human trials. A current focus is the contribution of p16-expressing cells to Alzheimer's disease and related dementias. He holds professorships in Biochemistry and Molecular Biology and in Pediatrics at Mayo Clinic in Rochester, Minnesota, and his honours include a Glenn Award for Research in Biological Mechanisms of Aging (2012), an Ellison Medical Foundation New Scholar award (2011) and Mayo's Fundamental Mechanisms of Aging Award (2025-2026).", "word_count": 195, "sources": ["https://www.mayo.edu/research/faculty/baker-darren-j-ph-d-m-s/bio-00027985", "https://www.nature.com/articles/nature10600"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No clearly attributable public Google Scholar profile found (three searches)"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Mayo Clinic research profile", "url": "https://www.mayo.edu/research/faculty/baker-darren-j-ph-d-m-s/bio-00027985"}]}, "sources": [{"url": "https://www.mayo.edu/research/faculty/baker-darren-j-ph-d-m-s/bio-00027985", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.nature.com/articles/nature10600", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s43587-026-01148-5", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.neuron.2026.06.020", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0128", "slug": "daniela-bakula", "name": {"display": "Daniela Bakula", "sort": "Bakula, Daniela"}, "categories": ["scientist", "academic"], "current_title": {"title": "Research Consultant, Molecular Aging Program (Scheibye-Knudsen Group)", "organisation": "University of Copenhagen, Department of Cellular and Molecular Medicine", "sources": ["https://research.ku.dk/search/result/profile/?id=550979", "https://icmm.ku.dk/english/research-groups/scheibye-knudsen-group/research-group/", "https://icmm.ku.dk/english/staff/"], "source_type": "institution_page", "checked": "2026-09-24", "status": "verified", "note": "Formal title as listed on the University of Copenhagen's own staff pages (Sept 2026). ARDD 2026 speaker page says 'Professor, University of Copenhagen'; Google Scholar and LinkedIn say 'Assistant Professor'. See review.conflicts."}, "other_positions": [{"title": "Co-organiser, Aging Research and Drug Discovery (ARDD) meeting (since 2020)", "organisation": "ARDD", "sources": ["https://agingpharma.org/speakers/daniela-bakula/"]}, {"title": "Associate Editor", "organisation": "Frontiers in Aging", "sources": ["https://agingpharma.org/speakers/daniela-bakula/"]}], "location": {"city": "Copenhagen", "region": "Capital Region of Denmark", "country_code": "DK", "sources": ["https://research.ku.dk/search/result/profile/?id=550979", "https://doi.org/10.1126/science.aee3844"], "checked": "2026-09-24", "status": "verified"}, "photo": {"status": "found", "image_url": "https://agingpharma.org/assets/tilda-migrated/5040070e93af-Daniela_Bakula.jpg", "page_url": "https://agingpharma.org/speakers/daniela-bakula", "source_type": "conference_listing", "credit": "ARDD 2026 speaker page", "checked": "2026-09-24"}, "impact": {"text": "Daniela Bakula studies how genomic instability contributes to ageing and helps run one of the field's main meetings on translating ageing biology into drugs. She trained in autophagy research at the University of Tübingen, where her PhD work on human WIPI proteins included a first-author 2017 Nature Communications paper showing that WIPI3 and WIPI4 act as scaffolds linking autophagy to LKB1-AMPK-TSC signalling. She then joined Morten Scheibye-Knudsen's group at the University of Copenhagen, which studies the cellular and organismal consequences of DNA damage. She co-authored work establishing nuclear morphology as a deep-learning biomarker of cellular senescence (Nature Aging, 2022), and in 2026 she co-wrote a Science perspective with Scheibye-Knudsen that reconsiders how the heritability of human ageing is estimated. She has co-organised the Aging Research and Drug Discovery (ARDD) meeting in Copenhagen since 2020. She co-authors its annual meeting reports and reviews on clinical trials and pharmacological interventions targeting ageing. She is also an associate editor of Frontiers in Aging.", "word_count": 160, "sources": ["https://agingpharma.org/speakers/daniela-bakula/", "https://researchprofiles.ku.dk/en/persons/daniela-janina-bakula/", "https://doi.org/10.1038/ncomms15637", "https://doi.org/10.1038/s43587-022-00263-3", "https://doi.org/10.1126/science.aee3844"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 19, "source_url": "https://scholar.google.com/citations?user=scglAbAAAAAJ", "checked": "2026-09-24", "status": "verified", "note": "Profile 'Daniela Bakula', Assistant Professor, Center for Healthy Aging, University of Copenhagen; verified email at sund.ku.dk. 'All' column (since 2021: 17); 1,875 citations"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=scglAbAAAAAJ", "status": "verified"}, "linkedin": {"url": "https://dk.linkedin.com/in/daniela-bakula-ab5777120", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0003-4107-1414", "status": "verified"}, "official": [{"label": "University of Copenhagen research profile", "url": "https://researchprofiles.ku.dk/en/persons/daniela-janina-bakula/"}, {"label": "Scheibye-Knudsen Group (ICMM)", "url": "https://icmm.ku.dk/english/research-groups/scheibye-knudsen-group/research-group/"}, {"label": "ARDD 2026 speaker page", "url": "https://agingpharma.org/speakers/daniela-bakula/"}]}, "sources": [{"url": "https://research.ku.dk/search/result/profile/?id=550979", "type": "institution_page", "accessed": "2026-09-24"}, {"url": "https://researchprofiles.ku.dk/en/persons/daniela-janina-bakula/", "type": "institution_page", "accessed": "2026-09-24"}, {"url": "https://icmm.ku.dk/english/research-groups/scheibye-knudsen-group/research-group/", "type": "lab_page", "accessed": "2026-09-24"}, {"url": "https://icmm.ku.dk/english/staff/", "type": "institution_page", "accessed": "2026-09-24"}, {"url": "https://agingpharma.org/speakers/daniela-bakula/", "type": "conference_bio", "accessed": "2026-09-24"}, {"url": "https://scholar.google.com/citations?user=scglAbAAAAAJ", "type": "registry", "accessed": "2026-09-24"}, {"url": "https://orcid.org/0000-0003-4107-1414", "type": "registry", "accessed": "2026-09-24"}, {"url": "https://doi.org/10.1126/science.aee3844", "type": "publication", "accessed": "2026-09-24"}, {"url": "https://doi.org/10.1038/s43587-022-00263-3", "type": "publication", "accessed": "2026-09-24"}, {"url": "https://doi.org/10.1038/ncomms15637", "type": "publication", "accessed": "2026-09-24"}, {"url": "https://agingpharma.org/speakers/daniela-bakula", "type": "conference_listing", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-24", "updated": "2026-09-29", "phase": "5.1"}}, {"id": "per_0011", "slug": "nir-barzilai", "name": {"display": "Nir Barzilai", "sort": "Barzilai, Nir"}, "categories": ["scientist", "academic", "doctor", "communicator"], "current_title": {"title": "Professor of Medicine and Genetics; Ingeborg and Ira Leon Rennert Chair in Aging Research; Director, Institute for Geroscience", "organisation": "Albert Einstein College of Medicine", "sources": ["https://www.einsteinmed.edu/faculty/484/nir-barzilai/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Bronx", "region": "NY", "country_code": "US", "sources": ["https://www.einsteinmed.edu/faculty/484/nir-barzilai/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://assets.montefioreeinstein.org/profiles/images/nir-barzilai.jpg", "page_url": "https://www.einsteinmed.edu/faculty/484/nir-barzilai/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Nir Barzilai is a physician-scientist at Albert Einstein College of Medicine whose work helped shape geroscience, the effort to target the biology of ageing itself rather than individual diseases. His studies of centenarians, largely in Ashkenazi Jewish families, supported the idea that people with exceptional longevity carry protective genes that delay ageing and age-related disease; early reports linked a distinctive lipoprotein phenotype and genotype to exceptional longevity (JAMA, 2003). His Einstein profile states that these findings informed CETP- and APOC3-targeted therapeutic approaches. He conceived the multicentre TAME (Targeting Aging with Metformin) trial, designed to establish biological ageing as a target for intervention, launched the AFAR SuperAgers Family Study, and is principal investigator of FAST, an AFAR-ARPA-H initiative to identify ageing biomarkers from existing clinical trials. He directs the Institute for Geroscience and the BIO-Vital Program, is President of the Global Academy for Health & Lifespan Research, sits on the AFAR Board (formerly its Scientific Director), and has received the NIA Nathan Shock Award and the IPSEN Longevity Award. He communicates widely to public audiences, including TEDx and TEDMED talks, the National Geographic documentary The Age of Aging, and his 2020 book Age Later.", "word_count": 193, "sources": ["https://www.einsteinmed.edu/faculty/484/nir-barzilai/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No clearly attributable Google Scholar profile found (two searches)"}, {"kind": "h_index", "for_category": "doctor", "platform": "google_scholar", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No clearly attributable Google Scholar profile found"}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "Candidate @NirBarzilaiMD (bio: 'Director @EinsteinAging ... President @ahlresearch', ~12K followers via api.fxtwitter.com) not linked from any first-party page checked (Einstein faculty page links only institutional accounts; Macmillan book page none); @nirbarzilai is a separate low-activity account. Not recorded."}, {"kind": "audience", "for_category": "communicator", "platform": "book", "value": null, "source_url": "https://www.einsteinmed.edu/faculty/484/nir-barzilai/", "checked": "2026-09-23", "status": "unavailable", "note": "Author of Age Later (2020); no verifiable sales figure"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Einstein faculty profile", "url": "https://www.einsteinmed.edu/faculty/484/nir-barzilai/"}]}, "sources": [{"url": "https://www.einsteinmed.edu/faculty/484/nir-barzilai/", "type": "institution_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0012", "slug": "juan-carlos-izpisua-belmonte", "name": {"display": "Juan Carlos Izpisua Belmonte", "sort": "Belmonte, Juan Carlos Izpisua"}, "categories": ["scientist", "academic"], "current_title": {"title": "Founding Scientist and Senior Vice President", "organisation": "Altos Labs (San Diego Institute of Science)", "sources": ["https://www.altoslabs.com/team/juan-carlos-izpisua-belmonte", "https://doi.org/10.1016/j.stem.2026.06.006"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": "Recent 2026 papers list Altos Labs San Diego Institute of Science; one (Protein & Cell, Sept 2026) also lists Salk Institute."}, "other_positions": [], "location": {"city": "San Diego", "region": "CA", "country_code": "US", "sources": ["https://doi.org/10.1016/j.stem.2026.06.006", "https://www.salk.edu/news-release/salk-institute-announces-departure-of-professor-juan-carlos-izpisua-belmonte/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://a-us.storyblok.com/f/1016638/768x921/57bc9347a0/juan-carlos-izpisua-belmonte.png", "page_url": "https://www.altoslabs.com/team/juan-carlos-izpisua-belmonte", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Juan Carlos Izpisua Belmonte is a developmental and stem-cell biologist known for work on cellular reprogramming and rejuvenation. During nearly three decades at the Salk Institute, where he held the Roger Guillemin Chair, his laboratory worked on the molecular basis of embryogenesis and regeneration and pioneered gene-editing, epigenetic-editing and stem-cell techniques to study how diseased cells can be reprogrammed and rejuvenated. Among his most-cited papers are studies of efficient generation of induced pluripotent stem cells from human keratinocytes, zebrafish heart regeneration, iPSC models of Hutchinson-Gilford progeria and Werner syndrome, and a 2016 Cell paper reporting in vivo amelioration of age-associated hallmarks by partial reprogramming. In January 2022 Salk announced he would close his laboratory to lead the San Diego institute of Altos Labs, a company focused on cellular rejuvenation programming, where he is Founding Scientist and Senior Vice President. Altos describes his current aim as developing technologies to return cells to states resembling early, healthy life, with the goal of therapeutics for disease and ageing. TIME named him among its 50 Most Influential People in Health Care for 2018.", "word_count": 179, "sources": ["https://www.altoslabs.com/team/juan-carlos-izpisua-belmonte", "https://www.salk.edu/news-release/salk-institute-announces-departure-of-professor-juan-carlos-izpisua-belmonte/", "https://scholar.google.com/citations?user=7FpRTZ4AAAAJ&hl=en"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 151, "source_url": "https://scholar.google.com/citations?user=7FpRTZ4AAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All-time h-index; profile name matches; affiliation still shows his former institution 'Salk Institute for Biological Studies' (salk.edu email)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=7FpRTZ4AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/juan-carlos-izpisua-belmonte-133357237", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0003-0557-8875", "status": "verified"}, "official": [{"label": "Altos Labs team page", "url": "https://www.altoslabs.com/team/juan-carlos-izpisua-belmonte"}]}, "sources": [{"url": "https://www.altoslabs.com/team/juan-carlos-izpisua-belmonte", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.salk.edu/news-release/salk-institute-announces-departure-of-professor-juan-carlos-izpisua-belmonte/", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=7FpRTZ4AAAAJ&hl=en", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.stem.2026.06.006", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1093/procel/pwag020", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0013", "slug": "daniel-belsky", "name": {"display": "Daniel Belsky", "sort": "Belsky, Daniel"}, "categories": ["scientist", "academic"], "current_title": {"title": "Associate Professor of Epidemiology (Robert N. Butler Columbia Aging Center); Director, Geroscience Computational Core", "organisation": "Columbia University Mailman School of Public Health", "sources": ["https://www.publichealth.columbia.edu/profile/daniel-belsky-phd"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "New York", "region": "NY", "country_code": "US", "sources": ["https://doi.org/10.1002/oby.70293"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.publichealth.columbia.edu/sites/default/files/styles/cola_media_200/public/cups-profile/headshot/7dba3270-1e69-11f1-8fdc-09d7849d3f03.png?itok=IPV3U-p1", "page_url": "https://www.publichealth.columbia.edu/profile/daniel-belsky-phd", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Daniel Belsky is an epidemiologist at Columbia University's Mailman School of Public Health who develops methods to measure the pace and progress of biological ageing in humans and applies them in epidemiological studies and clinical trials. With Terrie Moffitt and Avshalom Caspi he originated the Pace of Aging method, which quantifies ageing from longitudinal analysis of physiology (published in PNAS), and later translated it into a DNA-methylation blood test, the DunedinPACE epigenetic clock, that can be applied to a single time point. He leads NIH-funded projects testing how caloric restriction affects ageing-related genomic changes in the CALERIE trial, the long-term effects of prenatal famine exposure in the Dutch Hunger Winter Family Study, and whether anti-poverty policy can slow biological ageing. His work also addresses how social and life-history factors shape healthy ageing and inequalities in ageing outcomes. He directs the Geroscience Computational Core of the Robert N. Butler Columbia Aging Center, co-directs the AFAR FAST Initiative, and serves on scientific advisory boards of AFAR, the Biomarkers of Aging Consortium and XPRIZE Healthspan. He has been named an ISI Highly Cited Researcher since 2020 and received AFAR's Vincent Cristofalo Rising Star Award.", "word_count": 191, "sources": ["https://www.publichealth.columbia.edu/profile/daniel-belsky-phd", "https://www.pnas.org/doi/pdf/10.1073/pnas.1506264112", "https://elifesciences.org/articles/54870"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 81, "source_url": "https://scholar.google.com/citations?user=w3xyjf8AAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All-time h-index; profile 'Daniel W Belsky', 'Associate Professor, Columbia University Mailman School of Public Health' (verified email shown is duke.edu, his former institution)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=w3xyjf8AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Columbia Mailman profile", "url": "https://www.publichealth.columbia.edu/profile/daniel-belsky-phd"}, {"label": "Belsky Lab", "url": "https://www.belskylab.com/"}]}, "sources": [{"url": "https://www.publichealth.columbia.edu/profile/daniel-belsky-phd", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=w3xyjf8AAAAJ&hl=en", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1002/oby.70293", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0014", "slug": "joe-betts-lacroix", "name": {"display": "Joe Betts-LaCroix", "sort": "Betts-LaCroix, Joe"}, "categories": ["entrepreneur"], "current_title": {"title": "Co-Founder and CEO", "organisation": "Retro Biosciences", "sources": ["https://www.biocom.org/people/joe-betts-lacroix/", "https://www.retro.bio/team"], "source_type": "conference_listing", "checked": "2026-09-23", "status": "verified", "note": "Retro team page lists him first but gives no title text; title from Biocom speaker page and multiple 2026 event listings."}, "other_positions": [], "location": {"city": "San Francisco", "region": "CA", "country_code": "US", "sources": ["https://techcrunch.com/2025/01/24/retro-biosciences-backed-by-sam-altman-is-raising-1-billion-to-extend-human-lifespan/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://du66v1zcke7muftn.public.blob.vercel-storage.com/images/team/joe-betts-lacroix-8710ccc4.jpg", "page_url": "https://www.retro.bio/team", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Joe Betts-LaCroix is co-founder and CEO of Retro Biosciences, a company whose stated goal is to add ten years to healthy human lifespan by developing therapies aimed at cellular drivers of aging. Retro was seeded with a $180 million round provided by Sam Altman and in May 2026 announced the initial close of a further round at a $1.8 billion pre-money valuation, led by 4P Capital. The company reports advancing RTR242, an oral therapeutic designed to restart autophagy, into a Phase I trial, alongside cell therapy (including iPSC-derived hematopoietic stem cells), tissue reprogramming and AI-enabled protein engineering programmes. Before Retro, Betts-LaCroix trained in biophysics at Harvard, MIT and Caltech, where he worked on electron-tunnelling rates in proteins. He co-founded OQO, maker of a very small Windows computer later acquired by Google, and Vium, an automation- and AI-driven in vivo research company acquired by Recursion, and spent several years as a part-time partner at Y Combinator. He leads a large privately financed effort to turn aging biology into clinical-stage therapeutics.", "word_count": 169, "sources": ["https://www.biocom.org/people/joe-betts-lacroix/", "https://www.retro.bio/blog/fundraise-2026", "https://techcrunch.com/2025/01/24/retro-biosciences-backed-by-sam-altman-is-raising-1-billion-to-extend-human-lifespan/", "https://www.retro.bio/"]}, "metrics": [{"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Retro Biosciences", "label": "Retro Biosciences publicly reported seed round", "value": 180000000, "currency": "USD", "scope": "single_round", "source_url": "https://techcrunch.com/2025/01/24/retro-biosciences-backed-by-sam-altman-is-raising-1-billion-to-extend-human-lifespan/", "checked": "2026-09-23", "status": "verified", "note": "Seed round of $180M provided entirely by Sam Altman (TechCrunch, linking MIT Technology Review, 8 Mar 2023: https://www.technologyreview.com/2023/03/08/1069523/sam-altman-investment-180-million-retro-biosciences-longevity-death/). May 2026 round announced at $1.8B pre-money valuation (led by 4P Capital) but amount raised not disclosed on retro.bio/blog/fundraise-2026; earlier reports of a $1B Series A were a raise in progress, not a closed amount. Not a cumulative total."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": "https://www.linkedin.com/in/bettslacroix", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Retro Biosciences team", "url": "https://www.retro.bio/team"}]}, "sources": [{"url": "https://www.retro.bio/team", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.retro.bio/blog/fundraise-2026", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.biocom.org/people/joe-betts-lacroix/", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://techcrunch.com/2025/01/24/retro-biosciences-backed-by-sam-altman-is-raising-1-billion-to-extend-human-lifespan/", "type": "news", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-24", "phase": "3"}}, {"id": "per_0015", "slug": "evelyne-bischof", "name": {"display": "Evelyne Bischof", "sort": "Bischof, Evelyne"}, "categories": ["doctor"], "current_title": {"title": "Medical Director, Sheba Longevity Center", "organisation": "Sheba Medical Center", "sources": ["https://hlms.co/structure", "https://hlms.co/evelyne", "https://doi.org/10.14336/ad.2026.0279"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Sheba Longevity Center page (longevity.sheba.co.il) is geo-blocked; title from HLMS council page and 2026 paper affiliations."}, "other_positions": [{"title": "Professor of Medicine", "organisation": "Shanghai University of Medicine and Health Sciences", "sources": ["https://hlms.co/structure", "https://doi.org/10.14336/ad.2026.0279"]}, {"title": "President", "organisation": "Healthy Longevity Medicine Society", "sources": ["https://hlms.co/structure"]}], "location": {"city": "Ramat Gan", "region": "Tel Aviv District", "country_code": "IL", "sources": ["https://doi.org/10.14336/ad.2026.0279", "https://doi.org/10.1093/braincomms/fcag251"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://static.tildacdn.com/tild6230-6639-4162-b936-363661643836/Evelyne_Bischof.jpg", "page_url": "https://agingpharma.org/speakers/evelyne-bischof", "source_type": "conference_listing", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Evelyne Bischof is an internist working in longevity medicine, the clinical application of aging biology to prevention and care. She is medical director of the Sheba Longevity Center at Sheba Medical Center in Israel, a professor of medicine at the Shanghai University of Medicine and Health Sciences, and president of the Healthy Longevity Medicine Society, an international society for clinicians practising longevity medicine. Swiss board-certified in internal medicine, she trained and worked in Europe, the United States and China, including a decade of clinical and translational work in New York, Shanghai and Basel, and was previously a senior attending physician in internal medicine at University Hospital Basel. Her research covers oncology and longevity medicine, artificial intelligence and digital health, precision medicine, biogerontology and geronto-oncology, and she reports more than 100 peer-reviewed papers. Recent 2026 work includes a Delphi-derived framework for healthspan-oriented cardiometabolic care and an aging clock derived from pathology lipid data. Through HLMS she is involved in efforts to define clinical standards for longevity medicine.", "word_count": 166, "sources": ["https://hlms.co/structure", "https://hlms.co/evelyne", "https://agingpharma.org/speakers/evelyne-bischof", "https://doi.org/10.14336/ad.2026.0279", "https://doi.org/10.14336/ad.2026.0300"]}, "metrics": [{"kind": "h_index", "for_category": "doctor", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "A Scholar profile appears to exist (search result for user id h1sAumMAAAAJ) but scholar.google.com returned 403/captcha; not read.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0002-9871-927X", "status": "verified"}, "official": [{"label": "Healthy Longevity Medicine Society profile", "url": "https://hlms.co/evelyne"}, {"label": "Sheba Longevity Center profile", "url": "https://longevity.sheba.co.il/en/evelyne-bischof"}]}, "sources": [{"url": "https://hlms.co/structure", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://hlms.co/evelyne", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://agingpharma.org/speakers/evelyne-bischof", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.14336/ad.2026.0279", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.14336/ad.2026.0300", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://orcid.org/0000-0002-9871-927X", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-23", "phase": "3"}}, {"id": "per_0016", "slug": "maria-blasco", "name": {"display": "María Blasco", "sort": "Blasco, María"}, "categories": ["scientist", "academic"], "current_title": {"title": "Group Leader, Telomeres and Telomerase Group", "organisation": "Spanish National Cancer Research Centre (CNIO)", "sources": ["https://www.cnio.es/en/research-innovation/groups/telomeres-and-telomerase-group/", "https://www.cnio.es/en/personas/maria-a-blasco-2/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Madrid", "region": "Community of Madrid", "country_code": "ES", "sources": ["https://www.cnio.es/en/personas/maria-a-blasco-2/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.cnio.es/wp-content/uploads/cnio-sync/personas/img/mblasco.jpg", "page_url": "https://www.cnio.es/en/personas/maria-a-blasco-2/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "María A. Blasco leads the Telomeres and Telomerase Group at the Spanish National Cancer Research Centre (CNIO) in Madrid. Her group studies how telomere shortening limits the regenerative capacity of adult stem cells and contributes to aging, and why cancer cells are immortal. Its programme covers telomeres and telomerase as therapeutic targets in cancer and age-related disease, telomerase gene therapy for telomere syndromes and age-related conditions, telomeric non-coding RNAs (TERRA), telomeres in nuclear reprogramming to iPS cells, and telomerase reactivation as a unified approach to fibrosis, with recent mouse work on telomere dysfunction in lung and kidney fibrosis. She co-authored the 2023 Cell update 'Hallmarks of aging: an expanding universe'. Blasco served as CNIO scientific director from 2011 until January 2025, when the CNIO Board of Trustees removed her and the managing director from their posts; she continues to lead her research group. For longevity researchers, her work is a frequently cited reference for the role of telomeres in organismal aging and for telomerase-based interventions.", "word_count": 165, "sources": ["https://www.cnio.es/en/research-innovation/groups/telomeres-and-telomerase-group/", "https://www.cnio.es/en/personas/maria-a-blasco-2/", "https://www.elmundo.es/ciencia-y-salud/salud/2025/01/29/6799f670e85ece561a8b459b.html", "https://www.ncbi.nlm.nih.gov/pubmed/36599349"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 133, "source_url": "https://scholar.google.com/citations?user=gB2EEOEAAAAJ&hl=en", "note": "Profile 'Blasco MA (0000-0002-4211-233X)', Telomeres and Telomerase Group, CNIO; verified email at cnio.es. All-time h-index.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=gB2EEOEAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": "https://es.linkedin.com/in/maria-a-blasco-a0494b108", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0002-4211-233X", "status": "verified"}, "official": [{"label": "CNIO profile", "url": "https://www.cnio.es/en/personas/maria-a-blasco-2/"}, {"label": "Telomeres and Telomerase Group", "url": "https://www.cnio.es/en/research-innovation/groups/telomeres-and-telomerase-group/"}]}, "sources": [{"url": "https://www.cnio.es/en/personas/maria-a-blasco-2/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.cnio.es/en/research-innovation/groups/telomeres-and-telomerase-group/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=gB2EEOEAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://www.elmundo.es/ciencia-y-salud/salud/2025/01/29/6799f670e85ece561a8b459b.html", "type": "news", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0017", "slug": "helen-blau", "name": {"display": "Helen Blau", "sort": "Blau, Helen"}, "categories": ["scientist", "academic"], "current_title": {"title": "Donald E. and Delia B. Baxter Foundation Professor; Director, Baxter Laboratory for Stem Cell Biology", "organisation": "Stanford University", "sources": ["https://profiles.stanford.edu/helen-blau", "https://scholar.google.com/citations?user=d8-zj3IAAAAJ&hl=en"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Stanford", "region": "CA", "country_code": "US", "sources": ["https://profiles.stanford.edu/helen-blau"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://profiles.stanford.edu/proxy/api/cap/profiles/4517/resources/profilephoto/350x350.1754496947897.jpg", "page_url": "https://profiles.stanford.edu/helen-blau", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Helen Blau is a stem cell biologist at Stanford University, where she has directed the Baxter Laboratory for Stem Cell Biology since 2000. Her laboratory studies cellular reprogramming, muscle stem cell function in regeneration, and strategies to rejuvenate aged cells and tissues. A central line of her recent work concerns 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a prostaglandin E2-degrading enzyme her group identified as elevated in aged tissues, including skeletal muscle, and describes as a 'gerozyme'. Inhibiting 15-PGDH has been reported to improve muscle strength in aged mice, regenerate articular cartilage and reduce osteoarthritis-associated pain (Science, 2025), and support muscle repair during GLP-1 receptor agonist-induced weight loss (PNAS, 2026). She has also written on therapeutic approaches to sarcopenia (Nature Reviews Drug Discovery, 2026). Earlier work developed protein-interaction reporter assays, reflected in a series of patents. Blau is a member of the US National Academy of Sciences, the National Academy of Medicine and the Royal Society, received the US National Medal of Science in 2025, and served on the National Advisory Council of the National Institute on Aging (1996-2000). For longevity research, her work connects stem cell biology with drug targets for age-related muscle and joint decline.", "word_count": 193, "sources": ["https://profiles.stanford.edu/helen-blau", "https://doi.org/10.1038/s41573-026-01514-3"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 120, "source_url": "https://scholar.google.com/citations?user=d8-zj3IAAAAJ&hl=en", "note": "Profile 'Helen M. Blau', Donald E. and Delia B. Baxter Foundation Professor; Director Baxter Stem Cell Biology, Stanford (no verified email). All-time h-index.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=d8-zj3IAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Stanford Profiles", "url": "https://profiles.stanford.edu/helen-blau"}]}, "sources": [{"url": "https://profiles.stanford.edu/helen-blau", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=d8-zj3IAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0018", "slug": "vilhelm-bohr", "name": {"display": "Vilhelm Bohr", "sort": "Bohr, Vilhelm"}, "categories": ["scientist", "academic"], "current_title": {"title": "Affiliate Professor in Genome Instability and Neurodegeneration, Department of Cellular and Molecular Medicine (ICMM)", "organisation": "University of Copenhagen", "sources": ["https://icmm.ku.dk/english/research-groups/bohr-group/", "https://www.niagenbioscience.com/pages/leadership"], "source_type": "institution_page", "checked": "2026-09-24", "status": "verified", "note": "The ICMM page gives 'Affiliate Professor in Genome instability and neurodegeneration' with a KU email. Niagen Bioscience's leadership page says 'Dr. Vilhelm Bohr (retired from NIH) is a Professor (AFL) in Molecular Aging at the University of Copenhagen'. Both sources support a University of Copenhagen affiliate professorship. The NIA-based title is not used because Niagen states he has retired from NIH and the NIA lab and section URLs now return 404."}, "other_positions": [{"title": "Former Chief, Laboratory of Molecular Gerontology, and head of the Section on DNA Repair (retired from NIH; the section is still co-listed on 2025-26 paper affiliations)", "organisation": "National Institute on Aging (NIH), Baltimore", "sources": ["https://www.niagenbioscience.com/pages/leadership", "https://www.nia.nih.gov/about/naca/may-2022-directors-status-report", "https://doi.org/10.1038/s41586-026-10940-7", "https://doi.org/10.1038/s41593-026-02390-1"]}, {"title": "Member, advisory group listed on the leadership page (chaired by Roger Kornberg)", "organisation": "Niagen Bioscience (formerly ChromaDex)", "sources": ["https://www.niagenbioscience.com/pages/leadership"]}], "location": {"city": "Copenhagen", "region": "Capital Region", "country_code": "DK", "sources": ["https://icmm.ku.dk/english/research-groups/bohr-group/", "https://doi.org/10.1016/j.jinf.2026.106846"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://icmm.ku.dk/english/research-groups/bohr-group/vilhelmbohr.jpg", "page_url": "https://icmm.ku.dk/english/research-groups/bohr-group/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Vilhelm Bohr is a physician-scientist who studies how DNA repair, mitochondrial biology and energy metabolism interact in aging and age-associated neurodegeneration, including Alzheimer's disease. He is an affiliate professor at the University of Copenhagen's Department of Cellular and Molecular Medicine, part of its Molecular Aging Program, and his 2026 papers also list the Section on DNA Repair at the US National Institute on Aging. His group, with others, has identified NAD+ as a cofactor linking nuclear DNA damage to mitochondrial dysfunction and neurodegeneration, and has reported that NAD+ precursors and compounds that enhance mitophagy (autophagic removal of damaged mitochondria) improve outcomes in animal models, including a mouse model of Alzheimer's disease. Other projects address tau pathology, the mitochondrial role of the DNA repair enzyme aprataxin, and the RecQ helicase RECQL4, mutations in which cause premature-aging syndromes. Recent co-authored work includes a 2026 Nature study reporting that late-life semaglutide slows aging and extends lifespan in female mice, and a Nature Neuroscience paper describing mitochondrial plaques in Alzheimer's disease. For longevity research, his work is a reference point for the genome-maintenance and NAD+/mitophagy view of brain aging.", "word_count": 185, "sources": ["https://icmm.ku.dk/english/research-groups/bohr-group/", "https://researchprofiles.ku.dk/en/persons/vilhelm-bohr/", "https://doi.org/10.1038/s41586-026-10940-7", "https://doi.org/10.1038/s41593-026-02390-1"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "No clearly attributable Google Scholar profile found via search.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Bohr Group, ICMM, University of Copenhagen", "url": "https://icmm.ku.dk/english/research-groups/bohr-group/"}, {"label": "University of Copenhagen research profile", "url": "https://researchprofiles.ku.dk/en/persons/vilhelm-bohr/"}]}, "sources": [{"url": "https://icmm.ku.dk/english/research-groups/bohr-group/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://researchprofiles.ku.dk/en/persons/vilhelm-bohr/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41586-026-10940-7", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41593-026-02390-1", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://www.niagenbioscience.com/pages/leadership", "type": "company_page", "accessed": "2026-09-24"}, {"url": "https://www.nia.nih.gov/about/naca/may-2022-directors-status-report", "type": "institution_page", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0019", "slug": "martin-brand", "name": {"display": "Martin Brand", "sort": "Brand, Martin"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor Emeritus", "organisation": "Buck Institute for Research on Aging", "sources": ["https://www.buckinstitute.org/research/faculty/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Novato", "region": "CA", "country_code": "US", "sources": ["https://doi.org/10.1134/s0006297925602527", "https://doi.org/10.1097/in9.0000000000000085"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.buckinstitute.org/wp-content/uploads/2019/06/BRAND_0081-250x250.jpg", "page_url": "https://www.buckinstitute.org/research/faculty/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Martin Brand is a biochemist who studies mitochondrial energy transformation, energetic inefficiency and free-radical production, and their roles in physiology and the diseases of aging. Trained at the University of Manchester Institute of Science and Technology and the University of Bristol, with postdoctoral work under A.L. Lehninger at Johns Hopkins, he was on the biochemistry faculty at the University of Cambridge and a group leader at the Medical Research Council in Cambridge before moving his laboratory to the Buck Institute in 2008, where he is now professor emeritus. His laboratory helped define site-specific suppressors of mitochondrial reactive oxygen species production, S1QELs (acting at site IQ in complex I) and S3QELs (site IIIQo in complex III), which block superoxide formation at source without impairing oxidative phosphorylation. In a 2025 review he summarises reported benefits of these suppressors in preclinical models of diabetes, cardiac aging, inflammation, ischemia-reperfusion and intestinal barrier dysfunction, and lifespan extension in model organisms. He received the Keilin Medal of the Biochemical Society, an Ellison Medical Foundation senior scholarship, and election as a fellow of the Academy of Medical Sciences, and continues to publish with a Buck affiliation in 2026.", "word_count": 191, "sources": ["https://www.buckinstitute.org/research/faculty/", "https://doi.org/10.1134/s0006297925602527", "https://doi.org/10.1097/in9.0000000000000085"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 120, "source_url": "https://scholar.google.com/citations?user=HZcIGI4AAAAJ&hl=en", "note": "Profile 'Martin D Brand', Buck Institute for Research on Aging; verified email at buckinstitute.org. All-time h-index.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=HZcIGI4AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Buck Institute faculty", "url": "https://www.buckinstitute.org/research/faculty/"}]}, "sources": [{"url": "https://www.buckinstitute.org/research/faculty/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=HZcIGI4AAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1134/s0006297925602527", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1097/in9.0000000000000085", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0020", "slug": "anne-brunet", "name": {"display": "Anne Brunet", "sort": "Brunet, Anne"}, "categories": ["scientist", "academic"], "current_title": {"title": "Michele and Timothy Barakett Endowed Professor; Professor of Genetics", "organisation": "Stanford University", "sources": ["https://profiles.stanford.edu/anne-brunet", "https://profiles.stanford.edu/proxy/api/cap/profiles/6012", "https://scholar.google.com/citations?user=MdORQMcAAAAJ&hl=en"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Stanford", "region": "CA", "country_code": "US", "sources": ["https://profiles.stanford.edu/anne-brunet"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://profiles.stanford.edu/proxy/api/cap/profiles/6012/resources/profilephoto/350x350.1509495936109.jpg", "page_url": "https://profiles.stanford.edu/anne-brunet", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Anne Brunet is a professor of genetics at Stanford University who studies the molecular mechanisms of aging and longevity, with an emphasis on the nervous system. Her laboratory examines how external cues such as nutrient availability and mates influence aging, and how old stem cells, notably the regenerative stem cell pools of the brain, can be rejuvenated, with the aim of reversing features of brain aging and preventing cognitive decline. Earlier work addressed energy- and nutrient-sensing pathways, including FOXO transcription factors and AMPK in dietary-restriction-induced longevity. Her group showed that chromatin modifiers influence lifespan and reported that lifespan extension by chromatin modifiers can be inherited transgenerationally. Brunet's laboratory also developed the naturally short-lived African turquoise killifish as a vertebrate model for aging research, assembling its genome and building a CRISPR/Cas9 pipeline, and has used it to identify candidate genes behind vertebrate lifespan differences and to study 'suspended animation' states. Her recognition includes two NIH Director's Pioneer Awards (2012, 2025), the FNIH Lurie Prize (2022), the NOMIS Award (2023) and election to the American Academy of Arts and Sciences (2025).", "word_count": 179, "sources": ["https://profiles.stanford.edu/anne-brunet", "https://profiles.stanford.edu/proxy/api/cap/profiles/6012"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 99, "source_url": "https://scholar.google.com/citations?user=MdORQMcAAAAJ&hl=en", "note": "Profile 'Anne Brunet', Professor of Genetics, Stanford University; verified email at stanford.edu. All-time h-index.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=MdORQMcAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Stanford Profiles", "url": "https://profiles.stanford.edu/anne-brunet"}]}, "sources": [{"url": "https://profiles.stanford.edu/anne-brunet", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://profiles.stanford.edu/proxy/api/cap/profiles/6012", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=MdORQMcAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0021", "slug": "rochelle-buffenstein", "name": {"display": "Rochelle Buffenstein", "sort": "Buffenstein, Rochelle"}, "categories": ["scientist", "academic"], "current_title": {"title": "Visiting Research Professor, Department of Biological Sciences", "organisation": "University of Illinois Chicago", "sources": ["https://bios.uic.edu/profiles/buffenstein-rochelle/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "UIC first-party title is 'Visiting Research Professor' (Academy of Geroscience says 'Research Professor')."}, "other_positions": [], "location": {"city": "Chicago", "region": "IL", "country_code": "US", "sources": ["https://bios.uic.edu/profiles/buffenstein-rochelle/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://bios.uic.edu/wp-content/uploads/sites/286/2023/11/Rochelle_Buffenstein-revised-157x180.png", "page_url": "https://bios.uic.edu/profiles/buffenstein-rochelle/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Rochelle Buffenstein is a comparative biologist of aging best known for her research on the naked mole-rat, a rodent with an unusually long lifespan for its size and marked resistance to age-related diseases. Her work covers comparative and evolutionary biology of aging, long-lived models of attenuated aging, inflammaging, proteostasis, and cardiac and metabolic aging, asking what molecular mechanisms allow some mammals to maintain healthspan and resist cancer, neurodegeneration and heart disease. She has helped establish the naked mole-rat as a model organism in biomedical research, maintains a large captive colony and has supplied animals to laboratories worldwide. She is a visiting research professor in the Department of Biological Sciences at the University of Illinois Chicago; her 2024 publications listed Calico Life Sciences alongside UIC. Recent work from her group includes studies of the naked mole-rat's unusual immune system, its microbiome in relation to healthy aging and social structure (Cell Reports, 2026), and an autochthonous lung cancer model identifying requirements for cellular transformation in the species (Cancer Discovery, 2026). This work gives longevity research a naturally long-lived mammalian model for studying resistance to aging.", "word_count": 183, "sources": ["https://academyofgeroscience.org/rochelle-buffenstein-phd", "https://bios.uic.edu/profiles/buffenstein-rochelle/", "https://doi.org/10.1016/j.celrep.2026.117265", "https://doi.org/10.1158/2159-8290.cd-25-0526", "https://doi.org/10.1007/s11357-025-01874-5", "https://doi.org/10.1007/s11357-024-01420-9"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 69, "source_url": "https://scholar.google.com/citations?user=ycDY0VQAAAAJ&hl=en", "note": "Profile 'Rochelle Buffenstein', University of Illinois Chicago; verified email at uic.edu. All-time h-index.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=ycDY0VQAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/rochelle-buffenstein-8a604126", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UIC Biological Sciences profile", "url": "https://bios.uic.edu/profiles/buffenstein-rochelle/"}]}, "sources": [{"url": "https://bios.uic.edu/profiles/buffenstein-rochelle/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://academyofgeroscience.org/rochelle-buffenstein-phd", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=ycDY0VQAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.celrep.2026.117265", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1158/2159-8290.cd-25-0526", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1007/s11357-024-01420-9", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0022", "slug": "alex-cagan", "name": {"display": "Alex Cagan", "sort": "Cagan, Alex"}, "categories": ["scientist", "academic"], "current_title": {"title": "University Assistant Professor, Departments of Genetics, Pathology and Veterinary Medicine", "organisation": "University of Cambridge", "sources": ["https://www.gen.cam.ac.uk/people/alex-cagan"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Cambridge", "region": "England", "country_code": "GB", "sources": ["https://www.gen.cam.ac.uk/people/alex-cagan"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.gen.cam.ac.uk/sites/default/files/styles/3_4_sm/public/images/profile/alex_cagan.jpg?h=038a9462&itok=2-_JgRzs", "page_url": "https://www.gen.cam.ac.uk/people/alex-cagan", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Alex Cagan is a University Assistant Professor at the University of Cambridge, with appointments across the Departments of Genetics, Pathology and Veterinary Medicine. His group studies somatic evolution: the mutations that cells in the body accumulate with age, the clonal expansions these can drive, and their consequences for cancer and aging. Using laser capture microdissection and genome sequencing, the group develops methods to map somatic mutational landscapes across diverse species, drawing on comparative evolutionary genomics and samples from collaborations such as London Zoo. In a 2022 Nature study, Cagan and colleagues measured somatic mutation rates in 16 mammalian species and found that the rate at which animals accumulate somatic mutations correlates strongly with lifespan, so that species end their lives with broadly similar mutation burdens; for example, about 800 mutations per year in a mouse cell compared with about 50 in humans. His current work extends this comparative approach to rates of aging, cancer resistance in large, long-lived species (Peto's paradox), and mutational signatures of environmental pollutants. For longevity research, this work links somatic mutation directly to comparative lifespan.", "word_count": 179, "sources": ["https://www.gen.cam.ac.uk/people/alex-cagan", "https://www.gen.cam.ac.uk/cagan-group", "https://www.cam.ac.uk/stories/dr-alex-cagan", "https://www.nature.com/articles/s41586-022-04618-z"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 26, "source_url": "https://scholar.google.com/citations?user=WPvjtpcAAAAJ&hl=en", "note": "Profile 'Alex Cagan' lists former affiliation Wellcome Sanger Institute (verified email at sanger.ac.uk); same researcher (somatic mutation across species). All-time h-index.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=WPvjtpcAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Department of Genetics profile", "url": "https://www.gen.cam.ac.uk/people/alex-cagan"}, {"label": "Cagan Group", "url": "https://www.gen.cam.ac.uk/cagan-group"}]}, "sources": [{"url": "https://www.gen.cam.ac.uk/people/alex-cagan", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.gen.cam.ac.uk/cagan-group", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.cam.ac.uk/stories/dr-alex-cagan", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=WPvjtpcAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://www.nature.com/articles/s41586-022-04618-z", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0023", "slug": "joseph-castellano", "name": {"display": "Joseph Castellano", "sort": "Castellano, Joseph"}, "categories": ["scientist", "academic"], "current_title": {"title": "Associate Professor of Neuroscience", "organisation": "Icahn School of Medicine at Mount Sinai", "sources": ["https://www.castellanolab.org/investigator", "https://scholar.google.com/citations?user=fLrAHw8AAAAJ&hl=en"], "source_type": "lab_page", "checked": "2026-09-23", "status": "verified", "note": "Roster's 'Nash Family Department of Neuroscience' not re-confirmed on pages read; lab page and Scholar give Associate Professor of Neuroscience / Icahn School of Medicine at Mount Sinai."}, "other_positions": [], "location": {"city": "New York", "region": "NY", "country_code": "US", "sources": ["https://profiles.icahn.mssm.edu/joseph-m-castellano"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.mountsinai.org/files/images/fad-images/0000076810066569029931.jpg", "page_url": "https://profiles.icahn.mssm.edu/joseph-m-castellano", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Joseph Castellano is an associate professor of neuroscience at the Icahn School of Medicine at Mount Sinai whose laboratory studies how blood-borne factors influence brain aging and Alzheimer's disease. During his PhD with David Holtzman at Washington University in St. Louis he used in vivo microdialysis in mice to show that clearance of amyloid beta is slowed in the presence of ApoE4, the strongest genetic risk factor for Alzheimer's disease, compared with more protective ApoE forms. As a postdoctoral fellow in Tony Wyss-Coray's group at Stanford, he found that treatment with neonatal plasma revitalises hippocampal function in aged mice, part of the body of work on youth-associated plasma factors that reverse features of brain aging. His group now focuses on such circulating proteins, particularly TIMP2 (tissue inhibitor of metalloproteinases 2), and how they act on the extracellular matrix and neural circuits. A 2026 Nature Communications study from his lab reports that deleting TIMP2 in mice worsens aging-associated microglial phenotypes, including inflammation and impaired phagocytosis. His NIH/NIA-funded work examines mechanisms of youth-associated blood-borne factors in central nervous system rejuvenation.", "word_count": 178, "sources": ["https://www.castellanolab.org/investigator", "https://profiles.icahn.mssm.edu/joseph-m-castellano", "https://doi.org/10.1038/s41467-026-74906-z"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 22, "source_url": "https://scholar.google.com/citations?user=fLrAHw8AAAAJ&hl=en", "note": "Profile 'Joseph M. Castellano', Associate Professor, Icahn School of Medicine at Mount Sinai; verified email at mssm.edu. All-time h-index.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=fLrAHw8AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Castellano Laboratory", "url": "https://www.castellanolab.org/investigator"}, {"label": "Icahn School of Medicine profile", "url": "https://profiles.icahn.mssm.edu/joseph-m-castellano"}]}, "sources": [{"url": "https://www.castellanolab.org/investigator", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://profiles.icahn.mssm.edu/joseph-m-castellano", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=fLrAHw8AAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41467-026-74906-z", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0024", "slug": "george-church", "name": {"display": "George Church", "sort": "Church, George"}, "categories": ["scientist", "academic", "entrepreneur"], "current_title": {"title": "Robert Winthrop Professor of Genetics", "organisation": "Harvard Medical School", "sources": ["https://wyss.harvard.edu/team/core-faculty/george-church/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Only Rejuvenate Bio verified among aging-focused companies; other company co-founder roles not researched here."}, "other_positions": [{"title": "Founding Core Faculty and Lead, Synthetic Biology", "organisation": "Wyss Institute at Harvard University", "sources": ["https://wyss.harvard.edu/team/core-faculty/george-church/"]}, {"title": "Professor of Health Sciences and Technology", "organisation": "Harvard and MIT", "sources": ["https://wyss.harvard.edu/team/core-faculty/george-church/"]}, {"title": "Co-Founder and Scientific Advisory Board", "organisation": "Rejuvenate Bio", "sources": ["https://rejuvenatebio.com/team"]}], "location": {"city": "Boston", "region": "MA", "country_code": "US", "sources": ["https://wyss.harvard.edu/team/core-faculty/george-church/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://wyss-prod.imgix.net/app/uploads/2016/08/05095301/George_Church_headshot_1500x1000.jpg?auto=format%2Ccompress&crop=faces&fit=crop&h=370&w=650&s=03a3ab48e3cd5213b453184078d902ff", "page_url": "https://wyss.harvard.edu/team/core-faculty/george-church/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "George Church is the Robert Winthrop Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard and MIT, and founding core faculty member and lead of Synthetic Biology at the Wyss Institute. His contributions to genomics include the first direct genomic sequencing method (1984), which produced the first genome sequence, of the pathogen H. pylori; he helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. At the Wyss Institute his group works on directed evolution of molecules, polymers and whole genomes, and on faster, cheaper gene synthesis and genome engineering. In the longevity field he co-founded Rejuvenate Bio, launched from his laboratory in 2018, where he serves on the scientific advisory board. The San Diego company develops gene therapies aimed at extending healthy lifespan and treating age-related and chronic disease, initially in companion animals such as dogs with mitral valve disease, with the stated aim of eventual human applications; in 2026 it announced a research collaboration with Merck Animal Health. Church is a member of the US National Academy of Sciences and received the 2011 Bower Award and Prize for Achievement in Science.", "word_count": 194, "sources": ["https://wyss.harvard.edu/team/core-faculty/george-church/", "https://rejuvenatebio.com/team", "https://rejuvenatebio.com/press-releases/series", "https://rejuvenatebio.com/press-releases/rejuvenate-bio-announces-6-million-financing-and-strategic-rampd-collaboration-with-merck-animal-health"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 229, "source_url": "https://scholar.google.com/citations?user=SfDzdgEAAAAJ&hl=en", "note": "Profile 'George Church', Harvard Medical School; verified email at harvard.edu. All-time h-index.", "checked": "2026-09-23", "status": "verified"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Rejuvenate Bio", "label": "Rejuvenate Bio publicly disclosed Series A funding (2021)", "value": 10000000, "currency": "USD", "scope": "single_round", "source_url": "https://rejuvenatebio.com/press-releases/series", "checked": "2026-09-23", "status": "verified", "note": "Company release: 'raised over $10 million in a Series A funding round led by Kendall Capital Partners' (Apr 2021). Value is the stated lower bound ('over $10 million')."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Rejuvenate Bio", "label": "Rejuvenate Bio publicly disclosed financing round (Jun 2026)", "value": 6000000, "currency": "USD", "scope": "single_round", "source_url": "https://rejuvenatebio.com/press-releases/rejuvenate-bio-announces-6-million-financing-and-strategic-rampd-collaboration-with-merck-animal-health", "checked": "2026-09-23", "status": "verified", "note": "Company release (Business Wire, Jun 2026): closing of a $6 million financing round led by VCapital, with Merck Animal Health, Kendall Capital Partners, Connecticut Innovations and Digitalis. No cumulative total stated by the company."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=SfDzdgEAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/george-church-2b86301/", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Wyss Institute profile", "url": "https://wyss.harvard.edu/team/core-faculty/george-church/"}, {"label": "Harvard Medical School Genetics", "url": "https://genetics.hms.harvard.edu/faculty-staff/george-church"}, {"label": "Rejuvenate Bio team", "url": "https://rejuvenatebio.com/team"}]}, "sources": [{"url": "https://wyss.harvard.edu/team/core-faculty/george-church/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://rejuvenatebio.com/team", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://rejuvenatebio.com/press-releases/series", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://rejuvenatebio.com/press-releases/rejuvenate-bio-announces-6-million-financing-and-strategic-rampd-collaboration-with-merck-animal-health", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=SfDzdgEAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0025", "slug": "gary-churchill", "name": {"display": "Gary Churchill", "sort": "Churchill, Gary"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor, Karl Gunnar Johansson Endowed Chair", "organisation": "The Jackson Laboratory", "sources": ["https://www.jax.org/research-and-faculty/faculty/gary-churchill"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Bar Harbor", "region": "ME", "country_code": "US", "sources": ["https://www.jax.org/research-and-faculty/faculty/gary-churchill"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://media.jax.org/m/ae3fc9ff9a9b1b97/webimage-churchill_gary_mg_1159.png?w=400&h=400&fit=crop&fm=webp&q=80", "page_url": "https://www.jax.org/research-and-faculty/faculty/gary-churchill", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Gary Churchill is a statistical geneticist at The Jackson Laboratory in Bar Harbor, Maine, where he holds the Karl Gunnar Johansson Endowed Chair. His laboratory takes a systems approach to the genetics of health and disease in the mouse, developing statistical methods and software for quantitative trait locus mapping and gene-expression analysis. He has been involved in establishing two genetically diverse mouse resources for complex-trait analysis, the Collaborative Cross and the Diversity Outbred population. In aging research, these resources underpin large lifespan studies in which genetic background can be analysed alongside interventions. A 2024 Nature study, with Churchill as senior author, assessed graded caloric restriction (20% and 40%) and intermittent fasting in 960 genetically diverse female mice, finding that lifespan extension scaled with the degree of restriction, that genetics influenced lifespan more than diet, and that health effects did not consistently track lifespan gains. Related work has mapped longevity-associated loci across Diversity Outbred studies (Genetics, 2025) and linked longitudinal body-weight traits to lifespan (Nature Communications, 2026). For longevity research, his work applies population-scale mouse genetics to testing how genetic diversity shapes responses to anti-aging interventions.", "word_count": 185, "sources": ["https://www.jax.org/research-and-faculty/faculty/gary-churchill", "https://doi.org/10.1038/s41586-024-08026-3", "https://doi.org/10.1093/genetics/iyaf081", "https://doi.org/10.1038/s41467-026-68392-6"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 101, "source_url": "https://scholar.google.com/citations?user=lfdvCjEAAAAJ&hl=en", "note": "Profile 'Gary Churchill', The Jackson Laboratory; verified email at jax.org. All-time h-index.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=lfdvCjEAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "JAX faculty profile", "url": "https://www.jax.org/research-and-faculty/faculty/gary-churchill"}]}, "sources": [{"url": "https://www.jax.org/research-and-faculty/faculty/gary-churchill", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=lfdvCjEAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41586-024-08026-3", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1093/genetics/iyaf081", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41467-026-68392-6", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0026", "slug": "pinchas-cohen", "name": {"display": "Pinchas Cohen", "sort": "Cohen, Pinchas"}, "categories": ["scientist", "academic"], "current_title": {"title": "Dean, USC Leonard Davis School of Gerontology; Distinguished Professor of Gerontology, Medicine and Biological Sciences", "organisation": "University of Southern California", "sources": ["https://gero.usc.edu/faculty/cohen/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Executive Director", "organisation": "Ethel Percy Andrus Gerontology Center", "sources": ["https://gero.usc.edu/faculty/cohen/"]}, {"title": "Director", "organisation": "Ney Center for Healthspan Science", "sources": ["https://gero.usc.edu/faculty/cohen/"]}, {"title": "Co-founder", "organisation": "CohBar", "sources": ["https://gero.usc.edu/faculty/cohen/"]}], "location": {"city": "Los Angeles", "region": "CA", "country_code": "US", "sources": ["https://gero.usc.edu/faculty/cohen/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://gero.usc.edu/wp-content/uploads/2016/01/DeanCohen-edited-e1739583904337-272x297.jpg", "page_url": "https://gero.usc.edu/faculty/cohen/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Pinchas Cohen is a physician-scientist and dean of the USC Leonard Davis School of Gerontology, where he also holds the William and Sylvia Kugel Dean's Chair, serves as executive director of the Ethel Percy Andrus Gerontology Center and directs the Ney Center for Healthspan Science. He is a USC Distinguished Professor of Gerontology, Medicine and Biological Sciences. His research centres on mitochondria-derived peptides, a class of signalling microproteins encoded in the mitochondrial genome that his work helped discover. These include humanin, a 24-amino-acid peptide from the mt-16S rRNA region that acts as an insulin sensitiser and metaboloprotective factor; MOTS-c, encoded in the 12S region, with anti-diabetes and anti-obesity effects described as exercise-mimetic; and SHLP2, whose levels correlate with prostate cancer. He holds patents on novel peptides and co-founded CohBar, a company developing mitochondrial peptides for diabetes. Before joining USC in 2012 he was professor and vice chair for research at UCLA's Mattel Children's Hospital and co-director of the UCSD/UCLA Diabetes Research Center. His recognitions include an NIA EUREKA Award, an NIH Director's Transformative R01, the GSA Kleemeier Award and AFAR's Irving S. Wright Award.", "word_count": 184, "sources": ["https://gero.usc.edu/faculty/cohen/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 113, "source_url": "https://scholar.google.com/citations?user=W1wn0zAAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All column. Genuine profile: 'Dean, Davis School of Gerontology, University of Southern California', verified usc.edu; papers are his IGF/IGFBP, humanin, MOTS-c and mitochondrial-derived peptide work. The second USC-labelled profile (user=jR2SwZ4AAAAJ, h 117, i10 1018) is a merged record dominated by other authors (e.g. NP Singh/EL Schneider comet assay 1988, JF Fries, many 'P Chen' papers in physics, engineering and medicine) and was not used."}, {"kind": "h_index", "for_category": "doctor", "platform": "google_scholar", "value": 113, "source_url": "https://scholar.google.com/citations?user=W1wn0zAAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All column. Genuine profile: 'Dean, Davis School of Gerontology, University of Southern California', verified usc.edu; papers are his IGF/IGFBP, humanin, MOTS-c and mitochondrial-derived peptide work. The second USC-labelled profile (user=jR2SwZ4AAAAJ, h 117, i10 1018) is a merged record dominated by other authors (e.g. NP Singh/EL Schneider comet assay 1988, JF Fries, many 'P Chen' papers in physics, engineering and medicine) and was not used."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=W1wn0zAAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "USC Leonard Davis School faculty page", "url": "https://gero.usc.edu/faculty/cohen/"}]}, "sources": [{"url": "https://gero.usc.edu/faculty/cohen/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=W1wn0zAAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=jR2SwZ4AAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0027", "slug": "irina-conboy", "name": {"display": "Irina Conboy", "sort": "Conboy, Irina"}, "categories": ["scientist", "academic", "entrepreneur"], "current_title": {"title": "Co-Founder and Chief Science Officer", "organisation": "Generation Lab", "sources": ["https://www.generationlab.com/about", "https://www.nature.com/articles/s41551-026-01618-6"], "source_type": "company_page", "checked": "2026-09-24", "status": "verified", "note": "Generation Lab's About page lists her as 'Co-Founder & CSO'. Its blurb still calls her 'UC Berkeley Bioengineering Professor', but UC Berkeley's own Bioengineering faculty listing (core, joint, emeritus, adjunct and affiliated) no longer includes her, and Berkeley's California magazine (Fall 2026) calls her a 'former longtime Berkeley professor'. The Berkeley role is therefore recorded as former."}, "other_positions": [{"title": "Professor of Bioengineering (former)", "organisation": "University of California, Berkeley, Department of Bioengineering and QB3", "sources": ["https://alumni.berkeley.edu/california-magazine/2026-fall/research-radar-fall-2026/", "https://bioeng.berkeley.edu/people", "https://bioeng.berkeley.edu/news/conboy-lab-continues-to-make-strides-against-aging"]}], "location": {"city": "Burlingame", "region": "CA", "country_code": "US", "sources": ["https://www.generationlab.com/", "https://doi.org/10.1111/acel.70525"], "checked": "2026-09-24", "status": "verified", "note": "The Generation Lab website footer gives '1701 Old Bayshore Highway, Burlingame, CA 94010'. This matches the Aging Cell 2026 affiliation; Nature BME 2026 gives San Francisco, which is likely shorthand for the Bay Area."}, "photo": {"status": "found", "image_url": "https://www.generationlab.com/_next/image?url=%2Fabout%2Ffounders%2FIrina.webp&w=640&q=75", "page_url": "https://www.generationlab.com/about", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Irina Conboy studies how the systemic environment of blood controls stem-cell ageing and tissue repair. With Michael Conboy, Thomas Rando and colleagues she was first author of the 2005 Nature study showing that heterochronic parabiosis, joining the circulation of young and old mice, restored the regenerative capacity of aged muscle and liver progenitor cells. Her group later reported that diluting old plasma with saline-albumin, rather than adding young blood, rejuvenated several mouse tissues (Aging, 2020), and published a clinical study of therapeutic plasma exchange and biological age markers (GeroScience, 2022). Recent work includes human microphysiological 'aging-on-a-chip' systems for testing anti-geronic interventions (Nature Biomedical Engineering, 2026). In 2023 she co-founded Generation Lab, a company offering biological-age testing, where she is Chief Science Officer; the company announced an $11 million seed round led by Accel in 2025. Her long-held professorship in Bioengineering at UC Berkeley is described inconsistently across 2026 sources.", "word_count": 149, "sources": ["https://doi.org/10.1038/nature03260", "https://doi.org/10.18632/aging.103418", "https://doi.org/10.1007/s11357-022-00645-w", "https://www.nature.com/articles/s41551-026-01618-6", "https://www.generationlab.com/about", "https://fortune.com/2025/10/23/generation-lab-raises-11-million-becoming-accels-first-longevity-bet/", "https://alumni.berkeley.edu/california-magazine/2026-fall/research-radar-fall-2026/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": "https://scholar.google.com/citations?user=iE9XrasAAAAJ", "checked": "2026-09-23", "status": "unavailable", "note": "Scholar profile iE9XrasAAAAJ (found via search, labelled UC Berkeley) returned HTTP 404 on 2026-09-23; no other attributable profile found"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Generation Lab", "label": "Generation Lab publicly reported total funding (as of Oct 2025)", "value": 15000000, "currency": "USD", "scope": "total_disclosed", "source_url": "https://fortune.com/2025/10/23/generation-lab-raises-11-million-becoming-accels-first-longevity-bet/", "checked": "2026-09-23", "status": "verified", "note": "Fortune (23 Oct 2025): $11M seed round led by Accel brings the company's total funding to $15M."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Generation Lab - About", "url": "https://www.generationlab.com/about"}]}, "sources": [{"url": "https://www.generationlab.com/about", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.nature.com/articles/s41551-026-01618-6", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1111/acel.70525", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.18632/aging.206399", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://alumni.berkeley.edu/california-magazine/2026-fall/research-radar-fall-2026/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://fortune.com/2025/10/23/generation-lab-raises-11-million-becoming-accels-first-longevity-bet/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://bioeng.berkeley.edu/news/conboy-lab-continues-to-make-strides-against-aging", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/nature03260", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://www.generationlab.com/", "type": "company_page", "accessed": "2026-09-24"}, {"url": "https://bioeng.berkeley.edu/people", "type": "institution_page", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0028", "slug": "michael-conboy", "name": {"display": "Michael Conboy", "sort": "Conboy, Michael"}, "categories": ["scientist", "academic"], "current_title": {"title": "Research Scientist and Lecturer, Department of Bioengineering", "organisation": "University of California, Berkeley (Department of Bioengineering and QB3 Institute)", "sources": ["https://engineering.berkeley.edu/news/2023/05/forever-young/", "https://doi.org/10.18632/aging.206399"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Berkeley", "region": "CA", "country_code": "US", "sources": ["https://doi.org/10.18632/aging.206399", "https://scholar.google.com/citations?user=A1TtFs8AAAAJ"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "unavailable", "image_url": null, "page_url": null, "source_type": "", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Michael Conboy is a research scientist and lecturer in the Department of Bioengineering at UC Berkeley, where he works in the Conboy laboratory on stem-cell ageing and systemic regulation of tissue repair. He was a co-author of the 2005 Nature heterochronic parabiosis study showing that exposure to a young circulation restored regenerative capacity in aged mouse muscle and liver progenitor cells. As first author with Thomas Rando, he reported non-random template DNA strand segregation and asymmetric fate determination in dividing muscle stem cells (PLoS Biology, 2007). He co-authored the lab's later work on diluting old plasma with saline-albumin in mice (Aging, 2020) and a clinical study of plasma dilution and biological-age markers in humans (GeroScience, 2022). His 2026 papers, all with a UC Berkeley Bioengineering and QB3 affiliation, cover plasma dilution after cardiac ischaemia-reperfusion injury, human aging-on-a-chip models, and metabolic targeting of cancer and senescent cells in old mice.", "word_count": 149, "sources": ["https://engineering.berkeley.edu/news/2023/05/forever-young/", "https://doi.org/10.1038/nature03260", "https://doi.org/10.1371/journal.pbio.0050102", "https://doi.org/10.18632/aging.103418", "https://doi.org/10.1007/s11357-022-00645-w", "https://doi.org/10.1111/acel.70525", "https://doi.org/10.1038/s41551-026-01618-6", "https://doi.org/10.18632/aging.206399"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 32, "source_url": "https://scholar.google.com/citations?user=A1TtFs8AAAAJ", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Michael J. Conboy', QB3 Institute and Dept. of Bioengineering, UC Berkeley, verified berkeley.edu email; All column (since-2021: 27)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=A1TtFs8AAAAJ", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/michael-conboy-70889510", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UC Berkeley Engineering feature on the Conboy lab (2023)", "url": "https://engineering.berkeley.edu/news/2023/05/forever-young/"}]}, "sources": [{"url": "https://engineering.berkeley.edu/news/2023/05/forever-young/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=A1TtFs8AAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.18632/aging.206399", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1111/acel.70525", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41551-026-01618-6", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1371/journal.pbio.0050102", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/nature03260", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0029", "slug": "eileen-crimmins", "name": {"display": "Eileen Crimmins", "sort": "Crimmins, Eileen"}, "categories": ["scientist", "academic"], "current_title": {"title": "University Professor and AARP Chair in Gerontology", "organisation": "USC Leonard Davis School of Gerontology, University of Southern California", "sources": ["https://gero.usc.edu/faculty/crimmins/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Co-Director, USC/UCLA Center on Biodemography and Population Health", "organisation": "USC/UCLA", "sources": ["https://gero.usc.edu/faculty/crimmins/"]}, {"title": "Senior Fellow", "organisation": "USC Schaeffer Center", "sources": ["https://gero.usc.edu/faculty/crimmins/"]}], "location": {"city": "Los Angeles", "region": "CA", "country_code": "US", "sources": ["https://gero.usc.edu/faculty/crimmins/", "https://doi.org/10.1002/alz.71729"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://gero.usc.edu/wp-content/uploads/2015/07/Eileen-Crimmins1.jpg", "page_url": "https://gero.usc.edu/faculty/crimmins/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Eileen Crimmins is a demographer whose work on changes over time in health and mortality underpins much of the population-level evidence on how people age. At the USC Leonard Davis School of Gerontology she is University Professor and holds the AARP Chair in Gerontology. She has been instrumental in integrating biological indicators into large population surveys, which lets researchers link biomarkers of physiological ageing to social and economic conditions in representative samples. She co-directs the USC/UCLA Center on Biodemography and Population Health, one of the NIA-supported Demography of Aging Centers, and the NIA-sponsored Network on Biological Risk. She co-chaired a National Academy of Sciences committee on why US life expectancy lags other high-income countries, and has co-edited books on health expectancy, longevity and international mortality differences. She is a member of the National Academy of Sciences and the National Academy of Medicine and has received the Gerontological Society of America's Kleemeier Award and the Population Association of America's Irene B. Taeuber Award. Her 2026 publications include work on blood biomarkers of neuropathology, socioeconomic status and cognition.", "word_count": 176, "sources": ["https://gero.usc.edu/faculty/crimmins/", "https://doi.org/10.1002/alz.71729"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 112, "source_url": "https://scholar.google.com/citations?user=0aj9ZoEAAAAJ", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Eileen Crimmins', University of Southern California; All column (since-2021: 78)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=0aj9ZoEAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "USC Leonard Davis faculty profile", "url": "https://gero.usc.edu/faculty/crimmins/"}]}, "sources": [{"url": "https://gero.usc.edu/faculty/crimmins/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=0aj9ZoEAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1002/alz.71729", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.isci.2026.117256", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0030", "slug": "ana-maria-cuervo", "name": {"display": "Ana Maria Cuervo", "sort": "Cuervo, Ana Maria"}, "categories": ["scientist", "academic"], "current_title": {"title": "Distinguished Professor of Developmental & Molecular Biology and of Medicine; Robert and Renée Belfer Chair for the Study of Neurodegenerative Diseases; Co-Director, Institute for Geroscience", "organisation": "Albert Einstein College of Medicine", "sources": ["https://einsteinmed.edu/faculty/8784/ana-maria-cuervo"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Co-Editor-in-Chief", "organisation": "Aging Cell", "sources": ["https://einsteinmed.edu/faculty/8784/ana-maria-cuervo"]}], "location": {"city": "Bronx", "region": "NY", "country_code": "US", "sources": ["https://einsteinmed.edu/faculty/8784/ana-maria-cuervo", "https://doi.org/10.1080/15548627.2026.2672700"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://assets.montefioreeinstein.org/profiles/images/Cuervo_Ana_Maria_2x.jpg", "page_url": "https://einsteinmed.edu/faculty/8784/ana-maria-cuervo", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Ana Maria Cuervo studies how cells degrade and recycle proteins through lysosomes, and how failure of these autophagy pathways contributes to ageing and age-related disease. Her laboratory at Albert Einstein College of Medicine, founded in 2001, is best known for work on chaperone-mediated autophagy (CMA), a selective lysosomal pathway. Key findings include impaired degradation of mutant alpha-synuclein by CMA (Science, 2004), evidence that restoring CMA in aged mouse liver improves cellular maintenance and organ function (Nature Medicine, 2008), and the discovery that autophagy regulates lipid metabolism (Nature, 2009). Her group has linked defective autophagy to Parkinson's, Alzheimer's and Huntington's disease and to metabolic disorders, and has developed chemical modulators and reporters of CMA. She is Distinguished Professor of Developmental and Molecular Biology and of Medicine, holds the Robert and Renée Belfer Chair for the Study of Neurodegenerative Diseases, and co-directs Einstein's Institute for Geroscience. She is co-editor-in-chief of Aging Cell, has served on NIH advisory bodies including the NIA Board of Scientific Counselors, and is a member of the US National Academy of Sciences and the American Academy of Arts and Sciences.", "word_count": 182, "sources": ["https://einsteinmed.edu/faculty/8784/ana-maria-cuervo", "https://doi.org/10.1080/15548627.2026.2672700"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 149, "source_url": "https://scholar.google.com/citations?user=f9nCCogAAAAJ", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Ana Maria Cuervo', Albert Einstein College of Medicine; All column (since-2021: 107). A separate 'Ana Cuervo' profile (CSIC postdoc) is a different person"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=f9nCCogAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Einstein faculty profile", "url": "https://einsteinmed.edu/faculty/8784/ana-maria-cuervo"}]}, "sources": [{"url": "https://einsteinmed.edu/faculty/8784/ana-maria-cuervo", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=f9nCCogAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1080/15548627.2026.2672700", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0031", "slug": "rafael-de-cabo", "name": {"display": "Rafael de Cabo", "sort": "de Cabo, Rafael"}, "categories": ["scientist"], "current_title": {"title": "Senior Investigator and Chief, Translational Gerontology Branch", "organisation": "National Institute on Aging (NIH Intramural Research Program)", "sources": ["https://irp.nih.gov/pi/rafael-de-cabo"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Baltimore", "region": "MD", "country_code": "US", "sources": ["https://doi.org/10.1111/acel.70664", "https://irp.nih.gov/pi/rafael-de-cabo"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://i.irp.nih.gov/pi/0011074915.jpg", "page_url": "https://irp.nih.gov/pi/rafael-de-cabo", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Rafael de Cabo leads research at the US National Institute on Aging on how nutritional and pharmacological interventions affect the basic biology of ageing. He is a senior investigator and Chief of the NIA's Translational Gerontology Branch, where his Experimental Gerontology Section combines whole-body physiology with tissue-level molecular work in mice and rhesus monkeys. Over more than two decades his group has published widely cited studies on caloric restriction, time-restricted feeding and intermittent fasting, and on candidate geroprotective compounds including resveratrol and other sirtuin-activating compounds, metformin and disulfiram. Recent work has examined how fasting duration interacts with caloric restriction in female mice (Cell Metabolism, 2023), whether taurine is a biomarker of ageing (Science, 2025), and how calorie restriction and exercise interact in a breast cancer model (PNAS, 2026). His stated aim is to identify interventions that extend both healthspan and lifespan with translational potential for humans. His honours include the American Federation for Aging Research Irving S. Wright Award of Distinction (2023).", "word_count": 162, "sources": ["https://irp.nih.gov/pi/rafael-de-cabo", "https://doi.org/10.1111/acel.70664"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 132, "source_url": "https://scholar.google.com/citations?user=e99pY2sAAAAJ", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Rafael De Cabo', Translational Gerontology Branch, National Institute on Aging; All column (since-2021: 91)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=e99pY2sAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "NIH IRP investigator profile", "url": "https://irp.nih.gov/pi/rafael-de-cabo"}]}, "sources": [{"url": "https://irp.nih.gov/pi/rafael-de-cabo", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=e99pY2sAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1111/acel.70664", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/d41586-026-02468-7", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0032", "slug": "aubrey-de-grey", "name": {"display": "Aubrey de Grey", "sort": "de Grey, Aubrey"}, "categories": ["entrepreneur", "communicator", "scientist"], "current_title": {"title": "President and Chief Science Officer", "organisation": "LEV (Longevity Escape Velocity) Foundation", "sources": ["https://www.levf.org/team", "https://www.levf.org/aubreydegrey"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Editor Emeritus", "organisation": "Rejuvenation Research", "sources": ["https://www.levf.org/aubreydegrey"]}], "location": {"city": "San Francisco", "region": "CA", "country_code": "US", "sources": ["https://doi.org/10.18632/aging.206228"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://images.squarespace-cdn.com/content/v1/6359ac1b0afbb03499b805be/3ceb7ef4-ae0c-4470-aa44-c108261fd799/aubrey_degrey.jpg", "page_url": "https://www.levf.org/team", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Aubrey de Grey is a biomedical gerontologist who proposed the Strategies for Engineered Negligible Senescence (SENS), a framework that groups age-related molecular and cellular damage into seven categories and argues each could be repaired therapeutically. He set this out in academic papers and in the book Ending Aging (2007, with Michael Rae). He co-founded the Methuselah Foundation (2001), which ran the Methuselah Mouse Prize, and SENS Research Foundation (2009), which funded rejuvenation research and helped launch companies including Cyclarity and Oisín Biotechnologies. He edited the journal Rejuvenation Research from 2004 until 2022 and organised the SENS conference series and later longevity meetings. In 2022 he founded the LEV Foundation, where he is President and Chief Science Officer; its flagship Robust Mouse Rejuvenation programme tests combinations of interventions in mice. He holds a PhD in biology from the University of Cambridge.", "word_count": 140, "sources": ["https://www.levf.org/team", "https://www.levf.org/aubreydegrey", "https://www.statnews.com/2021/08/22/sens-research-foundation-removes-aubrey-de-grey/", "https://www.statnews.com/2021/11/09/anti-aging-research-foundation-stands-by-ouster-of-aubrey-de-grey-after-investigation-concludes/", "https://doi.org/10.1080/14728222.2024.2330425"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No attributable Google Scholar profile found via search"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "LEV Foundation", "label": "LEV Foundation publicly reported donations (total)", "value": null, "currency": "USD", "scope": "total_disclosed", "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "Non-profit (EIN 93-2716970). No donation or fundraising total stated by the foundation or reputable press. Its first IRS Form 990 (tax period ending Dec 2023, ProPublica) reports $480,000 contributions for a partial first year; this is an annual filing figure, not a fundraising total, so not recorded. Individual gifts are publicised (e.g. EUR 200,000 from Didier Coeurnelle, Oct 2024). LEVF page states SENS Research Foundation received >$27M from the 2021 PulseChain airdrop (donation to SRF, not LEVF)."}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "Candidate @aubreydegrey (bio: 'President and CSO of levf.org', ~74K followers via api.fxtwitter.com) is not linked from any first-party page checked (levf.org biography/team pages link only LEVF accounts). Not recorded."}, {"kind": "audience", "for_category": "communicator", "platform": "instagram", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "Candidate @aubreydegrey (Instagram) not linked from a first-party page; not recorded."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "LEV Foundation team", "url": "https://www.levf.org/team"}, {"label": "LEV Foundation biography", "url": "https://www.levf.org/aubreydegrey"}]}, "sources": [{"url": "https://www.levf.org/team", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.levf.org/aubreydegrey", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.18632/aging.206228", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1080/14728222.2024.2330425", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://www.statnews.com/2021/08/22/sens-research-foundation-removes-aubrey-de-grey/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://www.statnews.com/2021/11/09/anti-aging-research-foundation-stands-by-ouster-of-aubrey-de-grey-after-investigation-concludes/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://firstwordpharma.com/story/5380563", "type": "news", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0033", "slug": "titia-de-lange", "name": {"display": "Titia de Lange", "sort": "de Lange, Titia"}, "categories": ["scientist", "academic"], "current_title": {"title": "Leon Hess Professor; Head, Laboratory of Cell Biology and Genetics; Director, Anderson Center for Cancer Research", "organisation": "The Rockefeller University", "sources": ["https://www.rockefeller.edu/our-scientists/heads-of-laboratories/871-titia-de-lange/", "https://doi.org/10.1038/s41576-026-01001-w"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "New York", "region": "NY", "country_code": "US", "sources": ["https://www.rockefeller.edu/our-scientists/heads-of-laboratories/871-titia-de-lange/", "https://doi.org/10.1038/s41576-026-01001-w"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.rockefeller.edu/uploads/www.rockefeller.edu/sites/4/2020/04/deLange_2400x1200.1585931096.jpg", "page_url": "https://www.rockefeller.edu/our-scientists/heads-of-laboratories/871-titia-de-lange/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Titia de Lange studies telomeres, the protective structures at chromosome ends that shorten with cell division and are central to cellular ageing, replicative senescence and cancer. Her laboratory at The Rockefeller University identified shelterin, the six-subunit protein complex that binds telomeric DNA, and showed that without shelterin cells treat their natural chromosome ends as damaged DNA. The lab has mapped how individual shelterin subunits repress distinct DNA damage response pathways, including ATM and ATR signalling and both homology-directed and non-homologous end-joining repair, and identified the telomeric t-loop structure that hides chromosome ends. More recent work covers how the CST-polymerase alpha-primase complex maintains telomeric DNA, including a 'second end-replication problem' (Nature, 2024), how telomere crisis drives chromothripsis in cancer, and evidence that telomere shortening acts as a tumour-suppressor mechanism. She is the Leon Hess Professor, heads the Laboratory of Cell Biology and Genetics, and has directed Rockefeller's Anderson Center for Cancer Research since 2011. Her honours include the Canada Gairdner International Award (2014) and membership of the US National Academy of Medicine and the Royal Society.", "word_count": 175, "sources": ["https://www.rockefeller.edu/our-scientists/heads-of-laboratories/871-titia-de-lange/", "https://doi.org/10.1038/s41576-026-01001-w"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No attributable Google Scholar profile found via two searches"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Rockefeller University lab profile", "url": "https://www.rockefeller.edu/our-scientists/heads-of-laboratories/871-titia-de-lange/"}]}, "sources": [{"url": "https://www.rockefeller.edu/our-scientists/heads-of-laboratories/871-titia-de-lange/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41576-026-01001-w", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0034", "slug": "joao-pedro-de-magalhaes", "name": {"display": "João Pedro de Magalhães", "sort": "de Magalhães, João Pedro"}, "categories": ["scientist", "academic", "communicator"], "current_title": {"title": "Professor and Chair of Molecular Biogerontology; Lead, Genomics of Ageing and Rejuvenation Lab", "organisation": "University of Birmingham (Department of Inflammation and Ageing)", "sources": ["https://www.birmingham.ac.uk/staff/profiles/inflammation-ageing/magalhaes-pedro"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Birmingham", "region": "England", "country_code": "GB", "sources": ["https://www.birmingham.ac.uk/staff/profiles/inflammation-ageing/magalhaes-pedro"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://rejuvenomicslab.com/wp-content/uploads/2021/12/joao-pedro-de-magalhaes-premiado-catolica-porto-e1640690686643.jpeg.webp", "page_url": "https://rejuvenomicslab.com/", "source_type": "lab_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "João Pedro de Magalhães uses genomics and bioinformatics to study the ageing process and how it might be manipulated to prevent age-related disease. After a PhD at the University of Namur and a postdoctoral post with George Church at Harvard Medical School, he established a group on genomic approaches to ageing at the University of Liverpool in 2008 and moved to the University of Birmingham in 2022 as Chair of Molecular Biogerontology, where he leads the Genomics of Ageing and Rejuvenation Lab. His group maintains the Human Ageing Genomic Resources (HAGR), a set of openly available databases on ageing genetics and species longevity (including GenAge and AnAge) that have been described in successive Nucleic Acids Research database papers from 2012 to 2024. His lab has also worked on gene networks of ageing and on sequencing and analysing genomes of long-lived species, including the bowhead whale (Cell Reports, 2015). He has given three TEDx talks, and his research has been covered by the BBC, CNN and the Financial Times. He communicates about ageing research through the lab's @AgingBiology X account and a personal website of essays.", "word_count": 185, "sources": ["https://www.birmingham.ac.uk/staff/profiles/inflammation-ageing/magalhaes-pedro", "https://rejuvenomicslab.com/", "https://doi.org/10.1093/nar/gkad927", "https://doi.org/10.1093/nar/gks1155", "https://doi.org/10.1016/j.celrep.2014.12.008"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 82, "source_url": "https://scholar.google.com/citations?user=DZdgRE4AAAAJ", "checked": "2026-09-23", "status": "verified", "note": "Profile 'João Pedro de Magalhães', University of Birmingham; All column (since-2021: 62)"}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": 20536, "source_url": "https://x.com/jpsenescence", "checked": "2026-09-23", "status": "verified", "note": "followers; read via api.fxtwitter.com on 2026-09-23. Personal account linked from his personal website jp.senescence.info. The lab-site account @AgingBiology ('Aging Science News', ~34K) is a project/news account and is not counted."}, {"kind": "audience", "for_category": "communicator", "platform": "facebook", "value": 1723, "source_url": "https://www.facebook.com/jpsenescence", "checked": "2026-09-23", "status": "verified", "note": "followers; public page description ('1,723 followers'), linked from jp.senescence.info"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=DZdgRE4AAAAJ", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/joaopedrodemagalhaes/", "status": "verified"}, "x": {"url": "https://x.com/jpsenescence", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "University of Birmingham profile", "url": "https://www.birmingham.ac.uk/staff/profiles/inflammation-ageing/magalhaes-pedro"}, {"label": "Genomics of Ageing and Rejuvenation Lab", "url": "https://rejuvenomicslab.com/"}, {"label": "Personal website", "url": "https://jp.senescence.info/"}], "facebook": {"url": "https://www.facebook.com/jpsenescence", "status": "verified"}}, "sources": [{"url": "https://www.birmingham.ac.uk/staff/profiles/inflammation-ageing/magalhaes-pedro", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://rejuvenomicslab.com/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://jp.senescence.info/", "type": "personal_site", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=DZdgRE4AAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1093/nar/gkad927", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.celrep.2014.12.008", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0035", "slug": "marco-demaria", "name": {"display": "Marco Demaria", "sort": "Demaria, Marco"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Cellular Ageing and Senescence; Director, Institute for Mechanisms of Health, Ageing and Disease (MoHAD); Group Leader, ERIBA", "organisation": "University Medical Center Groningen / University of Groningen (ERIBA)", "sources": ["https://eriba.umcg.nl/people/marco-demaria/", "https://doi.org/10.1038/s41422-026-01295-9"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Co-founder", "organisation": "Cleara Biotech", "sources": ["https://eriba.umcg.nl/people/marco-demaria/"]}, {"title": "Editor-in-Chief", "organisation": "Aging-US", "sources": ["https://eriba.umcg.nl/people/marco-demaria/"]}, {"title": "President", "organisation": "International Cell Senescence Association", "sources": ["https://eriba.umcg.nl/people/marco-demaria/"]}], "location": {"city": "Groningen", "region": "Groningen", "country_code": "NL", "sources": ["https://eriba.umcg.nl/people/marco-demaria/", "https://doi.org/10.1038/s41422-026-01295-9"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://eriba.umcg.nl/wp-content/uploads/2016/01/MarcoSize_Smaller_highres-800x800.png", "page_url": "https://eriba.umcg.nl/people/marco-demaria/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Marco Demaria studies cellular senescence, the state in which damaged cells stop dividing and secrete inflammatory factors, and its roles in ageing, tissue repair and the side effects of cancer therapy. As a postdoctoral fellow with Judith Campisi at the Buck Institute from 2010, he developed tools and mouse models to track senescent cells in vivo; this work showed that senescent cells help optimal wound healing through secretion of PDGF-AA (Developmental Cell, 2014). Since 2015 he has led the Laboratory of Cellular Senescence and Age-Related Pathologies at ERIBA in Groningen, where his group works on molecular mechanisms and biomarkers of senescence, including how hypoxia restrains the senescence-associated secretory phenotype and how CDK4/6 inhibitors induce senescence. He co-authored the 2019 Cell consensus paper on defining cellular senescence. He is Professor of Cellular Ageing and Senescence at the University Medical Center Groningen and directs its Institute for Mechanisms of Health, Ageing and Disease. In 2018 he co-founded Cleara Biotech, which develops drugs that target senescent cells. He is Editor-in-Chief of Aging-US and President of the International Cell Senescence Association.", "word_count": 177, "sources": ["https://eriba.umcg.nl/people/marco-demaria/", "https://doi.org/10.1016/j.devcel.2014.11.012", "https://doi.org/10.1038/s41422-026-01295-9"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 63, "source_url": "https://scholar.google.com/citations?user=jjIT7QgAAAAJ", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Marco Demaria', UMCG/ERIBA; All column (since-2021: 56)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=jjIT7QgAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "ERIBA profile", "url": "https://eriba.umcg.nl/people/marco-demaria/"}, {"label": "Demaria Lab", "url": "https://demarialab.com/"}]}, "sources": [{"url": "https://eriba.umcg.nl/people/marco-demaria/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://demarialab.com/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=jjIT7QgAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41422-026-01295-9", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.arr.2026.103224", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.devcel.2014.11.012", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0036", "slug": "peter-h-diamandis", "name": {"display": "Peter H. Diamandis", "sort": "Diamandis, Peter H."}, "categories": ["entrepreneur", "communicator"], "current_title": {"title": "Founder and Executive Chairman", "organisation": "XPRIZE Foundation", "sources": ["https://www.xprize.org/people/peter-h-diamandis-m-d"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Co-Founder and Chairman", "organisation": "Fountain Life", "sources": ["https://www.xprize.org/people/peter-h-diamandis-m-d"]}, {"title": "Co-Founder", "organisation": "BOLD Capital Partners", "sources": ["https://www.xprize.org/people/peter-h-diamandis-m-d"]}, {"title": "Executive Founder", "organisation": "Singularity University", "sources": ["https://www.xprize.org/people/peter-h-diamandis-m-d"]}, {"title": "Co-founder and Vice-Chairman", "organisation": "Celularity; Vaxxinity", "sources": ["https://www.xprize.org/people/peter-h-diamandis-m-d"]}], "location": {"city": "Frisco", "region": "TX", "country_code": "US", "sources": ["https://www.xprize.org/contact"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://assets-us-01.kc-usercontent.com/9bc15d1f-8a5c-007d-b507-e3496e85af86/8d6cac38-4184-49a5-b188-5307a2ec24e8/peter%20d.jpg", "page_url": "https://www.xprize.org/people/peter-h-diamandis-m-d", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Peter Diamandis is an entrepreneur and author whose longevity work centres on incentive prizes, clinical ventures and public communication about healthspan technologies. He founded and is Executive Chairman of the XPRIZE Foundation, which designs large incentive competitions; its XPRIZE Healthspan, running from 2023 to 2030 with a $101 million prize purse, challenges teams to develop therapies that restore muscle, cognitive and immune function in older adults, and named finalist teams in August 2026. He is co-founder and chairman of Fountain Life, a company offering predictive and preventive health assessments, which raised an $18 million Series B round led by EOS Ventures in 2025. He also co-founded BOLD Capital Partners, a venture fund that invests in exponential technologies and longevity companies, is co-founder and vice-chairman of Celularity and Vaxxinity, and is executive founder of Singularity University. He co-authored the book Life Force with Tony Robbins, on healthcare and biotechnology advances, and communicates through a YouTube channel, podcast and newsletter. He holds degrees in molecular genetics and aerospace engineering from MIT and an MD from Harvard Medical School.", "word_count": 176, "sources": ["https://www.xprize.org/people/peter-h-diamandis-m-d", "https://www.xprize.org/competitions/healthspan", "https://longevity.technology/news/fountain-life-lands-18m-to-accelerate-longevity-clinic-expansion/", "https://www.youtube.com/@peterdiamandis"]}, "metrics": [{"kind": "audience", "for_category": "communicator", "platform": "youtube", "value": 534000, "source_url": "https://www.youtube.com/@peterdiamandis", "checked": "2026-09-23", "status": "verified", "note": "subscribers, as displayed ('534K subscribers')"}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": "https://x.com/peterdiamandis", "checked": "2026-09-23", "status": "unavailable", "note": "follower count requires login"}, {"kind": "audience", "for_category": "communicator", "platform": "newsletter", "value": null, "source_url": "https://www.diamandis.com/newsletter", "checked": "2026-09-23", "status": "unavailable", "note": "no subscriber count published on newsletter page"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Fountain Life", "label": "Fountain Life publicly reported Series B funding (2025)", "value": 18000000, "currency": "USD", "scope": "single_round", "source_url": "https://techcrunch.com/2025/08/13/tony-robbins-and-peter-diamandis-longevity-company-fountain-life-raises-18m/", "checked": "2026-09-23", "status": "verified", "note": "TechCrunch exclusive (13 Aug 2025): $18M Series B led by EOS Ventures with participation from most existing board members. Also reported by longevity.technology."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Fountain Life", "label": "Fountain Life publicly reported total funding (as of Aug 2025)", "value": 108000000, "currency": "USD", "scope": "total_disclosed", "source_url": "https://techcrunch.com/2025/08/13/tony-robbins-and-peter-diamandis-longevity-company-fountain-life-raises-18m/", "checked": "2026-09-23", "status": "verified", "note": "TechCrunch: 'Fountain previously raised an $80 million Series A and has raised about $108 million total, Kapp said' (CEO statement, approximate). Not from a company press release."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": "https://www.linkedin.com/in/peterdiamandis", "status": "verified"}, "x": {"url": "https://x.com/peterdiamandis", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "XPRIZE profile", "url": "https://www.xprize.org/people/peter-h-diamandis-m-d"}, {"label": "Personal website", "url": "https://www.diamandis.com/about"}]}, "sources": [{"url": "https://www.xprize.org/people/peter-h-diamandis-m-d", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.xprize.org/competitions/healthspan", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.xprize.org/contact", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.diamandis.com/about", "type": "personal_site", "accessed": "2026-09-23"}, {"url": "https://longevity.technology/news/fountain-life-lands-18m-to-accelerate-longevity-clinic-expansion/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://www.youtube.com/@peterdiamandis", "type": "social", "accessed": "2026-09-23"}, {"url": "https://techcrunch.com/2025/08/13/tony-robbins-and-peter-diamandis-longevity-company-fountain-life-raises-18m/", "type": "news", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-24", "phase": "3"}}, {"id": "per_0037", "slug": "andrew-dillin", "name": {"display": "Andrew Dillin", "sort": "Dillin, Andrew"}, "categories": ["scientist", "academic"], "current_title": {"title": "HHMI Investigator; Professor of Immunology and Molecular Medicine, Department of Molecular and Cell Biology", "organisation": "University of California, Berkeley / Howard Hughes Medical Institute", "sources": ["https://mcb.berkeley.edu/faculty/cdb/dillina", "https://www.hhmi.org/scientists/andrew-dillin", "https://doi.org/10.1101/gad.353720.126"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Berkeley", "region": "CA", "country_code": "US", "sources": ["https://doi.org/10.1101/gad.353720.126"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://mcb.berkeley.edu/sites/default/files/images/faculty/dillina_250_369.jpg", "page_url": "https://mcb.berkeley.edu/faculty/cdb/dillina", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Andrew Dillin studies why ageing organisms lose control of protein quality (proteostasis) and how stress signals are communicated between tissues to set the rate of ageing. Working mainly in C. elegans, with extensions to stem cells and mice, his laboratory showed that mitochondrial stress in one tissue can be sensed by distant cells, triggering a cell non-autonomous mitochondrial stress response that extends lifespan (Cell, 2011). His group has also identified regulators of longevity downstream of AMPK and calcineurin signalling (Nature, 2011), linked proteasome activity to longevity and to human embryonic stem cell function (Nature, 2012), and studied how the heat-shock transcription factor HSF-1 influences lifespan and thermotolerance. Earlier work showed that the timing of mitochondrial function during development affects rates of behaviour and ageing. He has been a Howard Hughes Medical Institute Investigator since 2008 and is Professor of Immunology and Molecular Medicine in the Department of Molecular and Cell Biology at UC Berkeley. His 2025-2026 publications include reviews of cross-organ mitochondrial communication and work on mitochondrial dysfunction linked to an ALS mutation.", "word_count": 173, "sources": ["https://mcb.berkeley.edu/faculty/cdb/dillina", "https://www.hhmi.org/scientists/andrew-dillin", "https://scholar.google.com/citations?user=sZE65UQAAAAJ", "https://doi.org/10.1101/gad.353720.126", "https://doi.org/10.1146/annurev-pharmtox-062124-024150"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 77, "source_url": "https://scholar.google.com/citations?user=sZE65UQAAAAJ", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Andrew Dillin', verified berkeley.edu email, affiliation field 'Unknown affiliation'; publication list matches (e.g. Cell 2011 ETC longevity). All column (since-2021: 62)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=sZE65UQAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UC Berkeley MCB faculty page", "url": "https://mcb.berkeley.edu/faculty/cdb/dillina"}, {"label": "HHMI investigator profile", "url": "https://www.hhmi.org/scientists/andrew-dillin"}, {"label": "Dillin Lab", "url": "https://www.dillinlab-berkeley.org/"}]}, "sources": [{"url": "https://mcb.berkeley.edu/faculty/cdb/dillina", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.hhmi.org/scientists/andrew-dillin", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=sZE65UQAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1101/gad.353720.126", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1146/annurev-pharmtox-062124-024150", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0038", "slug": "vishwa-deep-dixit", "name": {"display": "Vishwa Deep Dixit", "sort": "Dixit, Vishwa Deep"}, "categories": ["scientist", "academic"], "current_title": {"title": "Waldemar Von Zedtwitz Professor of Pathology and Professor of Immunobiology; Director, Yale Center for Research on Aging (Y-Age)", "organisation": "Yale School of Medicine", "sources": ["https://medicine.yale.edu/profile/vishwa-dixit/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "New Haven", "region": "CT", "country_code": "US", "sources": ["https://doi.org/10.1038/s43587-026-01107-0", "https://medicine.yale.edu/profile/vishwa-dixit/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://ysm-res.cloudinary.com/image/upload/c_limit,f_jpg,h_630,q_auto,w_1200/v1/yms/prod/5a6f61d7-bb83-4a1d-b8ca-24ee44d80ba1", "page_url": "https://medicine.yale.edu/profile/vishwa-dixit/", "source_type": "institution_page", "credit": "Yale School of Medicine", "checked": "2026-09-23"}, "impact": {"text": "Vishwa Deep Dixit studies immunometabolism and ageing, particularly how metabolic signals control age-related inflammation ('inflammaging') and immune decline. His group helped establish a role for the NLRP3 inflammasome in inflammaging, immunosenescence and age-related metabolic disease, and showed that the ketone body beta-hydroxybutyrate can suppress NLRP3-dependent inflammation. His laboratory found that the pro-longevity hormone FGF21 protects against thymic degeneration and T-cell senescence during ageing, and identified nerve-associated macrophages that regulate adipose tissue and age-related inflammation (Nature Aging, 2025). Using a reverse-translation approach built on samples from the CALERIE-II human caloric restriction trial, his team identified PLA2G7 and SPARC as calorie-restriction-inhibited proteins that affect inflammaging, and in 2026 reported complement deactivation as an immunometabolic checkpoint in calorie-restricted humans (Nature Aging). He is the Waldemar Von Zedtwitz Professor of Pathology and Professor of Immunobiology and Comparative Medicine at Yale School of Medicine, and Director of the Yale Center for Research on Aging (Y-Age). He trained in veterinary medicine in India, did PhD research at the University of Hannover, and completed postdoctoral work at Morehouse School of Medicine and the NIH.", "word_count": 177, "sources": ["https://medicine.yale.edu/profile/vishwa-dixit/", "https://doi.org/10.1038/s43587-026-01107-0", "https://doi.org/10.1038/s43587-025-00952-9"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 61, "source_url": "https://scholar.google.com/citations?user=AxHJjOAAAAAJ", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Vishwa Deep Dixit', Professor, Yale University; All column (since-2021: 47). Not to be confused with Vishva Dixit (Genentech)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=AxHJjOAAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Yale School of Medicine profile", "url": "https://medicine.yale.edu/profile/vishwa-dixit/"}, {"label": "Dixit Lab", "url": "https://medicine.yale.edu/ymsm/research/dixit/"}]}, "sources": [{"url": "https://medicine.yale.edu/profile/vishwa-dixit/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=AxHJjOAAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s43587-026-01107-0", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s43587-025-00952-9", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0039", "slug": "maria-ermolaeva", "name": {"display": "Maria Ermolaeva", "sort": "Ermolaeva, Maria"}, "categories": ["scientist", "academic"], "current_title": {"title": "Group Leader, Stress Tolerance and Homeostasis", "organisation": "Leibniz Institute on Aging - Fritz Lipmann Institute (FLI)", "sources": ["https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/ermolaeva-group", "https://doi.org/10.1038/s41467-026-71508-7"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Jena", "region": "Thuringia", "country_code": "DE", "sources": ["https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/ermolaeva-group", "https://doi.org/10.1038/s41467-026-71508-7"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.leibniz-fli.de//assets/uploads/general/Personen/_750x530_crop_center-center_100_none/Maria-Ermolaeva.jpg.pagespeed.ce.K_n-rLHyPE.jpg", "page_url": "https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/ermolaeva-group", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Maria Ermolaeva studies how cells and tissues tolerate stress and how resilience can be strengthened to extend the disease-free period of life. She leads the Stress Tolerance and Homeostasis group at the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena. At the University of Cologne, working with Björn Schumacher, she was first author of a Nature (2013) study showing that DNA damage in C. elegans germ cells triggers an innate immune response that confers systemic stress resistance on somatic tissues. At FLI her group investigates how mild stress can promote healthier ageing, supported by a two-million-euro ERC Consolidator Grant (LifeLongFit, awarded 2023). In 2026 her laboratory reported in Nature Communications that an age-associated decline in phosphatidylcholine synthesis drives loss of mitochondrial flexibility during natural ageing, and that dietary phosphatidylcholine can restore mitochondrial function in aged model organisms. Her earlier work in immunology addressed TRADD and FADD signalling in inflammation and cell death.", "word_count": 155, "sources": ["https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/ermolaeva-group", "https://doi.org/10.1038/nature12452", "https://doi.org/10.1038/s41467-026-71508-7", "https://scholar.google.com/citations?user=LTxnehcAAAAJ"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 21, "source_url": "https://scholar.google.com/citations?user=LTxnehcAAAAJ", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Maria Ermolaeva', Leibniz Institute on Aging - Fritz Lipmann Institute (FLI); All column (since-2021: 18)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=LTxnehcAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "FLI group page", "url": "https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/ermolaeva-group"}]}, "sources": [{"url": "https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/ermolaeva-group", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=LTxnehcAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41467-026-71508-7", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/nature12452", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0040", "slug": "evandro-fei-fang", "name": {"display": "Evandro Fei Fang", "sort": "Fang, Evandro Fei"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor, Department of Clinical Molecular Biology (Professor of Gerontology and Neuroscience; group leader)", "organisation": "University of Oslo, Institute of Clinical Medicine / Akershus University Hospital", "sources": ["https://www.med.uio.no/klinmed/english/people/aca/evandrof/", "https://evandrofanglab.com/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "UiO staff page lists him under the name Fei Fang-Stavem; lab site describes him as Professor of Gerontology and Neuroscience. Roster title 'Associate Professor' is superseded."}, "other_positions": [{"title": "Leader", "organisation": "NO-Age (Norwegian Centre on Healthy Ageing) network", "sources": ["https://evandrofanglab.com/"]}], "location": {"city": "Lørenskog", "region": "Akershus", "country_code": "NO", "sources": ["https://www.med.uio.no/klinmed/english/people/aca/evandrof/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.med.uio.no/klinmed/english/people/aca/evandrof/evandrofang_portrait-2022-05-30.png", "page_url": "https://www.med.uio.no/klinmed/english/people/aca/evandrof/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Evandro Fei Fang (also listed as Fei Fang-Stavem) leads a laboratory at the University of Oslo and Akershus University Hospital studying the molecular mechanisms of human ageing and age-predisposed Alzheimer's disease. His group's four stated research lines are NAD+ biology and ageing; the mechanisms of mitophagy and its protective role in Alzheimer's disease; the application of artificial intelligence to drug development for Alzheimer's disease and healthy longevity; and clinical trials built on the lab's preclinical findings. He previously worked at the US National Institute on Aging and at CUHK, according to his Scholar profile. He coordinates the NO-Age (Norwegian Centre on Healthy Ageing) network and the Hong Kong-Nordic Research Network, which link ageing researchers across Norway and Asia. In 2023 he received the Norwegian National Association for Public Health's dementia research prize. His lab discloses industry links, including a CRADA with ChromaDex and agreements with several longevity companies. For the longevity field he is a point of reference on NAD+ augmentation and mitophagy as intervention targets in brain ageing.", "word_count": 169, "sources": ["https://www.med.uio.no/klinmed/english/people/aca/evandrof/", "https://evandrofanglab.com/", "https://evandrofanglab.com/evandro-f-fang-cv/", "https://scholar.google.com/citations?user=VdZQ1EgAAAAJ&hl=en"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 63, "source_url": "https://scholar.google.com/citations?user=VdZQ1EgAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Evandro Fei Fang', University of Oslo / Akershus U. Hospital, verified medisin.uio.no email; 38,104 citations (All)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=VdZQ1EgAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UiO staff page", "url": "https://www.med.uio.no/klinmed/english/people/aca/evandrof/"}, {"label": "Lab website", "url": "https://evandrofanglab.com/"}]}, "sources": [{"url": "https://www.med.uio.no/klinmed/english/people/aca/evandrof/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://evandrofanglab.com/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://evandrofanglab.com/evandro-f-fang-cv/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=VdZQ1EgAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0041", "slug": "peter-fedichev", "name": {"display": "Peter Fedichev", "sort": "Fedichev, Peter"}, "categories": ["entrepreneur", "scientist"], "current_title": {"title": "CEO and Co-Founder", "organisation": "Gero (Gero PTE. LTD.)", "sources": ["https://www.gero.ai/team", "https://www.chugai-pharm.co.jp/english/news/detail/20250707160000_1156.html"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Singapore", "region": "", "country_code": "SG", "sources": ["https://www.chugai-pharm.co.jp/english/news/detail/20250707160000_1156.html"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://cdn.prod.website-files.com/656269fc239eb2514c12f92e/6a319b740ae9a54068ba4ed4_b0b5b811-c740-4831-835a-5498105cd2ac.jpg", "page_url": "https://www.gero.ai/team", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Peter Fedichev is a physicist who co-founded Gero, a Singapore-based biotechnology company that applies AI and physics-based modelling to human longitudinal data to find drug targets for ageing and age-related disease. He holds a PhD from the University of Amsterdam and previously worked in condensed matter physics before moving into drug discovery. Gero's team has published work on extracting biological age from biomedical data with deep learning, unsupervised learning of ageing principles from longitudinal data, and the effect of rare damaging germline variants on human healthspan and lifespan. The company's framework, formalised as the Fedichev-Gruber theory, separates ageing interventions into three classes, of which today's hallmark-targeting drugs are the first. In July 2025 Gero and Chugai Pharmaceutical signed a joint research and license agreement to develop antibodies against targets identified by Gero's platform, with potential milestone payments of up to about USD 250 million. For the longevity field he represents a quantitative, physics-informed approach to defining and targeting the ageing process itself.", "word_count": 162, "sources": ["https://www.gero.ai/team", "https://www.gero.ai/", "https://www.gero.ai/news", "https://www.chugai-pharm.co.jp/english/news/detail/20250707160000_1156.html", "https://scholar.google.com/citations?user=2HQQGnkAAAAJ&hl=en"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 43, "source_url": "https://scholar.google.com/citations?user=2HQQGnkAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Peter Fedichev', 'founder, Gero', verified gero.com email; 7,841 citations (All)"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Gero", "label": "Gero publicly disclosed total equity funding (as of Jun 2026)", "value": 34000000, "currency": "USD", "scope": "total_disclosed", "source_url": "https://www.businesswire.com/news/home/20260617389034/en/Gero-Reaches-%2434M-in-Equity-Funding-to-Turn-the-Physics-of-Aging-Into-Medicines", "checked": "2026-09-23", "status": "verified", "note": "Company press release (Business Wire, 17 Jun 2026), body read via syndicated copy https://www.financialcontent.com/article/bizwire-2026-6-17-gero-reaches-34m-in-equity-funding-to-turn-the-physics-of-aging-into-medicines: 'today announced $17M in new financing, bringing total equity funding to $34M' (participants incl. Melnichek Investments). Chugai/Roche milestones (up to $250M) are partnership payments, not included."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=2HQQGnkAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Gero team page", "url": "https://www.gero.ai/team"}, {"label": "Gero website", "url": "https://www.gero.ai/"}]}, "sources": [{"url": "https://www.gero.ai/team", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.gero.ai/news", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.gero.ai/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.chugai-pharm.co.jp/english/news/detail/20250707160000_1156.html", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.businesswire.com/news/home/20260617389034/en/Gero-Reaches-%2434M-in-Equity-Funding-to-Turn-the-Physics-of-Aging-Into-Medicines", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=2HQQGnkAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://www.financialcontent.com/article/bizwire-2026-6-17-gero-reaches-34m-in-equity-funding-to-turn-the-physics-of-aging-into-medicines", "type": "press_release", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0042", "slug": "luigi-ferrucci", "name": {"display": "Luigi Ferrucci", "sort": "Ferrucci, Luigi"}, "categories": ["scientist", "doctor"], "current_title": {"title": "Scientific Director; Senior Investigator, Longitudinal Studies Section", "organisation": "National Institute on Aging (NIH) Intramural Research Program", "sources": ["https://irp.nih.gov/pi/luigi-ferrucci"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Director", "organisation": "Baltimore Longitudinal Study of Aging (BLSA)", "sources": ["https://irp.nih.gov/pi/luigi-ferrucci"]}], "location": {"city": "Baltimore", "region": "MD", "country_code": "US", "sources": ["https://doi.org/10.1093/gerona/glag234"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://i.irp.nih.gov/pi/0011391454.jpg", "page_url": "https://irp.nih.gov/pi/luigi-ferrucci", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Luigi Ferrucci is a geriatrician and epidemiologist who has been Scientific Director of the US National Institute on Aging (NIA) since May 2011. Since 2002 he has led the NIA Longitudinal Studies Section and directed the Baltimore Longitudinal Study of Aging (BLSA), which he has refocused on normal ageing and the development of age-associated frailty. His research investigates the causal pathways that lead to progressive physical and cognitive decline in older people. Trained at the University of Florence, he earlier led geriatric rehabilitation and clinical epidemiology at the Italian National Institute of Aging and was principal investigator of the InCHIANTI study of risk factors for mobility disability in Tuscany. He has contributed to the design of other population studies, including the Women's Health and Aging Study and the AKEA study of centenarians in Sardinia. He was senior author of a 2024 Nature Medicine consensus paper on validating biomarkers of ageing. For the longevity field his work links ageing biology to long-term human cohort data and to the effort to define measurable biomarkers of human ageing.", "word_count": 175, "sources": ["https://irp.nih.gov/pi/luigi-ferrucci", "https://www.ncbi.nlm.nih.gov/pubmed/38355974", "https://scholar.google.com/citations?user=HhoOnBAAAAAJ&hl=en"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 290, "source_url": "https://scholar.google.com/citations?user=HhoOnBAAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Luigi Ferrucci', National Institute on Aging, NIH, verified mail.nih.gov email; 459,164 citations (All)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=HhoOnBAAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "NIH IRP profile", "url": "https://irp.nih.gov/pi/luigi-ferrucci"}]}, "sources": [{"url": "https://irp.nih.gov/pi/luigi-ferrucci", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1093/gerona/glag234", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=HhoOnBAAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0043", "slug": "tor-finkel", "name": {"display": "Tor Finkel", "sort": "Finkel, Tor"}, "categories": ["scientist", "academic"], "current_title": {"title": "Director, Aging Institute; G. Nicholas Beckwith III and Dorothy B. Beckwith Endowed Chair of Translational Medicine; Distinguished Professor of Medicine", "organisation": "University of Pittsburgh / UPMC", "sources": ["https://aging.pitt.edu/labs/finkel-lab/", "https://www.upmc.com/media/experts/toren-finkel"], "source_type": "lab_page", "checked": "2026-09-23", "status": "verified", "note": "Formal first name Toren (roster: Tor)."}, "other_positions": [], "location": {"city": "Pittsburgh", "region": "PA", "country_code": "US", "sources": ["https://aging.pitt.edu/labs/finkel-lab/", "https://www.upmc.com/media/experts/toren-finkel"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://dam.upmc.com/-/media/upmc/publishingimages/staff-headshots/high-resolution/finkel-toren-hr.jpg?la=en&rev=8c238164b5fc4b329c1f4a6856045c84&hash=9C5D332FC71CB71417157221B33F84F8", "page_url": "https://www.upmc.com/media/experts/toren-finkel", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Toren Finkel is a cardiologist and ageing biologist who has directed the Aging Institute of the University of Pittsburgh and UPMC since September 2017. Before that he spent 25 years in the intramural program of the US National Heart, Lung and Blood Institute, where he was Chief of the Cardiology Branch and of the Center for Molecular Medicine. His lab's interest in ageing grew from a 1995 Science paper showing that cells deliberately produce hydrogen peroxide as part of normal receptor signalling. That work helped establish reactive oxygen species as signalling molecules rather than only random damaging agents, and prompted a re-evaluation of the free radical theory of ageing. His group studies how mitochondrial function and metabolism regulate ageing, with current work on autophagy, mitochondrial calcium, lysosomal integrity and senescence, including a 2022 Nature paper on a phosphoinositide pathway for rapid lysosomal repair. With colleagues he develops small molecules for age-related diseases, several of which are in clinical development. He is an elected member of the National Academy of Medicine and a Fellow of the AAAS.", "word_count": 176, "sources": ["https://aging.pitt.edu/labs/finkel-lab/", "https://pubmed.ncbi.nlm.nih.gov/7569979/", "https://pubmed.ncbi.nlm.nih.gov/36071159/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 125, "source_url": "https://scholar.google.com/citations?user=vhRulQ4AAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Profile 'toren finkel', University of Pittsburgh, verified pitt.edu email; 114,728 citations (All)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=vhRulQ4AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Finkel Lab, Aging Institute", "url": "https://aging.pitt.edu/labs/finkel-lab/"}, {"label": "UPMC experts profile", "url": "https://www.upmc.com/media/experts/toren-finkel"}]}, "sources": [{"url": "https://aging.pitt.edu/labs/finkel-lab/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.upmc.com/media/experts/toren-finkel", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=vhRulQ4AAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0044", "slug": "luigi-fontana", "name": {"display": "Luigi Fontana", "sort": "Fontana, Luigi"}, "categories": ["scientist", "academic", "doctor"], "current_title": {"title": "Leonard P. Ullmann Chair of Translational Metabolic Health; Professor of Medicine and Nutrition; Director, Charles Perkins Centre RPA Clinic and 'Health for Life' Program", "organisation": "University of Sydney (Charles Perkins Centre)", "sources": ["https://profiles.sydney.edu.au/luigi.fontana", "https://www.sydney.edu.au/charles-perkins-centre/our-research/research-groups/healthy-longevity.html"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Clinical Academic, Department of Endocrinology", "organisation": "Royal Prince Alfred Hospital", "sources": ["https://profiles.sydney.edu.au/luigi.fontana"]}, {"title": "Editor-in-Chief", "organisation": "Nutrition and Healthy Aging", "sources": ["https://profiles.sydney.edu.au/luigi.fontana"]}, {"title": "Team member", "organisation": "Australian Ageing Network (AusAgeNet)", "sources": ["https://www.ausagenet.com/team/luigi-fontana"]}], "location": {"city": "Sydney", "region": "NSW", "country_code": "AU", "sources": ["https://profiles.sydney.edu.au/luigi.fontana"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://profiles.sydney.edu.au/luigi.fontana/thumbnail", "page_url": "https://profiles.sydney.edu.au/luigi.fontana", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Luigi Fontana is a physician scientist whose clinical research, begun in 2001, examines how calorie intake, meal frequency, diet composition and exercise training affect metabolic and molecular health in humans. His studies of dietary restriction in people contributed to the now widely accepted view of dietary restriction as an intervention relevant to obesity, type 2 diabetes, cardiovascular disease, cancer and dementia, with work published in JAMA, Science, Nature and Cell. Before moving to Australia he was Full Professor of Medicine and Nutritional Sciences at Washington University in St Louis and at Brescia, Italy, and co-director of the Washington University Longevity Research Program. Since July 2018 he has held the Leonard P. Ullmann Chair of Translational Metabolic Health at the University of Sydney's Charles Perkins Centre, where he directs the Charles Perkins Centre RPA Clinic and the Health for Life program; he is also a clinical academic in endocrinology at Royal Prince Alfred Hospital. His awards include the AFAR Breakthroughs in Gerontology Award (2009), the Glenn Award (2011) and the AFAR Vincent Cristofalo Award (2016). He has edited Nutrition and Healthy Aging since 2016.", "word_count": 183, "sources": ["https://profiles.sydney.edu.au/luigi.fontana", "https://www.sydney.edu.au/charles-perkins-centre/our-research/research-groups/healthy-longevity.html", "https://www.ausagenet.com/team/luigi-fontana"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 94, "source_url": "https://scholar.google.com/citations?user=q7oQtGIAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Luigi Fontana, MD, PhD, FRACP', University of Sydney, verified sydney.edu.au email; 42,377 citations (All). Distinct from an ophthalmologist of the same name (Bologna)."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=q7oQtGIAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "University of Sydney profile", "url": "https://profiles.sydney.edu.au/luigi.fontana"}, {"label": "Fontana healthy longevity research group", "url": "https://www.sydney.edu.au/charles-perkins-centre/our-research/research-groups/healthy-longevity.html"}]}, "sources": [{"url": "https://profiles.sydney.edu.au/luigi.fontana", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.sydney.edu.au/charles-perkins-centre/our-research/research-groups/healthy-longevity.html", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.ausagenet.com/team/luigi-fontana", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=q7oQtGIAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0045", "slug": "kristen-fortney", "name": {"display": "Kristen Fortney", "sort": "Fortney, Kristen"}, "categories": ["entrepreneur"], "current_title": {"title": "Co-Founder and CEO", "organisation": "BioAge Labs, Inc. (Nasdaq: BIOA)", "sources": ["https://bioagelabs.com/team", "https://svhealthinvestors.com/news/bioage-announces-170-million-oversubscribed-series-d-financing-to-accelerate-development-of-obesity-and-metabolic-disease-therapeutics"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Richmond", "region": "CA", "country_code": "US", "sources": ["https://www.stocktitan.net/news/BIOA/bio-age-labs-announces-closing-of-initial-public-offering-full-yhcwn8aa9hxl.html", "https://svhealthinvestors.com/news/bioage-announces-170-million-oversubscribed-series-d-financing-to-accelerate-development-of-obesity-and-metabolic-disease-therapeutics"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://images.ctfassets.net/zg8ll14nr0es/3TW2r8WRe7dqt9UnFk0btT/9317954dc88d6b729908809cc2ba75b7/Kristen-removebg-preview_1.png", "page_url": "https://bioagelabs.com/team", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Kristen Fortney is co-founder and CEO of BioAge Labs, a clinical-stage biotechnology company founded in 2015 that uses human ageing and longevity data to identify drug targets, now focused on cardiometabolic disease. She received a PhD in Medical Biophysics from the University of Toronto in 2012 and trained as a postdoctoral fellow at Stanford University, supported by the Ellison Medical Foundation / American Federation for Aging Research. Her research concerned computational drug discovery, biomarkers of ageing and the genetics of exceptional human longevity. Under her leadership BioAge raised a USD 170 million Series D in February 2024 and completed an initial public offering on Nasdaq in October 2024 with gross proceeds of about USD 238.3 million. The company's current pipeline includes BGE-102, an NLRP3 inhibitor being tested in Phase 2 studies for cardiometabolic and retinal disease, and APJ agonists positioned as exercise mimetics for obesity. For the longevity field she is an example of a company built on the premise of mining human ageing biology for drug targets and taking those programmes into clinical trials within conventional disease indications.", "word_count": 179, "sources": ["https://bioagelabs.com/team", "https://bioagelabs.com/", "https://healthspanpolicy.org/person/kristen-fortney-ph-d/", "https://svhealthinvestors.com/news/bioage-announces-170-million-oversubscribed-series-d-financing-to-accelerate-development-of-obesity-and-metabolic-disease-therapeutics", "https://www.stocktitan.net/news/BIOA/bio-age-labs-announces-closing-of-initial-public-offering-full-yhcwn8aa9hxl.html"]}, "metrics": [{"kind": "capital_raised", "for_category": "entrepreneur", "entity": "BioAge Labs", "label": "BioAge Labs publicly disclosed Series D funding (2024)", "value": 170000000, "currency": "USD", "scope": "single_round", "source_url": "https://svhealthinvestors.com/news/bioage-announces-170-million-oversubscribed-series-d-financing-to-accelerate-development-of-obesity-and-metabolic-disease-therapeutics", "checked": "2026-09-23", "status": "verified", "note": "Oversubscribed Series D (Feb 2024) led by Sofinnova Investments. No cumulative total found in a single first-party source."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "BioAge Labs", "label": "BioAge Labs publicly disclosed IPO proceeds (2024, incl. concurrent private placement)", "value": 238300000, "currency": "USD", "scope": "ipo_proceeds", "source_url": "https://www.stocktitan.net/news/BIOA/bio-age-labs-announces-closing-of-initial-public-offering-full-yhcwn8aa9hxl.html", "checked": "2026-09-23", "status": "verified", "note": "Company closing release (reproduced by StockTitan): combined gross proceeds from the Nasdaq IPO (12.65M shares at $18) and concurrent private placement totalled approximately $238.3 million, before underwriting discounts."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": "https://www.linkedin.com/in/kristenfortney", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "BioAge Labs team page", "url": "https://bioagelabs.com/team"}, {"label": "BioAge Labs website", "url": "https://bioagelabs.com/"}]}, "sources": [{"url": "https://bioagelabs.com/team", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://bioagelabs.com/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://svhealthinvestors.com/news/bioage-announces-170-million-oversubscribed-series-d-financing-to-accelerate-development-of-obesity-and-metabolic-disease-therapeutics", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.stocktitan.net/news/BIOA/bio-age-labs-announces-closing-of-initial-public-offering-full-yhcwn8aa9hxl.html", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://healthspanpolicy.org/person/kristen-fortney-ph-d/", "type": "secondary", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-24", "phase": "3"}}, {"id": "per_0046", "slug": "claudio-franceschi", "name": {"display": "Claudio Franceschi", "sort": "Franceschi, Claudio"}, "categories": ["scientist", "academic"], "current_title": {"title": "Emeritus Professor (Immunology)", "organisation": "University of Bologna (Alma Mater Studiorum)", "sources": ["https://www.unibo.it/sitoweb/claudio.franceschi/en", "https://dpm-ageing.unn.ru/en/leading-scientist/"], "source_type": "institution_page", "checked": "2026-09-24", "status": "verified", "note": "The University of Bologna page lists him as 'Emeritus Professor' with a unibo.it email, a Bologna phone number and office hours by appointment (Via Zamboni 33). Lobachevsky University's DPM-ageing project page, where he is the 'leading scientist', gives his position as 'Honorary Professor of Immunology, University of Bologna'. His research output in 2025-26 is mostly affiliated with Lobachevsky (see other_positions)."}, "other_positions": [{"title": "Leading scientist, Digital Personalized Medicine of Healthy Aging (DPM-ageing) project; researcher, Institute of Biogerontology", "organisation": "Lobachevsky State University of Nizhny Novgorod, Russia", "sources": ["https://dpm-ageing.unn.ru/en/leading-scientist/", "https://doi.org/10.1016/j.arr.2026.103280", "https://doi.org/10.1186/s13148-026-02195-w"]}], "location": {"city": "Bologna", "region": "Emilia-Romagna", "country_code": "IT", "sources": ["https://www.unibo.it/sitoweb/claudio.franceschi/en"], "checked": "2026-09-24", "status": "verified", "note": "The first-party Bologna page gives current Bologna contact details and office hours. Nizhny Novgorod is his main publication affiliation: it is the sole affiliation on about 23 of 28 papers from 2025-26 in Europe PMC, several with him as corresponding author. The Bologna DIMEC affiliation is co-listed on about 5 of those papers (for example Aging Cell, March 2026). No source states that he has relocated to Russia."}, "photo": {"status": "found", "image_url": "https://www.u-bordeaux.fr/application/files/cache/thumbnails/2018-03-12-hc-franceschi-1920x1372-165a368814b41bcea9304d7a666aa279.jpg", "page_url": "https://www.u-bordeaux.fr/en/about-us/honoris-causa/claudio-franceschi-university-bologna", "source_type": "institution_page", "credit": "© University of Bologna (as credited on the University of Bordeaux page)", "checked": "2026-09-23"}, "impact": {"text": "Claudio Franceschi is an immunologist and Emeritus Professor at the University of Bologna, where he has held emeritus status since 2016 after serving as Full Professor of Immunology. In the 1990s he described a chronic, low-grade inflammatory state accompanying human ageing that he named 'inflammaging', a concept since taken up in research on immunosenescence and age-related disease. He was among the early investigators to study ageing directly in humans rather than mainly in mice, and has worked extensively on centenarians, their offspring and spouses as a model of healthy ageing without major age-related disease. From 1996 to 2005 he was Scientific Director of the Italian National Research Centre on Aging (INRCA), and he coordinated the EU FP6 project GeHA (Genetics of Healthy Aging) from 2004 to 2009. He also founded and directed Bologna's 'L. Galvani' interdepartmental centre for bioinformatics, biophysics and biocomplexity. The University of Bordeaux awarded him an honorary doctorate in 2018. His 2026 publications list the Institute of Biogerontology at Lobachevsky State University, Nizhny Novgorod.", "word_count": 167, "sources": ["https://www.unibo.it/sitoweb/claudio.franceschi/en", "https://www.unibo.it/sitoweb/claudio.franceschi/cv-en", "https://www.u-bordeaux.fr/en/about-us/honoris-causa/claudio-franceschi-university-bologna", "https://doi.org/10.1016/j.arr.2026.103280"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 163, "source_url": "https://scholar.google.com/citations?user=Vu0SBi0AAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Claudio Franceschi', 'Prof Emeritus, University of Bologna and Lobachevsky State University, Nizhny Novgorod, Russia', verified unibo.it email; 134,374 citations (All)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=Vu0SBi0AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "University of Bologna page", "url": "https://www.unibo.it/sitoweb/claudio.franceschi/en"}, {"label": "University of Bologna CV", "url": "https://www.unibo.it/sitoweb/claudio.franceschi/cv-en"}]}, "sources": [{"url": "https://www.unibo.it/sitoweb/claudio.franceschi/en", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.unibo.it/sitoweb/claudio.franceschi/cv-en", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.u-bordeaux.fr/en/about-us/honoris-causa/claudio-franceschi-university-bologna", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.arr.2026.103280", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1186/s13148-026-02195-w", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=Vu0SBi0AAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://dpm-ageing.unn.ru/en/leading-scientist/", "type": "institution_page", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0047", "slug": "linda-p-fried", "name": {"display": "Linda P. Fried", "sort": "Fried, Linda P."}, "categories": ["scientist", "academic", "doctor"], "current_title": {"title": "Director, Robert N. Butler Columbia Aging Center; Robert N. Butler Professor of Healthy Aging; Dean Emerita, Mailman School of Public Health (Dean 2008-2025)", "organisation": "Columbia University Mailman School of Public Health", "sources": ["https://www.publichealth.columbia.edu/profile/linda-p-fried-md"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "New York", "region": "NY", "country_code": "US", "sources": ["https://www.publichealth.columbia.edu/profile/linda-p-fried-md"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.publichealth.columbia.edu/sites/default/files/styles/cola_media_400/public/cups-profile/headshot/8fe43f40-c98f-11ed-ac75-a11bc3df2fd1.jpg?itok=7ffiy09n", "page_url": "https://www.publichealth.columbia.edu/profile/linda-p-fried-md", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Linda P. Fried is a geriatrician and population scientist who directs the Robert N. Butler Columbia Aging Center and was Dean of Columbia University's Mailman School of Public Health from 2008 to 2025. Her research defined frailty as a clinical syndrome and examined its causes, together with the causes, consequences and prevention of disability, loneliness and chronic disease in older age. At Johns Hopkins, where she was Mason F. Lord Professor of Geriatric Medicine and founding director of the Center on Aging and Health, she led cohort studies including the Cardiovascular Health Study and the Women's Health and Aging Studies I and II. She co-designed and co-founded Experience Corps, an evidence-based senior volunteer programme intended to improve children's school outcomes and volunteers' health. She co-chaired the 2022 National Academy of Medicine report 'Global Roadmap for Healthy Longevity' and argues that investing in longer lives can yield a 'Third Demographic Dividend'. She is an elected member of the National Academy of Medicine and a past President of the Association of American Physicians. For the longevity field she connects geroscience with frailty research, public health and policy for ageing societies.", "word_count": 188, "sources": ["https://www.publichealth.columbia.edu/profile/linda-p-fried-md"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No clearly attributable public Google Scholar profile found via search."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Columbia Mailman School profile", "url": "https://www.publichealth.columbia.edu/profile/linda-p-fried-md"}]}, "sources": [{"url": "https://www.publichealth.columbia.edu/profile/linda-p-fried-md", "type": "institution_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0129", "slug": "fedor-galkin", "name": {"display": "Fedor Galkin", "sort": "Galkin, Fedor"}, "categories": ["scientist"], "current_title": {"title": "Director of AI Longevity Research", "organisation": "Insilico Medicine", "sources": ["https://www.youtube.com/watch?v=3PPd8kqsHTc", "https://doi.org/10.1038/s41587-026-03286-y", "https://doi.org/10.1016/j.cell.2026.08.026"], "source_type": "company_page", "checked": "2026-09-24", "status": "verified", "note": "Insilico Medicine's official YouTube channel (11 Sep 2026) titles him 'Director of Longevity AI Research' (same role, different word order); his LinkedIn headline reads 'Director of AI Longevity Research'. Earlier 2025–2026 sources say 'Senior Scientist'; see review.conflicts."}, "other_positions": [], "location": {"city": "Abu Dhabi", "region": "Abu Dhabi", "country_code": "AE", "sources": ["https://doi.org/10.1038/s41587-026-03286-y", "https://www.aging-us.com/interviews/longevity-aging-series-s4-e1-fedor-galkin"], "checked": "2026-09-24", "status": "verified"}, "photo": {"status": "found", "image_url": "https://deeplongevity.com/wp-content/uploads/2024/02/Fedor-Galkin.jpeg", "page_url": "https://deeplongevity.com/company/team-2/fedor-galkin/", "source_type": "company_page", "credit": "Deep Longevity", "checked": "2026-09-24"}, "impact": {"text": "Fedor Galkin develops machine-learning tools for measuring and studying biological ageing. He first worked at Insilico Medicine and then led research at its spin-off Deep Longevity. There he was first author on deep-learning aging clocks built from gut-microbiome profiles (iScience, 2020) and DNA methylation data (DeepMAge, Aging and Disease, 2021). He also co-wrote a widely cited 2020 review of biomarkers of aging and later work linking psychological factors to faster biological ageing. Now back at Insilico, he applies aging-biology AI to drug discovery. This includes a toolset connecting idiopathic pulmonary fibrosis with accelerated ageing (Aging-US, 2025) and, as second author, a 2026 Nature Biotechnology study that used proteomic aging clocks in a phase 2a clinical trial to assess possible geroprotective effects alongside the primary endpoints. He is senior author of a 2026 Cell paper that released LongevityBench, an open benchmark for testing large language models on aging-biology tasks, together with a family of compact longevity-focused language models. His work matters to longevity research mainly for building and openly benchmarking computational biomarkers and models that could serve as ageing endpoints in research and trials.", "word_count": 183, "sources": ["https://doi.org/10.1016/j.isci.2020.101199", "https://doi.org/10.14336/AD.2020.1202", "https://doi.org/10.1038/s41587-026-03286-y", "https://doi.org/10.1016/j.cell.2026.08.026", "https://insilico.com/news/cell170926en-ai-longevity-discovery-toolkit", "https://www.aging-us.com/interviews/longevity-aging-series-s4-e1-fedor-galkin"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 15, "source_url": "https://scholar.google.com/citations?user=sjbHXdwAAAAJ", "checked": "2026-09-24", "status": "verified", "note": "Profile 'Fedor Galkin', Insilico Medicine; verified email at insilico.com. 'All' column (since 2021: 15); 1,330 citations. The profile has some duplicate entries for the 2020 iScience paper."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=sjbHXdwAAAAJ", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/fgalkin/", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0002-5709-9529", "status": "verified"}, "official": [{"label": "Insilico Medicine", "url": "https://insilico.com/"}, {"label": "Deep Longevity team page (former role)", "url": "https://deeplongevity.com/company/team-2/fedor-galkin/"}, {"label": "LongevityBench", "url": "https://longevitybenchmarks.org/"}]}, "sources": [{"url": "https://www.youtube.com/watch?v=3PPd8kqsHTc", "type": "company_page", "accessed": "2026-09-24"}, {"url": "https://doi.org/10.1038/s41587-026-03286-y", "type": "publication", "accessed": "2026-09-24"}, {"url": "https://doi.org/10.1016/j.cell.2026.08.026", "type": "publication", "accessed": "2026-09-24"}, {"url": "https://insilico.com/news/cell170926en-ai-longevity-discovery-toolkit", "type": "press_release", "accessed": "2026-09-24"}, {"url": "https://www.aging-us.com/interviews/longevity-aging-series-s4-e1-fedor-galkin", "type": "secondary", "accessed": "2026-09-24"}, {"url": "https://bsra.org.uk/programme-and-speakers/", "type": "conference_bio", "accessed": "2026-09-24"}, {"url": "https://insilico.com/news/zxgcbd5dx1-ardd-for-healthy-longevity-how-science-t", "type": "press_release", "accessed": "2026-09-24"}, {"url": "https://deeplongevity.com/company/team-2/fedor-galkin/", "type": "company_page", "accessed": "2026-09-24"}, {"url": "https://scholar.google.com/citations?user=sjbHXdwAAAAJ", "type": "registry", "accessed": "2026-09-24"}, {"url": "https://orcid.org/0000-0002-5709-9529", "type": "registry", "accessed": "2026-09-24"}, {"url": "https://doi.org/10.1016/j.isci.2020.101199", "type": "publication", "accessed": "2026-09-24"}, {"url": "https://doi.org/10.14336/AD.2020.1202", "type": "publication", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-24", "updated": "2026-09-29", "phase": "5.1"}}, {"id": "per_0048", "slug": "david-gems", "name": {"display": "David Gems", "sort": "Gems, David"}, "categories": ["scientist", "academic", "communicator"], "current_title": {"title": "Professor of Biogerontology; Research Director, Institute of Healthy Ageing", "organisation": "University College London (UCL)", "sources": ["https://profiles.ucl.ac.uk/2485-david-gems"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "London", "region": "England", "country_code": "GB", "sources": ["https://profiles.ucl.ac.uk/2485-david-gems"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://profiles.ucl.ac.uk/2485-david-gems/thumbnail", "page_url": "https://profiles.ucl.ac.uk/2485-david-gems", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "David Gems is Professor of Biogerontology and Research Director of the UCL Institute of Healthy Ageing, of which he is a founder member. He began working on the biology of ageing in 1993 in Don Riddle's lab at the University of Missouri-Columbia and set up his own lab at UCL in 1997 with a Royal Society fellowship. His work mainly uses the nematode C. elegans to study the fundamental mechanisms that cause ageing and late-life disease, and he has contributed to ageing studies in other nematodes, Drosophila, mice and Pacific salmon. His most-cited papers include the discovery that loss of the insulin receptor substrate CHICO extends Drosophila lifespan, a study showing that metformin slows C. elegans ageing by altering microbial folate and methionine metabolism, and a review on the biological roles of reactive oxygen species. He is associated with 'programmatic' theories of ageing, which seek general evolutionary and mechanistic explanations of ageing and multifactorial late-life disease, and he also writes on ethical and philosophical issues in ageing research. His book for general readers, 'On Aging: Solving the Mysteries of Late-Life Maladies', is listed by Columbia University Press for March 2027.", "word_count": 190, "sources": ["https://profiles.ucl.ac.uk/2485-david-gems", "https://scholar.google.com/citations?user=vt82pW8AAAAJ&hl=en", "https://cup.columbia.edu/book/on-aging/9780231224543/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 72, "source_url": "https://scholar.google.com/citations?user=vt82pW8AAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Profile 'David Gems' (affiliation field blank) with verified ucl.ac.uk email; publication list matches (CHICO, metformin/C. elegans); 26,150 citations (All)"}, {"kind": "audience", "for_category": "communicator", "platform": "book", "value": null, "source_url": "https://cup.columbia.edu/book/on-aging/9780231224543/", "checked": "2026-09-23", "status": "unavailable", "note": "Forthcoming book 'On Aging: Solving the Mysteries of Late-Life Maladies' (Columbia University Press, pub date March 2027); no audience/sales figure available."}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No personal social-media account linked from UCL profile or lab homepage (homepages.ucl.ac.uk/~ucbtdag); none recorded."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=vt82pW8AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UCL profile", "url": "https://profiles.ucl.ac.uk/2485-david-gems"}]}, "sources": [{"url": "https://profiles.ucl.ac.uk/2485-david-gems", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=vt82pW8AAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://cup.columbia.edu/book/on-aging/9780231224543/", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0049", "slug": "vadim-gladyshev", "name": {"display": "Vadim Gladyshev", "sort": "Gladyshev, Vadim"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Medicine; Director, Center for Redox Medicine", "organisation": "Harvard Medical School / Brigham and Women's Hospital", "sources": ["https://bcmp.hms.harvard.edu/faculty-staff/vadim-gladyshev", "https://ogephd.hms.harvard.edu/people/vadim-gladyshev", "https://agingpharma.org/speakers/vadim-gladyshev/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Associate Member", "organisation": "Broad Institute", "sources": ["https://agingpharma.org/speakers/vadim-gladyshev/"]}], "location": {"city": "Boston", "region": "MA", "country_code": "US", "sources": ["https://bcmp.hms.harvard.edu/faculty-staff/vadim-gladyshev", "https://ogephd.hms.harvard.edu/people/vadim-gladyshev"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://agingpharma.org/images/ardd-vadim-gladyshev-tilda-migration.jpg", "page_url": "https://agingpharma.org/speakers/vadim-gladyshev/", "source_type": "conference_listing", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Vadim Gladyshev is Professor of Medicine at Harvard Medical School and Director of the Center for Redox Medicine at Brigham and Women's Hospital, and an associate member of the Broad Institute. His lab combines experimental and computational approaches to study ageing, lifespan control and rejuvenation. It builds 'longevity signatures' from comparisons of long- and short-lived species, lifespan-extending interventions and cell types, and uses them to screen for new interventions. Building on human epigenetic clocks, his group developed the first mouse epigenetic ageing clocks and a single-cell clock, scAge. It reported that biological age falls during early embryogenesis around gastrulation and can be reversed by heterochronic parabiosis. He proposed the 'deleteriome' as a framework for the nature of ageing. His lab is also known for identifying the full set of 25 human selenoprotein genes and for work on selenium and redox biology. He co-authored a 2024 Nature Medicine consensus paper on validating biomarkers of ageing. He has received NIH Pioneer, Transformative and Eureka awards and is an elected member of the US National Academy of Sciences.", "word_count": 175, "sources": ["https://ogephd.hms.harvard.edu/people/vadim-gladyshev", "https://agingpharma.org/speakers/vadim-gladyshev/", "https://scholar.google.com/citations?user=CosBFrUAAAAJ&hl=en", "https://www.ncbi.nlm.nih.gov/pubmed/38355974"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 146, "source_url": "https://scholar.google.com/citations?user=CosBFrUAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Vadim Gladyshev', Professor of Medicine, Brigham and Women's Hospital, Harvard Medical School; verified rics.bwh.harvard.edu email; 71,908 citations (All)"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=CosBFrUAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "HMS BCMP faculty page", "url": "https://bcmp.hms.harvard.edu/faculty-staff/vadim-gladyshev"}, {"label": "HMS PhD programs profile (lab research)", "url": "https://ogephd.hms.harvard.edu/people/vadim-gladyshev"}]}, "sources": [{"url": "https://bcmp.hms.harvard.edu/faculty-staff/vadim-gladyshev", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://ogephd.hms.harvard.edu/people/vadim-gladyshev", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://agingpharma.org/speakers/vadim-gladyshev/", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=CosBFrUAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0050", "slug": "vera-gorbunova", "name": {"display": "Vera Gorbunova", "sort": "Gorbunova, Vera"}, "categories": ["scientist", "academic"], "current_title": {"title": "Doris Johns Cherry Professor of Biology and Medicine; Co-director, Rochester Aging Research Center", "organisation": "University of Rochester", "sources": ["https://www.sas.rochester.edu/bio/labs/gorbunova/team/vera-gorbunova/", "https://www.rochester.edu/college/bio/people/faculty/gorbunova_vera/index.html"], "source_type": "lab_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Rochester", "region": "NY", "country_code": "US", "sources": ["https://www.sas.rochester.edu/bio/labs/gorbunova/team/vera-gorbunova/", "https://www.rochester.edu/college/bio/people/faculty/gorbunova_vera/index.html"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.sas.rochester.edu/bio/labs/gorbunova/wp-content/uploads/2017/03/Photo-Mar-25-2-27-39-PM-1024x683.png", "page_url": "https://www.sas.rochester.edu/bio/labs/gorbunova/team/vera-gorbunova/", "source_type": "lab_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Vera Gorbunova is the Doris Johns Cherry Professor of Biology and Medicine at the University of Rochester and co-director of the Rochester Aging Research Center, where she runs a laboratory with Andrei Seluanov. Her research examines the mechanisms of longevity and genome stability, with emphasis on exceptionally long-lived mammals. She pioneered a comparative-biology approach to ageing and identified rules that govern how tumour-suppressor mechanisms evolve with species lifespan and body mass. Her group identified high-molecular-weight hyaluronan as a key mediator of cancer resistance in the naked mole-rat, and has also studied the blind mole-rat, beavers and bats. She investigates how sirtuins, particularly SIRT6, maintain genome stability; her most-cited work includes a report that SIRT6 promotes DNA repair under stress by activating PARP1. It also includes a 2019 Nature paper showing that the retrotransposon L1 drives interferon responses in senescent cells and promotes age-associated inflammation. She trained at Saint Petersburg State University and the Weizmann Institute of Science. Her awards include the PNAS Cozzarelli Prize and support from the Ellison Medical Foundation, the Glenn Foundation and AFAR.", "word_count": 176, "sources": ["https://www.sas.rochester.edu/bio/labs/gorbunova/team/vera-gorbunova/", "https://www.rochester.edu/college/bio/people/faculty/gorbunova_vera/index.html", "https://scholar.google.com/citations?user=ZKlFrUIAAAAJ&hl=en"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 84, "source_url": "https://scholar.google.com/citations?user=ZKlFrUIAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Vera Gorbunova', University of Rochester, verified rochester.edu email; publications match (SIRT6/PARP1, L1 in senescence); 27,509 citations (All). A second Scholar profile with the same name (user=Lg7HfNEAAAAJ) was not used."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=ZKlFrUIAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Gorbunova & Seluanov Laboratory", "url": "https://www.sas.rochester.edu/bio/labs/gorbunova/team/vera-gorbunova/"}, {"label": "University of Rochester Biology faculty page", "url": "https://www.rochester.edu/college/bio/people/faculty/gorbunova_vera/index.html"}]}, "sources": [{"url": "https://www.sas.rochester.edu/bio/labs/gorbunova/team/vera-gorbunova/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.rochester.edu/college/bio/people/faculty/gorbunova_vera/index.html", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=ZKlFrUIAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0051", "slug": "jan-gruber", "name": {"display": "Jan Gruber", "sort": "Gruber, Jan"}, "categories": ["scientist", "academic"], "current_title": {"title": "Associate Professor, Department of Biochemistry; Healthy Longevity Translational Research Program", "organisation": "Yong Loo Lin School of Medicine, National University of Singapore", "sources": ["https://medicine.nus.edu.sg/bch/faculty/jan-gruber/", "https://doi.org/10.1038/s41467-026-76737-4", "https://doi.org/10.18632/aging.206378"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Rank 'Associate Professor' from the NUS Biochemistry page (Affiliations) and the Gero team page; the NUS page's experience table still lists 'Assistant Professor 2014-present' and a Yale-NUS appointment (not updated). Program affiliation from 2026 publications."}, "other_positions": [{"title": "Team member (listed as Associate Professor at NUS)", "organisation": "Gero", "sources": ["https://www.gero.ai/team"]}], "location": {"city": "Singapore", "region": "", "country_code": "SG", "sources": ["https://medicine.nus.edu.sg/bch/faculty/jan-gruber/", "https://doi.org/10.1038/s41467-026-76737-4"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://medicine.nus.edu.sg/bch/wp-content/uploads/sites/13/2020/01/team-5-1.jpg", "page_url": "https://medicine.nus.edu.sg/bch/faculty/jan-gruber/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Jan Gruber is an Associate Professor in the Department of Biochemistry at the National University of Singapore's Yong Loo Lin School of Medicine and part of its Healthy Longevity Translational Research Program. Trained in physics and applied mathematics at RWTH Aachen and Cambridge, he completed a DPhil in biochemistry at Oxford before moving to NUS, where he has run a laboratory since 2014. His early work used C. elegans to test the role of mitochondria and free radicals in ageing, including studies of mitochondria-targeted antioxidants and of oxidative-damage biomarkers, and a review of the mitochondrial free radical theory of ageing. More recent publications apply computational and physics-based approaches to ageing, including 'Foundations of Gerophysics', a pathology-trained lipid ageing clock, single-cell analyses of nonlinear immune ageing, and a proposal to reframe biological age as risk-equivalent age. He is listed on the team of the ageing-biotech company Gero, whose framework for classifying ageing interventions is named the Fedichev-Gruber theory. For the longevity field he works on quantitative definitions of biological age and on theory for choosing intervention strategies.", "word_count": 176, "sources": ["https://medicine.nus.edu.sg/bch/faculty/jan-gruber/", "https://doi.org/10.1038/s41467-026-76737-4", "https://doi.org/10.14336/ad.2026.0300", "https://doi.org/10.18632/aging.206378", "https://doi.org/10.1038/s43587-025-01038-2", "https://scholar.google.com/citations?user=s4XzRAYAAAAJ&hl=en", "https://www.gero.ai/team", "https://www.gero.ai/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 37, "source_url": "https://scholar.google.com/citations?user=s4XzRAYAAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "Profile 'Jan Gruber', Associate Professor at Yale-NUS College and National University of Singapore, verified yale-nus.edu.sg email; top papers include 'The mitochondrial free radical theory of ageing - where do we stand'; 5,302 citations (All). Affiliation text on profile is outdated (Yale-NUS)."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=s4XzRAYAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "NUS Biochemistry faculty page", "url": "https://medicine.nus.edu.sg/bch/faculty/jan-gruber/"}]}, "sources": [{"url": "https://medicine.nus.edu.sg/bch/faculty/jan-gruber/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41467-026-76737-4", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.14336/ad.2026.0300", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.18632/aging.206378", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s43587-025-01038-2", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://www.gero.ai/team", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.gero.ai/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=s4XzRAYAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0052", "slug": "leonard-guarente", "name": {"display": "Leonard Guarente", "sort": "Guarente, Leonard"}, "categories": ["scientist", "academic", "entrepreneur"], "current_title": {"title": "Novartis Professor of Biology", "organisation": "Massachusetts Institute of Technology (MIT), Department of Biology", "sources": ["https://biology.mit.edu/profile/leonard-p-guarente/", "https://www.elysiumhealth.com/blogs/leadership-team/leonard-guarente-phd"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "MIT Biology profile still lists Novartis Professor of Biology; the Guarente Lab site states the lab operated 1982-2025 and that he continues to teach at MIT and pursue ageing-related research."}, "other_positions": [{"title": "Co-founder and Chief Scientist", "organisation": "Elysium Health", "sources": ["https://www.elysiumhealth.com/pages/mission", "https://www.elysiumhealth.com/blogs/leadership-team/leonard-guarente-phd"]}], "location": {"city": "Cambridge", "region": "MA", "country_code": "US", "sources": ["https://guarentelab.mit.edu/", "https://biology.mit.edu/profile/leonard-p-guarente/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://biology.mit.edu/wp-content/uploads/2017/11/Guarente_Big.jpeg", "page_url": "https://biology.mit.edu/profile/leonard-p-guarente/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Leonard Guarente is the Novartis Professor of Biology at MIT, where his laboratory operated from 1982 to 2025; according to the lab website he continues to teach at MIT and to pursue ageing-related research. His research on the genetic and molecular basis of ageing, first in model organisms and later in mammals and humans, is best known for work on sirtuins. His group showed that SIR2 controls ageing in yeast cells and that SIR2 is an NAD-dependent histone deacetylase, linking NAD+ metabolism to ageing. It also reported that increased dosage of a sir-2 gene extends lifespan in C. elegans. Later work examined the mammalian homologue SIRT1 in metabolism, fat mobilisation, neuromuscular degeneration and brain ageing, including the rate of brain ageing as a risk factor for Alzheimer's disease together with APOE4. He is Chief Scientist of Elysium Health, a consumer health company that sells an NAD+ supplement and announced a USD 40 million Series C equity and debt financing in December 2019. For the longevity field his work is a reference point for sirtuin and NAD+ research and its commercial translation into supplements.", "word_count": 183, "sources": ["https://biology.mit.edu/profile/leonard-p-guarente/", "https://guarentelab.mit.edu/", "https://www.elysiumhealth.com/blogs/leadership-team/leonard-guarente-phd", "https://www.prnewswire.com/news-releases/elysium-health-announces-40-million-series-c-financing-led-by-gisev-family-office-300979014.html"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No Google Scholar profile for Leonard Guarente found via search."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Elysium Health", "label": "Elysium Health publicly disclosed Series C funding (2019)", "value": 40000000, "currency": "USD", "scope": "single_round", "source_url": "https://www.prnewswire.com/news-releases/elysium-health-announces-40-million-series-c-financing-led-by-gisev-family-office-300979014.html", "checked": "2026-09-23", "status": "verified", "note": "Series C equity and debt financing, announced 23 Dec 2019, led by GISEV Family Office. Total disclosed funding across rounds not verified. Guarente's founder status not confirmed (Elysium lists him as Chief Scientist; Eric Marcotulli is described as co-founder)."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "MIT Biology profile", "url": "https://biology.mit.edu/profile/leonard-p-guarente/"}, {"label": "Guarente Lab (archival)", "url": "https://guarentelab.mit.edu/"}, {"label": "Elysium Health leadership page", "url": "https://www.elysiumhealth.com/blogs/leadership-team/leonard-guarente-phd"}]}, "sources": [{"url": "https://biology.mit.edu/profile/leonard-p-guarente/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://guarentelab.mit.edu/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.elysiumhealth.com/blogs/leadership-team/leonard-guarente-phd", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.elysiumhealth.com/blogs/leadership-team/eric-marcotulli", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.prnewswire.com/news-releases/elysium-health-announces-40-million-series-c-financing-led-by-gisev-family-office-300979014.html", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.elysiumhealth.com/pages/mission", "type": "company_page", "accessed": "2026-09-24"}, {"url": "https://archivana.com/elysium-health/ktla-interviews-elysiums-leonard-guarente-phd-mktzm829", "type": "other", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0053", "slug": "malene-hansen", "name": {"display": "Malene Hansen", "sort": "Hansen, Malene"}, "categories": ["scientist", "academic"], "current_title": {"title": "Chief Scientific Officer and Professor", "organisation": "Buck Institute for Research on Aging", "sources": ["https://www.buckinstitute.org/lab/hansen-lab/"], "source_type": "lab_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Novato", "region": "CA", "country_code": "US", "sources": ["https://www.buckinstitute.org/lab/hansen-lab/", "https://www.buckinstitute.org/visit-us/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.buckinstitute.org/wp-content/uploads/2021/02/Malene-lab-retouched-smaller-e1676414297113.jpg", "page_url": "https://www.buckinstitute.org/lab/hansen-lab/", "source_type": "lab_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Malene Hansen studies autophagy, the lysosomal recycling pathway that maintains cellular homeostasis, and how its regulation changes with age. Her laboratory combines genetic, cytological, biochemical and pharmacological approaches in the nematode C. elegans and in human cell culture, with the aim of understanding age-dependent decline in autophagy and restoring the process in older organisms and in age-related disease. Trained in Denmark (M.Sc. and Ph.D., Copenhagen University), she was a postdoctoral fellow with Cynthia Kenyon at UCSF from 2001, established her lab at Sanford Burnham Prebys in 2007, and joined the Buck Institute in 2021 as Chief Scientific Officer and faculty member. Her recognitions include an Ellison Medical Foundation New Scholar in Aging Award, a Glenn Award, the AFAR Irving Wright Award of Distinction (2021) and the University of Michigan Bennett Cohen Award (2024). She is a past chair of the NIH Cellular and Molecular Mechanisms of Aging study section and has co-organised the Cold Spring Harbor Mechanisms of Aging meeting (2014-2018) and Gordon Research Conferences on autophagy. Her work connects autophagy and proteostasis to lifespan regulation, and she holds senior scientific leadership at an institute dedicated to aging research.", "word_count": 189, "sources": ["https://www.buckinstitute.org/lab/hansen-lab/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 53, "source_url": "https://scholar.google.com/citations?user=Vwc0nrAAAAAJ", "note": "All-time h-index; profile lists Professor, Buck Institute for Research on Aging", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=Vwc0nrAAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Hansen Lab, Buck Institute", "url": "https://www.buckinstitute.org/lab/hansen-lab/"}]}, "sources": [{"url": "https://www.buckinstitute.org/lab/hansen-lab/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=Vwc0nrAAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://www.buckinstitute.org/visit-us/", "type": "institution_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0054", "slug": "jan-hoeijmakers", "name": {"display": "Jan Hoeijmakers", "sort": "Hoeijmakers, Jan"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Molecular Genetics; Principal Investigator, Department of Molecular Genetics", "organisation": "Erasmus MC (Erasmus University Medical Center)", "sources": ["https://www.erasmusmc.nl/en/research/researchers/hoeijmakers-jan", "https://scholar.google.com/citations?user=F6Y9nxUAAAAJ"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Group leader", "organisation": "Princess Maxima Center for Pediatric Oncology", "sources": ["https://www.prinsesmaximacentrum.nl/en/professionals/researchers/jan-hoeijmakers"]}, {"title": "Guest Professor, International Faculty", "organisation": "University of Cologne", "sources": ["https://www.erasmusmc.nl/en/research/researchers/hoeijmakers-jan"]}], "location": {"city": "Rotterdam", "region": "South Holland", "country_code": "NL", "sources": ["https://www.erasmusmc.nl/en/research/researchers/hoeijmakers-jan", "https://scholar.google.com/citations?user=F6Y9nxUAAAAJ"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.erasmusmc.nl/-/media/erasmusmc/images/4-biomedische-wetenschappen/bmw-mg-jan-hoeijmakers.jpg", "page_url": "https://www.erasmusmc.nl/en/research/researchers/hoeijmakers-jan", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Jan Hoeijmakers is a molecular geneticist whose work links DNA damage and repair to aging. Since joining Erasmus University Rotterdam in 1981, and as Professor of Molecular Genetics since 1993, his group has identified human DNA repair genes (including isolation of the first human DNA repair gene, recognised in 1986), developed live-cell imaging methods to study repair, and generated mouse models of human repair-deficiency syndromes such as Cockayne syndrome and trichothiodystrophy. These models show that accumulating DNA damage drives segmental accelerated aging, with the severity and type of repair defect shaping the aging and cancer phenotype. His group has also described DNA damage-driven transcriptional stress as a contributor to aging and reported effects of nutritional interventions on repair-deficient mice, with proposed relevance to dementia, chemotherapy and ischemia-reperfusion injury. His honours include the Louis Jeantet Prize (1995), the NWO Spinoza Prize, EMBO membership, ERC Advanced and Proof-of-Concept grants, and a Royal Netherlands Academy professorship (2011-2016). He also leads a group at the Princess Maxima Center studying nutritional effects on genomic stability and holds a guest professorship at the University of Cologne. His work bears directly on genomic instability as a driver of aging.", "word_count": 192, "sources": ["https://www.erasmusmc.nl/en/research/researchers/hoeijmakers-jan", "https://www.prinsesmaximacentrum.nl/en/professionals/researchers/jan-hoeijmakers"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 146, "source_url": "https://scholar.google.com/citations?user=F6Y9nxUAAAAJ", "note": "All-time h-index; profile lists Prof. Molecular Genetics, Erasmus University Medical Center, Rotterdam; verified erasmusmc.nl email", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=F6Y9nxUAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Erasmus MC researcher profile", "url": "https://www.erasmusmc.nl/en/research/researchers/hoeijmakers-jan"}, {"label": "Princess Maxima Center profile", "url": "https://www.prinsesmaximacentrum.nl/en/professionals/researchers/jan-hoeijmakers"}]}, "sources": [{"url": "https://www.erasmusmc.nl/en/research/researchers/hoeijmakers-jan", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.prinsesmaximacentrum.nl/en/professionals/researchers/jan-hoeijmakers", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=F6Y9nxUAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0055", "slug": "steve-horvath", "name": {"display": "Steve Horvath", "sort": "Horvath, Steve"}, "categories": ["scientist", "academic", "entrepreneur"], "current_title": {"title": "Professor of Medicine (Division of Geriatrics); Director of Aging Biology Research, Department of Medicine", "organisation": "David Geffen School of Medicine, University of California, Los Angeles (UCLA)", "sources": ["https://www.uclahealth.org/news/article/leader-study-longevity-returning-ucla-health", "https://horvathaginglab.org/people"], "source_type": "institution_page", "checked": "2026-09-24", "status": "verified", "note": "UCLA Health announcement (June 2026): returning as professor in the David Geffen School of Medicine on 1 July 2026 and as director of aging biology research in the Department of Medicine; the Division of Geriatrics is his home division per the lab page and Scholar profile."}, "other_positions": [{"title": "Co-Founder & Chair, Scientific Advisory Board", "organisation": "Clock Foundation (Epigenetic Clock Development Foundation)", "sources": ["https://clockfoundation.org/", "https://doi.org/10.1038/s41514-026-00425-2"]}, {"title": "Principal Investigator (former; left in early 2026)", "organisation": "Altos Labs", "sources": ["https://agingpharma.org/speakers/steve-horvath/", "https://www.uclahealth.org/news/article/leader-study-longevity-returning-ucla-health", "https://ipscell.com/2026/05/did-altos-labs-just-reprogram-itself-to-focus-on-ai-peter-walter-steve-horvath-more-departures/"]}], "location": {"city": "Los Angeles", "region": "CA", "country_code": "US", "sources": ["https://www.uclahealth.org/news/article/leader-study-longevity-returning-ucla-health", "https://doi.org/10.1038/s41591-026-04524-1"], "checked": "2026-09-24", "status": "verified"}, "photo": {"status": "found", "image_url": "https://static.tildacdn.com/tild3662-6262-4031-a133-636235646332/Steve_Horvath.jpg", "page_url": "https://agingpharma.org/speakers/steve-horvath/", "source_type": "conference_listing", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Steve Horvath is a geroscientist and biostatistician best known for developing DNA methylation-based epigenetic clocks. With UCLA colleagues he published an epigenetic clock for saliva in 2011 and, in 2013, the pan-tissue clock widely called the Horvath clock; he is a primary developer of the PhenoAge and GrimAge clocks and led the international Mammalian Methylation Consortium, which produced universal clocks applicable across mammalian species. Epigenetic age exceeding chronological age has been associated with higher all-cause mortality risk, and these clocks are used as outcome measures in human studies and trials such as DO-HEALTH and in the Women's Health Initiative. Horvath was a professor of Human Genetics and Biostatistics at UCLA for 22 years, then spent about 4.5 years in industry, including as a principal investigator at Altos Labs, before returning to the David Geffen School of Medicine at UCLA on 1 July 2026. He is co-founder and chair of the scientific advisory board of the non-profit Clock Foundation. He received the 2026 Luminary Award of the Precision Medicine World Conference.", "word_count": 170, "sources": ["https://www.uclahealth.org/news/article/leader-study-longevity-returning-ucla-health", "https://agingpharma.org/speakers/steve-horvath/", "https://clockfoundation.org/", "https://horvathaginglab.org/people"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 161, "source_url": "https://scholar.google.com/citations?user=mEM8q5cAAAAJ", "note": "All-time h-index; profile lists Professor of Medicine, Geriatrics, UCLA; verified mednet.ucla.edu email; linked from lab page", "checked": "2026-09-23", "status": "verified"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Clock Foundation", "label": "Clock Foundation publicly reported fundraising total", "value": null, "currency": "USD", "scope": "total_disclosed", "source_url": "https://clockfoundation.org/", "checked": "2026-09-23", "status": "unavailable", "note": "501(c)(3) non-profit (Epigenetic Clock Development Foundation). No fundraising or donation total stated by the foundation or press. IRS Form 990 data (ProPublica, EIN 85-1457272) shows revenue mostly from programme services (testing); contributions reported per year (e.g. $1.5M in 2021, $0.5M in 2020) are annual, not a cumulative total, and are not recorded as capital raised."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=mEM8q5cAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0002-4110-3589", "status": "verified"}, "official": [{"label": "Horvath Lab", "url": "https://horvathaginglab.org/people"}, {"label": "UCLA Health announcement", "url": "https://www.uclahealth.org/news/article/leader-study-longevity-returning-ucla-health"}, {"label": "Clock Foundation", "url": "https://clockfoundation.org/"}]}, "sources": [{"url": "https://www.uclahealth.org/news/article/leader-study-longevity-returning-ucla-health", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://horvathaginglab.org/people", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://agingpharma.org/speakers/steve-horvath/", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://clockfoundation.org/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=mEM8q5cAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41591-026-04524-1", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://ipscell.com/2026/05/did-altos-labs-just-reprogram-itself-to-focus-on-ai-peter-walter-steve-horvath-more-departures/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://projects.propublica.org/nonprofits/organizations/851457272", "type": "other", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0056", "slug": "riekelt-houtkooper", "name": {"display": "Riekelt Houtkooper", "sort": "Houtkooper, Riekelt"}, "categories": ["scientist", "academic"], "current_title": {"title": "Full Professor, Genetic Metabolic Diseases (Professor of Translational Metabolism)", "organisation": "Amsterdam UMC, University of Amsterdam", "sources": ["https://www.amsterdamumc.org/en/research/researchers/riekelt-houtkooper-1", "https://www.nadis.eu/team/riekelt-houtkooper/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Amsterdam", "region": "North Holland", "country_code": "NL", "sources": ["https://www.amsterdamumc.org/en/research/researchers/riekelt-houtkooper-1"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.amsterdamumc.org/upload_mm/2/8/f/cid92284_1781050931997_Houtkooper_Riekelt_hoogleraar_AMC_square.jpeg", "page_url": "https://www.amsterdamumc.org/en/research/researchers/riekelt-houtkooper-1", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Riekelt Houtkooper is Professor of Translational Metabolism at Amsterdam UMC (University of Amsterdam), where his group in the Laboratory Genetic Metabolic Diseases studies mitochondrial metabolism in the contexts of inborn errors of metabolism and aging. After a PhD in Amsterdam and postdoctoral work at EPFL, he co-authored work proposing mitonuclear protein imbalance as a conserved longevity mechanism (Nature, 2013) and showing that the NAD+/sirtuin pathway modulates longevity through the mitochondrial unfolded protein response and FOXO signalling (Cell, 2013). His team uses cross-species multi-omics to study metabolic flexibility, with a particular focus on NAD+: with collaborators it has reported therapeutic effects of the NAD+ precursor nicotinamide riboside in mice, lifespan extension in C. elegans, NRH and NMNH as NAD+ boosters, and trials of nicotinamide riboside in people with compromised metabolic health. His group has also reported that NAD+ abundance associates with muscle function and healthy aging in humans (Nature Aging, 2022). He coordinates the MSCA Doctoral Network NADIS and serves on the boards of the Dutch Society for Research on Aging, the Dutch Metabolomics Center and the Emma Center for Personalized Medicine.", "word_count": 181, "sources": ["https://www.amsterdamumc.org/en/research/researchers/riekelt-houtkooper-1", "https://www.nadis.eu/team/riekelt-houtkooper/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 75, "source_url": "https://scholar.google.com/citations?user=GdeUrx8AAAAJ", "note": "All-time h-index; profile lists Professor of Translational Metabolism, Academic Medical Center (AMC), Amsterdam", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=GdeUrx8AAAAJ", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/riekelthoutkooper/", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0001-9961-0842", "status": "verified"}, "official": [{"label": "Amsterdam UMC researcher profile", "url": "https://www.amsterdamumc.org/en/research/researchers/riekelt-houtkooper-1"}, {"label": "NADIS team profile", "url": "https://www.nadis.eu/team/riekelt-houtkooper/"}]}, "sources": [{"url": "https://www.amsterdamumc.org/en/research/researchers/riekelt-houtkooper-1", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.nadis.eu/team/riekelt-houtkooper/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=GdeUrx8AAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0057", "slug": "heinrich-jasper", "name": {"display": "Heinrich Jasper", "sort": "Jasper, Heinrich"}, "categories": ["scientist"], "current_title": {"title": "Principal Fellow, Regenerative Medicine, Research Biology", "organisation": "Genentech", "sources": ["https://www.gene.com/scientists/our-scientists/heinrich-jasper"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "South San Francisco", "region": "CA", "country_code": "US", "sources": ["https://doi.org/10.1111/acel.70495", "https://doi.org/10.18632/aging.206368"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.gene.com/assets/content/scientist_profile/scientist-profile_heinrich-jasper_500x500.jpg", "page_url": "https://www.gene.com/scientists/our-scientists/heinrich-jasper", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Heinrich Jasper studies how stress and inflammatory signalling pathways influence tissue homeostasis, regeneration and longevity. Educated in Germany, he ran an academic laboratory for 12 years at the University of Rochester and then the Buck Institute for Research on Aging, using model organisms to study the age-related decline of somatic stem cell function. His work examined intrinsic, local and systemic cues controlling stem cell behaviour, and in particular how age-associated chronic inflammation perturbs regeneration in barrier epithelia such as the intestine; for example, his group reported that calcium signalling integrates signals regulating intestinal stem cell activity (Nature, 2015). He moved to Genentech, where he is a Principal Fellow in Regenerative Medicine, Research Biology. Work there has included immune modulation to promote retinal repair and improve cell replacement therapy (Science, 2016), maladaptive inflammatory signalling impairing colonic regeneration in old mice (Aging Cell, 2026), and perspectives on partial reprogramming and tissue healing. His career illustrates a route by which fundamental aging biology in model organisms is being carried into pharmaceutical research and development focused on regeneration and age-related disease.", "word_count": 177, "sources": ["https://www.gene.com/scientists/our-scientists/heinrich-jasper", "https://doi.org/10.1111/acel.70495"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 63, "source_url": "https://scholar.google.com/citations?user=pqNtuVoAAAAJ", "note": "All-time h-index; profile lists Staff Scientist, Genentech; verified gene.com email", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=pqNtuVoAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Genentech scientist profile", "url": "https://www.gene.com/scientists/our-scientists/heinrich-jasper"}]}, "sources": [{"url": "https://www.gene.com/scientists/our-scientists/heinrich-jasper", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=pqNtuVoAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1111/acel.70495", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0058", "slug": "bryan-johnson", "name": {"display": "Bryan Johnson", "sort": "Johnson, Bryan"}, "categories": ["entrepreneur", "communicator"], "current_title": {"title": "Founder", "organisation": "Blueprint (Blueprint Bryan Johnson)", "sources": ["https://blueprint.bryanjohnson.com/pages/about", "https://longevity.technology/news/bryan-johnsons-blueprint-raises-star-studded-60m-funding-round/", "https://www.linkedin.com/in/bryanrjohnson"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": null, "region": "CA", "country_code": "US", "sources": ["https://www.linkedin.com/in/bryanrjohnson"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://blueprint.bryanjohnson.com/cdn/shop/files/Blueprint_Bryan_1_2.jpg?v=1769195131&width=1200", "page_url": "https://blueprint.bryanjohnson.com/pages/about", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Bryan Johnson is a technology entrepreneur who founded the payments company Braintree, which with Venmo was sold for $800 million, and later turned to personal longevity experimentation. With a team of medical professionals he developed Blueprint, an intensive, heavily measured personal health protocol that he publishes free of charge and that underpins the consumer company Blueprint, which sells nutrition, supplement and personal-care products and offers biomarker testing. In October 2025 Blueprint announced a $60 million funding round from about 50 individual investors, with the stated aim of making the measurements, protocols and therapies in his regimen accessible to others. He also promotes 'Don't Die', a movement and philosophy framing the avoidance of death as a societal priority, through summits, an app and a Netflix documentary about his regimen. His relevance to the longevity field lies mainly in public communication and consumer products rather than peer-reviewed research; his YouTube channel has more than two million subscribers.", "word_count": 155, "sources": ["https://blueprint.bryanjohnson.com/pages/about", "https://longevity.technology/news/bryan-johnsons-blueprint-raises-star-studded-60m-funding-round/", "https://dontdie.com/", "https://www.youtube.com/@BryanJohnson"]}, "metrics": [{"kind": "audience", "for_category": "communicator", "platform": "youtube", "value": 2230000, "source_url": "https://www.youtube.com/@BryanJohnson", "note": "subscribers; YouTube displays rounded figure '2.23M'", "checked": "2026-09-23", "status": "verified"}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": "https://x.com/bryan_johnson", "status": "unavailable", "note": "follower count requires login", "checked": "2026-09-23"}, {"kind": "audience", "for_category": "communicator", "platform": "instagram", "value": null, "source_url": "https://www.instagram.com/bryanjohnson_/", "status": "unavailable", "note": "follower count requires login", "checked": "2026-09-23"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Blueprint", "label": "Blueprint publicly reported funding round (Oct 2025)", "value": 60000000, "currency": "USD", "scope": "single_round", "source_url": "https://longevity.technology/news/bryan-johnsons-blueprint-raises-star-studded-60m-funding-round/", "checked": "2026-09-23", "status": "verified", "note": "$60M from ~50 individual investors, reported late Oct 2025; round series not named; total including any other rounds not verified."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": "https://www.linkedin.com/in/bryanrjohnson", "status": "verified"}, "x": {"url": "https://x.com/bryan_johnson", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Blueprint - About Bryan Johnson", "url": "https://blueprint.bryanjohnson.com/pages/about"}, {"label": "Personal site", "url": "https://www.bryanjohnson.com/"}, {"label": "Don't Die", "url": "https://dontdie.com/"}]}, "sources": [{"url": "https://blueprint.bryanjohnson.com/pages/about", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.bryanjohnson.com/", "type": "personal_site", "accessed": "2026-09-23"}, {"url": "https://dontdie.com/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://longevity.technology/news/bryan-johnsons-blueprint-raises-star-studded-60m-funding-round/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://www.youtube.com/@BryanJohnson", "type": "social", "accessed": "2026-09-23"}, {"url": "https://www.linkedin.com/in/bryanrjohnson", "type": "social", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-24", "phase": "3"}}, {"id": "per_0059", "slug": "jamie-justice", "name": {"display": "Jamie Justice", "sort": "Justice, Jamie"}, "categories": ["scientist"], "current_title": {"title": "Executive Vice President, Health Domain", "organisation": "XPRIZE Foundation", "sources": ["https://www.xprize.org/people/jamie-justice-ph-d"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Adjunct Professor, Internal Medicine Section on Gerontology and Geriatric Medicine", "organisation": "Wake Forest University School of Medicine", "sources": ["https://www.xprize.org/people/jamie-justice-ph-d", "https://doi.org/10.1016/j.cmet.2026.06.015"]}], "location": {"city": "Culver City", "region": "CA", "country_code": "US", "sources": ["https://doi.org/10.1016/j.cmet.2026.06.015", "https://doi.org/10.1016/j.molmet.2025.102213"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://assets-us-01.kc-usercontent.com:443/9bc15d1f-8a5c-007d-b507-e3496e85af86/5ffe58ab-e545-4f3d-87e7-cdb26aae25c3/Jamie%20Justice.webp", "page_url": "https://www.xprize.org/people/jamie-justice-ph-d", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Jamie Justice is a geroscientist who works on testing the geroscience hypothesis - that targeting the basic biology of aging can delay or prevent multiple age-related diseases - in humans. Trained at the University of Colorado Boulder and Wake Forest University School of Medicine, she directed the Biogerontology Lab at Wake Forest, co-led the Integrative Biology Core of the Wake Forest Claude D. Pepper Older Americans Independence Center, was a principal investigator of the NIA-supported Geroscience Education and Training Network, and was active in the Translational Geroscience Network and as an officer of the Gerontological Society of America's ESPO section. She is Executive Vice President of the Health Domain at the XPRIZE Foundation, where she leads XPRIZE Healthspan, a competition running 2023-2030 with a $101 million prize purse that challenges teams to develop therapies restoring muscle, cognitive and immune function by at least 10 years; 20 finalist teams have been named and 10 milestone awards of $1 million each made. She remains an adjunct professor in gerontology and geriatric medicine at Wake Forest. Her honours include the 2022 Vincent Cristofalo Rising Star in Aging Research award and the 2022 NIA Nathan W. Shock award.", "word_count": 194, "sources": ["https://www.xprize.org/people/jamie-justice-ph-d", "https://www.xprize.org/prizes/healthspan"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 37, "source_url": "https://scholar.google.com/citations?user=ID2fISkAAAAJ", "note": "All-time h-index; profile 'Jamie N Justice', Wake Forest School of Medicine, verified wakehealth.edu email", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=ID2fISkAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "XPRIZE profile", "url": "https://www.xprize.org/people/jamie-justice-ph-d"}, {"label": "XPRIZE Healthspan", "url": "https://www.xprize.org/prizes/healthspan"}]}, "sources": [{"url": "https://www.xprize.org/people/jamie-justice-ph-d", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.xprize.org/prizes/healthspan", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=ID2fISkAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cmet.2026.06.015", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0060", "slug": "matt-kaeberlein", "name": {"display": "Matt Kaeberlein", "sort": "Kaeberlein, Matt"}, "categories": ["scientist", "academic", "entrepreneur", "communicator"], "current_title": {"title": "Affiliate Professor (Oral Health Sciences)", "organisation": "University of Washington", "sources": ["https://seattlered.com/healthcare/nad-longevity-supplement-study-uw-kaeberlein/4119111", "https://www.a4m.com/matt-kaeberlein.html", "https://x.com/mkaeberlein/status/2047764552654496106"], "source_type": "news", "checked": "2026-09-24", "status": "verified", "note": "Left Optispan April 2026; new role not publicly announced. His own X post (24 Apr 2026) says he is no longer at Optispan and is 'still considering what comes next'. Seattle Red (25 Jun 2026) describes him as 'an affiliate professor at the University of Washington'; the department (Oral Health Sciences) comes from 2025 speaker bios. No current first-party UW page was readable. His X bio still reads 'CEO' and links optispan.life, so it does not support an 'independent researcher' description."}, "other_positions": [{"title": "Co-founder and co-director", "organisation": "Dog Aging Project", "sources": ["https://halo.dlmp.uw.edu/people/matt-kaeberlein/", "https://www.a4m.com/matt-kaeberlein.html"]}, {"title": "Co-founder; CEO 2023-April 2026 (former)", "organisation": "Optispan", "sources": ["https://x.com/mkaeberlein/status/2047764552654496106"]}], "location": {"city": "Seattle", "region": "WA", "country_code": "US", "sources": ["https://halo.dlmp.uw.edu/people/matt-kaeberlein/", "https://doi.org/10.1016/j.cmet.2026.06.015"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://halo.dlmp.uw.edu/wp-content/uploads/2020/04/kaeberlein_headshot.jpg", "page_url": "https://halo.dlmp.uw.edu/people/matt-kaeberlein/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Matt Kaeberlein is a biogerontologist whose research has focused on biological mechanisms of aging with the goal of translational interventions that extend healthspan. After a PhD at MIT (2002) and postdoctoral work at the University of Washington, he joined the UW faculty, where he was the founding director of the Healthy Aging and Longevity Research Institute, director of the UW Nathan Shock Center of Excellence in the Basic Biology of Aging and director of an aging-biology training programme; he has published more than 200 papers and is a fellow of AAAS, the American Aging Association and the Gerontological Society of America. He is founder and co-director of the Dog Aging Project, a research project on aging in companion dogs. In 2023 he co-founded Optispan, a Seattle healthspan-medicine company, and led it as CEO until April 2026, when he announced he was no longer with the company and was considering his next step. He also communicates longevity science to the public through podcast, video and social-media channels.", "word_count": 166, "sources": ["https://halo.dlmp.uw.edu/people/matt-kaeberlein/", "https://x.com/mkaeberlein/status/2047764552654496106", "https://www.birminghammedicalnews.com/article/9276/optispan-builds-toolkit-for-medicine-30"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "Scholar profile ID found via search returned 404; no attributable profile confirmed", "checked": "2026-09-23"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Optispan", "label": "Optispan publicly disclosed total funding", "value": null, "currency": "USD", "scope": "total_disclosed", "source_url": "https://longevity.technology/news/we-want-to-help-people-add-10-20-years-of-healthspan/", "checked": "2026-09-23", "status": "unavailable", "note": "Reported only as 'several million dollars in seed funding' led by Sabey Corporation (longevity.technology); Puget Sound Business Journal (3 Mar 2026, https://www.bizjournals.com/seattle/news/2026/03/03/dave-sabey-optispan-longevity-lee-hood.html) reported the company seeking a $10M round. No closed amount or total disclosed; Tracxn/PitchBook not used."}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": "https://x.com/mkaeberlein", "checked": "2026-09-23", "status": "unavailable", "note": "api.fxtwitter.com shows 32,279 followers for @mkaeberlein (2026-09-23), but no first-party page linking the handle was found (UW HALo page links only @halo_uw; Optispan links @Optispan_Inc; kaeberleinlab.org has no social links; YouTube channel links not readable). Downgraded from verified pending first-party confirmation."}, {"kind": "audience", "for_category": "communicator", "platform": "youtube", "value": 68000, "source_url": "https://www.youtube.com/@mkaeberlein", "checked": "2026-09-23", "status": "verified", "note": "subscribers; channel header 'Matt Kaeberlein' (@mkaeberlein, channel UCYIlTJbHsx5w1h_cUmZkA2w) shows rounded '68K subscribers'. The previously recorded @matt.kaeberlein (22.9K) now resolves to the Optispan company channel (@optispan) and is not counted."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": "https://x.com/mkaeberlein", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UW Healthy Aging and Longevity Research Institute profile", "url": "https://halo.dlmp.uw.edu/people/matt-kaeberlein/"}, {"label": "Kaeberlein Lab", "url": "https://kaeberleinlab.org/"}]}, "sources": [{"url": "https://halo.dlmp.uw.edu/people/matt-kaeberlein/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://x.com/mkaeberlein/status/2047764552654496106", "type": "social", "accessed": "2026-09-23"}, {"url": "https://www.a4m.com/matt-kaeberlein.html", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://www.optispan.life/about-us", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cmet.2026.06.015", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://longevity.technology/news/we-want-to-help-people-add-10-20-years-of-healthspan/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://seattlered.com/healthcare/nad-longevity-supplement-study-uw-kaeberlein/4119111", "type": "news", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0061", "slug": "pankaj-kapahi", "name": {"display": "Pankaj Kapahi", "sort": "Kapahi, Pankaj"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor", "organisation": "Buck Institute for Research on Aging", "sources": ["https://www.buckinstitute.org/lab/kapahi-lab/", "https://doi.org/10.1016/j.cell.2026.07.013"], "source_type": "lab_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Novato", "region": "CA", "country_code": "US", "sources": ["https://doi.org/10.1016/j.cell.2026.07.013", "https://doi.org/10.1038/s41514-026-00373-x"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.buckinstitute.org/wp-content/uploads/2018/06/pankaj_kapahi_thumb.jpg", "page_url": "https://www.buckinstitute.org/research/faculty/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Pankaj Kapahi studies how nutrient signalling and metabolism influence aging and age-related disease. Trained with Tom Kirkwood at the University of Manchester and as a postdoctoral fellow with Seymour Benzer at Caltech and Michael Karin at UC San Diego, he joined the Buck Institute in 2004. His laboratory's earlier work, with others, showed that lifespan extension by inhibition of the TOR pathway overlaps with the effects of dietary restriction in flies, yeast and worms. Using worms, flies and mice, the lab examines how nutrients affect fat metabolism, circadian clocks, advanced glycation end products, calcification and intestinal permeability, and searches for genes and metabolites that act as calorie-restriction mimetics. A current translational focus is glycation stress: recent work reports glycation metabolites as predictors of age-related comorbidities, glycation-lowering compounds that reduce food intake via ghrelin signalling, and a published protocol for reducing glycation stress as a geroscience intervention in humans. He has also written on why studying females reveals more about aging (Cell, 2026). His awards include the NIA Eureka Award, an Ellison Medical Foundation New Scholar Award, a Glenn Award, the Nathan Shock Young Investigator Award and AFAR Breakthrough in Gerontology and Julie Martin Mid-career awards.", "word_count": 195, "sources": ["https://www.buckinstitute.org/lab/kapahi-lab/", "https://doi.org/10.1038/s41514-026-00373-x", "https://doi.org/10.1016/j.cell.2026.07.013", "https://doi.org/10.1016/j.celrep.2025.116422", "https://doi.org/10.1007/s11357-025-01652-3"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 65, "source_url": "https://scholar.google.com/citations?user=rhaCRIYAAAAJ", "note": "All-time h-index; profile lists Professor, Buck Institute; verified buckinstitute.org email", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=rhaCRIYAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Kapahi Lab, Buck Institute", "url": "https://www.buckinstitute.org/lab/kapahi-lab/"}]}, "sources": [{"url": "https://www.buckinstitute.org/lab/kapahi-lab/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.buckinstitute.org/research/faculty/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=rhaCRIYAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cell.2026.07.013", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41514-026-00373-x", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0062", "slug": "jan-karlseder", "name": {"display": "Jan Karlseder", "sort": "Karlseder, Jan"}, "categories": ["scientist", "academic"], "current_title": {"title": "Vice President and Chief Science Officer; Professor, Molecular and Cell Biology Laboratory; Donald and Darlene Shiley Chair", "organisation": "Salk Institute for Biological Studies", "sources": ["https://www.salk.edu/scientist/jan-karlseder/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "La Jolla", "region": "CA", "country_code": "US", "sources": ["https://www.salk.edu/scientist/jan-karlseder/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.salk.edu/wp-content/uploads/2015/10/karlseder.jpg", "page_url": "https://www.salk.edu/scientist/jan-karlseder/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Jan Karlseder studies telomeres, the protective ends of chromosomes that shorten with each cell division, and how they set proliferative limits that restrict cancer formation while contributing to aging. His laboratory at the Salk Institute follows telomere function across the cell cycle and the cell's lifetime, from young dividing cells to senescence and crisis, the two barriers that prevent primary human cells from becoming cancerous. The lab reported that cell death in crisis is executed by the macroautophagy machinery, revealing a tumour-suppressive pathway, and that fused telomeres arising after senescence bypass activate the spindle assembly checkpoint, amplifying damage signals and causing cell death within a single cell cycle. It also found that telomeres move to the nuclear periphery after replication, linking telomere positioning to gene regulation during division. The work also addresses age-related decline in DNA repair and its relevance to premature aging syndromes. Trained at the University of Innsbruck, the University of Vienna and The Rockefeller University, he received a Glenn Award for Research in Biological Mechanisms of Aging (2009). Besides his professorship, he is Vice President and Chief Science Officer of the Salk Institute, a senior scientific leadership role.", "word_count": 191, "sources": ["https://www.salk.edu/scientist/jan-karlseder/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": "https://scholar.google.com/citations?user=yLfjm1EAAAAJ", "status": "unavailable", "note": "Profile identified (Jan Karlseder, The Salk Institute, verified salk.edu email per search snippet) but Scholar blocked automated access on 2026-09-23", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=yLfjm1EAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Salk Institute profile", "url": "https://www.salk.edu/scientist/jan-karlseder/"}, {"label": "Karlseder Lab", "url": "https://karlseder.salk.edu/"}]}, "sources": [{"url": "https://www.salk.edu/scientist/jan-karlseder/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://karlseder.salk.edu/", "type": "lab_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0063", "slug": "brian-kennedy", "name": {"display": "Brian Kennedy", "sort": "Kennedy, Brian"}, "categories": ["scientist", "academic"], "current_title": {"title": "Distinguished Professor of Biochemistry & Physiology; Director, Healthy Longevity Translational Research Programme and NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality", "organisation": "Yong Loo Lin School of Medicine, National University of Singapore", "sources": ["https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/", "https://medicine.nus.edu.sg/researcher/brian-keith-kennedy/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Director, Centre for Healthy Longevity", "organisation": "National University Health System (NUHS)", "sources": ["https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/", "https://medicine.nus.edu.sg/researcher/brian-keith-kennedy/"]}, {"title": "Adjunct Senior Principal Investigator", "organisation": "Singapore Institute for Clinical Sciences, A*STAR", "sources": ["https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/"]}, {"title": "Adjunct Professor", "organisation": "USC Leonard Davis School of Gerontology", "sources": ["https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/"]}], "location": {"city": "Singapore", "region": null, "country_code": "SG", "sources": ["https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/", "https://medicine.nus.edu.sg/researcher/brian-keith-kennedy/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://medicine.nus.edu.sg/sites/briankennedylab/images/team_portrait/Brian_Kennedy.jpg", "page_url": "https://medicine.nus.edu.sg/sites/briankennedylab/", "source_type": "lab_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Brian Kennedy is a biogerontologist whose research addresses mechanisms of biological ageing and interventions that extend healthspan and lifespan. During his PhD with Leonard Guarente at MIT he published the first paper linking sirtuins to ageing, showing that mutation of the silencing gene SIR4 can delay aging in yeast (Cell, 1995). As a faculty member at the University of Washington (2001-2010) his group, with collaborators, used genome-scale yeast screens to identify long-lived gene deletions and showed roles for TOR signalling in yeast replicative and chronological lifespan; in mice he studied the mTOR pathway, including rapamycin rescue of lamin A/C-deficient models. He was President and CEO of the Buck Institute for Research on Aging from 2010 to 2016 and Co-Editor-in-Chief of Aging Cell from 2011 to 2021, and co-authored the 2014 Cell perspective that framed geroscience as linking ageing to chronic disease. Since 2017 he has been Distinguished Professor at the National University of Singapore, where he directs the Healthy Longevity Translational Research Programme and the Bia-Echo Asia Centre for Reproductive Longevity and Equality, and the NUHS Centre for Healthy Longevity. Recent work includes ageing biomarkers, clinical ageing clocks and human intervention studies such as alpha-ketoglutarate supplementation.", "word_count": 196, "sources": ["https://medicine.nus.edu.sg/researcher/brian-keith-kennedy/", "https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 100, "source_url": "https://scholar.google.com/citations?user=wCawLeIAAAAJ", "note": "All-time h-index; profile lists National University of Singapore", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=wCawLeIAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "NUS Biochemistry faculty page", "url": "https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/"}, {"label": "NUS Medicine researcher profile", "url": "https://medicine.nus.edu.sg/researcher/brian-keith-kennedy/"}, {"label": "Brian Kennedy Lab", "url": "https://medicine.nus.edu.sg/sites/briankennedylab/"}]}, "sources": [{"url": "https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://medicine.nus.edu.sg/researcher/brian-keith-kennedy/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://medicine.nus.edu.sg/sites/briankennedylab/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=wCawLeIAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0064", "slug": "cynthia-kenyon", "name": {"display": "Cynthia Kenyon", "sort": "Kenyon, Cynthia"}, "categories": ["scientist"], "current_title": {"title": "Vice President, Aging Research", "organisation": "Calico Life Sciences", "sources": ["https://www.calicolabs.com/people/cynthia-kenyon/"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "South San Francisco", "region": "CA", "country_code": "US", "sources": ["https://www.calicolabs.com/contact-us/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.calicolabs.com/wp-content/uploads/2020/02/Cynthia_Kenyon_2025-scaled-e1755736182849-1334x2000.jpg", "page_url": "https://www.calicolabs.com/people/cynthia-kenyon/", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Cynthia Kenyon is a molecular geneticist whose work in the roundworm C. elegans helped establish that the rate of aging is under genetic control. In 1993 her laboratory reported that changing a single gene could double the lifespan of healthy, fertile worms, a finding that prompted intensive study of the molecular biology of aging. Her work showed that animals contain genetic programs that influence aging by coordinating downstream genes that protect and repair cells and tissues, and contributed to recognition that a conserved hormone-signalling pathway influences the rate of aging across species, including mammals. After a PhD at MIT and postdoctoral work with Sydney Brenner in Cambridge, England, she joined the UCSF faculty in 1986, becoming Herb Boyer Distinguished Professor and an American Cancer Society Professor. In 2014 she joined Calico Life Sciences, where she is Vice President, Aging Research. She is a member of the US National Academy of Sciences, the National Academy of Medicine and the American Academy of Arts and Sciences, and a former president of the Genetics Society of America.", "word_count": 174, "sources": ["https://www.calicolabs.com/people/cynthia-kenyon/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "No attributable public Google Scholar profile found in search", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Calico leadership profile", "url": "https://www.calicolabs.com/people/cynthia-kenyon/"}]}, "sources": [{"url": "https://www.calicolabs.com/people/cynthia-kenyon/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.calicolabs.com/contact-us/", "type": "company_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0131", "slug": "max-kholin", "name": {"display": "Max Kholin", "sort": "Kholin, Max", "aliases": ["Maxim Kholin"]}, "categories": ["entrepreneur"], "current_title": {"title": "Co-Founder and Chief Corporate Development Officer", "organisation": "Gero", "sources": ["https://www.gero.ai/team"], "source_type": "company_page", "checked": "2026-09-29", "status": "verified", "note": "Business co-founder of Gero, alongside CEO and co-founder Peter Fedichev."}, "other_positions": [], "location": {"city": "Singapore", "region": "", "country_code": "SG", "sources": ["https://www.gero.ai/"], "checked": "2026-09-29", "status": "verified", "note": "Gero is headquartered in Singapore (Gero PTE. LTD.)."}, "photo": {"status": "found", "image_url": "https://cdn.prod.website-files.com/656269fc239eb2514c12f92e/6a2ad1bb9edacf690e78d087_Max%20Kholin%20Image.png", "page_url": "https://www.gero.ai/team", "source_type": "company_page", "credit": "Gero", "checked": "2026-09-29"}, "impact": {"text": "Max Kholin is a co-founder of Gero, the Singapore-based biotechnology company that applies physics and machine learning to large-scale human data to understand the dynamics of aging and to find interventions that target it. As Chief Corporate Development Officer he leads the company's business development, financing and partnerships, complementing the scientific direction of co-founder and chief executive Peter Fedichev. Gero is known for work using UK Biobank and other longitudinal data to model the loss of physiological resilience with age and to argue for the existence of a limit on human lifespan, and for a drug-discovery collaboration with Pfizer on fibrotic disease. Kholin has helped raise the company's disclosed equity financing, reported at about US$34 million as of 2026, and represents Gero in the longevity investment and partnership community.", "word_count": 133, "sources": ["https://www.gero.ai/team", "https://www.gero.ai/"]}, "metrics": [{"kind": "capital_raised", "for_category": "entrepreneur", "value": 34000000, "currency": "USD", "entity": {"name": "Gero", "lab_id": "lab_0010"}, "scope": "total_disclosed", "as_of": "2026-06", "source_url": "https://www.gero.ai/", "checked": "2026-09-29", "status": "verified", "note": "Company-disclosed total equity funding (~US$34M as of June 2026); raised by Gero, not by the individual."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Gero team page", "url": "https://www.gero.ai/team"}]}, "sources": [{"url": "https://www.gero.ai/team", "type": "company_page", "accessed": "2026-09-29"}, {"url": "https://www.gero.ai/", "type": "company_page", "accessed": "2026-09-29"}], "record": {"status": "draft", "created": "2026-09-29", "updated": "2026-09-29", "phase": "6"}}, {"id": "per_0065", "slug": "james-kirkland", "name": {"display": "James Kirkland", "sort": "Kirkland, James"}, "categories": ["scientist", "academic", "doctor"], "current_title": {"title": "Director, Center for Advanced Gerotherapeutics; Professor of Medicine", "organisation": "Cedars-Sinai Medical Center", "sources": ["https://agingpharma.org/speakers/james-kirkland/", "https://scholar.google.com/citations?user=jbYvEUQAAAAJ"], "source_type": "conference_listing", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Emeritus Professor of Medicine", "organisation": "Mayo Clinic", "sources": ["https://agingpharma.org/speakers/james-kirkland/"]}], "location": {"city": "Los Angeles", "region": "CA", "country_code": "US", "sources": ["https://agingpharma.org/speakers/james-kirkland/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://static.tildacdn.com/tild3331-6534-4931-b865-376535323738/James_Kirkland.jpg", "page_url": "https://agingpharma.org/speakers/james-kirkland/", "source_type": "conference_listing", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "James Kirkland is a physician-scientist who studies how aging processes, particularly cellular senescence, contribute to disease across the lifespan, and who develops gerotherapeutics that target those mechanisms. He is credited with discovering senolytic drugs, agents that selectively eliminate senescent cells; his group and then others showed that senolytics improve healthspan and treat multiple diseases in animal models, human cells and tissue explants. He published the first clinical trials of senolytic drugs and the first composite biomarker score of senescent cell burden responsive to drug intervention in humans, and is preparing or conducting clinical studies of senolytics in conditions including frailty, Alzheimer's disease, diabetes and obesity, osteoporosis, idiopathic pulmonary fibrosis and cancer survivorship. He is principal investigator of the NIH-funded Translational Geroscience Network, which coordinates translation of healthspan interventions across US institutions. Formerly at Mayo Clinic, where he is Emeritus Professor of Medicine, he now directs the Center for Advanced Gerotherapeutics at Cedars-Sinai in Los Angeles. He is board-certified in internal medicine, geriatrics and endocrinology and metabolism, is immediate past president of the American Federation for Aging Research and president-elect of the Healthy Longevity Medicine Society, and received AFAR's 2020 Irving S. Wright Award of Distinction.", "word_count": 195, "sources": ["https://agingpharma.org/speakers/james-kirkland/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 125, "source_url": "https://scholar.google.com/citations?user=jbYvEUQAAAAJ", "note": "All-time h-index; profile lists Professor of Medicine, Cedars-Sinai; verified cshs.org email. (ARDD bio states H index 110 - different/older source, not used.)", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=jbYvEUQAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Cedars-Sinai researcher profile", "url": "https://researchers.cedars-sinai.edu/James.Kirkland"}, {"label": "ARDD 2026 speaker page", "url": "https://agingpharma.org/speakers/james-kirkland/"}]}, "sources": [{"url": "https://agingpharma.org/speakers/james-kirkland/", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=jbYvEUQAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0066", "slug": "guido-kroemer", "name": {"display": "Guido Kroemer", "sort": "Kroemer, Guido"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor, Faculty of Medicine; Director, Metabolomics and Cell Biology Platforms (Gustave Roussy); Head, Inserm team \"Metabolism, Cancer and Immunity\"", "organisation": "Université Paris Cité / Gustave Roussy", "sources": ["https://www.gustaveroussy.fr/en/guido-kroemer", "https://scholar.google.com/citations?user=OU05Q_MAAAAJ&hl=en"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Gustave Roussy page names the faculty as Paris-Descartes University (now merged into Université Paris Cité, as listed on his Scholar profile). Also Deputy Director, Cordeliers Research Centre; practitioner, Hôpital Européen Georges-Pompidou."}, "other_positions": [{"title": "Deputy Director", "organisation": "Cordeliers Research Centre", "sources": ["https://www.gustaveroussy.fr/en/guido-kroemer"]}, {"title": "Adjunct Professor", "organisation": "Karolinska Institute", "sources": ["https://www.gustaveroussy.fr/en/guido-kroemer"]}, {"title": "Hospital practitioner", "organisation": "Hôpital Européen Georges-Pompidou (AP-HP)", "sources": ["https://www.gustaveroussy.fr/en/guido-kroemer"]}], "location": {"city": "Paris", "region": "Île-de-France", "country_code": "FR", "sources": ["https://www.gustaveroussy.fr/en/guido-kroemer", "https://scholar.google.com/citations?user=OU05Q_MAAAAJ&hl=en"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.gustaveroussy.fr/sites/default/files/portrait-pr-kroemer-guido.jpg", "page_url": "https://www.gustaveroussy.fr/en/guido-kroemer", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Guido Kroemer is a cell biologist whose work spans mitochondrial control of cell death, autophagy and ageing, and immune responses to cancer therapy. For the longevity field he is best known as a co-author, with Carlos López-Otín, Maria Blasco, Linda Partridge and Manuel Serrano, of \"The Hallmarks of Aging\" (Cell, 2013) and its 2023 update, a framework widely used to organise ageing research. With Frank Madeo he co-authored studies showing that the polyamine spermidine induces autophagy and extends lifespan in model organisms (Nature Cell Biology, 2009) and is cardioprotective in ageing mice (Nature Medicine, 2016). He directs the Metabolomics and Cell Biology platforms at Gustave Roussy, heads the Inserm team \"Metabolism, Cancer and Immunity\", is deputy director of the Cordeliers Research Centre, and is a professor at the Faculty of Medicine in Paris. Gustave Roussy reports more than 1,700 publications. He is editor-in-chief of several journals, including Cell Stress and Microbial Cell, and a member of academies including EMBO and the Leopoldina.", "word_count": 162, "sources": ["https://www.gustaveroussy.fr/en/guido-kroemer", "https://doi.org/10.1016/j.cell.2013.05.039", "https://doi.org/10.1016/j.cell.2022.11.001", "https://doi.org/10.1038/ncb1975", "https://doi.org/10.1038/nm.4222"]}, "metrics": [{"kind": "h_index", "value": 320, "source_url": "https://scholar.google.com/citations?user=OU05Q_MAAAAJ", "note": "All column; profile affiliation Université de Paris Cité / HEGP / Gustave Roussy, verified inserm.fr email", "checked": "2026-09-23", "status": "verified", "platform": "google_scholar", "for_category": "scientist"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=OU05Q_MAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Gustave Roussy biography", "url": "https://www.gustaveroussy.fr/en/guido-kroemer"}]}, "sources": [{"url": "https://www.gustaveroussy.fr/en/guido-kroemer", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=OU05Q_MAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cell.2013.05.039", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cell.2022.11.001", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/ncb1975", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/nm.4222", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0067", "slug": "dudley-lamming", "name": {"display": "Dudley Lamming", "sort": "Lamming, Dudley"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor, Department of Medicine (Division of Endocrinology, Diabetes and Metabolism); Vice Chair for Biomedical Research, Department of Medicine", "organisation": "University of Wisconsin–Madison School of Medicine and Public Health", "sources": ["https://lamminglab.medicine.wisc.edu/dudley-lamming/", "https://www.medicine.wisc.edu/directory/lamming_dudley"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Founding co-Director", "organisation": "Wisconsin Nathan Shock Center of Excellence in the Basic Biology of Aging", "sources": ["https://lamminglab.medicine.wisc.edu/dudley-lamming/"]}, {"title": "Research Health Scientist (WOC)", "organisation": "William S. Middleton Memorial Veterans Hospital", "sources": ["https://lamminglab.medicine.wisc.edu/dudley-lamming/"]}], "location": {"city": "Madison", "region": "WI", "country_code": "US", "sources": ["https://www.medicine.wisc.edu/directory/lamming_dudley"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.medicine.wisc.edu/sites/default/files/styles/large/public/images/4646.jpg?itok=njkteoJP", "page_url": "https://www.medicine.wisc.edu/directory/lamming_dudley", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Dudley Lamming studies how nutrient-responsive signalling pathways, particularly mTOR, can be harnessed to promote metabolic health and longevity. As first author of a 2012 Science paper, he showed that the insulin resistance caused by rapamycin is mediated by loss of mTOR Complex 2 and is separable from rapamycin's effect on lifespan, a finding that informs efforts to develop safer mTOR-targeting geroprotectors. His laboratory at the University of Wisconsin–Madison found that low-protein diets improve blood sugar control and reduce adiposity in humans and mice, and identified dietary branched-chain amino acids as key regulators of these effects; it also studies how reducing branched-chain amino acid intake affects longevity and fitness, the biology of mTORC2, and whether geroprotective interventions can treat or prevent Alzheimer's disease in mouse models. He is a professor and Vice Chair for Biomedical Research in the Department of Medicine and a founding co-director of the Wisconsin Nathan Shock Center of Excellence in the Basic Biology of Aging. He is a fellow of the American Aging Association and the Gerontological Society of America and received the GSA Nathan Shock New Investigator Award.", "word_count": 182, "sources": ["https://www.medicine.wisc.edu/directory/lamming_dudley", "https://lamminglab.medicine.wisc.edu/dudley-lamming/", "https://doi.org/10.1126/science.1215135"]}, "metrics": [{"kind": "h_index", "value": 61, "source_url": "https://scholar.google.com/citations?user=0mlEqPMAAAAJ", "note": "All column; profile: Professor of Medicine, University of Wisconsin-Madison, verified medicine.wisc.edu email", "checked": "2026-09-23", "status": "verified", "platform": "google_scholar", "for_category": "scientist"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=0mlEqPMAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Lamming Lab", "url": "https://lamminglab.medicine.wisc.edu/dudley-lamming/"}, {"label": "UW Department of Medicine directory", "url": "https://www.medicine.wisc.edu/directory/lamming_dudley"}]}, "sources": [{"url": "https://lamminglab.medicine.wisc.edu/dudley-lamming/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.medicine.wisc.edu/directory/lamming_dudley", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=0mlEqPMAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1126/science.1215135", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0068", "slug": "nathan-lebrasseur", "name": {"display": "Nathan LeBrasseur", "sort": "LeBrasseur, Nathan"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Physical Medicine and Rehabilitation; Director, Robert and Arlene Kogod Center on Aging; Co-director, Paul F. Glenn Center for Biology of Aging Research", "organisation": "Mayo Clinic", "sources": ["https://www.mayo.edu/research/faculty/lebrasseur-nathan-k-ph-d-m-s/bio-00055041"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Also Associate Professor of Physiology; Scientific Director, Office of Translation to Practice; Noaber Foundation Professor of Aging Research (2024)."}, "other_positions": [{"title": "Scientific director, Office of Translation to Practice", "organisation": "Mayo Clinic", "sources": ["https://www.mayo.edu/research/faculty/lebrasseur-nathan-k-ph-d-m-s/bio-00055041"]}, {"title": "Chair, Cellular Mechanisms in Aging and Development Study Section", "organisation": "National Institutes of Health", "sources": ["https://www.mayo.edu/research/faculty/lebrasseur-nathan-k-ph-d-m-s/bio-00055041"]}], "location": {"city": "Rochester", "region": "MN", "country_code": "US", "sources": ["https://www.mayo.edu/research/faculty/lebrasseur-nathan-k-ph-d-m-s/bio-00055041"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://scholar.googleusercontent.com/citations?view_op=medium_photo&user=5qen5VQAAAAJ", "page_url": "https://scholar.google.com/citations?user=5qen5VQAAAAJ&hl=en", "source_type": "scholarly_profile", "credit": "Google Scholar", "checked": "2026-09-29"}, "impact": {"text": "Nathan LeBrasseur studies the biological processes that drive ageing with the aim of developing interventions that delay age-related conditions, with a recent focus on cellular senescence and its effects on physical function, metabolism and resilience. He was a co-author of the 2011 Nature study showing that clearing p16Ink4a-positive senescent cells delays ageing-associated disorders in mice, and of the 2018 Nature Medicine study reporting that senolytic drugs improve physical function and increase lifespan in old mice. His laboratory works on mechanisms of skeletal muscle ageing, blood-based measures of biological age for use in clinical care and research, and how lifestyle factors such as exercise influence age-related damage and repair. Trained in physical therapy and applied physiology at Boston University, he is Professor of Physical Medicine and Rehabilitation at Mayo Clinic, directs the Robert and Arlene Kogod Center on Aging (since 2022), co-directs the Paul F. Glenn Center for Biology of Aging Research, and chairs an NIH study section on cellular mechanisms in ageing. He received AFAR's Vincent Cristofalo Rising Star Award in 2019.", "word_count": 172, "sources": ["https://www.mayo.edu/research/faculty/lebrasseur-nathan-k-ph-d-m-s/bio-00055041", "https://doi.org/10.1038/nature10600", "https://doi.org/10.1038/s41591-018-0092-9"]}, "metrics": [{"kind": "h_index", "value": 89, "source_url": "https://scholar.google.com/citations?user=5qen5VQAAAAJ", "note": "All column; profile affiliation Mayo Clinic, verified mayo.edu email", "checked": "2026-09-23", "status": "verified", "platform": "google_scholar", "for_category": "scientist"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=5qen5VQAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Mayo Clinic research profile", "url": "https://www.mayo.edu/research/faculty/lebrasseur-nathan-k-ph-d-m-s/bio-00055041"}]}, "sources": [{"url": "https://www.mayo.edu/research/faculty/lebrasseur-nathan-k-ph-d-m-s/bio-00055041", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=5qen5VQAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/nature10600", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41591-018-0092-9", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0069", "slug": "morgan-levine", "name": {"display": "Morgan Levine", "sort": "Levine, Morgan"}, "categories": ["scientist", "communicator"], "current_title": {"title": "Computational scientist and entrepreneur (building in AI x biology)", "organisation": "Not publicly disclosed", "sources": ["https://x.com/DrMorganLevine/status/2089124468652445745", "https://agingpharma.org/speakers/morgan-levine", "https://www.technologyreview.com/2026/09/15/1144129/ai-models-need-more-data-about-biology-and-openai-is-paying-to-create-it/"], "source_type": "social_media", "checked": "2026-09-24", "status": "verified", "note": "Her X post of 16 Aug 2026 announces she has left Altos Labs; her X bio reads 'Building in AIxBio | Former Professor at Yale & VP at Altos Labs'; LinkedIn headline reads 'Building at Stealth Startup'; MIT Technology Review (15 Sep 2026) calls her 'a former vice president for computation at Altos Labs'. No new organisation has been publicly named."}, "other_positions": [{"title": "Vice President of Computation (former, until Aug 2026)", "organisation": "Altos Labs", "sources": ["https://x.com/DrMorganLevine/status/2089124468652445745", "https://www.technologyreview.com/2026/09/15/1144129/ai-models-need-more-data-about-biology-and-openai-is-paying-to-create-it/"]}], "location": {"city": "San Francisco", "region": "CA", "country_code": "US", "sources": ["https://x.com/DrMorganLevine", "https://www.linkedin.com/in/morgan-levine-aa957463"], "checked": "2026-09-24", "status": "verified", "note": "Self-reported: X profile location 'San Francisco, CA'; LinkedIn 'San Francisco Bay Area'."}, "photo": {"status": "found", "image_url": "https://agingpharma.org/assets/ardd-2026/speakers/morgan-levine-gray-square-2026.png", "page_url": "https://agingpharma.org/speakers/morgan-levine", "source_type": "conference_listing", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Morgan Levine is a computational scientist known for developing widely used methods to quantify biological age. As first author of a 2018 paper in Aging, she introduced DNAm PhenoAge, an epigenetic biomarker trained on a clinical-chemistry measure of phenotypic age that predicts lifespan and healthspan better than earlier chronological-age clocks; she also co-authored the 2019 GrimAge clock paper. She led a laboratory at Yale School of Medicine that applied computational and experimental approaches to the molecular mechanisms of biological ageing, then served as VP of Computation at Altos Labs, where her work used machine learning to model how molecular changes propagate across cells, tissues, organs and organisms. In August 2026 she announced she was leaving Altos Labs; according to her ARDD 2026 speaker biography she is now building multimodal, multi-scale, multispecies world models of biology, and her new organisation has not been publicly named. She is the author of the general-audience book True Age (Penguin Random House), which presents the science of biological age and ways to measure and influence it.", "word_count": 171, "sources": ["https://agingpharma.org/speakers/morgan-levine", "https://doi.org/10.18632/aging.101414", "https://doi.org/10.18632/aging.101684", "https://www.morganlevinelab.com/", "https://www.penguinrandomhouse.com/books/659627/true-age-by-morgan-levine-phd/"]}, "metrics": [{"kind": "h_index", "value": 57, "source_url": "https://scholar.google.com/citations?user=AhzNAoEAAAAJ", "note": "All column. Profile still lists her former affiliation (Assistant Professor of Pathology, Yale Medical School; verified yale.edu email); identity is clear from name and publication record.", "checked": "2026-09-23", "status": "verified", "platform": "google_scholar", "for_category": "scientist"}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": 21139, "source_url": "https://x.com/DrMorganLevine", "checked": "2026-09-23", "status": "verified", "note": "followers; read via api.fxtwitter.com on 2026-09-23. Handle linked from morganlevinelab.com."}, {"kind": "audience", "for_category": "communicator", "platform": "instagram", "value": 7693, "source_url": "https://www.instagram.com/dr.morganlevine/", "checked": "2026-09-23", "status": "verified", "note": "followers; public profile description ('7,693 Followers'), linked from morganlevinelab.com"}, {"kind": "audience", "for_category": "communicator", "platform": "facebook", "value": 727, "source_url": "https://www.facebook.com/dr.morganlevine/", "checked": "2026-09-23", "status": "verified", "note": "followers; public page description ('727 followers'), linked from morganlevinelab.com"}, {"kind": "audience", "for_category": "communicator", "platform": "book", "value": null, "source_url": "https://www.penguinrandomhouse.com/books/659627/true-age-by-morgan-levine-phd/", "checked": "2026-09-23", "status": "unavailable", "note": "Author of True Age (Penguin Random House); no verifiable sales or readership figure"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=AhzNAoEAAAAJ", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/morgan-levine-aa957463", "status": "verified"}, "x": {"url": "https://x.com/DrMorganLevine", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "ARDD 2026 speaker page", "url": "https://agingpharma.org/speakers/morgan-levine"}, {"label": "Former Yale lab site (ALIS)", "url": "https://www.morganlevinelab.com/"}], "instagram": {"url": "https://www.instagram.com/dr.morganlevine/", "status": "verified"}, "facebook": {"url": "https://www.facebook.com/dr.morganlevine/", "status": "verified"}}, "sources": [{"url": "https://agingpharma.org/speakers/morgan-levine", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://x.com/DrMorganLevine/status/2089124468652445745", "type": "social_media", "accessed": "2026-09-23"}, {"url": "https://www.linkedin.com/in/morgan-levine-aa957463", "type": "social_media", "accessed": "2026-09-23"}, {"url": "https://www.morganlevinelab.com/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=AhzNAoEAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.18632/aging.101414", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.18632/aging.101684", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://www.penguinrandomhouse.com/books/659627/true-age-by-morgan-levine-phd/", "type": "publisher_page", "accessed": "2026-09-23"}, {"url": "https://www.technologyreview.com/2026/09/15/1144129/ai-models-need-more-data-about-biology-and-openai-is-paying-to-create-it/", "type": "news", "accessed": "2026-09-24"}, {"url": "https://x.com/DrMorganLevine", "type": "social_media", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0070", "slug": "gordon-lithgow", "name": {"display": "Gordon Lithgow", "sort": "Lithgow, Gordon"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor", "organisation": "Buck Institute for Research on Aging", "sources": ["https://www.buckinstitute.org/lab/lithgow-lab/", "https://academyofgeroscience.org/gordon-lithgow-phd"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Buck lab page lists 'Professor'. Academy of Geroscience bio (undated) also calls him Vice President for Academic Affairs; that administrative title was not confirmed on a current Buck page."}, "other_positions": [{"title": "Vice President for Academic Affairs (per Academy of Geroscience bio; not confirmed on Buck page)", "organisation": "Buck Institute for Research on Aging", "sources": ["https://academyofgeroscience.org/gordon-lithgow-phd"]}], "location": {"city": "Novato", "region": "CA", "country_code": "US", "sources": ["https://academyofgeroscience.org/gordon-lithgow-phd", "https://www.buckinstitute.org/lab/lithgow-lab/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.buckinstitute.org/wp-content/uploads/2018/06/22_GORDON_LITHGOW_0065-Edit.jpg", "page_url": "https://www.buckinstitute.org/lab/lithgow-lab/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Gordon Lithgow studies how small drug-like molecules can re-engage protective homeostatic mechanisms, particularly protein homeostasis, to extend lifespan and delay disease, using the nematode C. elegans and follow-up studies in mice. With Simon Melov he co-authored a 2000 Science paper reporting lifespan extension in C. elegans with superoxide dismutase/catalase mimetics, described by the Academy of Geroscience as the first use of a drug-like molecule to extend lifespan in an animal. His group later showed that amyloid-binding compounds maintain protein homeostasis during ageing and extend worm lifespan (Nature, 2011). In 2007 he led a federally funded Interdisciplinary Research Consortium on Geroscience at the Buck Institute, and the Academy of Geroscience credits him with coining the term \"geroscience\" for research connecting ageing biology and chronic disease. His lab is also involved in the multi-site Caenorhabditis Intervention Testing Program. Trained in genetics at the University of Glasgow, he started his lab at the University of Manchester before moving to the Buck Institute in 2000. He has received a Glenn Award, an Ellison Medical Foundation senior scholarship and the Tenovus Award, and has served on the National Institute on Aging's Board of Scientific Counselors.", "word_count": 190, "sources": ["https://www.buckinstitute.org/lab/lithgow-lab/", "https://academyofgeroscience.org/gordon-lithgow-phd"]}, "metrics": [{"kind": "h_index", "value": 60, "source_url": "https://scholar.google.com/citations?user=sO_6TgQAAAAJ", "note": "All column; profile shows 'Unknown affiliation' but verified buckinstitute.org email", "checked": "2026-09-23", "status": "verified", "platform": "google_scholar", "for_category": "scientist"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=sO_6TgQAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Lithgow Lab, Buck Institute", "url": "https://www.buckinstitute.org/lab/lithgow-lab/"}]}, "sources": [{"url": "https://www.buckinstitute.org/lab/lithgow-lab/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://academyofgeroscience.org/gordon-lithgow-phd", "type": "secondary", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=sO_6TgQAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0071", "slug": "valter-longo", "name": {"display": "Valter Longo", "sort": "Longo, Valter"}, "categories": ["scientist", "academic", "entrepreneur", "communicator"], "current_title": {"title": "Edna Jones Professor in Gerontology and Professor in Biological Science; Director, USC Longevity Institute", "organisation": "University of Southern California, Leonard Davis School of Gerontology", "sources": ["https://gero.usc.edu/faculty/longo/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Founder", "organisation": "L-Nutra", "sources": ["https://www.l-nutra.com/about/", "https://prolonlife.com/pages/valter-longo"]}, {"title": "Director, Longevity and Cancer Program", "organisation": "IFOM (FIRC Institute of Molecular Oncology), Milan", "sources": ["https://www.l-nutra.com/about/"]}, {"title": "Scientific director", "organisation": "Create Cures Foundation; Valter Longo Foundation", "sources": ["https://www.l-nutra.com/about/"]}], "location": {"city": "Los Angeles", "region": "CA", "country_code": "US", "sources": ["https://gero.usc.edu/faculty/longo/", "https://www.l-nutra.com/about/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://gero.usc.edu/wp-content/uploads/2015/07/Longo-Kleinman-2019-272x297.jpg", "page_url": "https://gero.usc.edu/faculty/longo/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Valter Longo studies conserved mechanisms of ageing in yeast, mice and humans, focusing on nutrient-responsive signalling pathways that regulate stress resistance and on how they can be modulated to prevent or treat cancer, Alzheimer's disease and other diseases of ageing. He is best known for developing the fasting-mimicking diet (FMD), a periodic low-calorie, plant-based regimen: his group reported in Cell Metabolism (2015) that it promoted multi-system regeneration and healthspan in mice, and a 2017 randomised trial in Science Translational Medicine found reductions in markers and risk factors for ageing, diabetes, cancer and cardiovascular disease. He directs the USC Longevity Institute at the Leonard Davis School of Gerontology and the Longevity and Cancer Program at IFOM in Milan. Commercial interest: he founded L-Nutra, which markets FMD-based products including Prolon; according to Prolon's website he donates the profits from his L-Nutra shares to the Create Cures Foundation. He has written general-audience books, including The Longevity Diet, and TIME named him in 2018 among the 50 most influential people in health care.", "word_count": 169, "sources": ["https://gero.usc.edu/faculty/longo/", "https://www.l-nutra.com/about/", "https://prolonlife.com/pages/valter-longo", "https://doi.org/10.1016/j.cmet.2015.05.012", "https://doi.org/10.1126/scitranslmed.aai8700"]}, "metrics": [{"kind": "h_index", "value": 94, "source_url": "https://scholar.google.com/citations?user=5qAeNNEAAAAJ", "note": "All column; profile 'Valter D. Longo', USC and IFOM, verified usc.edu email", "checked": "2026-09-23", "status": "verified", "platform": "google_scholar", "for_category": "scientist"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "L-Nutra", "label": "L-Nutra publicly disclosed Series D funding (cumulative Series D proceeds, Jan 2026)", "value": 83500000, "currency": "USD", "scope": "single_round", "source_url": "https://www.prnewswire.com/news-releases/l-nutra-secures-36-5m-investment-from-mubadala-raising-series-d-proceeds-to-83-5m-and-accelerating-global-expansion-of-its-longevity-and-medical-nutrition-therapies-302666171.html", "checked": "2026-09-23", "status": "verified", "note": "Series D proceeds total $83.5M per company press release of 21 Jan 2026, including a $36.5M investment led by Mubadala. Earlier rounds not totalled."}, {"kind": "audience", "for_category": "communicator", "platform": "facebook", "value": 149885, "source_url": "https://www.facebook.com/profvalterlongo/", "checked": "2026-09-23", "status": "verified", "note": "followers; public page description ('149,885 followers'), page linked from USC faculty page and valterlongo.com"}, {"kind": "audience", "for_category": "communicator", "platform": "instagram", "value": 152000, "source_url": "https://www.instagram.com/prof_valterlongo/", "checked": "2026-09-23", "status": "verified", "note": "followers; public profile shows rounded '152K Followers'; linked from valterlongo.com"}, {"kind": "audience", "for_category": "communicator", "platform": "book", "value": null, "source_url": "https://www.l-nutra.com/about/", "checked": "2026-09-23", "status": "unavailable", "note": "Author of The Longevity Diet and two Italian books; no verifiable readership figure"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=5qAeNNEAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "USC Leonard Davis faculty page", "url": "https://gero.usc.edu/faculty/longo/"}, {"label": "Longo Lab", "url": "https://gero.usc.edu/labs/longolab"}, {"label": "L-Nutra (founder)", "url": "https://www.l-nutra.com/about/"}], "facebook": {"url": "https://www.facebook.com/profvalterlongo/", "status": "verified"}, "instagram": {"url": "https://www.instagram.com/prof_valterlongo/", "status": "verified"}}, "sources": [{"url": "https://gero.usc.edu/faculty/longo/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.l-nutra.com/about/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://prolonlife.com/pages/valter-longo", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.prnewswire.com/news-releases/l-nutra-secures-36-5m-investment-from-mubadala-raising-series-d-proceeds-to-83-5m-and-accelerating-global-expansion-of-its-longevity-and-medical-nutrition-therapies-302666171.html", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=5qAeNNEAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cmet.2015.05.012", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1126/scitranslmed.aai8700", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0072", "slug": "carlos-lopez-otin", "name": {"display": "Carlos López-Otín", "sort": "López-Otín, Carlos"}, "categories": ["scientist", "academic"], "current_title": {"title": "Catedrático (Professor) of Biochemistry and Molecular Biology; affiliated with the Faculty of Life and Natural Sciences", "organisation": "Universidad Nebrija, Madrid", "sources": ["https://doi.org/10.1038/s41577-026-01291-5", "https://doi.org/10.1111/acel.70655", "https://doi.org/10.3389/fragi.2026.1840035", "https://www.nebrija.com/medios/actualidadnebrija/carlos-lopez-otin-la-curiosidad-es-el-mejor-elixir-de-la-longevidad/", "https://www.lavozdeasturias.es/noticia/asturias/2023/11/28/otindice-adios-universidad-oviedo-jubila-15-diciembre/00031701163404996716195.htm"], "source_type": "publication", "checked": "2026-09-24", "status": "conflicting", "note": "He retired from the Universidad de Oviedo on 15 Dec 2023 (La Voz de Asturias, 28 Nov 2023; El Comercio: 'in 2024 he will no longer be on the list of catedráticos'). Oviedo's GenCanAge group, which he founded, describes his lab in the past tense and does not list him among its members. 'Facultad de Ciencias de la Vida y la Naturaleza, Universidad Nebrija, Madrid' appears on every 2025-26 paper checked in Europe PMC. It is the sole affiliation, with a nebrija.es corresponding-author email, on Nat Rev Immunol (Apr 2026). Centre de Recherche des Cordeliers (Inserm U1138, Paris) is co-listed on most 2025-26 papers and is the sole affiliation on two (Ageing Res Rev, Jan 2026; J Sport Health Sci, Dec 2025). Nebrija's own 2026 pages call him 'catedrático de Bioquímica y Biología Molecular' and honorary doctor but give no appointment. No first-party Nebrija or Cordeliers staff page lists him, so the exact current title and his physical base (Madrid vs Paris) remain unconfirmed."}, "other_positions": [{"title": "Affiliated researcher, Metabolism, Cancer & Immunity team (per 2025-26 paper affiliations)", "organisation": "Centre de Recherche des Cordeliers, Inserm U1138, Université Paris Cité / Sorbonne Université, Paris", "sources": ["https://doi.org/10.1016/j.cmet.2026.05.002", "https://doi.org/10.3389/fragi.2026.1840035"]}, {"title": "Catedrático of Biochemistry and Molecular Biology (1993-2023; retired 15 Dec 2023); founder of the group now named GenCanAge", "organisation": "Universidad de Oviedo (Instituto Universitario de Oncología del Principado de Asturias, IUOPA)", "sources": ["https://www.lavozdeasturias.es/noticia/asturias/2023/11/28/otindice-adios-universidad-oviedo-jubila-15-diciembre/00031701163404996716195.htm", "https://gencanage.uniovi.es/origins/", "https://doi.org/10.1111/acel.70655"]}], "location": {"city": "Madrid", "region": "Comunidad de Madrid", "country_code": "ES", "sources": ["https://doi.org/10.1038/s41577-026-01291-5", "https://doi.org/10.1111/acel.70655"], "checked": "2026-09-24", "status": "conflicting", "note": "Based on the Universidad Nebrija (Madrid) affiliation on all 2025-26 papers. Many of the same papers also list Paris (Cordeliers), and LNE (15 Dec 2022) reported he had moved to a Paris laboratory. Oviedo is no longer his employer after his December 2023 retirement."}, "photo": {"status": "found", "image_url": "https://2025.womennow.es/media/34738704-50f9-4c33-b95b-bed221c584cf.png", "page_url": "https://2025.womennow.es/en/ponente/ponente/carlos-lopez-otin", "source_type": "conference_listing", "credit": "Women Now Summit 2025", "checked": "2026-09-23"}, "impact": {"text": "Carlos López-Otín is a Spanish biochemist and molecular biologist whose work spans cancer, hereditary diseases and ageing. For the longevity field he is best known as first author of \"The Hallmarks of Aging\" (Cell, 2013), written with Maria Blasco, Linda Partridge, Manuel Serrano and Guido Kroemer, which proposed nine candidate hallmarks of ageing and became a widely used organising framework; the same group published an expanded update, \"Hallmarks of aging: An expanding universe\", in 2023. With Kroemer he also co-authored the reviews \"Metabolic Control of Longevity\" (Cell, 2016, with Frank Madeo and others) and \"Hallmarks of Health\" (Cell, 2021). According to Universidad Nebrija, his research has identified and named about 60 genes, and his recent efforts focus on conceptual models and global approaches to health and ageing, including psychosocial isolation as a proposed ageing factor. He has received the FEBS European Prize for Biochemistry, the Spanish National Research Prize Santiago Ramón y Cajal and the Rey Jaime I Prize. He held a long-standing chair at the Universidad de Oviedo; 2026 papers list the Universidad Nebrija (Madrid) and the Centre de Recherche des Cordeliers (Paris).", "word_count": 184, "sources": ["https://doi.org/10.1016/j.cell.2013.05.039", "https://doi.org/10.1016/j.cell.2022.11.001", "https://doi.org/10.1016/j.cell.2016.07.031", "https://doi.org/10.1016/j.cell.2020.11.034", "https://www.nebrija.com/medios/actualidadnebrija/carlos-lopez-otin-la-curiosidad-es-el-mejor-elixir-de-la-longevidad/", "https://doi.org/10.1111/acel.70655"]}, "metrics": [{"kind": "h_index", "value": null, "source_url": "https://scholar.google.com/citations?user=EhU_C4MAAAAJ", "status": "unavailable", "note": "The only Scholar profile found lists his papers but is named 'carlos lopez' with an unrelated affiliation (politics student, unimilitar.edu.co); not clearly attributable, so not used.", "checked": "2026-09-23", "platform": "google_scholar", "for_category": "scientist"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Universidad Nebrija news (Feb 2026)", "url": "https://www.nebrija.com/medios/actualidadnebrija/carlos-lopez-otin-la-curiosidad-es-el-mejor-elixir-de-la-longevidad/"}]}, "sources": [{"url": "https://www.nebrija.com/medios/actualidadnebrija/carlos-lopez-otin-la-curiosidad-es-el-mejor-elixir-de-la-longevidad/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1111/acel.70655", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41577-026-01291-5", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cmet.2026.05.002", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.3389/fragi.2026.1840035", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cell.2013.05.039", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cell.2022.11.001", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cell.2016.07.031", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cell.2020.11.034", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=AUTH:%22Lopez-Otin%20C%22%20AND%20PUB_YEAR:2026&format=json", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://www.lavozdeasturias.es/noticia/asturias/2023/11/28/otindice-adios-universidad-oviedo-jubila-15-diciembre/00031701163404996716195.htm", "type": "news", "accessed": "2026-09-24"}, {"url": "https://gencanage.uniovi.es/origins/", "type": "lab_page", "accessed": "2026-09-24"}, {"url": "https://actos.nebrija.es/146548/detail/acto-solemne-de-santo-tomas-de-aquino-2026.html", "type": "institution_page", "accessed": "2026-09-24"}, {"url": "https://www.lne.es/asturias/2022/12/15/otin-abandona-forma-temporal-universidad-80008453.html", "type": "news", "accessed": "2026-09-24"}, {"url": "https://2025.womennow.es/en/ponente/ponente/carlos-lopez-otin", "type": "conference_listing", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0073", "slug": "frank-madeo", "name": {"display": "Frank Madeo", "sort": "Madeo, Frank"}, "categories": ["scientist", "academic"], "current_title": {"title": "Univ.-Prof. (Full Professor); group leader, Aging and Cell Death research area", "organisation": "Institute of Molecular Biosciences, NAWI Graz, University of Graz", "sources": ["https://molekularbiologie.uni-graz.at/en/our-research/alterung-und-zelltod/", "https://www.medunigraz.at/DK_MCD/Faculty_Madeo.htm"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Graz", "region": "Styria", "country_code": "AT", "sources": ["https://www.medunigraz.at/DK_MCD/Faculty_Madeo.htm", "https://molekularbiologie.uni-graz.at/en/our-research/alterung-und-zelltod/"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://static.uni-graz.at/fileadmin/_processed_/8/0/csm_uni-graz-biohealth-frank-madeo-4_ad775355b0.jpeg", "page_url": "https://molekularbiologie.uni-graz.at/en/our-research/alterung-und-zelltod/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Frank Madeo is a molecular biologist at the University of Graz whose group investigates the molecular basis of healthy ageing, including polyamine synthesis and autophagy, using model organisms together with omics data from clinical studies such as fasting trials. He is best known for work on the natural polyamine spermidine: he was senior author of a 2009 Nature Cell Biology study showing that spermidine induces autophagy and extends lifespan in yeast, flies and worms, and of a 2016 Nature Medicine study reporting cardioprotection and lifespan extension in mice given dietary spermidine. His group also led a 2019 Cell Metabolism study reporting that alternate-day fasting improved physiological and molecular markers of ageing in healthy, non-obese humans. He is a frequent collaborator of Guido Kroemer, including on the review \"Metabolic Control of Longevity\" (Cell, 2016). His research area at the Institute of Molecular Biosciences also covers regulated cell death and the use of natural cell-death processes therapeutically.", "word_count": 155, "sources": ["https://molekularbiologie.uni-graz.at/en/our-research/alterung-und-zelltod/", "https://doi.org/10.1038/ncb1975", "https://doi.org/10.1038/nm.4222", "https://doi.org/10.1016/j.cmet.2019.07.016", "https://doi.org/10.1016/j.cell.2016.07.031"]}, "metrics": [{"kind": "h_index", "value": 123, "source_url": "https://scholar.google.com/citations?user=P0qPkVAAAAAJ", "note": "All column; profile: Professor of Biochemistry, University of Graz, verified uni-graz.at email", "checked": "2026-09-23", "status": "verified", "platform": "google_scholar", "for_category": "scientist"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=P0qPkVAAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0002-5070-1329", "status": "verified"}, "official": [{"label": "Aging and Cell Death, Institute of Molecular Biosciences, University of Graz", "url": "https://molekularbiologie.uni-graz.at/en/our-research/alterung-und-zelltod/"}]}, "sources": [{"url": "https://molekularbiologie.uni-graz.at/en/our-research/alterung-und-zelltod/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.medunigraz.at/DK_MCD/Faculty_Madeo.htm", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=P0qPkVAAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/ncb1975", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/nm.4222", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cmet.2019.07.016", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cell.2016.07.031", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0074", "slug": "andrea-maier", "name": {"display": "Andrea Maier", "sort": "Maier, Andrea"}, "categories": ["doctor", "scientist", "academic"], "current_title": {"title": "Oon Chiew Seng Professor in Medicine; Co-Founder and Director, NUS Academy for Healthy Longevity", "organisation": "National University of Singapore (Yong Loo Lin School of Medicine)", "sources": ["https://longevityacademy.sg/about-us/our-team", "https://time.com/collection/longevity-leaders/2026/andrea-maier/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "NUS Discovery profile (roster source) requires JavaScript and could not be read; title taken from the NUS Academy for Healthy Longevity team page."}, "other_positions": [{"title": "Professor of Gerontology", "organisation": "Vrije Universiteit Amsterdam", "sources": ["https://longevityacademy.sg/about-us/our-team"]}, {"title": "Chair", "organisation": "AgeGlobal", "sources": ["https://longevityacademy.sg/about-us/our-team"]}, {"title": "Co-Founder", "organisation": "Chi Longevity (longevity clinic, Singapore)", "sources": ["https://chilongevity.com/about-us/"]}], "location": {"city": "Singapore", "region": "", "country_code": "SG", "sources": ["https://longevityacademy.sg/about-us/our-team", "https://time.com/collection/longevity-leaders/2026/andrea-maier/"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://cdn.durable.co/blocks/1OnpXAdh1PNtaHjrA1nHn0YW1OPwU2QYkNujEi6aOzrhvFxfJBwwBS2uoy5b2mcD.jpg", "page_url": "https://longevityacademy.sg/about-us/our-team", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Andrea Maier is an internal medicine specialist and geriatrician who works on translating ageing biology into tested clinical interventions, an approach she calls precision geromedicine. She is the Oon Chiew Seng Professor in Medicine and co-founder and director of the NUS Academy for Healthy Longevity at the National University of Singapore, and Professor of Gerontology at Vrije Universiteit Amsterdam; she has held senior roles in Europe, Australia and Asia. According to TIME, her clinical research tests whether interventions that extend healthy life in mice, including supplements such as NMN and alpha-ketoglutarate, translate to people, and her trials mainly enrol participants whose biological age exceeds their chronological age. In 2025 she helped open a clinical trial centre at NUS for long-term studies of supplements, exercise and lifestyle interventions, and her PROMETHEUS pilot tested a personalised multi-component programme. The NUS Academy reports more than 490 peer-reviewed publications and advisory work for the World Health Organization on healthy ageing. She chairs AgeGlobal. Commercial interest: she is listed as co-founder of Chi Longevity, a longevity medicine clinic.", "word_count": 173, "sources": ["https://longevityacademy.sg/about-us/our-team", "https://time.com/collection/longevity-leaders/2026/andrea-maier/", "https://chilongevity.com/about-us/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "value": 97, "source_url": "https://scholar.google.com/citations?user=NeJ05woAAAAJ", "note": "All column; profile 'Andrea B Maier', Professor of Ageing, University of Melbourne & Vrije Universiteit (older affiliation text), verified vu.nl email", "checked": "2026-09-23", "status": "verified", "platform": "google_scholar"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=NeJ05woAAAAJ", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/andreamaierprof/", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "NUS Academy for Healthy Longevity team page", "url": "https://longevityacademy.sg/about-us/our-team"}, {"label": "NUS Discovery profile", "url": "https://discovery.nus.edu.sg/19564-andrea-britta-maier"}]}, "sources": [{"url": "https://longevityacademy.sg/about-us/our-team", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://time.com/collection/longevity-leaders/2026/andrea-maier/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://chilongevity.com/about-us/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=NeJ05woAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0075", "slug": "joan-mannick", "name": {"display": "Joan Mannick", "sort": "Mannick, Joan"}, "categories": ["entrepreneur", "scientist"], "current_title": {"title": "Senior Vice President, Chief Medical Officer and Head of Product Development", "organisation": "Altos Labs", "sources": ["https://www.altoslabs.com/team/joan-mannick", "https://www.altoslabs.com/featured/press-releases/altos-labs-appoints-joan-mannick-m-d-as-chief-medical-officer-and-head-of-product-development"], "source_type": "company_page", "checked": "2026-09-24", "status": "verified", "note": "Exact wording from the Altos team page: 'Senior Vice President, Chief Medical Officer and Head of Product Development at Altos Labs'. The press release adds that she works within Altos' Institute of Medicine (IoM) and leads medical and scientific work on all clinical programmes. Appointed August 2025."}, "other_positions": [{"title": "Co-Founder and former Chief Executive Officer", "organisation": "Tornado Therapeutics (Cambrian Bio subsidiary)", "sources": ["https://www.altoslabs.com/team/joan-mannick", "https://www.lifespan.io/organizations/tornado-therapeutics/"]}, {"title": "Former Head of Research and Development", "organisation": "Life Biosciences", "sources": ["https://www.altoslabs.com/team/joan-mannick"]}, {"title": "Co-Founder and former Chief Medical Officer", "organisation": "resTORbio", "sources": ["https://www.altoslabs.com/team/joan-mannick"]}], "location": {"city": null, "region": null, "country_code": "US", "sources": ["https://www.altoslabs.com/featured/press-releases/altos-labs-appoints-joan-mannick-m-d-as-chief-medical-officer-and-head-of-product-development"], "checked": "2026-09-24", "status": "unavailable", "note": "No first-party source gives her work location. The Altos press release says only that Altos operates in the San Francisco Bay Area, San Diego and Cambridge, UK. Her only 2025-26 paper affiliation in Europe PMC (July 2026) is 'Tornado Therapeutics, New York, USA', a former role. The country (US) is inferred from her US-based roles and is not confirmed."}, "photo": {"status": "found", "image_url": "https://a-us.storyblok.com/f/1016638/1500x1694/f7837b68c2/joan-mannick.png", "page_url": "https://www.altoslabs.com/featured/press-releases/altos-labs-appoints-joan-mannick-m-d-as-chief-medical-officer-and-head-of-product-development", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Joan Mannick is a physician and drug developer known for early clinical trials of mTOR inhibition as a way to target ageing biology in humans. While an Executive Director in the New Indications Discovery Unit at the Novartis Institutes for BioMedical Research, she led studies reporting that the mTOR inhibitor everolimus improved vaccine responses in older adults (Science Translational Medicine, 2014) and that low-dose TORC1 inhibition enhanced immune function and reduced infections in the elderly (Science Translational Medicine, 2018). She co-founded and served as Chief Medical Officer of resTORbio, a spinout of that Novartis programme that developed TORC1 inhibitors for ageing-related conditions, and later was Head of Research and Development at Life Biosciences. She then co-founded and led, as CEO, Tornado Therapeutics, a Cambrian Bio subsidiary developing rapamycin analogues licensed from Novartis. In August 2025 she joined Altos Labs as Senior Vice President, Chief Medical Officer and Head of Product Development, providing medical and scientific leadership for its clinical programmes. Earlier she was a Medical Director at Genzyme and a faculty member at Harvard Medical School and the University of Massachusetts Medical School.", "word_count": 183, "sources": ["https://www.altoslabs.com/team/joan-mannick", "https://www.altoslabs.com/featured/press-releases/altos-labs-appoints-joan-mannick-m-d-as-chief-medical-officer-and-head-of-product-development", "https://doi.org/10.1126/scitranslmed.3009892", "https://doi.org/10.1126/scitranslmed.aaq1564", "https://www.lifespan.io/organizations/tornado-therapeutics/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "value": null, "source_url": "", "status": "unavailable", "note": "No Google Scholar profile for Joan Mannick found (search returned only other people)", "checked": "2026-09-23", "platform": "google_scholar"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "resTORbio", "label": "resTORbio publicly disclosed Series A funding (2017)", "value": 25000000, "currency": "USD", "scope": "single_round", "source_url": "https://www.biospace.com/restorbio-raises-40-million-to-advance-selective-torc1-inhibitors-for-aging-related-diseases-and-conditions", "checked": "2026-09-23", "status": "verified", "note": "$25M Series A completed earlier in 2017, as stated in the company's Series B release (Business Wire, reproduced on BioSpace)."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "resTORbio", "label": "resTORbio publicly disclosed Series B funding (2017)", "value": 40000000, "currency": "USD", "scope": "single_round", "source_url": "https://www.biospace.com/restorbio-raises-40-million-to-advance-selective-torc1-inhibitors-for-aging-related-diseases-and-conditions", "checked": "2026-09-23", "status": "verified", "note": "Oversubscribed $40M Series B led by OrbiMed (2017); release states this brings total capital raised that year to $65M."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "resTORbio", "label": "resTORbio publicly disclosed IPO proceeds (2018)", "value": 97800000, "currency": "USD", "scope": "ipo_proceeds", "source_url": "https://www.lse.co.uk/rns/PRTC/prtc-restorbio-closes-ipo-adds-13m-to-85m-raise-58415mtm7jd978t.html", "checked": "2026-09-23", "status": "verified", "note": "Closing of Nasdaq IPO (TORC, trading from 26 Jan 2018): 6,516,667 shares at $15.00 incl. full over-allotment; gross proceeds $97.8M before underwriting discounts (PureTech RNS reproducing resTORbio's release, 31 Jan 2018)."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Tornado Therapeutics", "label": "Tornado Therapeutics publicly disclosed total funding", "value": null, "currency": "USD", "scope": "total_disclosed", "source_url": "https://www.lifespan.io/organizations/tornado-therapeutics/", "checked": "2026-09-23", "status": "unavailable", "note": "Cambrian Bio subsidiary; no separate funding figure found"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": "https://www.linkedin.com/in/joan-mannick-8089a614", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Altos Labs team page", "url": "https://www.altoslabs.com/team/joan-mannick"}]}, "sources": [{"url": "https://www.altoslabs.com/team/joan-mannick", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.altoslabs.com/featured/press-releases/altos-labs-appoints-joan-mannick-m-d-as-chief-medical-officer-and-head-of-product-development", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.lifespan.io/organizations/tornado-therapeutics/", "type": "secondary", "accessed": "2026-09-23"}, {"url": "https://longevity.technology/news/is-altos-labs-gearing-up-for-clinical-trials/", "type": "news", "accessed": "2026-09-23"}, {"url": "https://www.biospace.com/restorbio-raises-40-million-to-advance-selective-torc1-inhibitors-for-aging-related-diseases-and-conditions", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1126/scitranslmed.3009892", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1126/scitranslmed.aaq1564", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0132", "slug": "jim-mellon", "name": {"display": "Jim Mellon", "sort": "Mellon, Jim", "aliases": ["James Mellon"]}, "categories": ["entrepreneur", "communicator"], "current_title": {"title": "Co-Founder and Deputy Chairman", "organisation": "Juvenescence", "sources": ["https://juvlabs.com/our-team/jim-mellon/"], "source_type": "company_page", "checked": "2026-09-29", "status": "verified", "note": "Company team page lists him as Co-Founder and Deputy Chairman; some third-party sources say Chairman."}, "other_positions": [{"title": "Co-Founder and Trustee", "organisation": "The Longevity Forum", "sources": ["https://www.thelongevityforum.com/"]}, {"title": "Executive Chairman", "organisation": "Manx Financial Group; Agronomics", "sources": ["https://juvlabs.com/our-team/jim-mellon/"]}], "location": {"city": "", "region": "", "country_code": "IM", "sources": ["https://juvlabs.com/our-team/jim-mellon/"], "checked": "2026-09-29", "status": "verified", "note": "Based in the Isle of Man (Burnbrae Group family office; Manx Financial Group)."}, "photo": {"status": "found", "image_url": "https://juvlabs.com/wp-content/uploads/2024/03/Jim_CircleHeadshot_Photo_7eb5be66-ce6e-4937-908a-feeba72814aa.webp", "page_url": "https://juvlabs.com/our-team/jim-mellon/", "source_type": "company_page", "credit": "Juvenescence", "checked": "2026-09-29"}, "impact": {"text": "Jim Mellon is a British entrepreneur and investor who has become one of the most visible commercial champions of longevity science. After a career in fund management, which he has since left, he co-founded Juvenescence in 2017 with Greg Bailey and Declan Doogan to build and finance a portfolio of companies developing therapies for aging and age-related disease. The venture grew out of his book Juvenescence: Investing in the Age of Longevity (2017), written after he travelled to meet leading aging researchers, which helped bring the field to a wider investor and public audience. He co-founded and is a trustee of The Longevity Forum and hosts the annual Longevity Investors Conference, sits on the boards of trustees of the Buck Institute for Research on Aging and the American Federation for Aging Research, and established the Mellon Centre for Longevity at Oriel College, Oxford. He is also active in cellular agriculture through Agronomics.", "word_count": 156, "sources": ["https://juvlabs.com/our-team/jim-mellon/", "https://www.thelongevityforum.com/", "https://www.amazon.com/Juvenescence-Investing-longevity-Mellon-Jim/dp/0993047815"]}, "metrics": [], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Juvenescence profile", "url": "https://juvlabs.com/our-team/jim-mellon/"}, {"label": "The Longevity Forum", "url": "https://www.thelongevityforum.com/"}]}, "sources": [{"url": "https://juvlabs.com/our-team/jim-mellon/", "type": "company_page", "accessed": "2026-09-29"}, {"url": "https://www.thelongevityforum.com/", "type": "company_page", "accessed": "2026-09-29"}, {"url": "https://www.amazon.com/Juvenescence-Investing-longevity-Mellon-Jim/dp/0993047815", "type": "other", "accessed": "2026-09-29"}], "record": {"status": "draft", "created": "2026-09-29", "updated": "2026-09-29", "phase": "6"}}, {"id": "per_0076", "slug": "simon-melov", "name": {"display": "Simon Melov", "sort": "Melov, Simon"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor; co-director, Mouse Phenotyping and Single-Cell Biology cores", "organisation": "Buck Institute for Research on Aging", "sources": ["https://www.buckinstitute.org/lab/melov-lab/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Novato", "region": "CA", "country_code": "US", "sources": ["https://www.buckinstitute.org/lab/melov-lab/", "https://academyofgeroscience.org/gordon-lithgow-phd"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://www.buckinstitute.org/wp-content/uploads/2018/06/13_SIMON_MELOV_0040.jpg", "page_url": "https://www.buckinstitute.org/lab/melov-lab/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Simon Melov is a geroscientist at the Buck Institute, where he was the third faculty hire when the institute opened in 1999. His laboratory combines invertebrate and mouse models, human cells and tissues, and genomic and computational methods to study how cells and tissues change with age and with pharmacological intervention. With Gordon Lithgow he co-authored a 2000 Science paper reporting that superoxide dismutase/catalase mimetics extended lifespan in C. elegans. His group also reported that late-life rapamycin treatment reversed age-related heart dysfunction in mice (Aging Cell, 2013), and he co-authored the 2014 Nature commentary \"Treat ageing\" with Luigi Fontana, Brian Kennedy, Valter Longo and Douglas Seals, which argued for targeting ageing itself in medical research. Recent work includes 2026 Nature Aging papers on the diversity of senescent cells and on senescent microglia in the ageing mouse brain. He co-directs the Buck Institute's Mouse Phenotyping and Single-Cell Biology cores, was a founding editor of Aging Cell and founding chair of the Gordon Research Conference on Oxidative Stress and Disease, and has twice received the Glenn Award for Research in Biological Mechanisms of Aging.", "word_count": 182, "sources": ["https://www.buckinstitute.org/lab/melov-lab/", "https://doi.org/10.1111/acel.12109", "https://doi.org/10.1038/511405a", "https://doi.org/10.1038/s43587-026-01148-5", "https://doi.org/10.1038/s43587-026-01154-7"]}, "metrics": [{"kind": "h_index", "value": 76, "source_url": "https://scholar.google.com/citations?user=BmHttisAAAAJ", "note": "All column; profile: Professor, verified buckinstitute.org email", "checked": "2026-09-23", "status": "verified", "platform": "google_scholar", "for_category": "scientist"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=BmHttisAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Melov Lab, Buck Institute", "url": "https://www.buckinstitute.org/lab/melov-lab/"}]}, "sources": [{"url": "https://www.buckinstitute.org/lab/melov-lab/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=BmHttisAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1111/acel.12109", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/511405a", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s43587-026-01148-5", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s43587-026-01154-7", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0077", "slug": "richard-miller", "name": {"display": "Richard Miller", "sort": "Miller, Richard"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Pathology and Research Professor, Institute of Gerontology; Director, Paul F. Glenn Center for Biology of Aging Research", "organisation": "University of Michigan Medical School", "sources": ["https://medschool.umich.edu/profile/1886/richard-miller", "https://www.richmillerlab.com/", "https://www.richmillerlab.com/biog"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Ann Arbor", "region": "MI", "country_code": "US", "sources": ["https://www.richmillerlab.com/"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://medschool.umich.edu/sites/default/files/styles/square_1_1/public/2024-07/research-richard_miller.jpg.jpg?h=eac24a47&itok=PkFJmbuA", "page_url": "https://medschool.umich.edu/profile/1886/richard-miller", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Richard A. Miller, MD, PhD, is a Professor of Pathology at the University of Michigan, where he directs the Paul F. Glenn Center for Biology of Aging Research and holds a research professorship in the Institute of Gerontology. His work focuses on interventions that slow ageing in mice and on the biology of long-lived mice. He was senior author of the multi-site 2009 Nature study showing that rapamycin fed late in life extended lifespan in genetically heterogeneous mice, an influential result that helped establish mTOR inhibition as a candidate anti-ageing strategy, and he continues to co-author multi-site mouse lifespan intervention studies and proteomic analyses of longevity-promoting interventions (Geroscience, 2024). He trained at Haverford College and Yale University (MD and PhD), and has been at Michigan since 1990. He served as one of the Editors-in-Chief of Aging Cell and in advisory roles for the American Federation for Aging Research and the National Institute on Aging. His awards include the Nathan Shock Award, the Irving Wright Award, a Glenn Foundation award and the Kleemeier Award; he is a Fellow of the AAAS and a member of the Association of American Physicians.", "word_count": 189, "sources": ["https://www.richmillerlab.com/biog", "https://medschool.umich.edu/profile/1886/richard-miller", "https://doi.org/10.1038/nature08221"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": "https://scholar.google.com/citations?user=wpaYnXAAAAAJ", "checked": "2026-09-23", "status": "unavailable", "note": "Scholar profile (University of Michigan, verified umich.edu, shows h 107) is contaminated with many papers by other R. Millers with citation counts above 107, e.g. 2% methylcellulose in ophthalmic surgery (1984), diffuse X-ray background (1980), anti-TNF treatment failure in Crohn's disease (2019, 2020, 2024), UK-PBC risk scores (2016), Flora of Turkey (1988), fluoxetine after stroke (2019), antiplatelet therapy after intracerebral haemorrhage (2019), Power system operation (1994), red nucleus (1973), female starling (1938). The displayed h-index is inflated and not recorded."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=wpaYnXAAAAAJ", "status": "conflicting", "note": "Profile is his but contains many misattributed papers from other R. Millers"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "U-M Medical School profile", "url": "https://medschool.umich.edu/profile/1886/richard-miller"}, {"label": "Richard Miller Laboratory", "url": "https://www.richmillerlab.com/"}]}, "sources": [{"url": "https://medschool.umich.edu/profile/1886/richard-miller", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.richmillerlab.com/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.richmillerlab.com/biog", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=wpaYnXAAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/nature08221", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0078", "slug": "sofiya-milman", "name": {"display": "Sofiya Milman", "sort": "Milman, Sofiya"}, "categories": ["scientist", "academic", "doctor"], "current_title": {"title": "Professor of Medicine (Endocrinology) and of Genetics; Vice Chair for Research, Department of Medicine; Director of Human Longevity Studies, Institute for Aging Research", "organisation": "Albert Einstein College of Medicine", "sources": ["https://einsteinmed.edu/faculty/12865/sofiya-milman"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Faculty page header lists 'Vice Chair for Research, Department of Medicine'; the same page's narrative says 'Interim Vice-Chair for Research'."}, "other_positions": [], "location": {"city": "Bronx", "region": "NY", "country_code": "US", "sources": ["https://einsteinmed.edu/faculty/12865/sofiya-milman"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://assets.montefioreeinstein.org/profiles/images/physphoto/Milman_Sofiya_MD_11119335.jpg", "page_url": "https://einsteinmed.edu/faculty/12865/sofiya-milman", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Sofiya Milman is an endocrinologist and clinical investigator who studies the biology of human longevity through centenarians and their families, a population generally free of age-related diseases in which healthy longevity appears heritable. At Albert Einstein College of Medicine she is Professor of Medicine and of Genetics, Vice Chair for Research in the Department of Medicine, and Director of Human Longevity Studies at the Institute for Aging Research. Her team conducts translational research on genomic mechanisms that regulate endocrine and metabolic pathways protecting against diabetes, cardiovascular disease and Alzheimer's disease. A central theme is the somatotropic (growth hormone/IGF-1) axis: her work showed that lower IGF-1 levels were associated with longer survival and better cognition in people with exceptional longevity, and provided evidence against giving growth hormone to older adults to delay ageing. With Nir Barzilai and others she has published on compression of morbidity in exceptionally long-lived cohorts and on using the genetics of extreme human longevity to guide drug discovery for healthy ageing (Nature Metabolism, 2020). Her team combines computational analysis of genetic data with clinical phenotyping.", "word_count": 178, "sources": ["https://einsteinmed.edu/faculty/12865/sofiya-milman", "https://einsteinmed.edu/sofiya-milman"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 29, "source_url": "https://scholar.google.com/citations?user=Fc7r_C0AAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All column. Profile shows 'Unknown affiliation' and no verified email, but identity confirmed by paper list: all 12 'Selected Publications' on the Einstein research page (e.g. Low IGF-1 predicts survival in exceptional longevity, Aging Cell 2014; Somatotropic axis in human aging, Cell Metab 2016; antagonistic pleiotropy of IGF-1, Aging Cell 2021) appear on the profile, with Einstein co-authors (Barzilai, Huffman, Atzmon, Verghese). No unrelated-author papers seen in top 100."}, {"kind": "h_index", "for_category": "doctor", "platform": "google_scholar", "value": 29, "source_url": "https://scholar.google.com/citations?user=Fc7r_C0AAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All column. Profile shows 'Unknown affiliation' and no verified email, but identity confirmed by paper list: all 12 'Selected Publications' on the Einstein research page (e.g. Low IGF-1 predicts survival in exceptional longevity, Aging Cell 2014; Somatotropic axis in human aging, Cell Metab 2016; antagonistic pleiotropy of IGF-1, Aging Cell 2021) appear on the profile, with Einstein co-authors (Barzilai, Huffman, Atzmon, Verghese). No unrelated-author papers seen in top 100."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=Fc7r_C0AAAAJ&hl=en", "status": "verified", "note": "No affiliation/verified email on profile; identity confirmed by match with Einstein publication list"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Einstein faculty profile", "url": "https://einsteinmed.edu/faculty/12865/sofiya-milman"}, {"label": "Einstein research page", "url": "https://einsteinmed.edu/sofiya-milman"}]}, "sources": [{"url": "https://einsteinmed.edu/faculty/12865/sofiya-milman", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://einsteinmed.edu/sofiya-milman", "type": "institution_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0079", "slug": "richard-morimoto", "name": {"display": "Richard Morimoto", "sort": "Morimoto, Richard"}, "categories": ["scientist", "academic"], "current_title": {"title": "Bill and Gayle Cook Professor of Biology; Director, Rice Institute for Biomedical Research", "organisation": "Northwestern University", "sources": ["https://www.morimotolab.org/current-lab-members", "https://molbiosci.northwestern.edu/people/core-faculty/richard-morimoto.html"], "source_type": "lab_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Founder", "organisation": "Proteostasis Therapeutics, Inc. (past)", "sources": ["https://www.morimotolab.org/current-lab-members"]}], "location": {"city": "Evanston", "region": "IL", "country_code": "US", "sources": ["https://www.morimotolab.org/current-lab-members", "https://www.morimotolab.org/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://molbiosci.northwestern.edu/images/people/faculty/morimoto-186x232.jpg", "page_url": "https://molbiosci.northwestern.edu/people/core-faculty/richard-morimoto.html", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Richard Morimoto studies cell stress regulatory pathways and protein homeostasis (proteostasis), the systems that keep the proteome stable under stress and in the presence of misfolded and aggregation-prone proteins. His laboratory at Northwestern University uses C. elegans and human iPS cells, together with genetic, molecular, small-molecule, proteomic and genomic methods, to identify how these pathways change during ageing and in age-associated diseases, including neurodegeneration, metabolic disease and cancer. Work from his group has described transcellular chaperone signalling that coordinates proteostasis across tissues, and found that repression of the heat shock response in C. elegans is a programmed event at the onset of reproduction. He joined the Northwestern faculty in 1982 and has served as department chair, Dean of The Graduate School and Associate Provost. He was a founder of Proteostasis Therapeutics, a company formed to develop small-molecule treatments for diseases of protein homeostasis. His honours include election to the American Academy of Arts and Sciences and MERIT awards from the NIGMS and the National Institute on Aging.", "word_count": 167, "sources": ["https://www.morimotolab.org/current-lab-members", "https://molbiosci.northwestern.edu/people/core-faculty/richard-morimoto.html", "http://www.sciencedirect.com/science/article/pii/S0092867413005813"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 146, "source_url": "https://scholar.google.com/citations?user=tMWwWEAAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Richard I. Morimoto', William and Gayle Cook Professor of Biology, Dept of Molecular Biosciences", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=tMWwWEAAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Lab website", "url": "https://www.morimotolab.org/"}, {"label": "Northwestern faculty page", "url": "https://molbiosci.northwestern.edu/people/core-faculty/richard-morimoto.html"}]}, "sources": [{"url": "https://molbiosci.northwestern.edu/people/core-faculty/richard-morimoto.html", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.morimotolab.org/current-lab-members", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.morimotolab.org/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=tMWwWEAAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0080", "slug": "pura-munoz-canoves", "name": {"display": "Pura Muñoz-Canoves", "sort": "Muñoz-Canoves, Pura"}, "categories": ["scientist", "academic"], "current_title": {"title": "Principal Investigator (Discovery Science)", "organisation": "Altos Labs, San Diego Institute of Science", "sources": ["https://cell-press-symposia.com/hallmarksofaging-2026/bio-munoz-canoves.html", "https://www.altoslabs.com/team/pura-munoz-canoves", "https://doi.org/10.1016/j.cell.2026.07.045"], "source_type": "conference_listing", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Affiliated (Department of Medicine and Life Sciences)", "organisation": "Universitat Pompeu Fabra, Barcelona", "sources": ["https://doi.org/10.1016/j.cell.2026.07.045"]}], "location": {"city": "San Diego", "region": "CA", "country_code": "US", "sources": ["https://cell-press-symposia.com/hallmarksofaging-2026/bio-munoz-canoves.html", "https://doi.org/10.1016/j.cell.2026.07.045"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://a-us.storyblok.com/f/1016638/417x500/b95de83910/pura-munoz-canoves.png", "page_url": "https://www.altoslabs.com/team/pura-munoz-canoves", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Pura Muñoz-Cánoves studies how skeletal muscle stem cells age and lose regenerative capacity. Her laboratory showed that at geriatric age, quiescent muscle stem cells undergo proteostatic failure that leads to senescence, altered circadian functions and impaired regeneration, work that reshaped how the field views adult stem-cell dormancy and its link to tissue ageing. She has been a Principal Investigator at Altos Labs in San Diego since 2022, as part of its Discovery Science team. Before that she was an ICREA Professor and Professor of Cell Biology at Pompeu Fabra University in Barcelona, and a Senior Scientist at the Spanish National Cardiovascular Research Center (CNIC) in Madrid; 2026 papers still list a Pompeu Fabra co-affiliation. Her honours include the King Jaume I Prize (2019), Spain's National Prize Santiago Ramón y Cajal in Biomedicine (2021), ERC awards, and membership of EMBO, Academia Europaea and the Spanish Royal Academy of Sciences.", "word_count": 148, "sources": ["https://www.altoslabs.com/team/pura-munoz-canoves", "https://cell-press-symposia.com/hallmarksofaging-2026/bio-munoz-canoves.html", "https://doi.org/10.1016/j.cell.2026.07.045"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "No clearly attributable public Google Scholar profile found", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": "https://www.linkedin.com/in/pura-munoz-canoves-711b03259", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Altos Labs profile", "url": "https://www.altoslabs.com/team/pura-munoz-canoves"}]}, "sources": [{"url": "https://www.altoslabs.com/team/pura-munoz-canoves", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://cell-press-symposia.com/hallmarksofaging-2026/bio-munoz-canoves.html", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cell.2026.07.045", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1101/cshperspect.a041479", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0081", "slug": "laura-niedernhofer", "name": {"display": "Laura Niedernhofer", "sort": "Niedernhofer, Laura"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor, Department of Biochemistry, Molecular Biology and Biophysics; Director, Masonic Institute on the Biology of Aging and Metabolism (MIBAM) and Medical Discovery Team on the Biology of Aging", "organisation": "University of Minnesota", "sources": ["https://med.umn.edu/bio/laura-niedernhofer", "https://niedernhofer.umn.edu/laura-niedernhofer-md-phd"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Minneapolis", "region": "MN", "country_code": "US", "sources": ["https://med.umn.edu/bio/laura-niedernhofer"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://med.umn.edu/sites/med.umn.edu/files/styles/bio_photo/public/web_profiles/2024-01/laura-niedernhofer-1x1.jpg?itok=vhA3PAxy", "page_url": "https://med.umn.edu/bio/laura-niedernhofer", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Laura Niedernhofer, MD, PhD, works on DNA damage and repair, genome instability, cellular senescence and ageing. Her group uses a mouse model of a human progeroid syndrome caused by a DNA repair defect, and showed that removing DNA repair defenses accelerates ageing, supporting the view that unrepaired DNA damage can drive ageing. Her lab also reported that transplanting muscle-derived stem cells from young mice slowed ageing in progeroid mice, evidence that stem-cell dysfunction contributes to ageing rather than only reflecting it. She contributed to the discovery of senolytics, a class of drugs that target senescent cells, and her programme focuses on therapies that target ageing itself to prevent or attenuate multiple age-related diseases at once. Her work on the repair enzyme ERCC1-XPF described its roles in repairing DNA interstrand crosslinks and double-strand breaks, relevant to platinum and radiation therapy. At the University of Minnesota she directs the Masonic Institute on the Biology of Aging and Metabolism and the Medical Discovery Team on the Biology of Aging, and is a Professor of Biochemistry, Molecular Biology and Biophysics. She has served on NCI, NIEHS and NIA study sections.", "word_count": 186, "sources": ["https://niedernhofer.umn.edu/laura-niedernhofer-md-phd", "https://med.umn.edu/bio/laura-niedernhofer"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 89, "source_url": "https://scholar.google.com/citations?user=WVfr6Z8AAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile lists Director, Institute on the Biology of Aging and Metabolism, Professor of Biochemistry", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=WVfr6Z8AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Lab website", "url": "https://niedernhofer.umn.edu/"}, {"label": "UMN Medical School bio", "url": "https://med.umn.edu/bio/laura-niedernhofer"}]}, "sources": [{"url": "https://med.umn.edu/bio/laura-niedernhofer", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://niedernhofer.umn.edu/laura-niedernhofer-md-phd", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=WVfr6Z8AAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0082", "slug": "janko-nikolich", "name": {"display": "Janko Nikolich", "sort": "Nikolich, Janko", "aliases": ["Janko Nikolich-Žugich", "Janko Nikolich-Zugich"]}, "categories": ["scientist", "academic"], "current_title": {"title": "Regents Professor; Associate Dean, Research", "organisation": "University of Arizona College of Medicine – Phoenix", "sources": ["https://phoenixmed.arizona.edu/leadership/janko-nikolich", "https://scholar.google.com/citations?user=t-yhY8QAAAAJ&hl=en"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Professor, Immunobiology; Co-Director, Arizona Center on Aging; Interim Director, AEGIS Center (as listed on Tucson department page)", "organisation": "University of Arizona", "sources": ["https://immunobiology.arizona.edu/person/janko-z-nikolich"]}], "location": {"city": "Phoenix", "region": "AZ", "country_code": "US", "sources": ["https://phoenixmed.arizona.edu/leadership/janko-nikolich"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://phoenixmed.arizona.edu/sites/default/files/2026-05/janko-nikolich-bio.jpg", "page_url": "https://phoenixmed.arizona.edu/leadership/janko-nikolich", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Janko Nikolich (publishing as Nikolich-Žugich) is an immunologist and gerontologist who studies how the immune system ages. His research covers basic mechanisms of T-cell function, immunity to acute viral infection in older adults, lifelong interactions between persistent viruses such as cytomegalovirus and the host, vaccine responses and biomarkers of declining immunity in older people, immune rejuvenation, and the effects of inflammation and nutritional interventions on ageing and metabolic disorders. After positions at Scripps, Memorial Sloan-Kettering/Cornell and Oregon Health & Science University, he joined the University of Arizona in 2008 to lead the Department of Immunobiology and the Arizona Center on Aging. During the COVID-19 pandemic he co-invented an antibody test and directed statewide antibody screening in Arizona, and he founded the university's Aegis Consortium on pandemic preparedness. In 2025 he moved to the College of Medicine – Phoenix as Associate Dean for Research and was named a Regents Professor. He was elected to the Serbian Academy of Sciences and Arts in 2024.", "word_count": 162, "sources": ["https://phoenixmed.arizona.edu/leadership/janko-nikolich", "https://immunobiology.arizona.edu/person/janko-z-nikolich"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 74, "source_url": "https://scholar.google.com/citations?user=t-yhY8QAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Janko Z. Nikolich', Regents Professor and Associate Dean for Research and Partnerships", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=t-yhY8QAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UA College of Medicine – Phoenix leadership page", "url": "https://phoenixmed.arizona.edu/leadership/janko-nikolich"}, {"label": "UA Immunobiology profile", "url": "https://immunobiology.arizona.edu/person/janko-z-nikolich"}]}, "sources": [{"url": "https://phoenixmed.arizona.edu/leadership/janko-nikolich", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://immunobiology.arizona.edu/person/janko-z-nikolich", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=t-yhY8QAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0083", "slug": "alejandro-ocampo", "name": {"display": "Alejandro Ocampo", "sort": "Ocampo, Alejandro"}, "categories": ["scientist", "academic", "entrepreneur"], "current_title": {"title": "Co-Founder and CEO", "organisation": "EPITERNA SA", "sources": ["https://www.startupticker.ch/en/news/longevity-startup-epiterna-raises-10m", "https://ggba.swiss/en/longevity-start-up-epiterna-raises-eur-10-million-to-slow-ageing-and-extend-lifespan/", "https://www.unil.ch/news/fr/1751895887932"], "source_type": "press_release", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Former Assistant Professor, Department of Biomedical Sciences (co-affiliation retained on 2026 papers)", "organisation": "University of Lausanne", "sources": ["https://www.unil.ch/news/fr/1751895887932", "https://doi.org/10.1016/j.celrep.2026.117897"]}], "location": {"city": "Epalinges", "region": "Vaud", "country_code": "CH", "sources": ["https://doi.org/10.1016/j.celrep.2026.117897"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://scholar.googleusercontent.com/citations?view_op=medium_photo&user=czeAtK0AAAAJ", "page_url": "https://scholar.google.com/citations?user=czeAtK0AAAAJ&hl=en", "source_type": "scholarly_profile", "credit": "Google Scholar", "checked": "2026-09-29"}, "impact": {"text": "Alejandro Ocampo studies how to slow or reverse ageing at the cellular and molecular level. At the Salk Institute he was among the first to show that epigenetic reprogramming could extend lifespan in mice, and he later led a laboratory in the Department of Biomedical Sciences at the University of Lausanne. His UNIL group developed a chemical partial reprogramming approach in which a mixture of small molecules improved several ageing markers in aged human cells while preserving cell identity, reported in EMBO Molecular Medicine. In 2022 he co-founded EPITERNA as a spin-off of his Lausanne laboratory, and he serves as its CEO. The company, based at the Biopôle in Epalinges, runs a high-throughput, cross-species drug-screening platform that tests already-approved medicines in animal models of ageing, with the aim of developing affordable products to slow ageing in companion dogs and cats and in people. A 2026 Cell Reports paper describing this platform lists both EPITERNA and the University of Lausanne as his affiliations. EPITERNA announced EUR 10 million in funding from Prima Materia in 2023.", "word_count": 174, "sources": ["https://www.startupticker.ch/en/news/longevity-startup-epiterna-raises-10m", "https://ggba.swiss/en/longevity-start-up-epiterna-raises-eur-10-million-to-slow-ageing-and-extend-lifespan/", "https://www.unil.ch/news/fr/1751895887932", "https://doi.org/10.1016/j.celrep.2026.117897"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 28, "source_url": "https://scholar.google.com/citations?user=czeAtK0AAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Alejandro Ocampo', University of Lausanne, verified unil.ch email", "checked": "2026-09-23"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "EPITERNA", "label": "EPITERNA publicly reported funding round (Prima Materia, 2023)", "value": 10000000, "currency": "EUR", "scope": "single_round", "source_url": "https://www.startupticker.ch/en/news/longevity-startup-epiterna-raises-10m", "checked": "2026-09-23", "status": "verified", "note": "EUR 10m from Prima Materia (Daniel Ek / Shakil Khan) announced August 2023 (also reported by GGBA); round series not named. No later disclosed rounds found; total may be higher."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=czeAtK0AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": "https://ch.linkedin.com/in/alejandro-ocampo-46678539", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "EPITERNA", "url": "https://www.epiterna.com/"}, {"label": "UNIL news on chemical partial reprogramming", "url": "https://www.unil.ch/news/fr/1751895887932"}]}, "sources": [{"url": "https://www.startupticker.ch/en/news/longevity-startup-epiterna-raises-10m", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://ggba.swiss/en/longevity-start-up-epiterna-raises-eur-10-million-to-slow-ageing-and-extend-lifespan/", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.unil.ch/news/fr/1751895887932", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.celrep.2026.117897", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=czeAtK0AAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0084", "slug": "s-jay-olshansky", "name": {"display": "S. Jay Olshansky", "sort": "Olshansky, S. Jay"}, "categories": ["scientist", "academic", "communicator"], "current_title": {"title": "Professor, School of Public Health", "organisation": "University of Illinois Chicago", "sources": ["https://publichealth.uic.edu/profiles/s-jay-olshansky/", "https://scholar.google.com/citations?user=U6Mgr6wAAAAJ&hl=en"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Research Associate, Center on Aging", "organisation": "University of Chicago", "sources": ["https://publichealth.uic.edu/profiles/s-jay-olshansky/"]}, {"title": "Co-founder; former Chief Scientist", "organisation": "Lapetus Solutions, Inc.", "sources": ["https://publichealth.uic.edu/profiles/s-jay-olshansky/"]}], "location": {"city": "Chicago", "region": "IL", "country_code": "US", "sources": ["https://publichealth.uic.edu/profiles/s-jay-olshansky/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://publichealth.uic.edu/wp-content/uploads/sites/302/2019/02/Olshansky-S-Jay-600-688-157x180.jpg", "page_url": "https://publichealth.uic.edu/profiles/s-jay-olshansky/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "S. Jay Olshansky is a demographer whose research concerns the upper limits of human longevity, forecasts of population size, survival and age structure, and the health and policy implications of individual and population ageing. With colleagues in the biological sciences he helped develop the biodemographic paradigm of mortality, which seeks to explain the biological basis of survival and dying-out processes. His 1990 Science paper 'In Search of Methuselah' estimated upper limits to human longevity, and a 2005 New England Journal of Medicine paper he led warned of a potential decline in US life expectancy in the twenty-first century. He is associated with the 'Longevity Dividend' argument that slowing ageing in people would bring broad health and economic returns, and a 2024 Nature Aging paper he led argued that radical life extension in the twenty-first century is implausible. He is a Professor in the School of Public Health at the University of Illinois Chicago and a Research Associate at the University of Chicago Center on Aging, co-founded Lapetus Solutions, and has written or co-edited several books on ageing. In 2022 he testified before the US House Committee on Science, Space, and Technology.", "word_count": 191, "sources": ["https://publichealth.uic.edu/profiles/s-jay-olshansky/", "https://doi.org/10.1038/s43587-024-00702-3"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 52, "source_url": "https://scholar.google.com/citations?user=U6Mgr6wAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'S Jay Olshansky', Professor of Public Health, University of Illinois at Chicago", "checked": "2026-09-23"}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No confirmed social-media account found (none linked from UIC profile, Scholar profile or personal homepage sjayolshansky.com; re-checked 2026-09-23). Communicator activity is mainly books and media commentary; no reliable audience count."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=U6Mgr6wAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UIC School of Public Health profile", "url": "https://publichealth.uic.edu/profiles/s-jay-olshansky/"}, {"label": "Personal homepage (linked from Scholar)", "url": "http://sjayolshansky.com/"}]}, "sources": [{"url": "https://publichealth.uic.edu/profiles/s-jay-olshansky/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s43587-024-00702-3", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=U6Mgr6wAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "http://sjayolshansky.com/", "type": "personal_site", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0085", "slug": "linda-partridge", "name": {"display": "Linda Partridge", "sort": "Partridge, Linda"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professorial Research Fellow, UCL Institute of Healthy Ageing, Department of Genetics, Evolution & Environment", "organisation": "University College London", "sources": ["https://profiles.ucl.ac.uk/9759-linda-partridge", "https://royalsociety.org/people/linda-partridge-12044/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Emeritus Founding Director", "organisation": "Max Planck Institute for Biology of Ageing, Cologne", "sources": ["https://profiles.ucl.ac.uk/9759-linda-partridge", "https://royalsociety.org/people/linda-partridge-12044/"]}, {"title": "Weldon Professor of Biometry", "organisation": "University College London", "sources": ["https://profiles.ucl.ac.uk/9759-linda-partridge", "https://ukrio.org/news/professor-dame-linda-partridge-appointed-as-new-chair-of-ukrio/"]}, {"title": "Chair of Trustees (from May 2025)", "organisation": "UK Research Integrity Office", "sources": ["https://ukrio.org/news/professor-dame-linda-partridge-appointed-as-new-chair-of-ukrio/"]}], "location": {"city": "London", "region": "England", "country_code": "GB", "sources": ["https://profiles.ucl.ac.uk/9759-linda-partridge"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://imagecdn.royalsociety.org/people/P28379.jpg", "page_url": "https://royalsociety.org/people/linda-partridge-12044/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Linda Partridge is a geneticist who studies the biology of ageing, both how the rate of ageing evolves in nature and the mechanisms by which healthy lifespan can be extended in laboratory organisms, particularly the fruit fly Drosophila melanogaster. Her work has focused on nutrient-sensing pathways, notably insulin/insulin-like growth factor signalling, and on dietary restriction; her group reported lifespan extension in flies lacking CHICO, an insulin receptor substrate protein. Her current focus is on pharmacological treatments that could improve health broadly during human ageing, and on age-related disorders such as Alzheimer's and Parkinson's disease. She was founding Director of the Max Planck Institute for Biology of Ageing in Cologne, where she is now Emeritus Founding Director, and she is Weldon Professor of Biometry and a Professorial Research Fellow at the UCL Institute of Healthy Ageing, which she has directed since 2007. She also promotes ageing research through policy work and science communication; she has served as Biological Secretary of the Royal Society and in 2025 became Chair of Trustees of the UK Research Integrity Office. She was made a DBE in 2009 and elected a Fellow of the Royal Society in 1996.", "word_count": 192, "sources": ["https://profiles.ucl.ac.uk/9759-linda-partridge", "https://royalsociety.org/people/linda-partridge-12044/", "https://ukrio.org/news/professor-dame-linda-partridge-appointed-as-new-chair-of-ukrio/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 148, "source_url": "https://scholar.google.com/citations?user=emmwQa0AAAAJ&hl=en", "checked": "2026-09-23", "status": "verified", "note": "All column (Scholar-displayed). Profile shows 'Unknown affiliation' and no verified email, but the paper list is clearly hers (Hallmarks of aging 2013/2023, CHICO lifespan extension 2001, rapamycin in Drosophila 2010, dietary restriction in Drosophila, dFOXO, evolution of ageing with Barton) matching her UCL/Royal Society research description. Minor contamination: two SIREN COVID-19 health-care-worker papers (Lancet 2021; 900 and 784 citations) list an 'L Partridge' as a SIREN study-group investigator, almost certainly a different person; excluding them the Scholar list would give about 146."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=emmwQa0AAAAJ&hl=en", "status": "verified", "note": "No affiliation/verified email on profile; identity confirmed by paper list; includes 2 likely misattributed SIREN papers"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UCL profile", "url": "https://profiles.ucl.ac.uk/9759-linda-partridge"}, {"label": "Royal Society Fellow page", "url": "https://royalsociety.org/people/linda-partridge-12044/"}]}, "sources": [{"url": "https://profiles.ucl.ac.uk/9759-linda-partridge", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://royalsociety.org/people/linda-partridge-12044/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://ukrio.org/news/professor-dame-linda-partridge-appointed-as-new-chair-of-ukrio/", "type": "press_release", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0086", "slug": "joao-passos", "name": {"display": "João Passos", "sort": "Passos, João"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Physiology; Director, Cell and Molecular Aging Laboratory; Associate Director, Robert and Arlene Kogod Center on Aging", "organisation": "Mayo Clinic", "sources": ["https://www.mayo.edu/research/faculty/passos-joao-ph-d/bio-20454365", "https://academyofgeroscience.org/joao-passos"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Rochester", "region": "MN", "country_code": "US", "sources": ["https://doi.org/10.1016/j.devcel.2026.08.004", "https://www.mayo.edu/research/faculty/passos-joao-ph-d/bio-20454365"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://scholar.googleusercontent.com/citations?view_op=medium_photo&user=diWUeu4AAAAJ", "page_url": "https://scholar.google.com/citations?user=diWUeu4AAAAJ&hl=en", "source_type": "scholarly_profile", "credit": "Google Scholar", "checked": "2026-09-29"}, "impact": {"text": "João Passos studies cellular senescence in ageing and age-related disease, with a focus on telomeres and mitochondria. His work showed that senescence depends on persistent DNA-damage signalling from irreparably damaged telomeres, and that telomeres can sense stress and become damaged during ageing in many tissues. He identified a key role for mitochondria in inducing senescence: dysfunctional mitochondria produce excess reactive oxygen species that accelerate telomere damage, and mitochondria also regulate the pro-inflammatory senescence-associated secretory phenotype, including through release of mitochondrial DNA and RNA that engages innate immune pathways. His laboratory has developed super-resolution and live-cell reporter methods to visualise telomere damage, and has studied senescence in ageing lung, heart, liver and skin. His current aim is to develop therapies targeting mitochondrial dysfunction and senescent cells to extend healthspan. At Mayo Clinic he is Professor of Physiology, directs the Cell and Molecular Aging Laboratory and is Associate Director of the Robert and Arlene Kogod Center on Aging; he also contributes to the NIH SenNet Consortium mapping senescent cells across tissues.", "word_count": 169, "sources": ["https://www.mayo.edu/research/faculty/passos-joao-ph-d/bio-20454365", "https://academyofgeroscience.org/joao-passos"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 75, "source_url": "https://scholar.google.com/citations?user=diWUeu4AAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Joao Passos', Professor, Mayo Clinic, MN, USA", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=diWUeu4AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Mayo Clinic faculty bio", "url": "https://www.mayo.edu/research/faculty/passos-joao-ph-d/bio-20454365"}]}, "sources": [{"url": "https://www.mayo.edu/research/faculty/passos-joao-ph-d/bio-20454365", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://academyofgeroscience.org/joao-passos", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=diWUeu4AAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.devcel.2026.08.004", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0087", "slug": "thomas-perls", "name": {"display": "Thomas Perls", "sort": "Perls, Thomas"}, "categories": ["scientist", "academic", "doctor"], "current_title": {"title": "Professor, Department of Medicine (Section of Geriatrics); Founder and Director, New England Centenarian Study", "organisation": "Boston University Chobanian & Avedisian School of Medicine", "sources": ["https://www.bumc.bu.edu/camed/profile/thomas-perls/", "https://www.bumc.bu.edu/medicine/profile/thomas-perls/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Boston", "region": "MA", "country_code": "US", "sources": ["https://www.bumc.bu.edu/camed/profile/thomas-perls/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://profiles.bu.edu/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx?NodeID=40128", "page_url": "https://www.bumc.bu.edu/camed/profile/thomas-perls/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Thomas Perls, MD, MPH, is a geriatrician and researcher on human exceptional longevity. He founded and directs the New England Centenarian Study, which describes itself as the largest study of centenarians and their families, and is a principal investigator of the NIA-funded Long Life Family Study. His group reported that siblings of centenarians have markedly higher chances of reaching 100, that children of centenarians have substantially lower rates of heart disease, stroke, diabetes and hypertension in their seventies, and that exceptional longevity clusters in families. Work on semi-supercentenarians and supercentenarians found that these individuals tend to delay age-related diseases until the last few percent of their lives, evidence consistent with the compression of morbidity hypothesis. He also led genetic studies, including a model of genetic markers that distinguished people aged 105 and older from controls, and whole-genome sequencing of two supercentenarians. He is a Professor at Boston University Chobanian & Avedisian School of Medicine in the Section of Geriatrics, and has been a public critic of the 'anti-aging' industry.", "word_count": 169, "sources": ["https://www.bumc.bu.edu/camed/profile/thomas-perls/", "https://www.bumc.bu.edu/medicine/profile/thomas-perls/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "DuckDuckGo returned a Scholar id (BjWiYaQAAAAJ) titled 'Thomas Perls', but the profile page returned 404 on 2026-09-23; no attributable public profile could be read.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "BU Chobanian & Avedisian School of Medicine profile", "url": "https://www.bumc.bu.edu/camed/profile/thomas-perls/"}, {"label": "BU Department of Medicine profile", "url": "https://www.bumc.bu.edu/medicine/profile/thomas-perls/"}]}, "sources": [{"url": "https://www.bumc.bu.edu/camed/profile/thomas-perls/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.bumc.bu.edu/medicine/profile/thomas-perls/", "type": "institution_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0088", "slug": "james-peyer", "name": {"display": "James Peyer", "sort": "Peyer, James"}, "categories": ["entrepreneur"], "current_title": {"title": "CEO, Founder and Board Director", "organisation": "Cambrian Bio", "sources": ["https://www.cambrianbio.com/team", "https://www.cambrianbio.com/news-and-publications/press-release-cambrian-bio-awarded-up-to-30-8-million-as-part-of-arpa-hs-prospr-program-to-advance-a-novel-mtorc1-selective-inhibitor-for-improving-intrinsic-capacity-in-older-people", "https://agingpharma.org/speakers/james-peyer/"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Former Founder and Managing Partner", "organisation": "Apollo Ventures", "sources": ["https://www.cambrianbio.com/team"]}], "location": {"city": "New York", "region": "NY", "country_code": "US", "sources": ["https://www.cambrianbio.com/news-and-publications/press-release-cambrian-bio-awarded-up-to-30-8-million-as-part-of-arpa-hs-prospr-program-to-advance-a-novel-mtorc1-selective-inhibitor-for-improving-intrinsic-capacity-in-older-people"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://cdn.prod.website-files.com/604c79c5c2649addebab824c/62e958adf53fef4fea76d256_James.jpg", "page_url": "https://www.cambrianbio.com/team", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "James Peyer, PhD, is the founder and Chief Executive Officer of Cambrian Bio, a New York-based clinical-stage drug development company working on therapeutics that target biological drivers of ageing and age-related disease. Cambrian operates a distributed model in which pipeline companies develop individual programmes, and Peyer holds board and executive roles across several of them. Its pipeline includes a selective mTORC1 inhibitor platform, for which Cambrian announced in February 2026 an award of up to $30.8 million from ARPA-H's PROSPR programme to target intrinsic capacity in older people, and Amplifier Therapeutics, which is developing the AMPK network activator ATX-304. Before Cambrian, Peyer was founder and managing partner of Apollo Ventures, a longevity-focused venture capital firm investing in the US and Europe, and a biotech R&D specialist at McKinsey & Company in New York. He earned a PhD in stem cell biology at UT Southwestern Medical Center as a National Science Foundation Fellow and a BA from the University of Chicago. He spoke at ARDD 2026.", "word_count": 165, "sources": ["https://www.cambrianbio.com/team", "https://www.cambrianbio.com/news-and-publications/press-release-cambrian-bio-awarded-up-to-30-8-million-as-part-of-arpa-hs-prospr-program-to-advance-a-novel-mtorc1-selective-inhibitor-for-improving-intrinsic-capacity-in-older-people", "https://www.cambrianbio.com/news-and-publications", "https://agingpharma.org/speakers/james-peyer/"]}, "metrics": [{"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Cambrian Bio", "label": "Cambrian Bio publicly reported Series C funding (2021)", "value": 100000000, "currency": "USD", "scope": "single_round", "source_url": "https://www.cambrianbio.com/news-and-publications", "checked": "2026-09-23", "status": "verified", "note": "$100M Series C (Oct 2021), as listed on Cambrian's news page citing Fierce Biotech. The news page also lists a Feb 2021 report of Cambrian 'raising $60 million' at launch (not confirmed as closed). A secondary source (Channel Point Capital, Jan 2025) reports ~$160M raised since 2019 plus $23M new funding; not verified first-party. ARPA-H award (up to $30.8M, 2026) is non-dilutive and not included."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Cambrian Bio team page", "url": "https://www.cambrianbio.com/team"}]}, "sources": [{"url": "https://www.cambrianbio.com/team", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.cambrianbio.com/news-and-publications", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.cambrianbio.com/news-and-publications/press-release-cambrian-bio-awarded-up-to-30-8-million-as-part-of-arpa-hs-prospr-program-to-advance-a-novel-mtorc1-selective-inhibitor-for-improving-intrinsic-capacity-in-older-people", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://agingpharma.org/speakers/james-peyer/", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://www.channelpointcapital.com/news/cambrian-bio-raises-23m-to-expand-longevity-therapeutics-platform", "type": "secondary", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-24", "phase": "3"}}, {"id": "per_0089", "slug": "daniel-promislow", "name": {"display": "Daniel Promislow", "sort": "Promislow, Daniel"}, "categories": ["scientist", "academic"], "current_title": {"title": "Senior Scientist and Scientific Advisor", "organisation": "Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA), Tufts University", "sources": ["https://hnrca.tufts.edu/people/faculty/daniel-promislow", "https://promislowlab.org/people/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Lab page says he was professor at the University of Washington 2013–2024 and moved to Tufts HNRCA in 2024; 2026 papers list HNRCA only, so no current UW role was found."}, "other_positions": [{"title": "Principal Investigator", "organisation": "Dog Aging Project", "sources": ["https://hnrca.tufts.edu/people/faculty/daniel-promislow", "https://promislowlab.org/people/"]}], "location": {"city": "Boston", "region": "MA", "country_code": "US", "sources": ["https://promislowlab.org/people/", "https://doi.org/10.1038/s41467-026-73193-y"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://hnrca.tufts.edu/sites/g/files/lrezom631/files/styles/large/public/2024-03/people-daniel-promislow-500x625.jpg?itok=onMljQtU", "page_url": "https://hnrca.tufts.edu/people/faculty/daniel-promislow", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Daniel Promislow is an evolutionary geneticist who has worked for more than 30 years on the biology of ageing, drawing on quantitative genetics, biodemography and comparative, systems and theoretical biology. His work asks whether ageing pathways identified in inbred laboratory organisms explain the variation in rates of ageing seen in genetically diverse natural populations, including humans. He has used metabolomics to link genes with rates of ageing, first in fruit flies and then in mice, marmosets, humans and companion dogs; his fly research concerns molecular biomarkers of ageing and interactions between social behaviour and ageing. He is Principal Investigator of the NIH-funded Dog Aging Project, a long-term longitudinal study of the biological and environmental determinants of healthy ageing in companion dogs that has enrolled more than 50,000 dogs and includes a clinical trial of rapamycin for healthspan in dogs. After faculty posts at the University of Georgia and the University of Washington (2013–2024), he moved in 2024 to the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University. He is a Fellow of the AAAS, the Gerontological Society of America and the American Aging Association.", "word_count": 188, "sources": ["https://hnrca.tufts.edu/people/faculty/daniel-promislow", "https://promislowlab.org/people/", "https://doi.org/10.1038/s41467-026-73193-y"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 71, "source_url": "https://scholar.google.com/citations?user=i6vuWgQAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'D Promislow', Tufts University", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=i6vuWgQAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/danielpromislow", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "HNRCA faculty page", "url": "https://hnrca.tufts.edu/people/faculty/daniel-promislow"}, {"label": "Promislow Lab", "url": "https://promislowlab.org/"}, {"label": "Dog Aging Project", "url": "https://www.dogagingproject.org/"}]}, "sources": [{"url": "https://hnrca.tufts.edu/people/faculty/daniel-promislow", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://promislowlab.org/people/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41467-026-73193-y", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=i6vuWgQAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0090", "slug": "marco-quarta", "name": {"display": "Marco Quarta", "sort": "Quarta, Marco"}, "categories": ["entrepreneur", "scientist"], "current_title": {"title": "Co-Founder and Chief Scientific Officer", "organisation": "Rubedo Life Sciences", "sources": ["https://www.rubedolife.com/about/", "https://agingpharma.org/speakers/marco-quarta/"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "President and Co-founder", "organisation": "Phaedon Institute", "sources": ["https://agingpharma.org/speakers/marco-quarta/"]}, {"title": "Co-founder", "organisation": "Turn Biotechnologies", "sources": ["https://agingpharma.org/speakers/marco-quarta/"]}, {"title": "Co-founder", "organisation": "Wetware Concepts", "sources": ["https://agingpharma.org/speakers/marco-quarta/"]}], "location": {"city": "Mountain View", "region": "CA", "country_code": "US", "sources": ["https://doi.org/10.1038/s41514-026-00388-4"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://agingpharma.org/images/ardd-marco-quarta-tilda-migration.jpg", "page_url": "https://agingpharma.org/speakers/marco-quarta/", "source_type": "conference_listing", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Marco Quarta, PhD, is a scientist and biotechnology entrepreneur developing therapeutics for ageing and age-related disease. He co-founded Rubedo Life Sciences, a clinical-stage company developing therapies that target senescent and other pathological ageing cells, served as its founding CEO, and is now its Chief Scientific Officer. As CEO he led Rubedo's $40 million Series A in 2024, raised to take its first clinical candidate, RLS-1496, into Phase 1 studies in chronic atopic dermatitis and psoriasis. Before Rubedo he led translational research in regenerative medicine at Stanford University and the VA Palo Alto, working across stem cell biology, tissue repair and ageing. He has authored more than 80 publications and patents, co-founded other biotechnology companies including Turn Biotechnologies and Wetware Concepts, and is President and co-founder of the Phaedon Institute, a nonprofit focused on longevity medicine. A 2026 paper listing him at Rubedo linked senescent fibroblast heterogeneity and the DNA damage response to idiopathic pulmonary fibrosis.", "word_count": 155, "sources": ["https://agingpharma.org/speakers/marco-quarta/", "https://www.rubedolife.com/about/", "https://www.biospace.com/rubedo-life-sciences-closes-40m-series-a-financing-led-by-khosla-ventures-and-ahren-innovation-capital", "https://doi.org/10.1038/s41514-026-00388-4"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "No clearly attributable public Google Scholar profile found in two searches", "checked": "2026-09-23"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Rubedo Life Sciences", "label": "Rubedo Life Sciences publicly disclosed Series A funding (2024)", "value": 40000000, "currency": "USD", "scope": "single_round", "source_url": "https://www.biospace.com/rubedo-life-sciences-closes-40m-series-a-financing-led-by-khosla-ventures-and-ahren-innovation-capital", "checked": "2026-09-23", "status": "verified", "note": "$40M Series A co-led by Khosla Ventures and Ahren Innovation Capital, Business Wire release 22 April 2024 (republished by BioSpace). Total to date not stated in release."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Turn Biotechnologies", "label": "Turn Biotechnologies publicly disclosed total funding", "value": null, "currency": "USD", "scope": "total_disclosed", "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "Co-founder per ARDD bio; funding not verified in this pass."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": "https://www.linkedin.com/in/marco4quarta", "status": "verified"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Rubedo Life Sciences leadership", "url": "https://www.rubedolife.com/about/"}, {"label": "Phaedon Institute profile", "url": "https://www.phaedon.institute/people/marco-quarta/"}]}, "sources": [{"url": "https://www.rubedolife.com/about/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://agingpharma.org/speakers/marco-quarta/", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://www.rubedolife.com/media-press-release/rubedo-life-sciences-closes-40m-series-a-financing-led-by-khosla-ventures-and-ahren-innovation-capital/", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.biospace.com/rubedo-life-sciences-closes-40m-series-a-financing-led-by-khosla-ventures-and-ahren-innovation-capital", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41514-026-00388-4", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0091", "slug": "peter-rabinovitch", "name": {"display": "Peter Rabinovitch", "sort": "Rabinovitch, Peter"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor Emeritus, Department of Laboratory Medicine and Pathology", "organisation": "University of Washington", "sources": ["https://dlmp.uw.edu/faculty/rabinovitch", "https://halo.dlmp.uw.edu/people/peter-s-rabinovitch/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "DLMP page labels him 'Professor Emeritus' / 'Emeritus Faculty' while its appointment list still reads 'Professor, 1992-present'. Current research evidenced by a June 2026 paper with UW DLMP affiliation."}, "other_positions": [{"title": "Joint Member", "organisation": "Fred Hutchinson Cancer Research Center", "sources": ["https://dlmp.uw.edu/faculty/rabinovitch", "https://halo.dlmp.uw.edu/people/peter-s-rabinovitch/"]}], "location": {"city": "Seattle", "region": "WA", "country_code": "US", "sources": ["https://dlmp.uw.edu/faculty/rabinovitch", "https://doi.org/10.3390/biology15131034"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://dlmp.uw.edu/content/faculty-img/88/rabinovitch_peter_headshot_color_neural_2019__profile.jpg", "page_url": "https://dlmp.uw.edu/faculty/rabinovitch", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Peter Rabinovitch, MD, PhD, is a pathologist and ageing researcher whose laboratory uses mouse models to study how enhancing mitochondrial function affects lifespan and healthspan. His group showed that transgenic mice overexpressing catalase targeted to mitochondria live longer and are protected against several age-related conditions, including cardiac ageing, sarcopenia and some cancers, and that similar benefits follow treatment with the mitochondria-targeted tetrapeptide elamipretide (SS-31). A central interest has been how mitochondrial energetics interact with signalling pathways that confer resistance to cardiac hypertrophy and failure. He was the founding director of the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging, has been funded by the NIA since 1981, including as PI of an ageing Program Project since 2004, and directed the university's flow cytometry laboratory from 1986 to 2020. He is now Professor Emeritus in the Department of Laboratory Medicine and Pathology and continues to publish, including a 2026 paper on SS-31 and cardiomyoblast senescence. His honours include the American Aging Association's Denham Harman Lifetime Achievement Award and AAAS fellowship.", "word_count": 175, "sources": ["https://dlmp.uw.edu/faculty/rabinovitch", "https://halo.dlmp.uw.edu/people/peter-s-rabinovitch/", "https://doi.org/10.3390/biology15131034"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 112, "source_url": "https://scholar.google.com/citations?user=nO5914YAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Peter Rabinovitch', University of Washington, Gerontology", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=nO5914YAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UW DLMP faculty page", "url": "https://dlmp.uw.edu/faculty/rabinovitch"}, {"label": "UW Healthy Aging and Longevity Research Institute profile", "url": "https://halo.dlmp.uw.edu/people/peter-s-rabinovitch/"}, {"label": "Rabinovitch Lab", "url": "http://www.pathology.washington.edu/research/labs/rabinovitch/"}]}, "sources": [{"url": "https://dlmp.uw.edu/faculty/rabinovitch", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://halo.dlmp.uw.edu/people/peter-s-rabinovitch/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.3390/biology15131034", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=nO5914YAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0092", "slug": "venki-ramakrishnan", "name": {"display": "Venki Ramakrishnan", "sort": "Ramakrishnan, Venki"}, "categories": ["communicator"], "current_title": {"title": "Emeritus Scientist, Structural Studies Division", "organisation": "MRC Laboratory of Molecular Biology", "sources": ["https://mrclmb.ac.uk/research-leaders/venki-ramakrishnan/", "https://mrclmb.ac.uk/research-leaders/emeritus/"], "source_type": "institution_page", "checked": "2026-09-24", "status": "verified", "note": "Exact LMB wording: his page is filed under 'Research Leaders / Emeritus' with the label 'Emeritus' and 'Group: Structural Studies'; the Emeritus index page describes these staff as 'Emeritus scientists within the LMB'. LMB does not use the phrase 'Emeritus Research Leader' or 'Group Leader' for him."}, "other_positions": [{"title": "President of the Royal Society (2015-2020, former)", "organisation": "The Royal Society", "sources": ["https://royalsociety.org/medals-and-prizes/science-book-prize/books/2024/why-we-die/"]}], "location": {"city": "Cambridge", "region": "England", "country_code": "GB", "sources": ["https://mrclmb.ac.uk/research-leaders/venki-ramakrishnan/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://mrclmb.ac.uk/wp-content/uploads/Ramakrishnan_2020_07_O124113cr_group_page_photo_SqCr-325x325.jpg", "page_url": "https://mrclmb.ac.uk/research-leaders/venki-ramakrishnan/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Venki Ramakrishnan is a structural biologist at the MRC Laboratory of Molecular Biology who shared the 2009 Nobel Prize in Chemistry for determining the structure of the ribosome; his group solved the first high-resolution structure of the bacterial 30S ribosomal subunit in 2000 and later used cryo-electron microscopy to study eukaryotic and mitochondrial translation initiation. He served as President of the Royal Society from 2015 to 2020. For the longevity field his relevance is chiefly as a communicator: his 2024 book Why We Die: The New Science of Aging and the Quest for Immortality surveys the biology of ageing and death, including caloric restriction, young-blood experiments, cryonics and long-lived species, and examines the scientific and social questions raised by efforts to extend lifespan. The book was shortlisted for the 2024 Royal Society Science Book Prize. He previously wrote Gene Machine (2018), a memoir of the race to solve the ribosome structure. His research group now also studies translation from circular RNAs, including their use in RNA therapeutics.", "word_count": 167, "sources": ["https://mrclmb.ac.uk/research-leaders/venki-ramakrishnan/", "https://royalsociety.org/medals-and-prizes/science-book-prize/books/2024/why-we-die/", "https://www.nyswritersinstitute.org/venkiramakrishnan"]}, "metrics": [{"kind": "audience", "for_category": "communicator", "platform": "book", "value": null, "source_url": "https://royalsociety.org/medals-and-prizes/science-book-prize/books/2024/why-we-die/", "checked": "2026-09-23", "status": "unavailable", "note": "Author of Why We Die (2024; shortlisted, 2024 Royal Society Science Book Prize). No verifiable sales/readership figure found."}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No confirmed personal social account found (MRC LMB page links only institutional accounts; re-checked 2026-09-23)."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=oTI5BjIAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0002-4699-2194", "status": "verified"}, "official": [{"label": "MRC LMB profile", "url": "https://mrclmb.ac.uk/research-leaders/venki-ramakrishnan/"}, {"label": "Personal group site", "url": "https://www2.mrc-lmb.cam.ac.uk/groups/ribo/"}]}, "sources": [{"url": "https://mrclmb.ac.uk/research-leaders/venki-ramakrishnan/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://royalsociety.org/medals-and-prizes/science-book-prize/books/2024/why-we-die/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.nyswritersinstitute.org/venkiramakrishnan", "type": "secondary", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=oTI5BjIAAAAJ", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://mrclmb.ac.uk/research-leaders/emeritus/", "type": "institution_page", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-24", "phase": "3"}}, {"id": "per_0093", "slug": "thomas-rando", "name": {"display": "Thomas Rando", "sort": "Rando, Thomas"}, "categories": ["scientist", "academic"], "current_title": {"title": "Director, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research; Professor of Neurology and of Molecular, Cell and Developmental Biology", "organisation": "University of California, Los Angeles (UCLA)", "sources": ["https://randolab.healthsciences.ucla.edu/people/thomas-rando-md-phd", "https://stemcell.ucla.edu/member-directory/thomas-rando-md-phd"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Los Angeles", "region": "CA", "country_code": "US", "sources": ["https://randolab.healthsciences.ucla.edu/people/thomas-rando-md-phd", "https://stemcell.ucla.edu/member-directory/thomas-rando-md-phd"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://stemcell.ucla.edu/sites/default/files/styles/landscape_500/public/person/58ecb134292432f8ec02a3db43560022.jpg.jpeg?h=7326f46f&itok=znsiEVXh", "page_url": "https://stemcell.ucla.edu/member-directory/thomas-rando-md-phd", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Thomas Rando is a neurologist and stem cell biologist who directs the UCLA Broad Stem Cell Research Center, which he joined in 2021 after a long faculty career at Stanford, where he was founding director of the Glenn Center for the Biology of Aging and deputy director of the Stanford Center on Longevity. His laboratory is credited with pioneering the use of heterochronic parabiosis to study stem cell ageing, showing that factors in the blood of young animals can promote stem cell activity and tissue repair in old animals while factors in old blood suppress it. This work helped establish systemic-environment approaches in ageing research and has led to clinical trials of interventions for age-related conditions. His group also studies the molecular regulation of stem cell quiescence, epigenetic changes in ageing stem cells, the effects of exercise on aged stem cells, and bioengineering approaches for muscle repair and muscular dystrophies. He has published over 200 peer-reviewed articles. Honours include an NIH Director's Pioneer Award, an NIH Transformative Research Award and AFAR's Breakthroughs in Gerontology Award; he is a member of the National Academy of Medicine and the American Academy of Arts and Sciences.", "word_count": 193, "sources": ["https://randolab.healthsciences.ucla.edu/people/thomas-rando-md-phd", "https://stemcell.ucla.edu/member-directory/thomas-rando-md-phd"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 110, "source_url": "https://scholar.google.com/citations?user=8_XnyZYAAAAJ", "note": "Profile 'Thomas A Rando', Director, Broad Stem Cell Research Center, UCLA; All column.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=8_XnyZYAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Rando Lab profile", "url": "https://randolab.healthsciences.ucla.edu/people/thomas-rando-md-phd"}, {"label": "UCLA BSCRC profile", "url": "https://stemcell.ucla.edu/member-directory/thomas-rando-md-phd"}]}, "sources": [{"url": "https://randolab.healthsciences.ucla.edu/people/thomas-rando-md-phd", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://stemcell.ucla.edu/member-directory/thomas-rando-md-phd", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=8_XnyZYAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0094", "slug": "antonio-regalado", "name": {"display": "Antonio Regalado", "sort": "Regalado, Antonio"}, "categories": ["communicator"], "current_title": {"title": "Senior Editor, Biomedicine", "organisation": "MIT Technology Review", "sources": ["https://www.technologyreview.com/author/antonio-regalado/"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Cambridge", "region": "MA", "country_code": "US", "sources": ["https://www.technologyreview.com/contact-us/"], "checked": "2026-09-23", "status": "unavailable", "note": "Personal work location not confirmed; organisation base (MIT Technology Review, owned by MIT, Cambridge MA) recorded as placeholder."}, "photo": {"status": "found", "image_url": "https://wp.technologyreview.com/wp-content/uploads/2020/01/antonio_regalado_1-1.png", "page_url": "https://www.technologyreview.com/author/antonio-regalado/", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Antonio Regalado is senior editor for biomedicine at MIT Technology Review, which he joined in July 2011; he previously wrote about science and politics in Latin America for Science and other outlets from São Paulo, and was science reporter and later foreign correspondent at the Wall Street Journal from 2000 to 2009. His reporting covers how technology is changing medicine and biomedical research, including gene editing, reproductive technology and the longevity and rejuvenation industry. In November 2018 he broke the story that Chinese scientist He Jiankui was creating gene-edited CRISPR babies, reporting that is used as an annotated teaching example by the Council for the Advancement of Science Writing. His recent coverage relevant to ageing includes reports on partial and chemical reprogramming, rejuvenation startups and their claims, and longevity-related clinical and prize efforts. These articles frequently examine the claims made by companies and scientists working on anti-ageing interventions.", "word_count": 148, "sources": ["https://www.technologyreview.com/author/antonio-regalado/", "https://connector.casw.org/resources/storygram-antonio-regalados-exclusive-chinese-scientists-are-creating-crispr-babies/"]}, "metrics": [{"kind": "audience", "for_category": "communicator", "platform": "x", "value": 28102, "source_url": "https://x.com/antonioregalado", "checked": "2026-09-23", "status": "verified", "note": "followers; read via api.fxtwitter.com on 2026-09-23. Handle linked from his MIT Technology Review author page."}, {"kind": "audience", "for_category": "communicator", "platform": "newsletter", "value": null, "source_url": "https://www.technologyreview.com/author/antonio-regalado/", "checked": "2026-09-23", "status": "unavailable", "note": "Writes for MIT Technology Review (690 posts listed on author page 2026-09-23); no personal readership figure available."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": "https://twitter.com/antonioregalado", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "MIT Technology Review author page", "url": "https://www.technologyreview.com/author/antonio-regalado/"}]}, "sources": [{"url": "https://www.technologyreview.com/author/antonio-regalado/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://connector.casw.org/resources/storygram-antonio-regalados-exclusive-chinese-scientists-are-creating-crispr-babies/", "type": "secondary", "accessed": "2026-09-23"}, {"url": "https://www.technologyreview.com/contact-us/", "type": "company_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-24", "phase": "3"}}, {"id": "per_0095", "slug": "wolf-reik", "name": {"display": "Wolf Reik", "sort": "Reik, Wolf"}, "categories": ["scientist", "academic"], "current_title": {"title": "Distinguished Investigator, Discovery Science", "organisation": "Altos Labs (Cambridge Institute of Science)", "sources": ["https://www.altoslabs.com/team/wolf-reik"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Honorary Professor of Epigenetics", "organisation": "University of Cambridge", "sources": ["https://www.altoslabs.com/team/wolf-reik"]}], "location": {"city": "Cambridge", "region": "England", "country_code": "GB", "sources": ["https://doi.org/10.1038/s41467-026-74118-5", "https://doi.org/10.1101/gr.280915.125"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://a-us.storyblok.com/f/1016638/512x614/2ae34ad341/wolf-reik.png", "page_url": "https://www.altoslabs.com/team/wolf-reik", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Wolf Reik is a Distinguished Investigator in Discovery Science at Altos Labs' Cambridge Institute of Science and an honorary Professor of Epigenetics at the University of Cambridge. He previously headed the Epigenetics Programme and then served as Director of the Babraham Institute in Cambridge. His laboratory discovered global epigenetic reprogramming in mammalian development and characterised its mechanisms and consequences. More recently the group developed single-cell multi-omics technologies to study cell-fate decisions in development and how cell fate and function degrade during ageing. Applying epigenetic reprogramming to resetting cellular age, his team developed a protocol by which human cells can be substantially rejuvenated without losing their cell identity, work relevant to the partial-reprogramming approaches now pursued in longevity research. His 2026 publications include work on cell-to-cell variability and gain of methylation at polycomb CpG islands as a hallmark of ageing. He is a Fellow of the Royal Society.", "word_count": 147, "sources": ["https://www.altoslabs.com/team/wolf-reik", "https://doi.org/10.1038/s41467-026-74118-5"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 153, "source_url": "https://scholar.google.com/citations?user=7ALpXoUAAAAJ", "note": "Profile 'Wolf Reik'; Scholar affiliation still reads 'Head, Epigenetics Programme, Babraham Institute' (his former post, per Altos Labs page). All column.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=7ALpXoUAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Altos Labs profile", "url": "https://www.altoslabs.com/team/wolf-reik"}]}, "sources": [{"url": "https://www.altoslabs.com/team/wolf-reik", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41467-026-74118-5", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1101/gr.280915.125", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=7ALpXoUAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0096", "slug": "arlan-richardson", "name": {"display": "Arlan Richardson", "sort": "Richardson, Arlan"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Biochemistry & Physiology; Donald W. Reynolds Endowed Chair of Aging Research", "organisation": "University of Oklahoma Health Sciences Center (OU College of Medicine)", "sources": ["https://medicine.ouhsc.edu/directory/details/arlan-richardson-phd-1"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Senior VA Career Scientist", "organisation": "Oklahoma City VA Medical Center", "sources": ["https://medicine.ouhsc.edu/directory/details/arlan-richardson-phd-1"]}], "location": {"city": "Oklahoma City", "region": "OK", "country_code": "US", "sources": ["https://medicine.ouhsc.edu/directory/details/arlan-richardson-phd-1"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://medicine.ouhsc.edu/Portals/1365/EasyDNNNews/18565/images/AR_Photo-300-350-c-T-97.jpg", "page_url": "https://medicine.ouhsc.edu/directory/details/arlan-richardson-phd-1", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Arlan Richardson is Professor of Biochemistry and Physiology and Donald W. Reynolds Endowed Chair of Aging Research at the University of Oklahoma Health Sciences Center and a Senior VA Career Scientist at the Oklahoma City VA Medical Center, and has worked in ageing research for about four decades. His research has examined the effects of ageing and dietary restriction on gene expression in rats and mice, tested the oxidative stress theory of ageing by altering antioxidant defences in transgenic and knockout mice and measuring lifespan and pathology, and studied the effect of rapamycin on ageing and age-related disease. Current work addresses oxidative stress, necroptosis and inflammation in ageing, including neuronal necroptosis in the ageing brain, and how genotype and level of restriction shape the effects of dietary restriction. He is lead co-PI on a VA-funded project developing a genetically heterogeneous rat model (OKC-HET B/W) for testing anti-ageing interventions. He has authored more than 240 peer-reviewed papers, received the Nathan Shock, Kleemeier, Harman and Irving Wright awards, and has served as president of the Gerontological Society of America and the American Aging Association and on the National Advisory Council on Aging.", "word_count": 190, "sources": ["https://medicine.ouhsc.edu/directory/details/arlan-richardson-phd-1"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 104, "source_url": "https://scholar.google.com/citations?user=ue-hqIAAAAAJ", "note": "Profile 'Arlan Richardson', University of Oklahoma (verified ouhsc.edu email); All column.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=ue-hqIAAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "OU College of Medicine profile", "url": "https://medicine.ouhsc.edu/directory/details/arlan-richardson-phd-1"}]}, "sources": [{"url": "https://medicine.ouhsc.edu/directory/details/arlan-richardson-phd-1", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=ue-hqIAAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0097", "slug": "michael-ristow", "name": {"display": "Michael Ristow", "sort": "Ristow, Michael"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Experimental Endocrinology and Diabetology; Director, Institute of Experimental Endocrinology", "organisation": "Charité – Universitätsmedizin Berlin", "sources": ["https://expendo.charite.de/metas/person/person/address_detail/prof_dr_michael_ristow/", "https://www.charite.de/en/service/press_reports/artikel/detail/metabolism_expert_joins_charite_to_advance_understanding_of_age_related_diseases/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Berlin", "region": "Berlin", "country_code": "DE", "sources": ["https://expendo.charite.de/metas/person/person/address_detail/prof_dr_michael_ristow/", "https://www.charite.de/en/service/press_reports/artikel/detail/metabolism_expert_joins_charite_to_advance_understanding_of_age_related_diseases/"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://expendo.charite.de/fileadmin/_processed_/3/8/csm_ristow_65da564a8c.jpg", "page_url": "https://expendo.charite.de/metas/person/person/address_detail/prof_dr_michael_ristow/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Michael Ristow is an endocrinologist and metabolism researcher who became Professor of Experimental Endocrinology and Diabetology and Director of the Institute of Experimental Endocrinology at Charité – Universitätsmedizin Berlin, after a decade as Professor of Energy Metabolism at ETH Zurich (2013–2022) and earlier as Professor of Human Nutrition at the University of Jena. His work centres on how metabolic regulation, and mitochondrial metabolism in particular, influences age-related disease and lifespan. He is closely associated with mitohormesis, the concept that transient increases in mitochondrial reactive oxygen species induce protective stress responses; a 2009 PNAS study he led reported that antioxidant supplements blocked some health-promoting effects of exercise in humans, and he has written on mitohormesis as an explanation for ROS-induced health benefits. His group uses C. elegans, cell culture, clinical samples and analysis of anonymised patient records to ask whether specific drugs or supplements help people stay healthy longer; recent work reports that reducing mitochondrial calcium levels enhances late-life survival and mobility via mitohormesis.", "word_count": 163, "sources": ["https://www.charite.de/en/service/press_reports/artikel/detail/metabolism_expert_joins_charite_to_advance_understanding_of_age_related_diseases/", "https://doi.org/10.1073/pnas.0903485106", "https://doi.org/10.1038/nm.3624", "https://doi.org/10.1111/acel.70247"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 73, "source_url": "https://scholar.google.com/citations?user=HkSI1LoAAAAJ", "note": "Profile 'Michael Ristow', Charité Institute for Experimental Endocrinology; All column. Profile may contain a misattributed highly cited paper (Petersen et al. 2004).", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=HkSI1LoAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Charité Institute of Experimental Endocrinology profile", "url": "https://expendo.charite.de/metas/person/person/address_detail/prof_dr_michael_ristow/"}]}, "sources": [{"url": "https://expendo.charite.de/metas/person/person/address_detail/prof_dr_michael_ristow/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.charite.de/en/service/press_reports/artikel/detail/metabolism_expert_joins_charite_to_advance_understanding_of_age_related_diseases/", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1073/pnas.0903485106", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/nm.3624", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1111/acel.70247", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=HkSI1LoAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0098", "slug": "paul-robbins", "name": {"display": "Paul Robbins", "sort": "Robbins, Paul"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Biochemistry, Molecular Biology and Biophysics; Associate Director, Masonic Institute on the Biology of Aging and Metabolism; Director, Minnesota Nathan Shock Center of Excellence on Genome Integrity and Aging", "organisation": "University of Minnesota", "sources": ["https://robbins.umn.edu/paul-robbins-phd", "https://cbs.umn.edu/directory/paul-robbins"], "source_type": "lab_page", "checked": "2026-09-23", "status": "verified", "note": "Lab page says Associate Director of MIBAM; CBS directory lists Co-Director."}, "other_positions": [], "location": {"city": "Minneapolis", "region": "MN", "country_code": "US", "sources": ["https://robbins.umn.edu/paul-robbins-phd", "https://cbs.umn.edu/directory/paul-robbins"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://robbins.umn.edu/sites/robbins.umn.edu/files/styles/folwell_full/public/2026-01/morehouse-27313mb.jpg.avif?itok=eDr5lvX2", "page_url": "https://robbins.umn.edu/paul-robbins-phd", "source_type": "lab_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Paul Robbins is Professor of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota, where he helps lead the Masonic Institute on the Biology of Aging and Metabolism and directs the Minnesota Nathan Shock Center of Excellence on Genome Integrity and Aging. Early in his career he helped identify enhancer elements that regulate transcription at a distance, showed that the retinoblastoma tumour suppressor regulates transcription, and developed gene therapies for autoimmune disease, including one in clinical testing for osteoarthritis. In ageing research he was part of the collaborative team that first identified senotherapeutic compounds and biologics able to reduce senescent-cell burden and extend healthspan and lifespan in mice; senotherapeutics are now being tested in clinical trials for age-related conditions. His laboratory targets hallmarks of ageing including genomic instability, senescence, inflammation, stem cell and mitochondrial dysfunction, with projects on optimising senotherapeutics, mapping senescent cells across tissues within the NIH SenNet Consortium, stem cell-derived extracellular vesicles as therapeutics, IKK/NF-κB signalling in DNA damage-induced senescence, longevity-associated rare variants in centenarians, and immune ageing.", "word_count": 171, "sources": ["https://robbins.umn.edu/paul-robbins-phd"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "No clearly attributable public Google Scholar profile found via search.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Robbins Lab", "url": "https://robbins.umn.edu/paul-robbins-phd"}, {"label": "CBS directory", "url": "https://cbs.umn.edu/directory/paul-robbins"}, {"label": "UMN Experts publications", "url": "https://experts.umn.edu/en/persons/paul-d-robbins/publications/"}]}, "sources": [{"url": "https://robbins.umn.edu/paul-robbins-phd", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://cbs.umn.edu/directory/paul-robbins", "type": "institution_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0099", "slug": "kenneth-rockwood", "name": {"display": "Kenneth Rockwood", "sort": "Rockwood, Kenneth"}, "categories": ["doctor", "scientist", "academic"], "current_title": {"title": "Professor of Medicine (Geriatric Medicine and Neurology); Clinical Research Professor of Frailty and Aging", "organisation": "Dalhousie University", "sources": ["https://medicine.dal.ca/departments/department-sites/medicine/divisions/geriatric-medicine/our-people/faculty/kenneth-rockwood.html", "https://medicine.dal.ca/news/2026/08/04/advancing_the_science_of_frailty.html"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Senior Medical Director, Frailty and Elder Care Network", "organisation": "Nova Scotia Health", "sources": ["https://medicine.dal.ca/news/2026/08/04/advancing_the_science_of_frailty.html"]}], "location": {"city": "Halifax", "region": "NS", "country_code": "CA", "sources": ["https://medicine.dal.ca/departments/department-sites/medicine/divisions/geriatric-medicine/our-people/faculty/kenneth-rockwood.html", "https://medicine.dal.ca/news/2026/08/04/advancing_the_science_of_frailty.html"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://cdn.dal.ca/faculty/medicine/departments/department-sites/medicine/divisions/geriatric-medicine/our-people/faculty/kenneth-rockwood/_jcr_content/contentPar/profile/bgBanner.adaptive.214.high.jpg/1716994428403.jpg", "page_url": "https://medicine.dal.ca/departments/department-sites/medicine/divisions/geriatric-medicine/our-people/faculty/kenneth-rockwood.html", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Kenneth Rockwood is a geriatrician and Professor of Medicine at Dalhousie University and senior medical director of the Frailty and Elder Care Network at Nova Scotia Health. His research helped turn frailty from a vague clinical impression into a measurable concept, showing that it reflects the accumulation of health deficits that shape how older people recover from illness, respond to treatment and keep their independence. This deficit-accumulation approach underlies the frailty index widely used in ageing research as a measure of biological ageing. He led development of the Clinical Frailty Scale, now used internationally in hospitals and clinics and prominently during the COVID-19 pandemic for triage decisions. His work has also shown frailty to be a key risk factor for dementia and that physical fitness can moderate the effects of neuropathology, and he has helped lead the Canadian Consortium on Neurodegeneration in Aging. He has published nearly 700 peer-reviewed papers and nine books and is editor-in-chief of Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Honours include the Ryman Prize, appointment as an Officer of the Order of Canada and the Royal College's 2026 James H. Graham Award of Merit.", "word_count": 189, "sources": ["https://medicine.dal.ca/news/2026/08/04/advancing_the_science_of_frailty.html", "https://medicine.dal.ca/departments/department-sites/medicine/divisions/geriatric-medicine/our-people/faculty/kenneth-rockwood.html"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 158, "source_url": "https://scholar.google.com/citations?user=YbS7wHYAAAAJ", "note": "Profile 'Kenneth Rockwood', Dalhousie University (verified dal.ca email); All column.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=YbS7wHYAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Dalhousie Geriatric Medicine faculty profile", "url": "https://medicine.dal.ca/departments/department-sites/medicine/divisions/geriatric-medicine/our-people/faculty/kenneth-rockwood.html"}]}, "sources": [{"url": "https://medicine.dal.ca/departments/department-sites/medicine/divisions/geriatric-medicine/our-people/faculty/kenneth-rockwood.html", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://medicine.dal.ca/news/2026/08/04/advancing_the_science_of_frailty.html", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=YbS7wHYAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0100", "slug": "david-rubinsztein", "name": {"display": "David Rubinsztein", "sort": "Rubinsztein, David"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Molecular Neurogenetics; UK Dementia Research Institute Group Leader; Deputy Director, Cambridge Institute for Medical Research", "organisation": "University of Cambridge", "sources": ["https://www.medschl.cam.ac.uk/people/david-rubinsztein", "https://www.cimr.cam.ac.uk/staff/professor-david-rubinsztein-fmedsci-frs"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Cambridge", "region": "England", "country_code": "GB", "sources": ["https://www.medschl.cam.ac.uk/people/david-rubinsztein", "https://www.cimr.cam.ac.uk/staff/professor-david-rubinsztein-fmedsci-frs"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://www.medschl.cam.ac.uk/sites/default/files/styles/media_miniature/public/2025-09/peo_David%20Rubinsztein.png?itok=RQcSioh3", "page_url": "https://www.medschl.cam.ac.uk/people/david-rubinsztein", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "David Rubinsztein is Professor of Molecular Neurogenetics and a UK Dementia Research Institute Group Leader at the University of Cambridge, and Deputy Director of the Cambridge Institute for Medical Research, where his laboratory is based. Trained in medicine and genetics at the University of Cape Town, he came to Cambridge in 1993 in genetic pathology. His research concerns autophagy, the bulk cellular recycling process, in the context of neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's disease, which involve accumulation of aggregate-prone proteins. His laboratory showed that autophagy can degrade these proteins and pioneered autophagy upregulation as a potential therapeutic strategy, identifying drugs and new pathways that could be used for this purpose. He has also shown how autophagy defects contribute to disease and has contributed to the basic cell biology of the process, including its links to ageing and age-related neurodegeneration. His group currently also studies ferroptosis in neurodegeneration. He is a Fellow of the Royal Society and of the Academy of Medical Sciences and an EMBO member, and was listed as a Clarivate Highly Cited Researcher from 2018 to 2023.", "word_count": 182, "sources": ["https://www.medschl.cam.ac.uk/people/david-rubinsztein", "https://www.cimr.cam.ac.uk/staff/professor-david-rubinsztein-fmedsci-frs"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 162, "source_url": "https://scholar.google.com/citations?user=2ZdUvsUAAAAJ", "note": "Profile 'David Rubinsztein', University of Cambridge (verified cam.ac.uk email); All column.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=2ZdUvsUAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Cambridge School of Clinical Medicine profile", "url": "https://www.medschl.cam.ac.uk/people/david-rubinsztein"}, {"label": "CIMR profile", "url": "https://www.cimr.cam.ac.uk/staff/professor-david-rubinsztein-fmedsci-frs"}]}, "sources": [{"url": "https://www.medschl.cam.ac.uk/people/david-rubinsztein", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.cimr.cam.ac.uk/staff/professor-david-rubinsztein-fmedsci-frs", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=2ZdUvsUAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0101", "slug": "david-sabatini", "name": {"display": "David Sabatini", "sort": "Sabatini, David"}, "categories": ["scientist", "academic"], "current_title": {"title": "Senior Group Leader, David Sabatini Group (Molecular Analysis of Growth Regulation in Animals)", "organisation": "Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague)", "sources": ["https://sabatini.group.uochb.cz/en", "https://www.uochb.cz/en/directory/1454/david-sabatini"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "IOCB group page lists the group as a 'Senior' research group in the BIO cluster; lab operates in Prague and the Boston, MA area."}, "other_positions": [{"title": "Head of research group, IOCB Prague Boston branch (lab's second site)", "organisation": "IOCB Prague (Boston, MA)", "sources": ["https://sabatini.group.uochb.cz/en", "https://www.statnews.com/2024/04/30/david-sabatini-mit-iocb-prague/"]}], "location": {"city": "Prague", "region": "Prague", "country_code": "CZ", "sources": ["https://sabatini.group.uochb.cz/en"], "checked": "2026-09-23", "status": "verified", "note": "Lab has two sites: Prague and the Boston, MA area."}, "photo": {"status": "found", "image_url": "https://www.uochb.cz/ipx/w:810,f:webp,q:90/upload/files/90/d3/90d31e86e5334e85f7f1b91fd88d3dface1116d7.jpg", "page_url": "https://www.uochb.cz/en/news/561/a-new-scientific-group-is-being-established-at-iocb-headed-by-dr-david-sabatini", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "David Sabatini leads the research group Molecular Analysis of Growth Regulation in Animals at IOCB Prague, with laboratory sites in Prague and the Boston area. His laboratory's early work on the mechanism of action of rapamycin led to discovery of its target, the mTOR protein kinase, now recognised as a central regulator of eukaryotic growth that balances anabolic and catabolic processes and a major pathway in ageing research. His group identified the mTOR-containing complexes mTORC1 and mTORC2 and much of the nutrient-sensing machinery upstream of mTORC1, including the Rag GTPases, GATOR complexes and the leucine and arginine sensors Sestrin and CASTOR, and showed that nutrient activation of mTORC1 involves its translocation to the lysosome surface. The lab developed rapid organelle-isolation methods (Lyso-IP, Mito-IP), genome-scale RNAi and CRISPR screening approaches and a human plasma-like culture medium. Current interests include nutrient sensing, lysosomal and mitochondrial function, and ageing; 2026 work includes an atlas of lysosomal ageing. He was previously a professor at MIT and a member of the Whitehead Institute.", "word_count": 168, "sources": ["https://sabatini.group.uochb.cz/en", "https://www.uochb.cz/en/directory/1454/david-sabatini", "https://www.uochb.cz/en/news/561/a-new-scientific-group-is-being-established-at-iocb-headed-by-dr-david-sabatini", "https://www.statnews.com/2024/04/30/david-sabatini-mit-iocb-prague/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": "https://scholar.google.com/citations?user=04BuffkAAAAJ", "status": "unavailable", "note": "Only Scholar profile found ('David M Sabatini', unknown affiliation, nyumc.org email, h=15) appears to mix records with David D. Sabatini; not clearly attributable.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "IOCB Prague group page", "url": "https://sabatini.group.uochb.cz/en"}, {"label": "IOCB directory", "url": "https://www.uochb.cz/en/directory/1454/david-sabatini"}, {"label": "Lab website", "url": "https://davidsabatinilab.com/"}]}, "sources": [{"url": "https://sabatini.group.uochb.cz/en", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.uochb.cz/en/directory/1454/david-sabatini", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.uochb.cz/en/news/561/a-new-scientific-group-is-being-established-at-iocb-headed-by-dr-david-sabatini", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.statnews.com/2024/04/30/david-sabatini-mit-iocb-prague/", "type": "news", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0102", "slug": "morten-scheibye-knudsen", "name": {"display": "Morten Scheibye-Knudsen", "sort": "Scheibye-Knudsen, Morten"}, "categories": ["scientist", "academic"], "current_title": {"title": "Associate Professor and Group Leader, Department of Cellular and Molecular Medicine (Molecular Aging Program / Center for Healthy Aging)", "organisation": "University of Copenhagen", "sources": ["https://researchprofiles.ku.dk/en/persons/morten-scheibye-knudsen/", "https://icmm.ku.dk/english/research-groups/scheibye-knudsen-group/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "President", "organisation": "Nordic Aging Society", "sources": ["https://researchprofiles.ku.dk/en/persons/morten-scheibye-knudsen/"]}, {"title": "Chief editor", "organisation": "Frontiers in Aging", "sources": ["https://researchprofiles.ku.dk/en/persons/morten-scheibye-knudsen/"]}, {"title": "Co-founder", "organisation": "Senoscope", "sources": ["https://researchprofiles.ku.dk/en/persons/morten-scheibye-knudsen/"]}, {"title": "Founding member", "organisation": "European Federation for Aging Research", "sources": ["https://researchprofiles.ku.dk/en/persons/morten-scheibye-knudsen/"]}], "location": {"city": "Copenhagen", "region": "Capital Region", "country_code": "DK", "sources": ["https://researchprofiles.ku.dk/en/persons/morten-scheibye-knudsen/", "https://icmm.ku.dk/english/research-groups/scheibye-knudsen-group/"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://icmm.ku.dk/english/research-groups/scheibye-knudsen-group/Morten_Scheibye-Knudsen_web.jpg", "page_url": "https://icmm.ku.dk/english/research-groups/scheibye-knudsen-group/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Morten Scheibye-Knudsen is a physician-scientist, Associate Professor and group leader in the Molecular Aging Program of the Department of Cellular and Molecular Medicine at the University of Copenhagen. After medical training and clinical work in Denmark and Greenland, he was a postdoctoral fellow at the US National Institute on Aging, where he studied cross-talk between DNA repair and mitochondrial function in ageing, and started his Copenhagen group in 2015. His laboratory studies the cellular and organismal consequences of DNA damage, and reports that DNA damage alters specific metabolites whose replenishment can change the rate of ageing in model organisms, suggesting a route to interventions for normal ageing and age-associated diseases; recent work also includes ageing clocks. He is active in field-building as president of the Nordic Aging Society, a founding member of the European Federation for Aging Research and a chief editor of Frontiers in Aging. His disclosed industry roles include co-founding Senoscope and consulting for the Healthy Longevity Clinic (as CSO), BOLD Longevity Growth Fund and Deep Longevity, in which he is a shareholder.", "word_count": 175, "sources": ["https://researchprofiles.ku.dk/en/persons/morten-scheibye-knudsen/", "https://icmm.ku.dk/english/research-groups/scheibye-knudsen-group/", "https://agingpharma.org/speakers/morten-scheibye-knudsen"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 53, "source_url": "https://scholar.google.com/citations?user=ijKy30IAAAAJ", "note": "Profile 'Morten Scheibye-Knudsen', Center for Healthy Aging, University of Copenhagen (verified sund.ku.dk email); All column.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=ijKy30IAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Scheibye-Knudsen Group (ICMM, KU)", "url": "https://icmm.ku.dk/english/research-groups/scheibye-knudsen-group/"}, {"label": "KU research profile", "url": "https://researchprofiles.ku.dk/en/persons/morten-scheibye-knudsen/"}]}, "sources": [{"url": "https://researchprofiles.ku.dk/en/persons/morten-scheibye-knudsen/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://icmm.ku.dk/english/research-groups/scheibye-knudsen-group/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://agingpharma.org/speakers/morten-scheibye-knudsen", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=ijKy30IAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0103", "slug": "bjorn-schumacher", "name": {"display": "Björn Schumacher", "sort": "Schumacher, Björn"}, "categories": ["scientist", "academic"], "current_title": {"title": "Full Professor and Director, Institute for Genome Stability in Ageing and Disease (IGSAD), Medical Faculty; CECAD Principal Investigator", "organisation": "University of Cologne (CECAD Cluster of Excellence for Aging Research)", "sources": ["https://schumacher.cecad-labs.uni-koeln.de/group-leader/bjoern-schumacher", "https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/bjoern-schumacher"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "President", "organisation": "German Society for DNA Repair (DGDR)", "sources": ["https://schumacher.cecad-labs.uni-koeln.de/group-leader/bjoern-schumacher"]}, {"title": "Co-Director, Minerva Center of the Biological Mechanisms of Healthy Aging", "organisation": "Bar-Ilan University", "sources": ["https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/bjoern-schumacher"]}, {"title": "Speaker, DFG Research Unit FOR 5504", "organisation": "Deutsche Forschungsgemeinschaft", "sources": ["https://schumacher.cecad-labs.uni-koeln.de/group-leader/bjoern-schumacher"]}], "location": {"city": "Cologne", "region": "North Rhine-Westphalia", "country_code": "DE", "sources": ["https://schumacher.cecad-labs.uni-koeln.de/group-leader/bjoern-schumacher", "https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/bjoern-schumacher"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://www.cecad.uni-koeln.de/fileadmin/_processed_/2/9/csm_schumacher_b_684744809c.png", "page_url": "https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/bjoern-schumacher", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Björn Schumacher has been Full Professor and Director of the Institute for Genome Stability in Ageing and Disease at the University of Cologne's CECAD Cluster of Excellence for Aging Research since 2013. His research treats DNA damage as a causal driver of ageing and asks how organisms maintain health as genome damage accumulates. Using C. elegans, his group showed how longevity assurance mechanisms respond to DNA damage and can maintain tissue function despite persistent lesions, suggesting two complementary strategies against ageing: DNA repair and raising tolerance to unrepaired damage. He pioneered the concept of non-cell-autonomous, systemic DNA damage responses, in which DNA damage in germ cells triggers elevated stress resistance and tissue maintenance in the soma. His team identified the DREAM complex as a master repressor of somatic DNA repair capacity; inhibiting DREAM induces repair genes across pathways and confers strong resistance to DNA damage, a mechanism conserved from nematodes to humans. He is President of the German Society for DNA Repair, co-directs the Minerva Center on healthy ageing at Bar-Ilan University, served as President of the German Society for Aging Research (2014–2020) and holds ERC and DFG Reinhart Koselleck funding.", "word_count": 191, "sources": ["https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/bjoern-schumacher", "https://schumacher.cecad-labs.uni-koeln.de/group-leader/bjoern-schumacher"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 51, "source_url": "https://scholar.google.com/citations?user=BRAPUlsAAAAJ", "note": "Profile 'Björn Schumacher', University of Cologne (verified uni-koeln.de email); All column.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=BRAPUlsAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "CECAD PI profile", "url": "https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/bjoern-schumacher"}, {"label": "IGSAD lab site", "url": "https://schumacher.cecad-labs.uni-koeln.de/group-leader/bjoern-schumacher"}]}, "sources": [{"url": "https://www.cecad.uni-koeln.de/research/principal-investigators/full-members/bjoern-schumacher", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://schumacher.cecad-labs.uni-koeln.de/group-leader/bjoern-schumacher", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=BRAPUlsAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0104", "slug": "paola-sebastiani", "name": {"display": "Paola Sebastiani", "sort": "Sebastiani, Paola"}, "categories": ["scientist", "academic"], "current_title": {"title": "Director, Center for Quantitative Methods and Data Sciences (Institute for Clinical Research and Health Policy Studies); Director, Tufts CTSI BERD Center; Faculty, Data Intensive Studies Center", "organisation": "Tufts Medical Center / Tufts University", "sources": ["https://disc.tufts.edu/paola-sebastiani"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "DISC page heading lists 'Project Director' of the Center for Quantitative Methods and Data Sciences; its biography text says 'director'."}, "other_positions": [], "location": {"city": "Boston", "region": "MA", "country_code": "US", "sources": ["https://disc.tufts.edu/paola-sebastiani", "https://doi.org/10.1093/bioinformatics/btag588"], "checked": "2026-09-23", "status": "verified", "note": ""}, "photo": {"status": "found", "image_url": "https://disc.tufts.edu/sites/g/files/lrezom931/files/styles/large/public/2023-11/people-Paola-Sebastiani.png?itok=uWz93fsr", "page_url": "https://disc.tufts.edu/paola-sebastiani", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Paola Sebastiani is a biostatistician at Tufts Medical Center and Tufts University, where she directs the Center for Quantitative Methods and Data Sciences in the Institute for Clinical Research and Health Policy Studies and the Tufts CTSI Biostatistics, Epidemiology and Research Design (BERD) Center. Before joining Tufts in 2020 she held faculty posts in Italy, the UK and at Boston University. Her methodological work spans Bayesian statistics, decision theory, machine learning and experimental design, and she introduced Bayesian techniques for genomic and genetic data analysis and network models of the genetic basis of sickle cell anaemia complications. In longevity research she collaborates on studies of centenarians and long-lived families, including the Long Life Family Study. Recent work includes evidence of increased genetic protection against Alzheimer's disease in centenarians, a bank of induced pluripotent stem cells from centenarians and their offspring, studies of cognitive resilience in long-lived families, and a 2026 cross-cohort analysis linking exceptional parental longevity to later onset of morbidity and mortality.", "word_count": 163, "sources": ["https://disc.tufts.edu/paola-sebastiani", "https://doi.org/10.1001/jamanetworkopen.2026.30964", "https://doi.org/10.1007/s11357-025-01774-8", "https://doi.org/10.1111/acel.14351", "https://doi.org/10.1037/neu0001039"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 77, "source_url": "https://scholar.google.com/citations?user=FIicf6kAAAAJ", "note": "Profile 'Paola Sebastiani', Tufts Medical Center; All column.", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=FIicf6kAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Tufts DISC profile", "url": "https://disc.tufts.edu/paola-sebastiani"}]}, "sources": [{"url": "https://disc.tufts.edu/paola-sebastiani", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1001/jamanetworkopen.2026.30964", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1093/bioinformatics/btag588", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1007/s11357-025-01774-8", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1111/acel.14351", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=FIicf6kAAAAJ", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0105", "slug": "john-sedivy", "name": {"display": "John Sedivy", "sort": "Sedivy, John"}, "categories": ["scientist", "academic"], "current_title": {"title": "Director, Center on the Biology of Aging; Professor, Department of Molecular Biology, Cell Biology and Biochemistry", "organisation": "Brown University", "sources": ["https://aging.brown.edu/people/john-sedivy-phd", "https://www.brown.edu/news/2026-02-24/aging-research-arpa"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Associate Dean", "organisation": "Brown University", "sources": ["https://www.brown.edu/news/2026-02-24/aging-research-arpa"]}], "location": {"city": "Providence", "region": "RI", "country_code": "US", "sources": ["https://aging.brown.edu/people/john-sedivy-phd", "https://www.brown.edu/news/2026-02-24/aging-research-arpa"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://aging.brown.edu/sites/default/files/styles/portrait_classic_xsml/public/2021-03/jsedivy_photo_.jpg?h=7fd709e3&itok=eWGQCb7g", "page_url": "https://aging.brown.edu/people/john-sedivy-phd", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "John Sedivy is a cell biologist who directs Brown University's Center on the Biology of Aging. His laboratory studies cellular senescence, the epigenetic and chromatin changes of senescent cells, and the consequences of their accumulation in aging tissues. With Vera Gorbunova, he showed over more than a decade that retrotransposons, virus-like repetitive sequences in the genome, become active in senescent cells and with age, and that LINE-1 retrotransposons can trigger interferon signalling and age-associated inflammation. His group also reported that reduced MYC expression extends lifespan and healthspan in mice (Cell, 2015) and documented senescent cell accumulation in aging primates (Science, 2006). This work has moved toward intervention: in 2026 Sedivy and Gorbunova were announced as leads of an ARPA-H–funded, multi-institution project (award of up to $22 million) testing whether the reverse transcriptase inhibitor censavudine (TPN-101) can reduce retrotransposon-driven inflammation and markers of biological aging in adults aged 60 to 65. For longevity readers he is a central figure in the 'dark genome' or transposon theory of inflammaging and its translation into a human trial.", "word_count": 174, "sources": ["https://aging.brown.edu/people/john-sedivy-phd", "https://www.brown.edu/news/2026-02-24/aging-research-arpa", "https://vivo.brown.edu/display/jsedivy"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 89, "source_url": "https://scholar.google.com/citations?user=GD1rQqcAAAAJ", "note": "All-time h-index; profile 'John Sedivy', Brown University, verified brown.edu email", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=GD1rQqcAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0001-9363-4253", "status": "verified"}, "official": [{"label": "Center on the Biology of Aging profile", "url": "https://aging.brown.edu/people/john-sedivy-phd"}, {"label": "Brown Research Profile (VIVO)", "url": "https://vivo.brown.edu/display/jsedivy"}]}, "sources": [{"url": "https://aging.brown.edu/people/john-sedivy-phd", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.brown.edu/news/2026-02-24/aging-research-arpa", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://vivo.brown.edu/display/jsedivy", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=GD1rQqcAAAAJ", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1002/mds.70470", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0130", "slug": "raghav-sehgal", "name": {"display": "Raghav Sehgal", "sort": "Sehgal, Raghav"}, "categories": ["scientist", "academic"], "current_title": {"title": "PhD researcher (computational aging biology); Director of Bioinformatics, Healthy Longevity Clinic", "organisation": "Yale University", "sources": ["https://openalex.org/works?filter=author.id:raghav-sehgal", "https://agingpharma.org/speakers2024"], "source_type": "institution_page", "checked": "2026-09-29", "status": "verified", "note": "Doctoral researcher at Yale (Levine / Higgins-Chen labs); concurrent Director of Bioinformatics at the Healthy Longevity Clinic."}, "other_positions": [], "location": {"city": "New Haven", "region": "Connecticut", "country_code": "US", "sources": ["https://orcid.org/0000-0002-9387-1758"], "checked": "2026-09-29", "status": "verified"}, "photo": {"status": "found", "image_url": "https://agingpharma.org/images/tild3335-6564-4464-a264-623630626432__raghav_sehgal.jpg", "page_url": "https://agingpharma.org/speakers2024", "source_type": "conference_listing", "credit": "ARDD / agingpharma.org", "checked": "2026-09-29"}, "impact": {"text": "Raghav Sehgal is a computational biologist working on machine-learning measures of biological age. During doctoral research at Yale University, in the laboratories of Morgan Levine and Albert Higgins-Chen, he developed Systems Age, a DNA-methylation biomarker derived from a single blood draw that reports aging across eleven organ systems rather than as a single number; the method was licensed to the consumer-testing company TruDiagnostic. He also serves as Director of Bioinformatics at the Healthy Longevity Clinic and has advised the Longevity Tech Fund and TruDiagnostic on aging biomarkers. His work integrates multi-omic and multi-modal data to identify the biological systems that drive aging, to measure them accurately, and to map how individuals respond to candidate interventions. He has received an Impetus Longevity grant and a Gruber Research Fellowship, and presented this work at the Aging Research and Drug Discovery (ARDD) meeting.", "word_count": 149, "sources": ["https://orcid.org/0000-0002-9387-1758", "https://agingpharma.org/speakers2024", "https://www.trudiagnostic.com/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "openalex", "value": 12, "source_url": "https://orcid.org/0000-0002-9387-1758", "checked": "2026-09-29", "status": "verified", "note": "OpenAlex author record (ORCID 0000-0002-9387-1758), Yale University; h-index 12, 98 works as of 2026-09-29."}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0002-9387-1758", "status": "verified"}, "official": [{"label": "ARDD speaker profile", "url": "https://agingpharma.org/speakers2024"}]}, "sources": [{"url": "https://orcid.org/0000-0002-9387-1758", "type": "scholarly_profile", "accessed": "2026-09-29"}, {"url": "https://agingpharma.org/speakers2024", "type": "conference_listing", "accessed": "2026-09-29"}, {"url": "https://www.trudiagnostic.com/", "type": "company_page", "accessed": "2026-09-29"}], "record": {"status": "draft", "created": "2026-09-29", "updated": "2026-09-29", "phase": "6"}}, {"id": "per_0106", "slug": "andrei-seluanov", "name": {"display": "Andrei Seluanov", "sort": "Seluanov, Andrei"}, "categories": ["scientist", "academic"], "current_title": {"title": "Dean's Professor; Professor of Biology", "organisation": "University of Rochester", "sources": ["https://www.sas.rochester.edu/bio/people/faculty/seluanov_andrei/index.html"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Faculty page states 'On sabbatical until Jan 2027'. Roster also listed Professor of Medicine; not shown on the biology faculty page."}, "other_positions": [], "location": {"city": "Rochester", "region": "NY", "country_code": "US", "sources": ["https://www.sas.rochester.edu/bio/people/faculty/seluanov_andrei/index.html", "https://www.sas.rochester.edu/bio/news-events/2023_08_23_molerats.html"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.sas.rochester.edu/bio/people/faculty/seluanov_andrei/assets/images/seluanov2016.jpg", "page_url": "https://www.sas.rochester.edu/bio/people/faculty/seluanov_andrei/index.html", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Andrei Seluanov is a University of Rochester biologist who, in a long-running joint laboratory with Vera Gorbunova, studies how long-lived and cancer-resistant mammals achieve their longevity. The group's work on the naked mole-rat, a rodent with a maximum lifespan of about 30 years, identified 'early contact inhibition' as an anticancer mechanism and characterised the role of high-molecular-weight hyaluronan. In 2023 the team reported in Nature that transferring the naked mole-rat hyaluronan synthase gene into mice improved health and extended lifespan, a proof of principle that longevity mechanisms evolved in one species can be exported to another. Other lines of work include SIRT6 and genome stability, telomerase regulation in long-lived rodents such as the grey squirrel, and comparative approaches to Peto's paradox, the question of why large, long-lived species do not develop more cancer. Recent collaborative work links LINE-1 retrotransposon derepression and cGAS-dependent inflammation to aging (Nature Aging, 2026). For longevity readers he is a key contributor to comparative biology of aging and to the idea of mining naturally long-lived species for interventions.", "word_count": 172, "sources": ["https://www.sas.rochester.edu/bio/people/faculty/seluanov_andrei/index.html", "https://www.sas.rochester.edu/bio/news-events/2023_08_23_molerats.html", "https://doi.org/10.1038/s41586-023-06463-0", "https://doi.org/10.1038/s43587-026-01206-y"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 78, "source_url": "https://scholar.google.com/citations?user=2KHusF4AAAAJ", "note": "All-time h-index; profile 'Andrei Seluanov', University of Rochester, verified rochester.edu email", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=2KHusF4AAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "University of Rochester faculty page", "url": "https://www.sas.rochester.edu/bio/people/faculty/seluanov_andrei/index.html"}, {"label": "Gorbunova-Seluanov lab", "url": "http://gorbunova.biology.rochester.edu/"}]}, "sources": [{"url": "https://www.sas.rochester.edu/bio/people/faculty/seluanov_andrei/index.html", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.sas.rochester.edu/bio/news-events/2023_08_23_molerats.html", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=2KHusF4AAAAJ", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41586-023-06463-0", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s43587-026-01206-y", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0107", "slug": "manuel-serrano", "name": {"display": "Manuel Serrano", "sort": "Serrano, Manuel"}, "categories": ["scientist", "academic"], "current_title": {"title": "Member, Discovery Science team", "organisation": "Altos Labs (Cambridge Institute of Science)", "sources": ["https://www.altoslabs.com/team/manuel-serrano", "https://doi.org/10.1016/j.cmet.2026.08.014"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Affiliated (listed in 2026 paper affiliation)", "organisation": "Institute for Research in Biomedicine (IRB Barcelona)", "sources": ["https://doi.org/10.1016/j.cmet.2026.08.014"]}], "location": {"city": "Cambridge", "region": "England", "country_code": "GB", "sources": ["https://doi.org/10.1016/j.cmet.2026.08.014", "https://doi.org/10.1038/s41577-026-01335-w"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://a-us.storyblok.com/f/1016638/512x614/b934712a27/manuel-serrano.png", "page_url": "https://www.altoslabs.com/team/manuel-serrano", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Manuel Serrano is a molecular biologist at Altos Labs' Cambridge Institute of Science whose work links two central themes of aging biology: cellular senescence and cellular reprogramming. He has worked on senescence for almost 30 years, beginning with his discovery of p16, the cyclin-dependent kinase inhibitor now widely used as a marker and driver of senescence. His group was the first to report that reprogramming to pluripotency can be achieved within living tissues, and showed that this process is strongly promoted by tissue damage signals, connecting senescence, injury and plasticity. His team now focuses on mechanisms of rejuvenation by partial, reversible reprogramming and its similarities with tissue repair, with the stated aim of finding pharmacological and dietary interventions that mimic partial reprogramming. Recent publications with collaborators address immune surveillance of senescent cells, including a 2026 Cell Metabolism study reporting that blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction. For longevity readers he is a reference point for both senolytic-adjacent senescence biology and the in vivo reprogramming field.", "word_count": 168, "sources": ["https://www.altoslabs.com/team/manuel-serrano", "https://doi.org/10.1016/j.cmet.2026.08.014", "https://doi.org/10.1038/s41577-026-01335-w"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "Search returned several 'Manuel Serrano' Scholar profiles; none clearly attributable to this Manuel Serrano (Altos Labs/IRB Barcelona) was confirmed.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Altos Labs profile", "url": "https://www.altoslabs.com/team/manuel-serrano"}]}, "sources": [{"url": "https://www.altoslabs.com/team/manuel-serrano", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cmet.2026.08.014", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41577-026-01335-w", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0108", "slug": "jerry-shay", "name": {"display": "Jerry Shay", "sort": "Shay, Jerry"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor of Cell Biology; Distinguished Teaching Professor; Southland Financial Corporation Distinguished Chair in Geriatrics", "organisation": "UT Southwestern Medical Center", "sources": ["https://profiles.utsouthwestern.edu/profile/16566/jerry-shay.html", "https://labs.utsouthwestern.edu/shay-lab"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Associate Director, Education and Training", "organisation": "UT Southwestern Harold Simmons Comprehensive Cancer Center", "sources": ["https://profiles.utsouthwestern.edu/profile/16566/jerry-shay.html"]}], "location": {"city": "Dallas", "region": "TX", "country_code": "US", "sources": ["https://labs.utsouthwestern.edu/shay-lab"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://profileplus.swmed.edu/facultydata/16566/images/shay-jerry-fis.jpg", "page_url": "https://profiles.utsouthwestern.edu/profile/16566/jerry-shay.html", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Jerry Shay is a cell biologist at UT Southwestern Medical Center, where he has been on the faculty since 1975 and professor of cell biology since 1993. His laboratory studies the relationships between aging and cancer through telomeres and telomerase. Telomeres shorten with each division of human somatic cells, limiting replicative lifespan, while almost all cancer cells reactivate telomerase to escape this limit. Shay's group has worked on both sides of this relationship: the lab describes the 'bench to bedside' development of telomerase inhibitors for cancer, a telomerase-dependent telomere-uncapping small molecule, and control of telomerase through alternative splicing of TERT, including in stimulated T lymphocytes. The lab also studies telomere dysfunction diseases (telomeropathies) and developed TeSLA, the Telomere Shortest Length Assay, for measuring the shortest telomeres in cells and tissues. His patents include methods for detecting cancer by assaying telomerase activity. His faculty profile lists external relationships with companies including Maia Biotechnology, Telos Biotech and LifeLength. For longevity readers he is a long-standing authority on telomere biology as a mechanism linking replicative aging, tissue regeneration and cancer.", "word_count": 177, "sources": ["https://labs.utsouthwestern.edu/shay-lab", "https://profiles.utsouthwestern.edu/profile/16566/jerry-shay.html", "https://labs.utsouthwestern.edu/node/10291/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 170, "source_url": "https://scholar.google.com/citations?user=5iXE9k0AAAAJ", "note": "All-time h-index; profile 'Jerry W. Shay', UT Southwestern, verified utsouthwestern.edu email", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=5iXE9k0AAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Shay Lab", "url": "https://labs.utsouthwestern.edu/shay-lab"}, {"label": "UT Southwestern faculty profile", "url": "https://profiles.utsouthwestern.edu/profile/16566/jerry-shay.html"}]}, "sources": [{"url": "https://labs.utsouthwestern.edu/shay-lab", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://profiles.utsouthwestern.edu/profile/16566/jerry-shay.html", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://labs.utsouthwestern.edu/node/10291/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=5iXE9k0AAAAJ", "type": "scholar_profile", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0109", "slug": "david-sinclair", "name": {"display": "David Sinclair", "sort": "Sinclair, David"}, "categories": ["scientist", "academic", "entrepreneur", "communicator"], "current_title": {"title": "Professor of Genetics", "organisation": "Harvard Medical School", "sources": ["https://genetics.hms.harvard.edu/faculty-staff/david-andrew-sinclair", "https://agingresearch.hms.harvard.edu/faculty/sinclair/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Member", "organisation": "Paul F. Glenn Center for Biology of Aging Research, Harvard Medical School", "sources": ["https://agingresearch.hms.harvard.edu/faculty/sinclair/"]}, {"title": "Co-founder and co-chief editor", "organisation": "Aging (journal)", "sources": ["https://sinclair.hms.harvard.edu/people/david-sinclair", "https://sinclair.hms.harvard.edu/david-sinclairs-affiliations"]}, {"title": "Founder, investor, board member (per self-reported affiliations list, updated Oct 2024)", "organisation": "Life Biosciences", "sources": ["https://sinclair.hms.harvard.edu/david-sinclairs-affiliations"]}], "location": {"city": "Boston", "region": "MA", "country_code": "US", "sources": ["https://genetics.hms.harvard.edu/faculty-staff/david-andrew-sinclair", "https://agingresearch.hms.harvard.edu/faculty/sinclair/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://genetics.hms.harvard.edu/sites/default/files/profile-photos/david_sinclair_web.jpg", "page_url": "https://genetics.hms.harvard.edu/faculty-staff/david-andrew-sinclair", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "David Sinclair is a professor in the Department of Genetics at Harvard Medical School and a member of its Paul F. Glenn Center for Biology of Aging Research. His laboratory is known for work on sirtuins, NAD+ metabolism and epigenetic change in aging. The lab reports early findings linking NAD+ biosynthesis to lifespan regulation, the identification of small-molecule SIRT1 activators such as resveratrol, and a series of hypotheses including xenohormesis and the 'information theory of aging', which proposes that loss of epigenetic information drives aging. In 2020 the lab reported in Nature that expressing Oct4, Sox2 and Klf4 in mouse retinal ganglion cells restored youthful DNA methylation patterns and improved vision in aged and glaucoma models, and a 2023 Cell paper used the ICE mouse model to test whether induced epigenetic change accelerates aging. He is co-founder and co-chief editor of the journal Aging, an inventor on patents, and has co-founded several companies, including Sirtris Pharmaceuticals and Life Biosciences, which in 2026 was running a Phase 1 trial of the partial epigenetic reprogramming therapy ER-100 in optic neuropathies. He also communicates widely through books, media and the Lifespan podcast.", "word_count": 189, "sources": ["https://sinclair.hms.harvard.edu/people/david-sinclair", "https://agingresearch.hms.harvard.edu/faculty/sinclair/", "https://sinclair.hms.harvard.edu/david-sinclairs-affiliations", "https://genetics.hms.harvard.edu/faculty-staff/david-andrew-sinclair", "https://www.lifebiosciences.com/life-biosciences-secures-80-million-series-d-financing/", "https://www.youtube.com/channel/UCwD5YYkbYmN2iFHON9FyDXg"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 122, "source_url": "https://scholar.google.com/citations?user=lfLudSQAAAAJ", "note": "All-time h-index; profile 'David A. Sinclair', Harvard Medical School (Genetics), verified hms.harvard.edu email", "checked": "2026-09-23", "status": "verified"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Life Biosciences", "label": "Life Biosciences publicly disclosed Series D funding (2026)", "value": 80000000, "currency": "USD", "scope": "single_round", "source_url": "https://www.lifebiosciences.com/life-biosciences-secures-80-million-series-d-financing/", "checked": "2026-09-23", "status": "verified", "note": "Series D, announced 8 Apr 2026 (company press release). Total cumulative funding not verified. Sinclair listed as founder on his lab's affiliations page. Other companies he co-founded (e.g. MetroBiotech, Tally Health, Sirtris) not researched for funding."}, {"kind": "audience", "for_category": "communicator", "platform": "youtube", "value": 513000, "source_url": "https://www.youtube.com/channel/UCwD5YYkbYmN2iFHON9FyDXg", "checked": "2026-09-23", "status": "verified", "note": "subscribers; channel's own header (David Sinclair, @LifespanOfficial) states '513K subscribers' on 2026-09-23. Smaller 504K-505K figures on the same page come from cached video-owner cards, not the channel header."}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "X follower count requires login; not read."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=lfLudSQAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "HMS Genetics faculty page", "url": "https://genetics.hms.harvard.edu/faculty-staff/david-andrew-sinclair"}, {"label": "Sinclair Lab", "url": "https://sinclair.hms.harvard.edu/people/david-sinclair"}, {"label": "Paul F. Glenn Center profile", "url": "https://agingresearch.hms.harvard.edu/faculty/sinclair/"}, {"label": "Lifespan YouTube channel", "url": "https://www.youtube.com/channel/UCwD5YYkbYmN2iFHON9FyDXg"}]}, "sources": [{"url": "https://genetics.hms.harvard.edu/faculty-staff/david-andrew-sinclair", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://sinclair.hms.harvard.edu/people/david-sinclair", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://sinclair.hms.harvard.edu/david-sinclairs-affiliations", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://agingresearch.hms.harvard.edu/faculty/sinclair/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.lifebiosciences.com/life-biosciences-secures-80-million-series-d-financing/", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=lfLudSQAAAAJ", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://www.youtube.com/channel/UCwD5YYkbYmN2iFHON9FyDXg", "type": "platform_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0134", "slug": "richard-siow", "name": {"display": "Richard Siow", "sort": "Siow, Richard", "aliases": ["Richard C. Siow", "Richard C M Siow"]}, "categories": ["scientist", "academic"], "current_title": {"title": "Director of Ageing Research at King's (ARK) and Reader in Vascular Biology", "organisation": "King's College London, School of Cardiovascular and Metabolic Medicine & Sciences", "sources": ["https://www.kcl.ac.uk/people/richard-siow"], "source_type": "university_page", "checked": "2026-09-29", "status": "verified", "note": "Reader is the UK equivalent of Associate Professor. Has led ARK since 2016."}, "other_positions": [{"title": "Industry Partnerships Lead", "organisation": "NIHR HealthTech Research Centre in Brain Health", "sources": ["https://www.kcl.ac.uk/people/richard-siow"]}, {"title": "Visiting Professor", "organisation": "Department of Physiology, Anatomy and Genetics, University of Oxford", "sources": ["https://www.kcl.ac.uk/people/richard-siow"]}, {"title": "Honorary Secretary General", "organisation": "European Society of Preventive Medicine", "sources": ["https://www.kcl.ac.uk/people/richard-siow"]}], "location": {"city": "London", "region": "England", "country_code": "GB", "sources": ["https://www.kcl.ac.uk/people/richard-siow"], "checked": "2026-09-29", "status": "verified", "note": "Based at the Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH."}, "photo": {"status": "found", "image_url": "https://www.kcl.ac.uk/newimages/folsm/person-profile/scms/richard-siow.xb9be7f5f.png?f=webp", "page_url": "https://www.kcl.ac.uk/people/richard-siow", "source_type": "university_page", "credit": "King's College London", "checked": "2026-09-29"}, "impact": {"text": "Richard Siow is a vascular biologist who has built and led one of the UK's most prominent cross-disciplinary aging research consortia. Since 2016 he has directed Ageing Research at King's (ARK), a King's College London and King's Health Partners initiative that connects researchers across faculties to study the mechanisms of aging and to improve healthspan and longevity in the community. As a Reader in Vascular Biology in the School of Cardiovascular and Metabolic Medicine & Sciences, his laboratory studies redox signalling in cardiovascular and cerebrovascular aging, including how phytochemicals and nutrigenomics modulate the Nrf2 antioxidant response and mechanotransduction in blood vessels. He has published more than ninety peer-reviewed papers and secured over four million pounds in collaborative funding, and he is an elected Fellow of the Royal Society of Biology. He also contributes to public and policy engagement on aging, including work with the All-Party Parliamentary Group for Longevity.", "word_count": 150, "sources": ["https://www.kcl.ac.uk/people/richard-siow", "https://appg-longevity.org/bio-dr-richard-siow", "https://scholar.google.com/citations?user=zdCLoFEAAAAJ&hl=en"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 53, "source_url": "https://scholar.google.com/citations?user=zdCLoFEAAAAJ&hl=en", "note": "Profile 'Richard Siow', King's College London (verified kcl.ac.uk email); All column. Total citations ~8,970.", "checked": "2026-09-29", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=zdCLoFEAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": "https://x.com/rcmsiow", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "King's College London profile", "url": "https://www.kcl.ac.uk/people/richard-siow"}, {"label": "KCL Pure research portal", "url": "https://kclpure.kcl.ac.uk/portal/en/persons/richard.siow/"}]}, "sources": [{"url": "https://www.kcl.ac.uk/people/richard-siow", "type": "university_page", "accessed": "2026-09-29"}, {"url": "https://scholar.google.com/citations?user=zdCLoFEAAAAJ&hl=en", "type": "google_scholar", "accessed": "2026-09-29"}, {"url": "https://appg-longevity.org/bio-dr-richard-siow", "type": "other", "accessed": "2026-09-29"}, {"url": "https://kclpure.kcl.ac.uk/portal/en/persons/richard.siow/", "type": "university_page", "accessed": "2026-09-29"}], "record": {"status": "draft", "created": "2026-09-29", "updated": "2026-09-29", "phase": "6"}}, {"id": "per_0110", "slug": "andrew-steele", "name": {"display": "Andrew Steele", "sort": "Steele, Andrew"}, "categories": ["communicator"], "current_title": {"title": "Director and Co-Founder", "organisation": "The Longevity Initiative", "sources": ["https://andrewsteele.co.uk/about/", "https://thelongevityinitiative.org/about/"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Author", "organisation": "Ageless: The new science of getting older without getting old (book)", "sources": ["https://andrewsteele.co.uk/about/", "https://andrewsteele.co.uk/ageless/"]}, {"title": "Science writer, presenter and YouTube creator", "organisation": "Independent", "sources": ["https://andrewsteele.co.uk/about/"]}], "location": {"city": "Berlin", "region": "", "country_code": "DE", "sources": ["https://andrewsteele.co.uk/about/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://thelongevityinitiative.org/files/member.jpg", "page_url": "https://thelongevityinitiative.org/about/", "source_type": "company_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Andrew Steele is a Berlin-based scientist, writer and campaigner who works to bring the science of aging to general and policy audiences. After a PhD in physics at the University of Oxford he moved into computational biology, working at the Francis Crick Institute on machine learning applied to genomic data and to predicting heart attacks from NHS medical records. He is the author of Ageless: The new science of getting older without getting old, and is now a full-time science writer and presenter, with articles in outlets including the Wall Street Journal, Sunday Times, Guardian and WIRED, and appearances on Netflix's Don't Die, BBC News and NBC's TODAY. He runs a YouTube channel on longevity science. As Director and Co-Founder of The Longevity Initiative, a non-profit working towards a world where longevity medicines are accessible to everyone, he focuses on public explanation of longevity research and advocacy for research funding and policy; the organisation states he has given policy advice to A4LI, the Tony Blair Institute and UK parliamentary science select committees. For the longevity field he is a prominent evidence-focused communicator and advocate rather than a laboratory researcher.", "word_count": 189, "sources": ["https://andrewsteele.co.uk/about/", "https://thelongevityinitiative.org/about/", "https://www.youtube.com/DrAndrewSteele"]}, "metrics": [{"kind": "audience", "for_category": "communicator", "platform": "youtube", "value": 53800, "source_url": "https://www.youtube.com/DrAndrewSteele", "note": "Subscribers as displayed ('53.8K') on the @DrAndrewSteele channel page", "checked": "2026-09-23", "status": "verified"}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": null, "status": "unavailable", "note": "Account twitter.com/statto linked from personal site; follower count requires login", "checked": "2026-09-23"}, {"kind": "audience", "for_category": "communicator", "platform": "instagram", "value": null, "source_url": null, "status": "unavailable", "note": "Account instagram.com/andrewjsteele linked from personal site; count not read", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": "https://twitter.com/statto", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Personal website", "url": "https://andrewsteele.co.uk/about/"}, {"label": "The Longevity Initiative - About", "url": "https://thelongevityinitiative.org/about/"}, {"label": "YouTube channel", "url": "https://www.youtube.com/DrAndrewSteele"}]}, "sources": [{"url": "https://andrewsteele.co.uk/about/", "type": "personal_site", "accessed": "2026-09-23"}, {"url": "https://thelongevityinitiative.org/about/", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://www.youtube.com/DrAndrewSteele", "type": "platform_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-23", "phase": "3"}}, {"id": "per_0111", "slug": "stephanie-studenski", "name": {"display": "Stephanie Studenski", "sort": "Studenski, Stephanie"}, "categories": ["scientist", "academic", "doctor"], "current_title": {"title": "Professor Emerita of Medicine (Geriatric Medicine)", "organisation": "University of Pittsburgh", "sources": ["https://people.dom.pitt.edu/people/stephanie-studenski-md-mph"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Associate Editor", "organisation": "JAMA Network Open", "sources": ["https://doi.org/10.1001/jamanetworkopen.2025.17283"]}], "location": {"city": "Pittsburgh", "region": "PA", "country_code": "US", "sources": ["https://people.dom.pitt.edu/people/stephanie-studenski-md-mph", "https://doi.org/10.1016/j.nbas.2025.100143"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://people.dom.pitt.edu/sites/default/files/styles/person_image/public/person-img/Studenski_S_Geri.jpg?h=d72ff27f&itok=1X-indD3", "page_url": "https://people.dom.pitt.edu/people/stephanie-studenski-md-mph", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Stephanie Studenski is a geriatrician and clinical researcher, now Professor Emerita of Medicine in the Division of Geriatric Medicine at the University of Pittsburgh. Her work centres on physical function, mobility and their prognostic value in older adults. She led the widely cited 2011 JAMA pooled analysis of nine cohort studies covering 34,485 community-dwelling adults aged 65 or older, which related usual gait speed to survival and showed that this simple physical performance measure can help individualise life-expectancy estimates beyond age and sex. This work helped establish gait speed as a practical clinical vital sign of aging and a functional outcome relevant to trials of interventions targeting aging. She remains publishing in 2025-2026, including studies with Pittsburgh colleagues on nigrostriatal dopaminergic function, resilience to systemic risk factors and skeletal muscle energy metabolism in older adults, and serves as an Associate Editor for JAMA Network Open. For longevity readers she represents the clinical-gerontology side of the field: measuring functional aging in people and linking it to survival and healthspan outcomes.", "word_count": 169, "sources": ["https://people.dom.pitt.edu/people/stephanie-studenski-md-mph", "https://doi.org/10.1001/jama.2010.1923", "https://doi.org/10.1001/jamanetworkopen.2025.17283", "https://doi.org/10.1093/gerona/glag039", "https://doi.org/10.1016/j.nbas.2025.100143"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "No clearly attributable Google Scholar profile found via search.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "University of Pittsburgh Department of Medicine profile", "url": "https://people.dom.pitt.edu/people/stephanie-studenski-md-mph"}]}, "sources": [{"url": "https://people.dom.pitt.edu/people/stephanie-studenski-md-mph", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1001/jama.2010.1923", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1001/jamanetworkopen.2025.17283", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1093/gerona/glag039", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.nbas.2025.100143", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0112", "slug": "george-sutphin", "name": {"display": "George Sutphin", "sort": "Sutphin, George"}, "categories": ["scientist", "academic"], "current_title": {"title": "Associate Professor, Department of Molecular and Cellular Biology; Associate Professor, BIO5 Institute", "organisation": "University of Arizona", "sources": ["https://mcb.arizona.edu/person/george-sutphin"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Scientific Member", "organisation": "Arizona Center on Aging", "sources": ["https://cancercenter.arizona.edu/person/george-l-sutphin-phd"]}, {"title": "Research Member", "organisation": "University of Arizona Cancer Center", "sources": ["https://cancercenter.arizona.edu/person/george-l-sutphin-phd"]}], "location": {"city": "Tucson", "region": "AZ", "country_code": "US", "sources": ["https://doi.org/10.1016/j.jpet.2026.104321"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://mcb.arizona.edu/sites/default/files/styles/az_medium/public/2024-08/Sutphin_glass2.jpg.webp?itok=0Lsrc4qF", "page_url": "https://mcb.arizona.edu/person/george-sutphin", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "George Sutphin is a biologist of aging at the University of Arizona whose laboratory aims to identify molecular processes that can be targeted to slow aging and extend healthy lifespan. The lab combines systems and comparative genetics in C. elegans, mice and cultured cells to find genes that influence longevity and to understand how they interact with known aging pathways and environmental variables such as temperature. Through this approach his group identified the kynurenine pathway of tryptophan metabolism as a candidate intervention target for slowing aging, and has examined its links to NAD+ synthesis and mitochondrial function; current projects test kynurenine pathway interventions on longevity, on cancer onset during normal aging and on established cancer. The lab also develops high-content methods for drug and genetic screening in the context of aging. He is a scientific member of the Arizona Center on Aging and a research member of the University of Arizona Cancer Center. For longevity readers he represents a translational, screening-oriented model-organism approach to identifying metabolic targets for geroprotective drugs.", "word_count": 170, "sources": ["https://sutphinlab.org/", "https://cancercenter.arizona.edu/person/george-l-sutphin-phd", "https://mcb.arizona.edu/person/george-sutphin", "https://doi.org/10.1016/j.exger.2020.110841"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 26, "source_url": "https://scholar.google.com/citations?user=tbuJVpUAAAAJ", "note": "All-time h-index; profile 'George Sutphin', University of Arizona, verified arizona.edu email (profile title still reads Assistant Professor)", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=tbuJVpUAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "MCB faculty page", "url": "https://mcb.arizona.edu/person/george-sutphin"}, {"label": "Sutphin Lab", "url": "https://sutphinlab.org/"}, {"label": "Cancer Center profile", "url": "https://cancercenter.arizona.edu/person/george-l-sutphin-phd"}]}, "sources": [{"url": "https://doi.org/10.1016/j.jpet.2026.104321", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://mcb.arizona.edu/person/george-sutphin", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://sutphinlab.org/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://cancercenter.arizona.edu/person/george-l-sutphin-phd", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=tbuJVpUAAAAJ", "type": "scholar_profile", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.exger.2020.110841", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0113", "slug": "nektarios-tavernarakis", "name": {"display": "Nektarios Tavernarakis", "sort": "Tavernarakis, Nektarios"}, "categories": ["scientist", "academic"], "current_title": {"title": "Research Director (Professor), Neurogenetics and Ageing laboratory; Professor of Molecular Systems Biology, Medical School, University of Crete", "organisation": "Institute of Molecular Biology and Biotechnology (IMBB), Foundation for Research and Technology-Hellas (FORTH)", "sources": ["https://tavernarakislab.gr/en/members/head/", "https://www.imbb.forth.gr/en/research/Nektarios-Tavernarakis.64/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "President", "organisation": "European Molecular Biology Conference (EMBC)", "sources": ["https://tavernarakislab.gr/en/members/head/"]}, {"title": "Distinguished Member", "organisation": "Foundation for Research and Technology-Hellas (FORTH)", "sources": ["https://tavernarakislab.gr/en/members/head/"]}], "location": {"city": "Heraklion", "region": "Crete", "country_code": "GR", "sources": ["https://tavernarakislab.gr/en/members/head/", "https://doi.org/10.18632/aging.206419"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://tavernarakis.apogeecdn.eu/files/repository/20250205162517_p_Nektarios_Tavernarakis.jpg?width=350&enlarge=0", "page_url": "https://tavernarakislab.gr/en/members/head/", "source_type": "lab_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Nektarios Tavernarakis heads the Neurogenetics and Ageing laboratory at IMBB-FORTH in Heraklion and is Professor of Molecular Systems Biology at the University of Crete Medical School. Using the nematode C. elegans, his group studies the molecular mechanisms of aging and neurodegeneration, necrotic cell death, and the interplay between cellular metabolism and aging. Key papers in Nature include work showing that eIF4E-mediated control of protein synthesis in somatic cells modulates aging (2007), that prohibitin couples diapause signalling to mitochondrial energy metabolism during aging (2009), and that mitophagy and mitochondrial biogenesis are coordinated during aging (2015); the lab has also published on spermidine and autophagy. He has held two ERC Advanced Grants and major science-policy roles, including Vice President of the ERC Scientific Council, President of the European Institute of Innovation and Technology Governing Board and President of the FORTH Board of Directors, and currently serves as President of the European Molecular Biology Conference. He is a member of EMBO and the Leopoldina. For longevity readers he is a leading figure in mitochondrial quality control, autophagy and neuronal aging research, and an influential voice in European research policy.", "word_count": 186, "sources": ["https://tavernarakislab.gr/en/members/head/", "https://www.imbb.forth.gr/en/research/Nektarios-Tavernarakis.64/", "https://doi.org/10.18632/aging.206419"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 90, "source_url": "https://scholar.google.com/citations?user=afQKKl8AAAAJ", "note": "All-time h-index; profile 'Nektarios Tavernarakis', Professor, Medical School, University of Crete, verified uoc.gr email", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=afQKKl8AAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Tavernarakis Lab - head profile", "url": "https://tavernarakislab.gr/en/members/head/"}, {"label": "IMBB-FORTH group page", "url": "https://www.imbb.forth.gr/en/research/Nektarios-Tavernarakis.64/"}]}, "sources": [{"url": "https://tavernarakislab.gr/en/members/head/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://www.imbb.forth.gr/en/research/Nektarios-Tavernarakis.64/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.18632/aging.206419", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=afQKKl8AAAAJ", "type": "scholar_profile", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0114", "slug": "tamara-tchkonia", "name": {"display": "Tamar Tchkonia", "sort": "Tchkonia, Tamar", "previous": ["Tamara Tchkonia"]}, "categories": ["scientist", "academic"], "current_title": {"title": "Co-Director, Center for Advanced Gerotherapeutics; Director, Facility for Geroscience Analyses", "organisation": "Cedars-Sinai Medical Center", "sources": ["https://www.cedars-sinai.org/stories-and-insights/healthy-living/how-to-think-about-your-biological-age", "https://researchers.cedars-sinai.edu/Tamar.Tchkonia", "https://www.elsevier.com/events/conferences/people/tamar-tchkonia", "https://orcid.org/0000-0003-4623-7145"], "source_type": "institution_page", "checked": "2026-09-24", "status": "verified", "note": "Cedars-Sinai (Oct 2025 story) calls her 'co-director of the Cedars-Sinai Center for Advanced Gerotherapeutics and director of the Facility for Geroscience Analysis'. Her academic rank is inconsistent across sources and is therefore left out of the title. The Cedars-Sinai researcher profile lists 'Acting Associate Professor of Medicine' and 'Research Scientist III' (15 Jul 2024-present). Her ORCID record and an Elsevier conference bio list 'Professor' of Medicine (Division of Endocrinology). All first-party pages spell her name 'Tamar Tchkonia'."}, "other_positions": [{"title": "Director", "organisation": "Facility for Geroscience Analyses (Translational Geroscience Network)", "sources": ["https://www.elsevier.com/events/conferences/people/tamar-tchkonia"]}, {"title": "Principal Investigator (one of four)", "organisation": "Translational Geroscience Network", "sources": ["https://www.elsevier.com/events/conferences/people/tamar-tchkonia"]}], "location": {"city": "Los Angeles", "region": "CA", "country_code": "US", "sources": ["https://researchers.cedars-sinai.edu/Tamar.Tchkonia", "https://doi.org/10.1016/j.cmet.2026.08.014"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://media.ffycdn.net/eu/elsevier/d/4c854e2258c84b4a8d310a1ee06a56c5?w=1200&q=75", "page_url": "https://www.elsevier.com/events/conferences/people/tamar-tchkonia", "source_type": "conference_listing", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Tamar Tchkonia is a senescence biologist who co-directs the Center for Advanced Gerotherapeutics at Cedars-Sinai in Los Angeles, which she joined in 2024 after many years at Mayo Clinic. Her research focuses on interventions that target senescent cells and on how removing them affects age-related dysfunction, loss of physical resilience and chronic disease in animal models and humans. With James Kirkland she was among the first to discover senolytic drugs that eliminate senescent cells in vitro and in vivo, showing that pharmacological targeting of these cells can alleviate age-related frailty and symptoms of multiple diseases; these drugs have since entered clinical trials. She is one of the co-inventors of a mouse model in which senescent cells can be selectively removed and a named inventor on patent applications for senescent-cell therapies. She is one of four principal investigators of the Translational Geroscience Network, a consortium of US aging centres building infrastructure for clinical trials of interventions targeting fundamental aging processes, and directs its Facility for Geroscience Analyses. Recent 2026 papers address p16-positive cell clearance after radiation and PD-L2 blockade to prevent senescent cell accumulation.", "word_count": 183, "sources": ["https://www.elsevier.com/events/conferences/people/tamar-tchkonia", "https://researchers.cedars-sinai.edu/Tamar.Tchkonia", "https://orcid.org/0000-0003-4623-7145", "https://doi.org/10.1016/j.cmet.2026.08.014", "https://doi.org/10.1111/acel.70693"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "No clearly attributable Google Scholar profile found via search.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0003-4623-7145", "status": "verified"}, "official": [{"label": "Cedars-Sinai researcher profile", "url": "https://researchers.cedars-sinai.edu/Tamar.Tchkonia"}]}, "sources": [{"url": "https://www.elsevier.com/events/conferences/people/tamar-tchkonia", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://researchers.cedars-sinai.edu/Tamar.Tchkonia", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://orcid.org/0000-0003-4623-7145", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cmet.2026.08.014", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1111/acel.70693", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.isci.2026.116770", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://www.cedars-sinai.org/stories-and-insights/healthy-living/how-to-think-about-your-biological-age", "type": "institution_page", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0115", "slug": "eric-topol", "name": {"display": "Eric Topol", "sort": "Topol, Eric"}, "categories": ["communicator", "scientist", "academic"], "current_title": {"title": "Executive Vice President; Founder and Director, Scripps Research Translational Institute; Gary and Mary West Chair of Innovative Medicine", "organisation": "Scripps Research", "sources": ["https://www.scripps.edu/about/leadership/eric-topol/", "https://www.scripps.edu/faculty/topol/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Faculty page also lists Chair, Department of Translational Medicine, and Senior Consultant, Scripps Clinic Division of Cardiovascular Diseases."}, "other_positions": [{"title": "Chair, Department of Translational Medicine", "organisation": "Scripps Research", "sources": ["https://www.scripps.edu/faculty/topol/"]}, {"title": "Senior Consultant, Division of Cardiovascular Diseases", "organisation": "Scripps Clinic", "sources": ["https://www.scripps.edu/faculty/topol/"]}, {"title": "Author and editor", "organisation": "Ground Truths (Substack newsletter)", "sources": ["https://erictopol.substack.com/about"]}], "location": {"city": "La Jolla", "region": "CA", "country_code": "US", "sources": ["https://scholar.google.com/citations?user=E2-uIQYAAAAJ", "https://www.scripps.edu/faculty/topol/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.scripps.edu/wp-content/uploads/resized/2026/05/2023-Topol-Eric-high-res-1024x557-720x720-c-center.jpg", "page_url": "https://www.scripps.edu/about/leadership/eric-topol/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Eric Topol is a cardiologist and physician-scientist who is Executive Vice President of Scripps Research and founder and director of the Scripps Research Translational Institute, established in 2007. His work combines genomics, digital technologies and artificial intelligence to advance individualised medicine, and he is principal investigator of large NIH programmes including the All of Us Research Program and a Clinical and Translational Science Award. Scripps reports that he has published over 1,300 peer-reviewed articles. His relevance to longevity lies mainly in translation and communication: his 2025 book Super Agers: An Evidence-Based Approach to Longevity, a New York Times bestseller, focuses on extending healthspan through prevention of cancer, cardiovascular disease and neurodegenerative disease, drawing on the genomics of healthy aging and AI. He writes the Ground Truths newsletter on Substack and appears widely in media and podcasts. Before Scripps he chaired cardiovascular medicine at Cleveland Clinic, where he founded the Lerner College of Medicine, and he was elected to the National Academy of Medicine in 2004. He remains clinically active as a cardiologist.", "word_count": 172, "sources": ["https://www.scripps.edu/about/leadership/eric-topol/", "https://www.scripps.edu/faculty/topol/", "https://magazine.scripps.edu/noteworthy/2025/fall/eric-topol-authors-book-on-the-science-of-healthy-aging/", "https://erictopol.substack.com/about"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 260, "source_url": "https://scholar.google.com/citations?user=E2-uIQYAAAAJ", "note": "All-time h-index; profile 'Eric Topol', Professor and EVP, Scripps Research, verified scripps.edu email", "checked": "2026-09-23", "status": "verified"}, {"kind": "audience", "for_category": "communicator", "platform": "newsletter", "value": 216000, "source_url": "https://erictopol.substack.com/about", "checked": "2026-09-23", "status": "verified", "note": "subscribers; Ground Truths (Substack) states 'Over 216,000 subscribers' — this Substack figure includes free subscribers; paid tier shown only as 'Thousands of paid subscribers'."}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": null, "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "X follower count requires login; not read."}, {"kind": "audience", "for_category": "communicator", "platform": "book", "value": null, "source_url": "https://magazine.scripps.edu/noteworthy/2025/fall/eric-topol-authors-book-on-the-science-of-healthy-aging/", "checked": "2026-09-23", "status": "unavailable", "note": "Super Agers (2025) described as a New York Times bestseller; no sales/audience figure available."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=E2-uIQYAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Scripps Research leadership page", "url": "https://www.scripps.edu/about/leadership/eric-topol/"}, {"label": "Scripps Research faculty page", "url": "https://www.scripps.edu/faculty/topol/"}, {"label": "Ground Truths newsletter", "url": "https://erictopol.substack.com/"}]}, "sources": [{"url": "https://www.scripps.edu/about/leadership/eric-topol/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.scripps.edu/faculty/topol/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://magazine.scripps.edu/noteworthy/2025/fall/eric-topol-authors-book-on-the-science-of-healthy-aging/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://erictopol.substack.com/about", "type": "platform_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=E2-uIQYAAAAJ", "type": "scholar_profile", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0116", "slug": "dario-valenzano", "name": {"display": "Dario Valenzano", "sort": "Valenzano, Dario"}, "categories": ["scientist", "academic"], "current_title": {"title": "Scientific Director; Group Leader, Evolutionary Biology / Microbiome-Host Interactions in Aging", "organisation": "Leibniz Institute on Aging - Fritz Lipmann Institute (FLI)", "sources": ["https://www.leibniz-fli.de/news/a-new-exciting-challenge", "https://www.leibniz-fli.de/news/aging-in-fast-motion-short-lived-fish-offer-new-insights-into-the-aging-immune-system", "https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/valenzano-group", "https://valenzano-lab.github.io/labsite/dario.html"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": "Roster listed Group Leader only; FLI press releases (Jan 2024, Mar 2026) confirm he is Scientific Director."}, "other_positions": [{"title": "Full Professor in Functional Host-Microbiome Interactions", "organisation": "Friedrich Schiller University Jena", "sources": ["https://valenzano-lab.github.io/labsite/dario.html", "https://doi.org/10.1371/journal.pbio.3003815"]}], "location": {"city": "Jena", "region": "Thuringia", "country_code": "DE", "sources": ["https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/valenzano-group", "https://doi.org/10.1371/journal.pbio.3003815"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.leibniz-fli.de//assets/uploads/general/_550x410_crop_center-center_none/4D4A0443_ausschnitt.jpg.pagespeed.ce.-uzimJfv1_.jpg", "page_url": "https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/valenzano-group", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Dario Riccardo Valenzano is an evolutionary biologist who has been Scientific Director of the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena since January 2024, where he also leads a research group and holds a professorship at Friedrich Schiller University Jena. His group studies how evolution shapes life-history traits across species and applies an evolutionary and ecological perspective to host-microbiome interactions in health, disease and aging, combining statistical modelling, genomics, experimental biology and fieldwork. He is closely associated with the turquoise killifish (Nothobranchius furzeri), a vertebrate that lives only a few months, as an experimental model for aging; FLI describes him as a pioneer of killifish research. Using this model, his lab reports that young-derived microbiomes can restore youthful functions in older fish and, in a 2026 Nature Aging study, mapped conserved features of immune aging including chronic inflammation, DNA damage in progenitor cells and remodelling of the hematopoietic organ. Current work examines how declining immune surveillance lets the gut microbiome shift with age. For longevity readers he links evolutionary theory of aging with a fast vertebrate model for testing interventions, especially microbiome-based ones.", "word_count": 187, "sources": ["https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/valenzano-group", "https://www.leibniz-fli.de/news/a-new-exciting-challenge", "https://www.leibniz-fli.de/news/aging-in-fast-motion-short-lived-fish-offer-new-insights-into-the-aging-immune-system", "https://valenzano-lab.github.io/labsite/dario.html", "https://doi.org/10.1371/journal.pbio.3003815"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 33, "source_url": "https://scholar.google.com/citations?user=YILt54YAAAAJ", "note": "All-time h-index; profile 'Dario Riccardo Valenzano', Leibniz Institute on Aging - Fritz Lipmann Institute, verified leibniz-fli.de email", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=YILt54YAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "FLI research group page", "url": "https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/valenzano-group"}, {"label": "Lab website", "url": "https://valenzano-lab.github.io/labsite/dario.html"}]}, "sources": [{"url": "https://www.leibniz-fli.de/research/research-groups/research-groups-at-fli/valenzano-group", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.leibniz-fli.de/news/a-new-exciting-challenge", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.leibniz-fli.de/news/aging-in-fast-motion-short-lived-fish-offer-new-insights-into-the-aging-immune-system", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://valenzano-lab.github.io/labsite/dario.html", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1371/journal.pbio.3003815", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=YILt54YAAAAJ", "type": "scholar_profile", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0117", "slug": "eric-verdin", "name": {"display": "Eric Verdin", "sort": "Verdin, Eric"}, "categories": ["scientist", "academic"], "current_title": {"title": "President and Chief Executive Officer", "organisation": "Buck Institute for Research on Aging", "sources": ["https://www.buckinstitute.org/about/leadership/", "https://www.buckinstitute.org/lab/verdin-lab/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Professor of Medicine", "organisation": "University of California, San Francisco", "sources": ["https://www.buckinstitute.org/lab/verdin-lab/"]}], "location": {"city": "Novato", "region": "CA", "country_code": "US", "sources": ["https://doi.org/10.1093/brain/awag311", "https://doi.org/10.1038/s43587-026-01175-2"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.buckinstitute.org/wp-content/uploads/2022/06/Eric-CEO-portrait-leadership-1.jpg", "page_url": "https://www.buckinstitute.org/about/leadership/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Eric Verdin is a Belgian-born physician-scientist who is President and Chief Executive Officer of the Buck Institute for Research on Aging in Novato, California, and a professor of medicine at the University of California, San Francisco. Trained in medicine at the University of Liège and at Harvard Medical School, he held positions at the University of Brussels, the NIH and the Picower Institute before joining the Buck. His laboratory was the first to clone a family of histone deacetylases (HDACs), and studies how metabolism, diet and small molecules regulate HDACs and sirtuins and thereby aging and age-related diseases including Alzheimer's disease. Current work focuses on immune aging and chronic inflammation, including how metabolites such as NAD+, acetyl-CoA and the ketone body beta-hydroxybutyrate change with obesity, calorie restriction, fasting and ketogenic diets and shape immune responses, and how HIV infection drives inflammation and accelerated aging. Recent 2026 papers link trained immunity in hematopoietic stem cells to age-associated inflammation. He founded Acylin (acquired by AbbVie) and has advised companies including Calico and Sirtris. For longevity readers he is both a leading researcher on metabolism and epigenetic regulation in aging and head of a major independent aging research institute.", "word_count": 196, "sources": ["https://www.buckinstitute.org/about/leadership/", "https://www.buckinstitute.org/lab/verdin-lab/", "https://doi.org/10.1038/s43587-026-01175-2"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 144, "source_url": "https://scholar.google.com/citations?user=SKFD2LcAAAAJ", "note": "All-time h-index; profile 'Eric Verdin', CEO & President, Buck Institute for Research on Aging, verified buckinstitute.org email", "checked": "2026-09-23", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=SKFD2LcAAAAJ", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Buck Institute leadership", "url": "https://www.buckinstitute.org/about/leadership/"}, {"label": "Verdin Lab", "url": "https://www.buckinstitute.org/lab/verdin-lab/"}]}, "sources": [{"url": "https://www.buckinstitute.org/about/leadership/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.buckinstitute.org/lab/verdin-lab/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1093/brain/awag311", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s43587-026-01175-2", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=SKFD2LcAAAAJ", "type": "scholar_profile", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0118", "slug": "jan-vijg", "name": {"display": "Jan Vijg", "sort": "Vijg, Jan"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor and Chair, Department of Genetics; Lola and Saul Kramer Chair in Molecular Genetics; Professor, Department of Ophthalmology & Visual Sciences", "organisation": "Albert Einstein College of Medicine", "sources": ["https://einsteinmed.edu/faculty/11318/jan-vijg"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Bronx", "region": "NY", "country_code": "US", "sources": ["https://einsteinmed.edu/faculty/11318/jan-vijg"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://assets.montefioreeinstein.org/profiles/images/Vijg_Jan_2x.jpg", "page_url": "https://einsteinmed.edu/faculty/11318/jan-vijg", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Jan Vijg chairs the Department of Genetics at Albert Einstein College of Medicine, where his group studies genome and epigenome instability as a possible cause of aging and genome maintenance as a longevity assurance system. His laboratory developed transgenic mutational reporter systems in mice and fruit flies to measure tissue-specific frequencies of point mutations, deletions and translocations with age, and later moved to single-cell whole-genome sequencing to quantify somatic mutation frequencies and spectra in human tissues, including B lymphocytes, liver and bronchial epithelium. His group also reported increased cell-to-cell variation in gene expression in the aging mouse heart (Nature, 2006) and, with Dong and Milholland, published a demographic analysis arguing for a limit to human lifespan (Nature, 2016). Comparative work with Gorbunova, Seluanov and Gladyshev examined genome sequence integrity in long- and short-lived rodent species. For the longevity field, he is a principal proponent of somatic mutation and genome mosaicism as mechanisms of aging, set out in reviews such as 'Pathogenic Mechanisms of Somatic Mutation and Genome Mosaicism in Aging' (Cell, 2020).", "word_count": 172, "sources": ["https://einsteinmed.edu/faculty/11318/jan-vijg"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "No clearly attributable public Google Scholar profile found via DuckDuckGo; Scholar author search blocked (403).", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0002-8457-9595", "status": "verified"}, "official": [{"label": "Einstein faculty profile", "url": "https://einsteinmed.edu/faculty/11318/jan-vijg"}, {"label": "Vijg Lab", "url": "https://www.vijglab.org/"}]}, "sources": [{"url": "https://einsteinmed.edu/faculty/11318/jan-vijg", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://orcid.org/0000-0002-8457-9595", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://www.vijglab.org/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://europepmc.org/article/MED/42140662", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0119", "slug": "saul-villeda", "name": {"display": "Saul Villeda", "sort": "Villeda, Saul"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor, Department of Anatomy; Endowed Professor of Biomedical Sciences", "organisation": "University of California, San Francisco (School of Medicine)", "sources": ["https://profiles.ucsf.edu/saul.villeda"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "San Francisco", "region": "CA", "country_code": "US", "sources": ["https://profiles.ucsf.edu/saul.villeda"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://researcherprofiles.org/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx?NodeID=173474&cachekey=0f7a91b8-ac3e-40bb-a04a-ad4f94e5e6df", "page_url": "https://profiles.ucsf.edu/saul.villeda", "source_type": "institution_page", "credit": "UCSF Profiles", "checked": "2026-09-23"}, "impact": {"text": "Saul Villeda is a Professor of Anatomy at UCSF School of Medicine, affiliated with the Bakar Aging Research Institute, whose laboratory studies how systemic factors in blood regulate brain aging. His group showed that heterochronic parabiosis, young blood plasma and exercise-induced blood factors can partially reverse age-related loss of plasticity in the aged brain, and that pro-aging factors in old blood can drive premature brain aging, suggesting that either restoring youthful factors or blocking pro-aging ones could promote rejuvenation. Recent work from the lab includes identification of a liver-derived exerkine that reverses aging- and Alzheimer's-related memory loss via the vasculature (Cell, 2026), targeting of the iron-associated protein Ftl1 in the brains of old mice to improve age-related cognitive impairment (Nature Aging, 2025), and evidence that aged circulating CD8+ T cells and their secreted factors drive cognitive decline (Immunity, 2026). For the longevity field, his work is a central strand of the blood-borne 'rejuvenation factor' research programme and its application to cognitive aging and dementia.", "word_count": 164, "sources": ["https://profiles.ucsf.edu/saul.villeda"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 38, "source_url": "https://scholar.google.com/citations?user=Zv4vXrkAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; Scholar profile 'Saul Villeda', affiliation line reads 'Associate Professor, University of California San Francisco' (stale title, same institution).", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=Zv4vXrkAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": "https://x.com/VilledaLab", "status": "verified"}, "orcid": {"url": "https://orcid.org/0000-0002-2726-9582", "status": "verified"}, "official": [{"label": "UCSF Profiles", "url": "https://profiles.ucsf.edu/saul.villeda"}, {"label": "Villeda Lab", "url": "http://villedalab.ucsf.edu/"}]}, "sources": [{"url": "https://profiles.ucsf.edu/saul.villeda", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=Zv4vXrkAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.immuni.2026.04.014", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0120", "slug": "amy-wagers", "name": {"display": "Amy Wagers", "sort": "Wagers, Amy"}, "categories": ["scientist", "academic"], "current_title": {"title": "Forst Family Professor of Stem Cell and Regenerative Biology; Chair, Harvard Department of Stem Cell and Regenerative Biology", "organisation": "Harvard University", "sources": ["https://hscrb.harvard.edu/people/amy-wagers/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Executive Committee Member", "organisation": "Harvard Stem Cell Institute", "sources": ["https://hscrb.harvard.edu/people/amy-wagers/"]}, {"title": "Senior Investigator, Section on Islet Cell and Regenerative Biology", "organisation": "Joslin Diabetes Center", "sources": ["https://hscrb.harvard.edu/people/amy-wagers/"]}, {"title": "Member", "organisation": "Paul F. Glenn Center for the Biology of Aging, Harvard Medical School", "sources": ["https://hscrb.harvard.edu/people/amy-wagers/"]}], "location": {"city": "Cambridge", "region": "MA", "country_code": "US", "sources": ["https://hscrb.harvard.edu/people/amy-wagers/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://hscrb.harvard.edu/wp-content/uploads/2019/04/WAGERS_Amy_feature_Harvard_1440x824-1.png", "page_url": "https://hscrb.harvard.edu/people/amy-wagers/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Amy Wagers is the Forst Family Professor of Stem Cell and Regenerative Biology and Chair of Harvard's Department of Stem Cell and Regenerative Biology, and a senior investigator at the Joslin Diabetes Center. Her laboratory studies the factors and mechanisms that regulate the migration, expansion and regenerative potential of adult blood-forming and muscle-forming stem cells. Across more than 150 research and review articles, her group has identified intrinsic and extrinsic regulators of stem cell activity in injury repair, degenerative disease and malignancy, with particular attention to blood-borne mediators, cellular niches, and inflammatory and metabolic cues. For the aging field, her work on systemic regulation of stem cell function, including studies of GDF11 and myostatin and reviews of stem cell aging mechanisms and therapeutic opportunities (Nature Medicine, 2014), bears directly on circulating-factor approaches to tissue rejuvenation. Her group has also developed methods for modifying stem cell genomes in situ, including in vivo gene editing in dystrophic mouse muscle and muscle stem cells (Science, 2016). She trained with Irving Weissman at Stanford, received a 2018 NIH Pioneer Award, and is a member of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School.", "word_count": 195, "sources": ["https://hscrb.harvard.edu/people/amy-wagers/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": null, "source_url": null, "status": "unavailable", "note": "No clearly attributable public Google Scholar profile found via DuckDuckGo.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "HSCRB profile", "url": "https://hscrb.harvard.edu/people/amy-wagers/"}, {"label": "Wagers Lab", "url": "https://hscrb.harvard.edu/labs/wagers-lab/"}]}, "sources": [{"url": "https://hscrb.harvard.edu/people/amy-wagers/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41467-026-68630-x", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0121", "slug": "david-walker", "name": {"display": "David Walker", "sort": "Walker, David"}, "categories": ["scientist", "academic"], "current_title": {"title": "Professor and Vice Chair of Academic Personnel, Department of Integrative Biology and Physiology", "organisation": "University of California, Los Angeles", "sources": ["https://www.ibp.ucla.edu/faculty/david-walker/"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [], "location": {"city": "Los Angeles", "region": "CA", "country_code": "US", "sources": ["https://www.ibp.ucla.edu/faculty/david-walker/"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://wp.lifesci.ucla.edu/ibp/wp-content/uploads/sites/2/2019/12/David-Walker.jpg", "page_url": "https://www.ibp.ucla.edu/faculty/david-walker/", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "David Walker is a Professor and Vice Chair of Academic Personnel in UCLA's Department of Integrative Biology and Physiology, where his laboratory uses Drosophila melanogaster genetics to study the molecular and cellular basis of aging, with the aim of identifying therapeutic targets for age-related disease. Early work with Seymour Benzer linked mitochondrial function and apolipoprotein D to stress resistance and lifespan. His group later showed that RNAi of mitochondrial respiratory chain genes and expression of yeast NDI1 can extend fly lifespan, and that promoting Drp1-mediated mitochondrial fission in midlife, Parkin overexpression, neuronal BNIP3-mediated mitophagy and upregulation of the autophagy adaptor p62/SQSTM1 can each prolong healthy lifespan. A second line of work established intestinal barrier dysfunction as a marker linking metabolic and inflammatory changes to death in aging flies (PNAS, 2012) and connected shifts in gut microbiota to intestinal decline and mortality, which his group has argued is an evolutionarily conserved hallmark of aging. He showed with colleagues that AMPK modulates aging non-cell-autonomously and co-authored, with Malene Hansen and David Rubinsztein, a review of autophagy as a promoter of longevity (Nature Reviews Molecular Cell Biology, 2018).", "word_count": 185, "sources": ["https://www.ibp.ucla.edu/faculty/david-walker/", "https://scholar.google.com/citations?user=VwvOwWQAAAAJ&hl=en"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 36, "source_url": "https://scholar.google.com/citations?user=VwvOwWQAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'DAVID WALKER', Professor, UCLA, verified g.ucla.edu email, interest Biology of Aging.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=VwvOwWQAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UCLA IBP faculty page", "url": "https://www.ibp.ucla.edu/faculty/david-walker/"}]}, "sources": [{"url": "https://www.ibp.ucla.edu/faculty/david-walker/", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=VwvOwWQAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1371/journal.pone.0342910", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0122", "slug": "ashley-webb", "name": {"display": "Ashley Webb", "sort": "Webb, Ashley"}, "categories": ["scientist", "academic"], "current_title": {"title": "Associate Professor", "organisation": "Buck Institute for Research on Aging", "sources": ["https://www.buckinstitute.org/lab/webb-lab/"], "source_type": "lab_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Co-Director, Glenn Center for Biology of Aging Research", "organisation": "Buck Institute for Research on Aging", "sources": ["https://www.buckinstitute.org/lab/webb-lab/"]}, {"title": "Chair, Cellular Mechanisms of Aging and Development study section", "organisation": "National Institutes of Health", "sources": ["https://www.buckinstitute.org/lab/webb-lab/"]}], "location": {"city": "Novato", "region": "CA", "country_code": "US", "sources": ["https://www.buckinstitute.org/lab/webb-lab/"], "note": "Buck Institute is located in Novato, CA.", "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.buckinstitute.org/wp-content/uploads/2023/07/Ashley-Webb.webp", "page_url": "https://www.buckinstitute.org/lab/webb-lab/", "source_type": "lab_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Ashley Webb is an Associate Professor at the Buck Institute for Research on Aging, where her laboratory studies the transcriptional and epigenetic mechanisms of brain aging and neurodegeneration. A long-standing focus is adult hippocampal neurogenesis and why neural stem cells fail to generate new neurons in the aging brain; her group has linked transcriptional and epigenetic changes in aged neural stem cells to impaired proteostasis and metabolism, and has implicated similar mechanisms in defective neurogenesis in Alzheimer's disease models. A newer line of work examines hypothalamic aging, identifying cell-type-specific and sex-specific transcriptional changes with age in a region that controls sleep, circadian rhythms, metabolism and hormone status. Her earlier work, including postdoctoral research with Anne Brunet at Stanford, showed that FoxO3 regulates neural stem cell homeostasis (Cell Stem Cell, 2009), and she co-authored a widely cited review of FOXO transcription factors as regulators of cellular quality control. Before joining the Buck in 2023 she was Associate Director of the Center on the Biology of Aging at Brown University. She co-directs the Buck's Glenn Center for Biology of Aging Research, chairs an NIH aging study section, and has received a Glenn Award and an AFAR junior faculty award.", "word_count": 197, "sources": ["https://www.buckinstitute.org/lab/webb-lab/", "https://scholar.google.com/citations?user=tBgoNfUAAAAJ&hl=en"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 28, "source_url": "https://scholar.google.com/citations?user=tBgoNfUAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Ashley Webb', The Buck Institute for Research on Aging, verified buckinstitute.org email. Other same-name Scholar profiles exist and were not used.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=tBgoNfUAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Webb Lab, Buck Institute", "url": "https://www.buckinstitute.org/lab/webb-lab/"}]}, "sources": [{"url": "https://www.buckinstitute.org/lab/webb-lab/", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=tBgoNfUAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.arr.2026.103123", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0135", "slug": "david-weinkove", "name": {"display": "David Weinkove", "sort": "Weinkove, David", "aliases": []}, "categories": ["scientist", "academic", "entrepreneur"], "current_title": {"title": "Professor", "organisation": "Durham University, Department of Biosciences", "sources": ["https://www.durham.ac.uk/staff/david-weinkove/"], "source_type": "university_page", "checked": "2026-09-29", "status": "verified", "note": "Durham staff page and Google Scholar list him as Professor; he was promoted to Associate Professor in 2016 and has since advanced to full Professor."}, "other_positions": [{"title": "Chair (Trustee 2014-2019)", "organisation": "British Society for Research on Ageing (BSRA)", "sources": ["https://bsra.org.uk/trustees/david-weinkove-chair/"]}, {"title": "Co-Founder and Chief Scientific Officer", "organisation": "Magnitude Biosciences", "sources": ["https://magnitudebiosciences.com/2022/01/31/magnitude-biosciences-ceo-david-weinkove-appointed-new-chair-of-british-society-for-research-on-ageing/"]}], "location": {"city": "Durham", "region": "England", "country_code": "GB", "sources": ["https://www.durham.ac.uk/staff/david-weinkove/"], "checked": "2026-09-29", "status": "verified", "note": "Department of Biosciences, Durham University, Durham, UK."}, "photo": {"status": "found", "image_url": "https://apps.dur.ac.uk/biography/image/1322", "page_url": "https://www.durham.ac.uk/staff/david-weinkove/", "source_type": "university_page", "credit": "Durham University", "checked": "2026-09-29"}, "impact": {"text": "David Weinkove is a biologist of aging whose work uses the nematode Caenorhabditis elegans to dissect how gut bacteria shape lifespan and health in later life. Based at Durham University, where he has worked since 2008, his laboratory made the influential discovery that inhibiting folate synthesis in the worm's Escherichia coli food source extends lifespan, not by limiting folate supply to the animal but by altering bacterial metabolism, helping to establish the microbiome as a modifiable determinant of aging. To increase throughput and reproducibility he co-invented automated systems for measuring worm healthspan and mobility, which he commercialised in 2018 through the Durham spin-out Magnitude Biosciences, where he is Chief Scientific Officer. He also serves the wider field as Chair of the British Society for Research on Ageing, following earlier service as a trustee, and communicates aging science through interviews and public talks.", "word_count": 141, "sources": ["https://www.durham.ac.uk/staff/david-weinkove/", "https://bsra.org.uk/trustees/david-weinkove-chair/", "https://magnitudebiosciences.com/2022/01/31/magnitude-biosciences-ceo-david-weinkove-appointed-new-chair-of-british-society-for-research-on-ageing/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 21, "source_url": "https://scholar.google.com/citations?user=FDY3YScAAAAJ&hl=en", "note": "Profile 'David Weinkove', Durham University (verified durham.ac.uk email); All column. Total citations ~4,800.", "checked": "2026-09-29", "status": "verified"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=FDY3YScAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Durham University staff profile", "url": "https://www.durham.ac.uk/staff/david-weinkove/"}, {"label": "BSRA Chair profile", "url": "https://bsra.org.uk/trustees/david-weinkove-chair/"}]}, "sources": [{"url": "https://www.durham.ac.uk/staff/david-weinkove/", "type": "university_page", "accessed": "2026-09-29"}, {"url": "https://scholar.google.com/citations?user=FDY3YScAAAAJ&hl=en", "type": "google_scholar", "accessed": "2026-09-29"}, {"url": "https://bsra.org.uk/trustees/david-weinkove-chair/", "type": "other", "accessed": "2026-09-29"}, {"url": "https://magnitudebiosciences.com/2022/01/31/magnitude-biosciences-ceo-david-weinkove-appointed-new-chair-of-british-society-for-research-on-ageing/", "type": "company_page", "accessed": "2026-09-29"}], "record": {"status": "draft", "created": "2026-09-29", "updated": "2026-09-29", "phase": "6"}}, {"id": "per_0123", "slug": "cornelia-weyand", "name": {"display": "Cornelia Weyand", "sort": "Weyand, Cornelia"}, "categories": ["scientist", "academic", "doctor"], "current_title": {"title": "Professor of Medicine and Professor of Immunology; Research Chair, Division of Rheumatology, Department of Internal Medicine; Benjamin Stinson Professor in Honor of Dr. Joseph Kiely", "organisation": "Mayo Clinic", "sources": ["https://www.mayo.edu/research/faculty/weyand-cornelia-m-m-d-ph-d/bio-20527870", "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=AUTH:%22Weyand%20CM%22%20AND%20PUB_YEAR:2026&format=json&pageSize=3&resultType=core"], "source_type": "institution_page", "note": "Mayo also lists consultant appointments in Rheumatology, Cardiovascular Medicine and Immunology.", "checked": "2026-09-23", "status": "verified"}, "other_positions": [{"title": "Professor of Medicine (Immunology and Rheumatology), Emerita", "organisation": "Stanford University School of Medicine", "sources": ["https://profiles.stanford.edu/cornelia-weyand"]}, {"title": "Chair, Atherosclerosis and Vascular Inflammation Study Section", "organisation": "National Institutes of Health", "sources": ["https://www.mayo.edu/research/faculty/weyand-cornelia-m-m-d-ph-d/bio-20527870"]}], "location": {"city": "Rochester", "region": "MN", "country_code": "US", "sources": ["https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=AUTH:%22Weyand%20CM%22%20AND%20PUB_YEAR:2026&format=json&pageSize=3&resultType=core", "https://doi.org/10.1038/s41584-026-01402-5"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.vibconferences.be/sites/default/files/styles/speaker_detail/public/2024-08/Cornelia%20Weyand%20-%20VIB%20Conferences%20-%20Speaker%20picture.jpg?h=6c83441f&itok=R3DoQl9K", "page_url": "https://www.vibconferences.be/speaker/cornelia-weyand", "source_type": "conference_listing", "credit": "VIB Conferences", "checked": "2026-09-29"}, "impact": {"text": "Cornelia Weyand is a rheumatologist and immunologist at Mayo Clinic, where she is Professor of Medicine and of Immunology and Research Chair in the Division of Rheumatology, and Professor of Medicine, Emerita, at Stanford University, where she previously led the Division of Immunology and Rheumatology (2013-2019). Her research addresses how immune cells become pro-inflammatory, disease-inducing effector cells, with a focus on rheumatoid arthritis, large-vessel vasculitis such as giant cell arteritis, and immune dysfunction in coronary artery disease. Her group studies immunometabolism, including how mitochondria, lysosomes and the endoplasmic reticulum regulate metabolic fluxes in inflammatory cells, and immune checkpoints in vasculitis, and has developed a humanised 'immune avatar' mouse model that grafts human joint and vascular tissue for testing immune interventions. For the longevity field, she and long-time collaborator Jorg Goronzy are known for work on immune aging, including recent reviews on immune responses in aging adults (Journal of Clinical Investigation, 2026), immune aging in rheumatoid arthritis, metabolic exhaustion and immune ageing in rheumatoid arthritis (Nature Reviews Rheumatology, 2026), and the argument that sustained immune youth carries autoimmune risk in the aging host (Nature Aging, 2025).", "word_count": 185, "sources": ["https://www.mayo.edu/research/faculty/weyand-cornelia-m-m-d-ph-d/bio-20527870", "https://profiles.stanford.edu/cornelia-weyand", "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=AUTH:%22Weyand%20CM%22%20AND%20PUB_YEAR:2026&format=json&pageSize=3&resultType=core"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 156, "source_url": "https://scholar.google.com/citations?user=kxubYhkAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Cornelia Weyand', affiliation 'Professor of Medicine and Immunology, Mayo College of Medicine; Professor of Medicine, Stanford', verified stanford.edu email. Also applies to doctor category.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=kxubYhkAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0003-2230-9802", "status": "verified"}, "official": [{"label": "Mayo Clinic research profile", "url": "https://www.mayo.edu/research/faculty/weyand-cornelia-m-m-d-ph-d/bio-20527870"}, {"label": "Stanford Profiles", "url": "https://profiles.stanford.edu/cornelia-weyand"}]}, "sources": [{"url": "https://www.mayo.edu/research/faculty/weyand-cornelia-m-m-d-ph-d/bio-20527870", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://profiles.stanford.edu/cornelia-weyand", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=kxubYhkAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=AUTH:%22Weyand%20CM%22%20AND%20PUB_YEAR:2026&format=json&pageSize=3&resultType=core", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1038/s41584-026-01402-5", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0124", "slug": "tony-wyss-coray", "name": {"display": "Tony Wyss-Coray", "sort": "Wyss-Coray, Tony"}, "categories": ["scientist", "academic", "entrepreneur"], "current_title": {"title": "D.H. Chen Distinguished Professor of Neurology and Neurological Sciences; Director, Phil and Penny Knight Initiative for Brain Resilience", "organisation": "Stanford University", "sources": ["https://profiles.stanford.edu/tony-wyss-coray"], "source_type": "institution_page", "note": "Profile header reads 'D. H. Chen Professor II'; bio uses 'D.H. Chen Distinguished Professor'. Knight Initiative directorship 2022-present.", "checked": "2026-09-23", "status": "verified"}, "other_positions": [{"title": "Co-founder", "organisation": "Alkahest Inc.", "sources": ["https://profiles.stanford.edu/tony-wyss-coray", "https://www.prnewswire.com/news-releases/grifols-to-make-a-major-equity-investment-in-alkahest-300045224.html"]}, {"title": "Co-Founder", "organisation": "Teal Rise", "sources": ["https://tealrise.com/"]}], "location": {"city": "Stanford", "region": "CA", "country_code": "US", "sources": ["https://profiles.stanford.edu/tony-wyss-coray"], "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://profiles.stanford.edu/proxy/api/cap/profiles/3929/resources/profilephoto/350x350.1509553296450.jpg", "page_url": "https://profiles.stanford.edu/tony-wyss-coray", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Tony Wyss-Coray is the D.H. Chen Distinguished Professor of Neurology and Neurological Sciences at Stanford University and, since 2022, Director of the Phil and Penny Knight Initiative for Brain Resilience. His laboratory studies brain aging and neurodegeneration, with a focus on age-related cognitive decline and Alzheimer's disease. His group showed that circulatory blood factors can modulate brain structure and function and that factors from young organisms can rejuvenate aspects of the aged brain, including a 2014 Nature Medicine study reporting that young blood restored mental capabilities in old animals. Current work examines how the body's organ systems communicate with the brain, using genetic, cell-biological and -omics approaches in killifish, mice and humans, including plasma proteomics used to estimate the biological age of individual organs. He co-founded Alkahest in 2014 with Karoly Nikolich to develop plasma-based therapies from this research; Grifols made a $37.5 million equity investment in Alkahest in 2015. He is also a co-founder of Teal Rise, a company building aging analytics on his lab's organ-aging research. His awards include an NIH Director's Pioneer Award and an Alzheimer's Association Zenith Award.", "word_count": 182, "sources": ["https://profiles.stanford.edu/tony-wyss-coray", "https://www.prnewswire.com/news-releases/grifols-to-make-a-major-equity-investment-in-alkahest-300045224.html", "https://tealrise.com/"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 119, "source_url": "https://scholar.google.com/citations?user=huboyZcAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Tony Wyss-Coray', Stanford University, verified stanford.edu email.", "checked": "2026-09-23"}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Alkahest", "label": "Alkahest publicly disclosed Grifols equity investment (2015)", "value": 37500000, "currency": "USD", "scope": "single_round", "source_url": "https://www.prnewswire.com/news-releases/grifols-to-make-a-major-equity-investment-in-alkahest-300045224.html", "checked": "2026-09-23", "status": "verified", "note": "Grifols $37.5M equity investment for 45% of shares (announced 4 Mar 2015); a further $12.5M payment and development funding not counted. Total lifetime funding not verified."}, {"kind": "capital_raised", "for_category": "entrepreneur", "entity": "Teal Rise", "label": "Teal Rise publicly disclosed total funding", "value": null, "currency": "USD", "scope": "total_disclosed", "source_url": null, "checked": "2026-09-23", "status": "unavailable", "note": "No first-party or reputable disclosure of funding found; relationship to 'Teal Omics' (name seen in search results) not verified."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=huboyZcAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": "https://orcid.org/0000-0001-5893-0831", "status": "verified"}, "official": [{"label": "Stanford Profiles", "url": "https://profiles.stanford.edu/tony-wyss-coray"}, {"label": "Wyss-Coray Lab", "url": "http://web.stanford.edu/group/twclab/cgi-bin/"}]}, "sources": [{"url": "https://profiles.stanford.edu/tony-wyss-coray", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=huboyZcAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://www.prnewswire.com/news-releases/grifols-to-make-a-major-equity-investment-in-alkahest-300045224.html", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://tealrise.com/", "type": "company_page", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0125", "slug": "ming-xu", "name": {"display": "Ming Xu", "sort": "Xu, Ming"}, "categories": ["scientist", "academic"], "current_title": {"title": "Associate Professor, Masonic Institute on the Biology of Aging and Metabolism and Department of Biochemistry, Molecular Biology and Biophysics", "organisation": "University of Minnesota Medical School", "sources": ["https://med.umn.edu/bio/ming-xu", "https://xu.umn.edu/ming-xu-phd"], "source_type": "institution_page", "checked": "2026-09-24", "status": "verified", "note": "UMN Medical School bio lists 'Associate Professor', Masonic Institute on the Biology of Aging and Metabolism, and Department of Biochemistry, Molecular Biology and Biophysics, at 7-126 MCB, 420 Washington Ave SE, Minneapolis, MN 55455. The Xu Lab page says he joined UMN as Associate Professor in 2024. The roster's UConn Health affiliation is outdated; a stale UConn directory page still lists him."}, "other_positions": [], "location": {"city": "Minneapolis", "region": "MN", "country_code": "US", "sources": ["https://med.umn.edu/bio/ming-xu", "https://xu.umn.edu/ming-xu-phd"], "checked": "2026-09-24", "status": "verified"}, "photo": {"status": "found", "image_url": "https://med.umn.edu/sites/med.umn.edu/files/styles/bio_photo/public/images/morehouse-good.jpg?itok=9XaGq-vl", "page_url": "https://med.umn.edu/bio/ming-xu", "source_type": "institution_page", "credit": "University of Minnesota Medical School; image alt text 'Ming Xu' but file name 'morehouse-good.jpg' - identity of image should be checked", "checked": "2026-09-23"}, "impact": {"text": "Ming Xu is an Associate Professor in the Masonic Institute on the Biology of Aging and Metabolism and the Department of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota, which he joined in 2024 after six years as an Assistant Professor at the UConn Center on Aging. He trained as a postdoctoral fellow with James Kirkland at the Mayo Clinic's Kogod Center on Aging, where he worked on cellular senescence in age-related physical and metabolic dysfunction. He is first author of the 2018 Nature Medicine study 'Senolytics improve physical function and increase lifespan in old age', and a co-author of work on targeting cellular senescence to prevent age-related bone loss (Nature Medicine, 2017) and on fisetin as a senotherapeutic that extends health and lifespan (EBioMedicine, 2018). His independent laboratory developed an inducible p21-Cre mouse model to monitor and eliminate p21-highly-expressing senescent cells in vivo, and reported that intermittent clearance of these cells extends lifespan and physical function in mice (Cell Metabolism, 2024) and alleviates obesity-related insulin resistance. His work continues on senescent cell heterogeneity and interventions to extend healthspan.", "word_count": 181, "sources": ["https://xu.umn.edu/ming-xu-phd", "https://med.umn.edu/bio/ming-xu", "https://facultydirectory.uchc.edu/profile?profileId=Xu-Ming", "https://scholar.google.com/citations?user=v59W39sAAAAJ&hl=en"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 31, "source_url": "https://scholar.google.com/citations?user=v59W39sAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Ming Xu', University of Minnesota, verified umn.edu email, interests incl. cellular senescence and aging; top paper 'Senolytics improve physical function and increase lifespan in old age'.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=v59W39sAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "UMN Medical School bio", "url": "https://med.umn.edu/bio/ming-xu"}, {"label": "Xu Lab (UMN)", "url": "https://xu.umn.edu/"}]}, "sources": [{"url": "https://med.umn.edu/bio/ming-xu", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://xu.umn.edu/ming-xu-phd", "type": "lab_page", "accessed": "2026-09-23"}, {"url": "https://facultydirectory.uchc.edu/profile?profileId=Xu-Ming", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=v59W39sAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=AUTH:%22Xu%20M%22%20AND%20PUB_YEAR:2026%20AND%20(senescence%20OR%20senescent)%20AND%20AFF:%22Minnesota%22&format=json&pageSize=3&resultType=core", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://doi.org/10.1016/j.cmet.2026.08.014", "type": "publication", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0126", "slug": "shinya-yamanaka", "name": {"display": "Shinya Yamanaka", "sort": "Yamanaka, Shinya"}, "categories": ["scientist", "academic"], "current_title": {"title": "Director Emeritus and Professor, Center for iPS Cell Research and Application (CiRA)", "organisation": "Kyoto University", "sources": ["https://www.cira.kyoto-u.ac.jp/e/research/yamanaka_summary.html", "https://gladstone.org/people/shinya-yamanaka"], "source_type": "institution_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Senior Investigator; L.K. Whittier Foundation Investigator in Stem Cell Biology", "organisation": "Gladstone Institutes", "sources": ["https://gladstone.org/people/shinya-yamanaka"]}, {"title": "Professor, Department of Anatomy", "organisation": "University of California, San Francisco", "sources": ["https://gladstone.org/people/shinya-yamanaka"]}, {"title": "Former Senior Scientific Advisor (unpaid; 2022–2026)", "organisation": "Altos Labs", "sources": ["https://www.cira.kyoto-u.ac.jp/e/pressrelease/other/220119-160000.html", "https://www.altoslabs.com/team"], "note": "Announced January 2022; no longer listed among the Altos Labs team as of September 2026 (individual team page returns HTTP 404)."}], "location": {"city": "Kyoto", "region": "", "country_code": "JP", "sources": ["https://www.cira.kyoto-u.ac.jp/e/research/yamanaka_summary.html"], "note": "Also holds appointments at Gladstone Institutes, San Francisco, CA, US.", "checked": "2026-09-23", "status": "verified"}, "photo": {"status": "found", "image_url": "https://www.cira.kyoto-u.ac.jp/e/research/img/yamanaka_master.jpg", "page_url": "https://www.cira.kyoto-u.ac.jp/e/research/yamanaka_summary.html", "source_type": "institution_page", "credit": "", "checked": "2026-09-23"}, "impact": {"text": "Shinya Yamanaka is Director Emeritus and Professor at Kyoto University's Center for iPS Cell Research and Application (CiRA), which he directed from 2008, and a Senior Investigator at the Gladstone Institutes in San Francisco. In 2006 his laboratory showed that introducing four transcription factors into mouse somatic cells could reprogram them into induced pluripotent stem (iPS) cells with properties nearly identical to embryonic stem cells, a result extended to human cells in 2007. This work established iPS cell technology for disease modelling, drug screening and cell therapy, and earned him the 2012 Nobel Prize in Physiology or Medicine, along with awards including the Lasker, Wolf and Shaw prizes. For the longevity field, the reprogramming factors he identified underpin research on partial reprogramming, in which older cells are reprogrammed only partway in an effort to rejuvenate them and slow some aging processes; Gladstone describes this as one of the most actively researched areas in longevity science. He served from 2022 to 2026 as an unpaid senior scientific advisor to Altos Labs, overseeing its rejuvenation research in Japan, and is no longer listed on the company's team. His current CiRA laboratory studies NAT1 (eIF4G2), organoids and stem cells, and multi-omics.", "word_count": 198, "sources": ["https://www.cira.kyoto-u.ac.jp/e/research/yamanaka_summary.html", "https://gladstone.org/people/shinya-yamanaka", "https://www.cira.kyoto-u.ac.jp/e/pressrelease/other/220119-160000.html", "https://gladstone.org/news/shinya-yamanaka-made-cells-young-again-can-reverse-aging", "https://scholar.google.com/citations?user=k6hepIAAAAAJ&hl=en", "https://www.altoslabs.com/team"]}, "metrics": [{"kind": "h_index", "for_category": "scientist", "platform": "google_scholar", "value": 131, "source_url": "https://scholar.google.com/citations?user=k6hepIAAAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Shinya Yamanaka', Kyoto University, Gladstone Institute, verified cira.kyoto-u.ac.jp email.", "checked": "2026-09-23"}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=k6hepIAAAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "CiRA profile", "url": "https://www.cira.kyoto-u.ac.jp/e/research/yamanaka_summary.html"}, {"label": "Gladstone Institutes profile", "url": "https://gladstone.org/people/shinya-yamanaka"}, {"label": "Yamanaka Lab (Gladstone)", "url": "https://labs.gladstone.org/yamanaka/"}]}, "sources": [{"url": "https://www.cira.kyoto-u.ac.jp/e/research/yamanaka_summary.html", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://gladstone.org/people/shinya-yamanaka", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://www.cira.kyoto-u.ac.jp/e/pressrelease/other/220119-160000.html", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://gladstone.org/news/shinya-yamanaka-made-cells-young-again-can-reverse-aging", "type": "institution_page", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=k6hepIAAAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-29", "phase": "3"}}, {"id": "per_0133", "slug": "sergey-young", "name": {"display": "Sergey Young", "sort": "Young, Sergey", "aliases": []}, "categories": ["communicator"], "current_title": {"title": "Founder", "organisation": "Longevity Vision Fund", "sources": ["https://sergeyyoung.com/", "https://www.xprize.org/people/sergey-young"], "source_type": "personal_website", "checked": "2026-09-29", "status": "verified", "note": "Founded the $100M Longevity Vision Fund in 2019. Tagged communicator only under project rule D-005 (primarily an investor and public communicator, not an operating-biotech entrepreneur)."}, "other_positions": [{"title": "Co-Founder", "organisation": "BOLD Longevity Growth Fund (with Peter Diamandis)", "sources": ["https://sergeyyoung.com/"]}, {"title": "Benefactor and co-creator", "organisation": "XPRIZE Healthspan; Innovation Board member, XPRIZE Foundation", "sources": ["https://www.xprize.org/people/sergey-young"]}, {"title": "Board of Directors member", "organisation": "American Federation for Aging Research (AFAR)", "sources": ["https://www.afar.org/ask-the-expert/ask-the-expert-sergey-young-on-his-experience-as-a-pioneering-longevity-investor-and-thought-leader-and-vision-for-the-future-of-geroscience"]}], "location": {"city": "", "region": "", "country_code": "US", "sources": ["https://sergeyyoung.com/"], "checked": "2026-09-29", "status": "unverified", "note": "Public profiles do not state a specific city; commonly described as US-based. Country recorded provisionally, city/region left blank pending confirmation."}, "photo": {"status": "found", "image_url": "https://assets-us-01.kc-usercontent.com/9bc15d1f-8a5c-007d-b507-e3496e85af86/9695d327-68fe-4b4f-935c-9c17f4457c0e/Sergey%20Young%20%28cropped%29.jpg", "page_url": "https://www.xprize.org/people/sergey-young", "source_type": "foundation_page", "credit": "XPRIZE Foundation", "checked": "2026-09-29"}, "impact": {"text": "Sergey Young is a longevity investor, author and public communicator who has helped bring aging science to a wider investor and general audience. After a career in fund management, he founded the Longevity Vision Fund in 2019, a $100 million fund backing companies that develop therapies, diagnostics and services to extend healthy lifespan, with portfolio holdings including Life Biosciences and Freenome. In 2023 he co-founded the BOLD Longevity Growth Fund with Peter Diamandis. He is a co-creator and benefactor of XPRIZE Healthspan, a $101 million competition rewarding therapies that restore muscle, cognitive and immune function in older adults, and serves on the Innovation Board of the XPRIZE Foundation and the board of the American Federation for Aging Research. His 2021 book, The Science and Technology of Growing Young, a Wall Street Journal and USA Today bestseller, surveys near-term and longer-term routes to extending healthspan for a broad readership.", "word_count": 152, "sources": ["https://sergeyyoung.com/", "https://www.xprize.org/people/sergey-young", "https://www.afar.org/ask-the-expert/ask-the-expert-sergey-young-on-his-experience-as-a-pioneering-longevity-investor-and-thought-leader-and-vision-for-the-future-of-geroscience"]}, "metrics": [], "links": {"google_scholar": {"url": null, "status": "unavailable"}, "linkedin": {"url": null, "status": "unavailable"}, "x": {"url": null, "status": "unavailable"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Personal website", "url": "https://sergeyyoung.com/"}, {"label": "XPRIZE profile", "url": "https://www.xprize.org/people/sergey-young"}]}, "sources": [{"url": "https://sergeyyoung.com/", "type": "personal_website", "accessed": "2026-09-29"}, {"url": "https://www.xprize.org/people/sergey-young", "type": "foundation_page", "accessed": "2026-09-29"}, {"url": "https://www.afar.org/ask-the-expert/ask-the-expert-sergey-young-on-his-experience-as-a-pioneering-longevity-investor-and-thought-leader-and-vision-for-the-future-of-geroscience", "type": "other", "accessed": "2026-09-29"}], "record": {"status": "draft", "created": "2026-09-29", "updated": "2026-09-29", "phase": "6"}}, {"id": "per_0127", "slug": "alex-zhavoronkov", "name": {"display": "Alex Zhavoronkov", "sort": "Zhavoronkov, Alex"}, "categories": ["entrepreneur", "communicator"], "current_title": {"title": "Founder; Chairman of the Board, Executive Director and Chief Executive Officer (also Chief Business Officer)", "organisation": "Insilico Medicine", "sources": ["https://insilico.com/team", "https://agingpharma.org/speakers/alex-zhavoronkov", "https://www.prnewswire.com/news-releases/insilico-medicine-lists-on-hong-kong-stock-exchange-showing-ai-drug-discovery-momentum-with-2025s-largest-hong-kong-biotech-ipo-302650606.html"], "source_type": "company_page", "checked": "2026-09-23", "status": "verified", "note": ""}, "other_positions": [{"title": "Adjunct Professor of Artificial Intelligence", "organisation": "Buck Institute for Research on Aging", "sources": ["https://insilico.com/team"]}, {"title": "Co-chair, Aging Research, Drug Discovery and AI Forum (ARDD)", "organisation": "ARDD", "sources": ["https://insilico.com/team"]}], "location": {"city": "Abu Dhabi", "region": "", "country_code": "AE", "sources": ["https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=AUTH:%22Zhavoronkov%20A%22%20AND%20PUB_YEAR:2026&format=json&pageSize=4&resultType=core", "https://doi.org/10.1016/j.cell.2026.08.052"], "status": "verified", "note": "2026 papers list Insilico Medicine AI, Masdar City, Abu Dhabi first; other listed Insilico sites include Hong Kong, Shanghai and Cambridge, MA. Company and bio pages give no personal base.", "checked": "2026-09-23"}, "photo": {"status": "found", "image_url": "https://insilico.com/images/tild6636-6566-4830-b662-353233633263__alex_at_the_entrance.jpg", "page_url": "https://insilico.com/mediakit", "source_type": "company_page", "credit": "Insilico Medicine (media kit)", "checked": "2026-09-24"}, "impact": {"text": "Alex Zhavoronkov founded Insilico Medicine in 2014 and serves as its Chairman, Executive Director, Chief Executive Officer and Chief Business Officer. Insilico develops generative artificial intelligence and automation platforms for drug discovery and biomarker development, and describes extending healthy longevity as part of its mission. According to the company, he applied AI to data types including aging, disease mechanisms and target identification, and from 2016 applied generative adversarial networks and reinforcement learning to target discovery and molecule generation. Insilico listed on the Main Board of the Hong Kong Stock Exchange on 30 December 2025. Before Insilico he held senior roles at ATI Technologies and the Biogerontology Research Foundation. He has published over 300 peer-reviewed papers, including recent work on aging clocks, AI benchmarks for aging biology and a control-theory framework for gerotherapeutic drug discovery, and has written three books, among them 'The Ageless Generation'. He is an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging, serves on editorial or advisory boards of aging journals including Aging and npj Aging, and co-chairs the annual Aging Research, Drug Discovery and AI Forum (ARDD).", "word_count": 186, "sources": ["https://insilico.com/team", "https://agingpharma.org/speakers/alex-zhavoronkov", "https://www.prnewswire.com/news-releases/insilico-medicine-lists-on-hong-kong-stock-exchange-showing-ai-drug-discovery-momentum-with-2025s-largest-hong-kong-biotech-ipo-302650606.html", "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=AUTH:%22Zhavoronkov%20A%22%20AND%20PUB_YEAR:2026&format=json&pageSize=4&resultType=core"]}, "metrics": [{"kind": "h_index", "for_category": "academic_scientist", "platform": "google_scholar", "value": 79, "source_url": "https://scholar.google.com/citations?user=8Icccp0AAAAJ&hl=en", "status": "verified", "note": "All-time h-index; profile 'Alex Zhavoronkov (Aleksandrs Zavoronkovs)', Insilico Medicine, verified insilico.com email; profile linked from Insilico team page.", "checked": "2026-09-23"}, {"kind": "audience", "for_category": "communicator", "platform": "x", "value": 43935, "source_url": "https://x.com/biogerontology", "checked": "2026-09-23", "status": "verified", "note": "followers; read via api.fxtwitter.com on 2026-09-23. Handle linked from his Forbes contributor author page (forbes.com/sites/alexzhavoronkov). @AlexZhavoronkov is a separate near-empty account (18 followers), not counted."}, {"kind": "audience", "for_category": "communicator", "platform": "linkedin", "value": null, "source_url": "https://www.linkedin.com/in/zhavoronkov", "checked": "2026-09-23", "status": "unavailable", "note": "Profile linked from his Forbes contributor page; public (logged-out) view shows only '500+ connections', no follower count."}, {"kind": "market_cap", "for_category": "entrepreneur", "entity": "Insilico Medicine", "label": "Insilico Medicine market capitalisation (company, not personal wealth)", "value": 33770000000, "currency": "HKD", "ticker": "3696.HK", "as_of": "2026-09-23", "source_url": "https://stockanalysis.com/quote/hkg/3696/market-cap/", "source_name": "StockAnalysis (data: S&P Global Market Intelligence)", "checked": "2026-09-24", "status": "verified", "note": "Source-stated HKD 33.77B as of 23 Sep 2026 close (price HKD 58.65 x ~575.84M shares outstanding per same site). On 24 Sep 2026 the stock closed at HKD 56.30 (StockAnalysis; Yahoo Finance chart), implying ~HKD 32.4B (56.30 x 575.84M; computed, not source-stated). No USD figure stated by the source."}], "links": {"google_scholar": {"url": "https://scholar.google.com/citations?user=8Icccp0AAAAJ&hl=en", "status": "verified"}, "linkedin": {"url": "https://www.linkedin.com/in/zhavoronkov", "status": "verified"}, "x": {"url": "https://x.com/biogerontology", "status": "verified"}, "orcid": {"url": null, "status": "unavailable"}, "official": [{"label": "Insilico Medicine team page", "url": "https://insilico.com/team"}, {"label": "ARDD 2026 speaker page", "url": "https://agingpharma.org/speakers/alex-zhavoronkov"}]}, "sources": [{"url": "https://insilico.com/team", "type": "company_page", "accessed": "2026-09-23"}, {"url": "https://agingpharma.org/speakers/alex-zhavoronkov", "type": "conference_listing", "accessed": "2026-09-23"}, {"url": "https://www.prnewswire.com/news-releases/insilico-medicine-lists-on-hong-kong-stock-exchange-showing-ai-drug-discovery-momentum-with-2025s-largest-hong-kong-biotech-ipo-302650606.html", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://www.bio-itworld.com/pressreleases/2025/06/17/insilico-medicine-completes-oversubscribed-series-e-bringing-total-funding-to-$123-million", "type": "press_release", "accessed": "2026-09-23"}, {"url": "https://scholar.google.com/citations?user=8Icccp0AAAAJ&hl=en", "type": "registry", "accessed": "2026-09-23"}, {"url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=AUTH:%22Zhavoronkov%20A%22%20AND%20PUB_YEAR:2026&format=json&pageSize=4&resultType=core", "type": "publication", "accessed": "2026-09-23"}, {"url": "https://insilico.com/mediakit", "type": "company_page", "accessed": "2026-09-24"}, {"url": "https://stockanalysis.com/quote/hkg/3696/market-cap/", "type": "other", "accessed": "2026-09-24"}], "record": {"status": "draft", "created": "2026-09-23", "updated": "2026-09-24", "phase": "3"}}]